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ABSTRACT 
 
Introduction: Prescribing by non medical personnel (NMP) has been introduced in 
the UK. The objectives of this study were to (a) describe pharmacist discharge 
prescription transcription service (PDPTS) provided in UK hospitals prior to NMP b) 
investigate the implementation of supplementary prescribing (SP) by pharmacists in 
England c) explore patient opinions on development of pharmacists and nurses as 
independent prescribers (IP). 
 
Methods: Two postal questionnaires were undertaken, one of hospital clinical 
pharmacy managers (Q1) and one of PCTPs and CPs (Q2). Depth interviews with 
patients were also used. Ethics approval was obtained. 
 
Key Findings: For Q1 the response rate was 66% (135/206). PDPTS was offered by 
49/135 (36%) of hospitals and was the most common prescribing activity undertaken. 
The majority of pharmacists wrote <5 prescriptions per day (n=25, 52%) and required 
counter-signature from a medical practitioner (65%, n=31, 1=missing data).  
The response rate for Q2 was 68%.  Both sectors intended to implement pharmacist 
SP by the end of 2005 (57%, n=55 and 56%, n=100 respectively). 
Within secondary care, the clinical areas provided were based upon established roles. 
Within primary care, the clinical areas were influenced by the General Medical 
Services (GMS) Quality and Outcomes Framework. 
Patient concerns included doubting ability to deal with serious conditions and 
diagnostic skills. Nurse prescribing was more acceptable because nurses were 
considered to be trustworthy. Community pharmacists were perceived as being “non-
NHS” and had a negative image. Experience of pharmacist SP enforced views that 
pharmacists would be capable as IPs.  
 
Conclusion:  The majority of the PDPTS schemes were not extensive and principles 
of clinical governance were not met. Consensus upon authorisation requirements of 
PDPTS and the legal position was unclear.  
Regarding implementation of NMP, community pharmacists face more obstacles, 
such as obtaining funding for such services and public acceptance.  
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CHAPTER 1: INTRODUCTION 
 
1.1 THE THESIS 
The introduction chapter (Chapter 1) will provide background information upon the 
political climate, key legislative and governmental reports that have led towards the 
development of non-medical prescribing, and the impact of clinical governance and 
risk upon the activity of prescribing.  
A timeline of when this research was developed and conducted compared to when 
important reports and changes in legislation were made is also provided. 
 
The next chapter of the thesis, the literature review (Chapter 2) will examine the 
existing body of knowledge regarding nurses in the prescribing role and what has 
been established from the studies that have been undertaken. The body of literature 
that is available upon pharmacists in prescribing roles is then also examined and the 
outcomes that have been established from these studies. 
After considering the existing literature, the hypotheses and detailed objectives are 
presented. 
 
In Chapter 3, methods, a detailed research plan is presented including a brief 
discussion of the methodology. The results are presented in detail in Chapter 4. 
Chapter 5, the discussion, is divided into two sections. In the first section the 
methodology is critically reviewed and discussed in detail. In the second section the 
results are discussed in light of previous research findings. Chapter 6 presents the 
conclusions from the research and the final chapter (Chapter 7) presents 
recommendations for both development of the prescribing role of pharmacists and 
future research.  
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1.2 BACKGROUND: DEVELOPMENT OF EXTENDED PRESCRIBING 
ROLES FOR NON-MEDICAL HEALTHCARE PROFESSIONALS; WHY 
HAS NON-MEDICAL PRESCRIBING DEVELOPED? 
 
1.2.1 The political climate 
In 1995, the Royal Pharmaceutical Society of Great Britain (RPSGB) initiated the 
Pharmacy in a New Age Project (PIANA)- a strategic planning programme. Via 
debate with the profession, in 1997, a publication called “Building the future”1 
identified key areas considered critical to the future of pharmacy. These were: the 
management of prescribed medicines; the management of long-term conditions; the 
management of common ailments; the promotion and support of healthy lifestyles and 
advice and support for other healthcare professionals. The project aimed at realizing 
the potential of pharmacy on the grounds that pharmacists were a massively 
underused resource in healthcare. This project was undertaken as a response to the 
suggestion that the pharmacy profession was becoming deskilled. The RPSGB led this 
campaign for reprofessionalisation and suitable professional recognition by seeking to 
redefine community pharmacys’ role in the primary healthcare team.2  
Alongside this desire from within the profession to improve the status of pharmacy, 
the Government has also been driven to extend roles of non-medical healthcare 
professionals as a means of increasing access to healthcare for patients.  
The National Health Service (NHS) Plan was launched in July 2000.3 The NHS Plan 
outlines the vision of a health service designed around the patient: a new delivery 
system for the NHS as well as changes between health and social services, changes 
for NHS doctors, for nurses, midwives, therapists and other NHS staff, for patients 
and in the relationship between the NHS and the private sector. 
Based around 10 core principles, the plan aimed to bring about a high quality, patient-
centered health service. It outlines the government's plans for giving patients better 
access to pharmacy services and for helping them to use medicines more effectively. 
Of critical interest to this research thesis, the paper also stated that the services would 
be restructured to meet the needs of patients and to integrate more closely with other 
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local services. Also, the plan stated that prescribing rights were to be extended to 
include suitably qualified pharmacists amongst other healthcare professionals. 
 
Prescribing was the one role that made doctors “unique” from other health care 
professionals. Further examination of what led the Government to consider extending 
prescribing rights to other healthcare professionals should therefore be considered. 
The development of non-medical prescribing has been closely linked to the shortage 
of doctors that was apparent in the 1990’s.4 There were specific concerns about the 
numbers of general practitioners. In a warning to Liberal Democrat delegates in 1996, 
the British Medical Association (BMA) informed delegates that the number of general 
practitioners under the age of 35 had fallen from 6491 in 1988 to 5830 in 1994, and 
the number of general practice registrars had fallen by 15% in the same period to 
1840. There had also been a reduction in the number of doctors working beyond the 
age of 60 and they warned that in the next decade over a third of the doctors retiring 
originate from overseas, which would make recruitment even more difficult in the 
areas where these doctors had been maintaining the NHS.5 
Although the Government had been insistent that prescribing policy had not been 
driven by medical shortages, but rather as a positive way of enhancing patient care, it 
has been reported that it is unlikely that they were not influenced by this.4 
Indeed published research of attitudes of healthcare professionals also suggests some 
cynicism about why non-medical prescribing was being introduced with participants 
stating that they wondered whether it was a means of addressing the shortage of 
doctors and reducing NHS costs and it was also seen as a way of resolving resource 
problems.6 
Dr June Crown, who wrote the Review of Prescribing, Supply and Administration of 
Medicines, final report in 1999 stipulated that her remit when compiling this report 
was to make better and more appropriate use of nurses and pharmacists, and that non-
medical prescribing was NOT developed due to a shortage of doctors (Dr. June 
Crown, lecture at University of Bath, 2
nd
 May 2007 “Pharmacist prescribing- What 
difference will it make to you and your patients?”) 
By mid-1992 anecdotal reports of nurses taking over important parts of junior hospital 
doctors’ clinical work were already beginning to appear in the health service press.7 
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The shortage of junior doctors was fuelled by the requirements of the “new deal” to 
reduce junior doctor’s hours,8 so that by 31st December 1996, no junior doctor would 
work more than 56 hours per week.  
This limitation on working hours of junior doctors will have inevitably lead towards 
the boundaries between the clinical work of doctors and the other large group of 
health professionals, namely nurses, to become redrawn. Alongside this political 
climate in the early 1990’s, momentum was increasing within the nursing profession 
for the extension of their clinical role, especially in the field of prescribing (as 
discussed in the history of nurse prescribing section 1.6 p31). Although district nurses 
and health visitors achieved limited prescribing rights from a Nurse Prescriber’s 
Formulary (NPF) in 1998,9 in this same year, the Government asked Dr June Crown 
to evaluate prescribing by non-medical professionals in recognition that practice had 
moved on, and with it the need for expansion of the Nurse Prescribers Formulary. 
 
1.3 WHAT DOES THE HEALTH COMMUNITY THINK ABOUT THE ROLE 
EXTENSION? 
 
1.3.1 Opposition from the medical profession 
Extension of prescribing rights to non-medical healthcare professionals has been a 
key policy in NHS modernisation which could lead to an “over-lapping” of inter-
professional roles within healthcare.10 
When the Crown report was published in 1999,11 it quickly lead towards further 
expansion of non-medical prescribing by not only nurses, but also pharmacists, and 
then onto chiropodists and podiatrists, physiotherapists, radiographers12 and 
optometrists in 2005.13 (For detail see History of non-medical prescribing section 1.7 
p35) 
Each time that further expansion of prescribing rights was consulted upon, the BMA 
vigorously criticised further expansion. After the 1999 Crown Report11 was published, 
the BMA made a press release criticising some of the main recommendations of this 
report.14 The BMA stated that they believed that the report "fails to establish a case for 
a change to pharmacy prescribing." On the proposal that two types of prescribers
independent and dependent should be recognised, the BMA stated that an extended 
role for pharmacists would best be facilitated by health professionals working as part 
of a closely integrated team. It supported appropriately trained pharmacists and 
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practice nurses assuming the role of dependent prescriber but had reservations about 
high street pharmacists doing likewise. The BMA rejected the idea that dependent 
prescribers would be able to alter prescriptions issued by General Practitioners (GPs). 
It also stated that problems of patient confidentiality could arise if, as the report 
recommended, local pharmacists had access to practice records. Several resource 
issues are raised in the report, the association says, "Not least that there will be an 
overall increase in prescribing and a consequent increase in costs. This would have 
implications for primary care group budgets."  
In 2002, the consultation for supplementary prescribing by nurse and pharmacists was 
underway15 and during that year, the editor of the Lancet, Richard Horton, went on 
record with his concerns about the extension of nurse prescribing and the rate at 
which it was happening.16 Dr Horton illustrated his argument with the opposing views 
from the medical and nursing profession, with a BMA representative stating that “The 
training nurses will get is nothing like sufficient and will not give them the clinical 
knowledge they need to prescribe these drugs”17 and Mark Jones, a primary-care 
policy adviser at the Royal College of Nursing stating that “nurses should be able to 
prescribe anything they need for the care of their patients from the whole British 
National Formulary”. Dr Horton thought that both positions were untenable, and 
thought that the rate at which nurse-prescribing was being implemented was too fast. 
He thought that nurses were being manipulated, under the guise of providing quicker 
and more efficient access to health care, to fill gaps left by too few doctors. He 
thought that giving nurses prescribing rights was not a major advance in professional 
status for nurses but merely redrawing the boundaries of a profession to serve an acute 
political problem, with little regard for the impact it would have on nursing or the care 
of patients. Dr Horton also went onto question the curricula of nursing courses and 
whether there was sufficient pharmacology education and also to question whether 
this would lead towards the blurring of inter-professional barriers. 
In response to the aforementioned letter, an American healthcare professional agreed 
that nurse prescribing was developed in United States of America (USA) in response 
to a physician shortage in rural areas, and states that in such times, the medical 
profession has not shortened training duration nor lowered its standards. Yet, nursing 
has allowed a faster turnout of nurses, and now is being lured under the guise of 
power and glamour, to allow lesser-educated and trained nurses to obtain prescriptive 
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authority. The author advocates that nurse training in the United Kingdom (UK) 
should be standardised to reduce discrepancies between training of basic registered 
nurses, for whom education ranges from 2 to 4 years.18 
In November 2005, when it was announced that pharmacists and nurses were to have 
their prescribing rights further extended to become independent prescribers and the 
BMA were again, highly critical of the government’s decision. The chairman of the 
BMA stated that “It is difficult to see how healthcare professionals who are not 
trained to diagnose disease can safely prescribe appropriate treatment”.19 The 
chairman of the BMA’s Central Consultants and Specialists Committee described the 
extension of prescribing powers as “an irresponsible and dangerous move” and that 
“Patients will suffer. I would not have me or my family subject to anything other than 
the highest level of care and prescribing, which is that provided by a fully trained 
doctor”. The chairman of the General Practitioners Committee stated that “This 
announcement raises patient safety issues, and we are extremely concerned that the 
training provided is not remotely equivalent to the five or six year’s training every 
doctor has” and also that “While we support the ability of suitably trained nurses and 
pharmacists to prescribe from a limited range of medicines for specific conditions, we 
believe only doctors have the necessary diagnostic and prescribing training that 
justifies access to the full range of medicines for all conditions”.19 
 
1.3.2 Support from the medical profession 
However, not all correspondence in the British Medical Journal (BMJ) has been 
negative about the extension of prescribing rights. Avery and Pringle wrote that “just 
because these professionals can prescribe any drug from the British National 
Formulary (BNF), does it follow that they will do so? Furthermore, is it likely that 
they will prescribe beyond their competencies?” The authors do state that “It is 
worrying that, before launching this new policy, the Department of Health (DoH) has 
not waited for further evidence to accumulate, including studies that it has only 
recently commissioned.” But conclude that “with appropriate training, support and 
governance in place, extended prescribing could combine the benefits of high quality 
pharmaceutical care with greater convenience and improved access to treatments for 
patients”.20 A consultant neonatologist also wrote in the BMJ to support specialist 
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nurses in special care baby units being able to prescribe independently, stating that it 
was a “triumph of common sense”.21 So there are some areas of the medical 
profession that are supportive of the extension of non-medical prescribing. 
Underlying all of this commentary that the BMA have published about non-medical 
prescribing is the issue of the medical profession having to deal with the 
psychological issue of other professionals encroaching on their territory. They may be 
feeling that their power, status and roles are under threat from other professionals.10 
The development of non-medical prescribing will lead towards redefinition of tasks 
and responsibilities and could potentially affect the hierarchy that exists where 
doctors are the most powerful healthcare professionals at the top of the chain of 
command.22 Blenkinsopp summarizes the work of Child, Fores and Glover in her 
research paper to explain that if an innovation is perceived to threaten power and 
status of a profession, the members may seek to maintain the status quo.10  Although 
it could be seen by the medical profession that extending pharmacy’s role is a way of 
encroaching upon their territory, it could also be seen as a way of expanding their 
empire through further subordination of pharmacy (as pharmacists are viewed as an 
occupational group to which doctors can delegate difficult or mundane tasks), or 
indeed it could be viewed in more “altruistic” terms, as a way of improving patient 
care.2 
It has been suggested that the resistance of GPs to an increased clinical role for 
pharmacists may well be rooted in the fact that clinical identity is particularly 
important to doctors’ identity because of their lengthy training and the centrality of 
the concept of clinical autonomy.2 
However, it is unsurprising that the medical profession has not welcomed this 
development with open arms, as the introduction of the development has been thrust 
upon them by the Government. Doctors may view this extension of prescribing rights 
as a challenge to their professional competence. By reacting like this, they will 
maintain a sense of control and reinforce their professional identity.2 
A qualitative evaluation of GPs’ opinions upon extended roles for community 
pharmacists found that the doctors were happy to accommodate those parts of 
extended roles for community pharmacy that were routine and objected to those they 
considered undermined the boundary between the occupations.2 Similar findings were 
reported from a qualitative evaluation of stakeholders in one NHS trust, where 
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medical staff had reservations about the introduction of non-medical prescribing, and 
thought that it should operate within controlled protocols.23  Therefore doctors want to 
maintain ultimate authority by having controls and limitations of the powers that non-
medical professionals will have. It is apparent that as a profession, they have serious 
misgivings about non-medical healthcare professionals having clinical autonomy as 
independent prescribers.  
A recent qualitative exploration of GP’s views10 suggested that it was perceived that 
the introduction of the role extension for non-medical healthcare professionals was 
undertaken to meet two agendas; firstly under the NHS modernisation agenda of 
moving some clinical areas from secondary to primary care to contain costs and 
secondly to enhance access to prescribed medicines. Some of the participants 
perceived a hidden Government agenda to destabilise the medical profession’s power 
base as they would no longer be the only healthcare professional (bar dentists) 
capable of independently prescribing.10 
It is apparent that failure to embed this new role development within the culture and 
working practices of the healthcare team will run the risk of it being rejected or not 
taken seriously. Successful implementation of non-medical prescribing will depend 
upon the degree to which the healthcare team are prepared to accommodate 
innovation.6   
 
1.3.3 Opposition from the Drugs and Therapeutics Bulletin and Committee on 
the Safety of Medicines (CSM). 
Concerns regarding non-medical prescribing have also been forthcoming from 
publications and committee’s. Concerns were raised about the safety of non-medical 
prescribing in 2006 by the Drugs and Therapeutics Bulletin (2006, 44;33). They stated 
“We have concerns about safety, including lack of access to complete medical 
records, the brevity of prescribing training, the potential for adverse drug reactions 
and the possibility of prescribing outside areas of competence or expertise”. The 
reason for these concerns was prompted by the fact that doctors’ prescribing can be 
associated with high rates of adverse drug reactions, some of which might be 
avoidable. It added that “there is a lack of comparative data on prescribing errors or 
safety of prescribing by different professional groups.”24 
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At a CSM meeting in October 2005 relating to the importance of prescribers 
developing diagnostic competence, and training and governance issues within and 
outside the NHS, the CSM emphasised the need for non-medical prescribers to have 
access to patients’ records and said that this was a key point given that electronic 
medical records were not expected to be fully rolled out in England until 2010.24 
 
1.4 CONCERN OVER NURSES’ PHARMACOLOGY KNOWLEDGE FOR 
PRESCRIBING 
The issue of the content of nurses’ background training and whether it is sufficient for 
prescribing activities has not only been raised by other healthcare professions as a 
potential weakness in their ability to prescribe but has also been raised by the nursing 
profession themselves. In a literature review of the first phase of nurse prescribing 
(1993-2002)25 and nurses’ and others’ views of their prescribing role, adequacy of 
nurses’ knowledge base in pharmacology was identified as a concern, together with 
the need for further pharmacology training. 
In a qualitative study of nurse lecturers’ observations on nurse prescribing training, 
respondents felt that their students had particular concerns about pharmacology, and 
that students often cited lack of pharmacological knowledge as being a concern in 
order to ensure informed decisions could be made about prescribing. However other 
lecturers felt that nurses claimed inadequate knowledge of pharmacology when what 
they were actually lacking was confidence or motivation to prescribe. Some lecturers 
had considered whether preparatory material would benefit nurses who felt weak in 
this area.26 
Similar observations were made in the results of a mail survey undertaken by While 
and Biggs27 where health visitors and district nurses who had qualified as independent 
prescribers in three trusts in Southern England did not rate their pharmacological 
training as highly as other aspects in their course. The authors suggest that this could 
also reflect a reluctance of some nurse practitioners to prescribe.  
A qualitative study of nurse prescribers’ perceptions of their pharmacology 
educational needs found that nurses had a limited understanding of pharmacology and 
dissatisfaction with the teaching of pharmacology, with resulting anxiety on 
qualifying.28 
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As illustrated in the section above (section 1.3.1 p. 23), although there has been a lot 
of negativity from the medical profession about nurses being prescribers and about 
their pharmacology knowledge, some members of the British Pharmacological 
Society have also been critical about the quality of prescribing by doctors, pointing 
out that in 1994, UK medical students received a median of 61 hours of teaching 
related to pharmacology, clinical pharmacology and therapeutics.29 They state that the 
root cause of prescribing errors among final year medical students is the lack of an 
integrated scientific and clinical knowledge base and advocate the use of a syllabus to 
ensure that medical students are adequately trained and that partnerships with other 
prescribers, such as pharmacists and nurses might also be useful. 
When prescribing by non-medical healthcare professionals is commented upon in 
literature, it tends to focus upon nurses. This could be because pharmacists are a much 
smaller group of healthcare professionals compared to nurses, or because any 
concerns being discussed are not applicable to pharmacists. Obviously, with the 
extensive pharmacology training that pharmacists have as part of their undergraduate 
course, this is not a concern that can be raised against pharmacists as non-medical 
prescribers. Instead, as is recognised by the profession itself, it is the diagnostic and 
physical examination skills that pharmacists are lacking. It is recognised that 
diagnosis itself is a complex skill, which doctors themselves do not always get right, 
so there is certainly concern as to how well nurses and especially pharmacists will be 
equipped to undertake this activity as an independent prescriber.19  
Considering that nurses and pharmacists are having intensive training in how to 
prescribe, it has been suggested that there ought to be one exam that ALL prescribers 
(including doctors) should take in order to assess competency to prescribe. (Oral 
communication, Professor Judy Cantrill, British Pharmaceutical Conference, 
Manchester 2003.) It will be interesting to see whether the General Medical Council 
(GMC) will start to provide prescribing training in line with the standards brought in 
by the nursing and midwifery council and the Royal Pharmaceutical Society of Great 
Britain. 
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1.5 REASONING FOR REVIEWING NURSE PRESCRIBING HISTORY AND 
EVIDENCE 
 
Nurses have had a much longer history of prescribing privileges than pharmacists and 
development of nurse prescribing has “paved the way” for non-medical prescribing. 
Indeed district nurses and health visitors have nationally been able to independently 
prescribe from the Nurse Prescriber’s Formulary (NPF)9 since 1998. In March 2007 
there were 10,750/686,886 (1.57%) qualified nurse independent/supplementary 
prescribers, 34,000 (4.95%) community practitioner nurse prescribers, and 1648 
(0.24%) nurse independent prescribers (most up to date figures available).30 In March 
2008 there were 1065 registered supplementary prescribing pharmacists (figures from 
RPSGB) out of a total of 47,621 (2008)31 pharmacists on the register (2.24%), there 
are 75 registered independent prescriber pharmacists and 327 pharmacists that are 
registered as both supplementary and independent prescribers. Hence nurses form the 
largest category of non-medical prescribers. 
It is recognized that without the development of nurse prescribing, pharmacist 
prescribing (leading onto prescribing rights for other non-medical health care 
professionals) would not have come into fruition. Hence it is important to discuss how 
non-medical prescribing started by reviewing how it developed in the nursing 
profession. 
 
1.5.1 Reasoning for not including other healthcare professionals prescribing 
evidence 
 
In November 2002, it was announced that supplementary prescribing by nurses and 
pharmacists was going to become legalized in the United Kingdom, pending 
legislative changes.32 This lead onto other non-medical professionals such as 
registered chiropodists and podiatrists, physiotherapists, radiographers12 and 
optometrists13 having supplementary prescribing rights extended to them (once 
appropriate training is undertaken) in May 2005 (June 2005 for optometrists). 
However, uptake of supplementary prescribing by these allied health professionals 
has been minimal (chiropodists and podiatrists 13/12,537 =0.1%, physiotherapists 
20/39,821= 0.05%), radiographers 0/23,84533 –(figures as of March 2007), 
Optometrists= 10/11,056 0.09% (figures supplied by the General Optical Council 
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www.optical.org/ April 2007) and independent prescribing has not (yet) been 
extended to these other groups of health care professionals. Hence when discussing 
non-medical prescribing, the focus shall be reviewing the research available from the 
nursing and pharmacy profession. 
 
1.6 HISTORY OF NURSE PRESCRIBING 1986-2005  
 
1.6.1 Origins- supply versus prescription (Patient Group Directions (PGDs)) 
 
It is important to note when discussing the development of nurse prescribing, there are 
various methods of supply of medicines which are sometimes included under the 
“umbrella-term” of “prescribing” by people without fully understanding the distinct 
difference between supply and prescription of medicines.  
During the development of nurse prescribing, a method for supply of medicines was 
developed that could be used by any fully qualified and registered health 
professionals. This method of supply is NOT a form of prescribing, but was a move 
towards non-medical health care professionals being able to supply medicines without 
the need for a doctor to write a prescription. The method developed was called group 
protocols, which is defined as follows: 
 
“A Group Protocol is a specific written instruction for the supply or administration of 
named medicines in an identified clinical situation. It is drawn up locally by doctors, 
pharmacists and other appropriate professionals, and approved by the employer, 
advised by the relevant professional advisory committees. It applies to groups of 
patients or other service users who may not be individually identified before 
presentation for treatment”.
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This method of supply was then re-named “Patient Group Directions” (PGDs) in 
2000, but used the same definition. This was done in order to distinguish them from 
policies, procedures or clinical guidelines.4 The health service circular regarding 
PGDs  (2000)35 further defined who could supply or administer medicines under a 
patient group direction as nurses; midwives; health visitors; optometrists; 
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pharmacists; chiropodists; radiographers; orthoptists; physiotherapists and ambulance 
paramedics. They can only do so as named individuals. 
As PGDs are not a recognised form of prescribing, they will not be further discussed 
in this thesis. 
 
1.6.2 The development of nurse prescribing 
 
 Neighbourhood Nursing Review (Cumberlege Report) (DHSS, 1986) 
 Crown I, 1989 (DoH, 1989) 
 Medicinal Products; Prescription by Nurses etc Act 1992 
 Medicinal Products; Prescription by Nurses etc Act (Commencement No 1) 
Order. (Secondary enabling legislation) 1994 
 Pilot sites for use of the Extended Formulary for Nurse Prescribers (1994), 
expanded 1996 
 Crown II, Part 1 (Group protocols) (DoH, 1998) –(see origins section 1.6.1 
p.31) 
 Crown II, Part 2 (Prescribing) (DoH, 1999) 
 Patient Group Directions, (NHS Executive, 2000) –(see origins section 1.6.1 
p.31) 
 Consultation on expansion of nurse prescribing, (DoH, 2000) 
 Extended prescribing proposals (DoH, 2001) 
 Health and Social Care Act, 2001  
 Consultation on Supplementary Prescribing (MCA, 2002) –Discussed in 
“History of Non-Medical Prescribing” (from 1997) section 1.7 p.35 
 Supplementary prescribing proposals, (DoH, 2002) –Discussed in “History of 
Non-Medical Prescribing” (from 1997) section 1.7 p.35  
 Nurse prescribers extended formulary: proposals to extend range of 
prescription only medicines - consultation. (DoH, 2003) 
 Nurse and pharmacist prescribing powers extended. (DoH, 2005) 
 
Figure 1: Key landmarks in the development of Nurse Prescribing 1986-2005 
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Figure 1 (p 32) shows the landmark reports that have led to the development of nurse 
prescribing. As shown in Figure 1 (p32), the Cumberlege report of 198636 first 
suggested that nurses ought to be able to prescribe in the community. In 1989 an 
advisory group chaired by June Crown developed the emphasis on extended nurse 
roles further by suggesting that health visitors and district nurses ought to be able to 
prescribe from a limited formulary.37  
 
Community nurses first started to prescribe medication in 1994 in eight pilot sites, 
from the Extended Formulary for Nurse Prescribers, when enabling secondary 
legislation was brought in.38 These sites expanded to 60 in 1996.4 In 1998, after 
piloting and evaluation, the secretary of state announced plans to extend nurse 
prescribing nationally and hence district nurses and health visitors were able to 
independently prescribe from the Nurse Prescriber’s Formulary (NPF).9 
Extension of prescriptive authority was developed further in the second Crown 
report11 where it was advocated that nurses should be able to prescribe from a wider 
list of medications within a supervised relationship, termed supplementary 
prescribing. 
The Department of Health39 advocated that nurse prescribing should be seen as part of 
the modernizing agenda for the nursing profession in the report “Making a 
Difference” and further recommended that over half of all registered nurses should 
have limited prescriptive authority by 2004.40  
In October 2000, the Department of Health announced the publication of a 
consultation upon the further extension of nurse prescribing41 to become extended 
prescribers who could prescribe any General Sales List (GSL) and Pharmacy-only (P) 
medicines plus certain Prescription Only Medicine (POM) for specified conditions. 
The announcement that an extension to their prescribing was going to be legalized 
happened in May 2001.42 
 
Since April 2002, other groups of nurses, following extended training, were able to 
independently prescribe from a specific list of POMs, alone or in combination to treat 
specific conditions (e.g. trimethoprim for uncomplicated urinary-tract infections in 
women) as well as all GSL and P medicines  as Extended Formulary Nurse 
Prescribers (EFNPs).43,44 At the end of April 2003, a consultation was published by 
the Department of Health to further extend the range of medicines that this group of 
 34 
nurses could prescribe and also extend the range of conditions they could treat.44 This 
went ahead, but by the time that independent prescribing was being consulted upon, it 
was apparent that there was no need for extended prescribing by nurses and hence on 
10th November 2005 it was announced that from spring 2006, qualified Extended 
Formulary nurse prescribers would be able to prescribe any licensed medicine for any 
medical condition (and some specified controlled drugs for specified medical 
conditions) as independent prescribers and that the extended formulary would cease to 
exist.45 
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1.7 THE HISTORY OF NON-MEDICAL PRESCRIBING FROM 1997  
(Applicable to nurses and pharmacists) 
During 1999 to 2002 there were several important reports published from the 
Department of Health and various other agencies which culminated in the legalisation 
of supplementary prescribing by nurses and pharmacists: 
 
1.7.1 Review of Prescribing, Supply and Administration of Medicines Final 
Report –March 1999.
11
 
In 1997, the Government started a consultation process, chaired by Dr June Crown, 
which lead to a complete review of prescribing, supply and administration of 
medicines.11 It was felt that the time had come for a review of these processes as the 
systems that were in use no longer reflected the needs of modern clinical practice.11 
There had been changes in the training and roles of healthcare professionals from all 
disciplines, changes in the range, potency and formulation of medicines available and 
a perceived need to allow patients to become more involved in their treatment and to 
improve access to healthcare for patients.11  
This report advocated the extension of prescribing rights beyond the currently 
authorised prescribers (doctors, dentists and certain nurses). The review team 
suggested two different types of prescriber that should be recognised: 
 
a.) the independent prescriber who is responsible for the assessment of patients with 
undiagnosed conditions and for decisions about the clinical management required, 
including prescribing. 11  
 
b.) the dependent prescriber who is responsible for the continuing care of patients who 
have been clinically assessed by an independent prescriber. This continuing care may 
include prescribing, which will usually be informed by clinical guidelines and will be 
consistent with individual treatment plans; or continuing established treatments by 
issuing repeat prescriptions, with the authority to adjust the dose or dosage form 
according to the patient’s needs. There should be provision for regular clinical review 
by the assessing clinician.11 
 
It was suggested that pharmacists and nurses in specialist areas would be suitable 
candidates to become dependent prescribers, and that chiropodists, podiatrists, 
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specialist physiotherapists and optometrists would be suitable candidates to become 
independent prescribers.   
The report stipulated that the newly prescribing professional groups should “normally 
be limited to prescribing medicines in specific therapeutic areas related to the 
particular competence and expertise of the group and may include prescription only 
medicines within those areas”.11 
 
The report also suggested that “a UK-wide advisory body, provisionally entitled the 
“New Prescribers Advisory Committee”, should be established to assess submissions 
from professional organisations seeking powers for suitably trained members to 
become independent or dependent prescribers.” 
 
1.7.2  Pharmacy in the Future-Implementing the NHS plan (Sept 2000) 
46
 
 
This document established how the Government envisaged the development of 
pharmacy services. It mainly focused on increasing access to healthcare for patients 
and also giving patients more support and advice about taking their medicines, to 
reduce morbidity and waste.46 
This report echoed recommendations in the Review of prescribing, supply and 
administration of medicines report (1999)11 by repeating that pharmacists would be 
able to prescribe in certain circumstances and also stipulated that pharmacists would 
be able to dispense repeat prescriptions for patients so that patients did not need to see 
the GP every time they needed a repeat supply of medication.46 
 
1.7.3 The Health and Social Care Act  (May) 2001
47
 
 
Section 63 of the Health and Social Care Act 2001 enabled the Government to extend 
prescribing responsibilities to other health professions, including pharmacists. It also 
enabled the introduction of new types of prescriber, including the concept of 
supplementary prescriber, by allowing Ministers by Order to attach conditions to their 
prescribing. Section 42 (for England and Wales) and Section 44 (Scotland) also relate 
to dispensing by community pharmacists of prescriptions written by these new 
prescribers. 
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Provisions in Northern Ireland (NI) are a matter for relevant NI legislation. It was 
expected that amendments to the POM Order and NHS regulations to allow 
supplementary prescribing by suitably trained nurses and pharmacists would be in 
place by April 2003.48 
 
1.7.4 A spoonful of sugar- Medicines management in NHS hospitals (Dec 2001)
49
 
 
This report by the audit commission identified the pharmacist as a central figure in 
medicines management. The report states that pharmacists should concentrate on their 
clinical, patient-centred roles, to help minimize medication errors and manage risk. It 
also considers that pharmacists should reduce their traditional role of retrospective 
prescription monitoring. It also advocated the introduction of pharmacist prescribing. 
 
1.7.5 The Right Medicine- A strategy for pharmaceutical care in Scotland (Feb 
2002).
50
 
 
This report upon the development of pharmacy services in Scotland also stated that 
after the recommendations of the Review of Prescribing, Supply and Administration 
of Medicines report11 it would implement pharmacist prescribing by December 2003. 
 
1.7.6 MLX284- Proposals for supplementary prescribing by nurses and 
pharmacists and proposed amendments to the prescription only medicines 
(human) order 1997 (April 2002)
15
 
 
This consultation document set out the proposed framework for supplementary 
prescribing. (Dependent prescribing was renamed as supplementary prescribing which 
was deemed to be a more appropriate term.) These proposed changes to the POM 
order would allow POM medicines to be prescribed by a supplementary prescriber 
throughout the UK. However, the extent to which supplementary prescribing was 
adopted within the NHS in devolved administrations is a matter for each of the 
separate administrations.15 
The consultation document set out a new definition for supplementary prescribing as 
well; 
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“ A voluntary partnership between the responsible independent prescriber and a 
supplementary prescriber, to implement an agreed patient-specific clinical 
management plan with the patient’s agreement, particularly but not only in relation to 
prescribing for a specific non-acute medical condition or health need affecting the 
patient.”15 
 
The document also set out the conditions that need to be met for supplementary 
prescribing to take place; 
 
• The independent prescriber must be a doctor or dentist, as appropriate 
• The supplementary prescriber must be a registered nurse, (including a 
registered health visitor), a registered midwife or a registered pharmacist 
• There must be a written clinical management plan (CMP) relating to a named 
patient and to that patient’s specific condition, and that plan must be agreed 
and signed by both the independent and supplementary prescribers 
• The CMP must specify the range of medicines that may be prescribed for the 
named patient by the supplementary prescriber, also specify the range and 
circumstances within which the supplementary prescriber can vary dosage, 
frequency and formulation of the specified range of medicines as appropriate, 
and when to refer back to the independent prescriber. 
• The CMP must contain the relevant warnings about any known sensitivities of 
the patient to particular medicines and include arrangements for the 
notification of any adverse drug reactions. 
• The CMP must contain the date on which the supplementary prescribing 
arrangements should be reviewed, which should normally be no longer than 
one year. 
• Both independent and supplementary prescribers must share access to, consult 
and use the same common patient record.15 
 
It was proposed that supplementary prescribing would be utilised most frequently to 
treat non-acute, chronic conditions such as asthma, diabetes etc. or for specific health 
needs such as anticoagulant monitoring, Hormone Replacement Therapy (HRT) or 
prophylaxis against coronary heart disease.15  
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It was also proposed that the range of medicines that could be prescribed in this 
arrangement should not be restricted. The only type of drugs that could not be 
prescribed were controlled drugs as this would require changes in home office 
legislation.15 
The supplementary prescriber would be responsible for monitoring and assessing the 
patient’s progress and prescribing for the patient as set out in the clinical management 
plan. The supplementary prescriber would also only prescribe within their clinical 
competence, and accept clinical responsibility and professional accountability for 
their prescribing decisions in practice.15 
The pharmacist or nurse wishing to undertake the supplementary prescribing role 
would have to undertake a period of training (25 days) followed by a period of 
supervision in practice by the independent prescriber (12 days).15 However, if the 
nurse had already become qualified as an extended formulary nurse prescriber, they 
would only need to undertake an extra 2 days of training.  
 
On 21st November 2002, it was announced that supplementary prescribing by nurses 
and pharmacists was going to become legalised, pending legislative changes.32  It was 
expected that pharmacists would start training in England and Wales for 
supplementary prescribing by spring 2003.51 
 
1.7.6.1 Aims of supplementary prescribing 
 
Supplementary prescribing was intended to provide patients with quicker and more 
efficient access to medicines, and to make the best use of the skills of trained nurses 
and pharmacists. Over time, it was envisaged that supplementary prescribing would 
also reduce doctors’ workloads, freeing up their time to concentrate on patients with 
more complicated conditions and more complex treatments. Time spent initially 
developing a simple CMP, should be time saved when the patient returns for review 
to the supplementary prescriber rather than the doctor.  
 
1.7.7 The Royal Pharmaceutical Society of Great Britain Pharmacist Prescribing 
Task Group, First Report, Supplementary prescribing by pharmacists (July 
2002)
52 
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This report was an interim report addressing the issues related to the introduction of 
supplementary prescribing by pharmacists, and was produced to assist the Society in 
the preparation of a response to the Government’s consultation document, MLX284.15 
Several recommendations were made for the Department of Health, the RPSGB and 
to the NHS and higher educational funding councils. A new definition of 
supplementary prescribing was suggested; 
 
“ A voluntary partnership between the independent prescriber and a supplementary 
prescriber, to implement an agreed patient-specific clinical management plan with the 
patient’s agreement”.52 
 
For the Department of Health, the task group recommended that the prescribing 
partnership must have as a prerequisite an agreement on access to medical records and 
clear arrangements for sharing information. It also suggested that serious 
consideration should be given to the introduction of patient held records and that more 
clear definition and guidance was needed upon the clinical management plan.52 
 
There were several recommendations for the RPSGB; firstly that they needed to 
develop national standards for clinical governance programmes designed to meet the 
specific needs of all supplementary prescribers. That they draw up appropriate course 
and programme specifications to meet the needs of pharmacists and pharmacy 
undergraduates. Also they should work with the DoH to develop a competency 
framework for pharmacist supplementary prescribing, and also criteria for the 
demonstration of ongoing competency as part of continuing professional 
development. Novel approaches to Continuing Professional Development (CPD) also 
need to be developed, and an appropriate byelaw needed to be drafted to allow 
separate indication or annotation of the Register of Pharmaceutical Chemists to record 
the prescribing status of registered pharmacists.52 
 
The task group also recommended that the workforce confederation of the NHS and 
the higher education funding councils be requested to consider resource implications 
for the education and training requirements, and provide the necessary funding 
support.52 
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1.7.8 Outcome of the consultation exercise on proposals for supplementary 
prescribing by nurses and pharmacists (September 2002)
53 
 
The Medicines Controls Agency (MCA) received 765 valid replies. Nine of these 
replies made no comment on the proposals or had no views either way. 678 replies 
supported the proposal overall although had some concerns about various aspects. 78 
replies objected in principal to supplementary prescribing. 
 
An outline curriculum for training programmes to prepare pharmacist supplementary 
prescribers was published by the RPSGB in November 2002.54 
Amendments to the POM order and NHS Regulations were laid early in 2003 to 
enable the introduction of supplementary prescribing.51 
 
1.7.9 Consultation on proposals to introduce independent prescribing (IP) by 
pharmacists (MLX 321) (2
nd
 March 2005-25
th
 May 2005)
55
 
This 12 week consultation was undertaken to help determine:   
 
 Whether any restrictions should be placed on prescribing in terms of 
medical conditions and / or range of medicines that might be used.  
 The requirements of the different ranges of prescribing; activity in the 
different sectors where pharmacists work.  
 What kind of training and support is needed?  
 Which individuals will be considered to go forward for prescribing 
training?  
 
1.7.10 Nurse and pharmacist prescribing powers extended- press release 10th 
November 2005
45
 
This press release announced that from spring 2006, qualified Extended Formulary 
nurse prescribers and pharmacist independent prescribers would be able to prescribe 
any licensed medicine for any medical condition - with the exception of controlled 
drugs (CDs). (Consultation by the Home Office upon CD prescribing by IPs occurred 
in April-June 200756 and the right to prescribe controlled drugs were subsequently 
extended to nurse and pharmacist independent prescribers) 
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1.7.11 Improving patient's access to medicines: A Guide to Implementing Nurse 
and Pharmacist Independent Prescribing within the NHS in England (April 
2006)
57
 
 
The DoH working definition of Independent Prescribing from this guide to 
implementation is as follows: 
 
“Prescribing by a practitioner (e.g. doctor, dentist, nurse, and pharmacist) 
responsible and accountable for the assessment of patients with undiagnosed or 
diagnosed conditions and for decisions about the clinical management required, 
including prescribing”.  
 
The aims of Independent Prescribing from this guide are as follows: 
• Improve patient care without compromising patient safety 
• Make it easier for patients to get the medicines they need 
• Increase patient choice in accessing medicines 
• Make better use of the skills of health professionals 
• Contribute to the introduction of more flexible team working across the 
NHS 
• Nurses must have 3 yrs post-registration experience, of which 1 year must be 
in the clinical area they are to prescribe in 
• Pharmacists must have 2 years post-registration experience in a clinical 
environment (primary/secondary care) 
 
 
1.7.12 Curriculum for the Education and Training of Pharmacist Supplementary 
Prescribers to become Independent Prescribers (RPSGB) (September 2006)
58 
 
This curriculum to prepare pharmacist independent prescribers was developed 
from the curriculum for supplementary prescribers published by the RPSGB in 
November 2002.54 The increase in professional autonomy, clinical assessment and 
responsibility and the associated legal and ethical implications form the basis of 
the curriculum for conversion programmes. Pharmacists who successfully 
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complete an accredited programme are awarded a Practice Certificate in 
Independent Prescribing.  
 
The following health care professionals can act as IP’s in the UK: 
• Registered nurses (First Level) 
• Registered specialist Community Public Health Nurses 
• Registered Midwives 
• Registered Pharmacists 
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1.8 CLINICAL GOVERNANCE, RISK AND PRESCRIBING 
 
Figure 2: Clinical governance; Setting quality standards, delivering quality 
standards and monitoring quality standards. (Reproduced from Pharmacy In 
Practice Journal
59
) 
 
1.8.1 What is Clinical Governance? 
 
The theory of clinical governance was first developed in the Department of Health 
publication “A first class service: quality in the NHS”.60 This report set out the 
government’s policy for raising quality for NHS patients and services. The policy 
involved setting standards through the National Institute for Clinical Excellence 
(NICE) and the National Service Frameworks (NSF), and monitoring standards 
through the Commission for Health Improvement (CHI), patient forums and national 
patient satisfaction surveys (as illustrated above in Figure 2). Central to this process 
would be delivering higher quality services through better self-regulation.61  
The definition of clinical governance given in the report “A first class service: quality 
in the NHS”60 was: “A framework through which NHS organisations are accountable 
for continuously improving the quality of their services and safeguarding high 
standards of care, by creating an environment in which excellence in clinical care will 
flourish”. 
National Institute for Clinical Excellence 
National Service Frameworks 
Clinical Governance 
Commission for Health Improvement 
National Performance Framework 
National Patient and User Survey 
Professional 
self-regulation 
Lifelong 
Learning 
Setting quality 
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Delivering 
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The RPSGB then published its policy document “Achieving excellence in pharmacy 
through clinical governance”62 in 1999. This document set out a framework for how 
pharmacists could deliver clinical governance. 
Reports such as “Building a safer NHS for patients”63 and the launch of the National 
Patient Safety Agency (NPSA) in 2001 have changed the focus of clinical governance 
and have mapped out the quality agenda in terms of the NHS plan’s40 objective of a 
patient-centred NHS.61 
Clinical governance consists of a series of processes (Continuing Professional 
Development (CPD), evidence-based practice, audit, dealing with poor performance, 
risk management, monitoring clinical care and patient involvement) for improving 
quality and ensuring that professionals are accountable for their practice. These 
processes are extremely relevant to the non-medical prescriber, and help to provide a 
framework to ensure patient safety. 
 
1.8.2 The issue of legal responsibility for pharmacist-written prescriptions before 
supplementary prescribing was legalised (pre 2004). 
 
When this research work was started in 2001, there were published studies available 
which showed that various forms of pharmacist prescribing were being undertaken 
within secondary care: 
 
Reported types of pharmacist “prescribing” being undertaken in the UK until 2001 
 Writing discharge prescriptions64-75 
 Pre-admission clinic prescribing (in-patient charts & discharge prescriptions)76-82 
 Anticoagulant prescribing83-92 
 Specialist clinics93-95 
 Prescription amendment/ therapeutic substitution96-98 
 
However, hospitals that have employed pharmacists in a “prescribing” capacity faced 
the problem of this role not being a legal one for pharmacists to undertake. Some 
hospitals overcame this obstacle by asking the doctor to co-sign the in-patient drug-
chart or discharge prescription that the pharmacist had written.70, 74-75, 77, 78, 99 
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The Medicines Act 1968 100 does not define what a prescription is or what a hospital 
is. It is therefore not surprising that there was no authoritative interpretation of the 
legality of prescriptions written by non-medically qualified personnel.101  
The inpatient drug chart is not a prescription, but is an authority to administer a 
medicine. Cousins and Luscombe questioned whether there was a need for a doctor to 
co-sign the in-patient drug chart when it has been written by a pharmacist. –As long 
as a medical practitioner had originally prescribed the drug, and this could be traced 
back to the GP or a written protocol, it should not be necessary to seek a co-
signature.102 
Therefore some hospitals have developed pharmacist prescribing without the issue of 
authorisation of the discharge prescription becoming an obstacle, as the law is not 
clear in this area and could be interpreted in different ways.  
 
As previously stated, during this period there was no legal framework for non-
medical professionals to write discharge prescriptions. In the absence of a recognised 
definition of transcribing, it was also unclear whether the process of writing the 
discharge prescription was prescribing or transcribing.  
The guidance in the Medicines, Ethics and Practice guide (2006)103 suggested that the 
process was transcription, and states that “Providing the entry (upon the patient’s bed 
card) fulfils the requirements, the details can be transposed onto an order form, to be 
used in pharmacy to prepare the take home medication. It is good practice for the 
transposition to be carried out by a pharmacist. By carrying out this transposition the 
pharmacist is NOT prescribing, as the original direction to supply was made by a 
practitioner.” 
However, in undertaking the act of transcription, there is an implied professional 
obligation upon the pharmacist to review the prescribed medicines and to respond 
appropriately to any errors or inappropriate prescribing. If this process did not occur 
then you would not need a pharmacist to copy one list of medicines to another- a 
medical secretary could do this. Therefore does this professional review of the 
prescription change the process from merely transcribing to prescribing? 
One of the key issues seems to be the question of who would be legally responsible 
for discharge prescriptions that are written by pharmacists. Anecdotal evidence 
suggests that some hospitals operating Pharmacist Discharge Prescription 
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Transcription Service (PDPTS) are asking the doctor to co-sign the prescriptions that 
are written by pharmacists, whilst other hospitals are not.  
The Department of Health’s recent discharge document104 suggests that the medical 
practitioner is still responsible for signing the prescription where medication changes 
have been made. This would suggest that only if the pharmacist reviews the drug chart 
and wants to change any of the medications, the discharge prescription would need 
signing by the doctor. If the pharmacist makes no changes to the medication, it would 
not need signing by the medical practitioner, but the medical practitioner would be 
responsible for it. It would appear that hospitals that are not asking a doctor to sign 
the discharge prescription where changes have been made to the medication are 
producing illegal prescriptions. 
 
1.8.3 Clinical Governance and Prescribing from 2004 
It is acknowledged that non-medical prescribing will not work without tight 
adherence to clinical governance processes as outlined above. An editorial in the BMJ 
concluded that “with appropriate training, support and governance in place, extended 
prescribing could combine the benefits of high quality pharmaceutical care with 
greater convenience and improved access to treatments for patients”.20 The Drugs and 
Therapeutics Bulletin (DTB) (2006, 44;33) which raised concerns about non-medical 
prescribing also emphasized how important adherence to clinical governance 
processes would be:  “It is therefore crucial that non-medical prescribing occurs 
within the context of rigorous clinical governance frameworks, close monitoring of 
safety, and ongoing training and professional development.” David Pruce, the director 
of practice and quality improvement at the Royal Pharmaceutical Society, responded 
to this article by stating that “We are pleased that the DTB recognises the potential of 
pharmacist prescribing and we want to reassure it and the public that pharmacist 
prescribing will be safe and the training is adequate to prepare pharmacists to be 
independent prescribers. We concur fully that non-medical prescribing needs to occur 
within the context of a rigorous clinical governance framework and this is why we 
developed a clinical governance framework….We are confident that pharmacists will 
only prescribe within their areas of competence just as other prescribers with similar 
prescribing rights also limit their prescribing to their areas of competence”.24 
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1.8.4 Clinical Governance guidance available to pharmacist prescribers 
 
The Royal Pharmaceutical Society published a clinical governance framework to help 
ensure that patient safety is an integral part of pharmacist prescribing.105 This 
framework was for the use of individual pharmacist prescribers as well as 
organisations throughout Britain that commission or participates in pharmacist 
prescribing. For the individual it provides suggested indicators of good practice for 
pharmacist prescribing and examples of good clinical governance practice relating to 
prescribing. On the organisational side it looks at the organisational components of 
clinical governance and what might need to be put in place within an organisation to 
support clinical governance of pharmacist prescribing.106 
The Society’s head of quality improvement, Heidi Wright, said: “This clinical 
governance framework should be used in conjunction with the competency 
framework for pharmacist supplementary prescribers developed by the National 
Prescribing Centre (NPC). Many of the recommendations in the Society’s clinical 
governance framework need to be implemented as part of the wider organisational 
work on managing prescribing and medicines management”.106 
Another key document that pharmacist supplementary prescribers need to refer to in 
terms of maintaining their competency is the “Maintaining Competency in 
Prescribing- An outline framework to help pharmacist supplementary prescribers”107 
published by the National Prescribing Centre. Although this document only focuses 
on competency, this is an integral process within the clinical governance framework. 
This document is very important for helping local organisations as well as the 
individual recognise the standard that they need to achieve in different aspects of 
prescribing. 
The RPSGB Code of Ethics103 (Annex A) also details specific professional 
obligations for pharmacist prescribers that require pharmacists to prescribe 
responsibly and in their patient’s best interest.  
 
1.8.5 Risk Management 
 
It is important that non-medical prescribers engage with clinical governance processes 
because prescribing is a high-risk activity108 where patients can be seriously harmed if 
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it is not done in a safe manner. Errors made during  prescribing are the most common 
type of avoidable medication error.108 Hence it is not surprising that there would be 
concern about non-medical healthcare professionals undertaking this new role, not 
only from the medical profession, but also from the non-medical professionals 
themselves.  
The report “Building a Safer NHS for patients. Improving medication safety (2001)”63 
reviewed the causes and frequency of medication error and identified models of good 
practice to improve medication safety. 
It found that the causes of errors were complex, involving human lapses and mistakes. 
Attention was usually focused on the actions of individuals who were considered to 
be the cause of error, the report warned. However, it found that systems weaknesses 
that predisposed to human error were important and recommended checks and error 
traps that should be built into all medication processes, including prescribing, 
dispensing, and drug administration.109 
Key steps proposed by the report for safer prescribing63 included active management 
and review of long term repeat prescribing; clear treatment plans shared with all 
professionals involved in a patient’s care and double-checking of all complex dose 
calculations. Also, greater use of information technology- including implementation 
of electronic care records and effective electronic prescribing systems was considered 
central to reducing risk of medication error. 
The report noted that current guidance and standards on prescribing, dispensing and 
administration of medicines are fragmented and divided between a range of 
professional and NHS regulatory bodies. A suggestion was therefore made that 
“Overarching national standards should be developed linking the various strands of 
medicines use within the NHS." The National Patient Safety Agency and the National 
Institute for Clinical Excellence (NICE) have been asked to develop such standards.109 
“Building a Safer NHS for patients. Improving medication safety”63 formed part of 
government efforts to reduce the number of serious errors in the use of prescribed 
drugs by 40% by 2005, an aim set by the Chief Medical Officer in 2001 (Organisation 
with a memory110). The health minister, Lord Norman Warner, said: "Improving 
quality of care and patient safety has always been at the heart of the government’s 
health strategy. A prescribed medicine is the most frequent treatment provided for 
NHS patients, so ensuring that drug treatment is safe is key".109 
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The Audit Commission further emphasized the problem of medication errors in UK 
hospitals and highlighted the importance of hospital pharmacists in preventing them.49 
More recently, media reports that blamed poor teaching of therapeutics to medical 
students for an apparent rise in safety incidents caused by poor prescribing has lead 
the General Medical Council (GMC) funding new research (£100,000 initially) into 
the prevalence and causes of errors in prescribing in the NHS.111 
 
Non-medical prescribers therefore need to be fully engaged with the clinical 
governance process to ensure that patient safety is maintained. Within the clinical 
governance framework, pharmacists are responsible for ensuring that their practice is 
safe and effective. For organisations that have pharmacist prescribers as employees, 
the RPSGB’s guidance on clinical governance105 stipulates that pharmacist 
prescribing should be included in clinical risk management (including Root Cause 
Analysis), patient safety (including the NPSA National Reporting and Learning 
Scheme), confidentiality, handling complaints and controls assurance programmes. 
For the individual pharmacist prescriber, they need to participate in local clinical risk 
assessment and management programmes, report any adverse drug reactions that their 
patients have via the CSM scheme and report critical incidents as part of the local 
critical incident reporting system (including the NPSA National Reporting and 
Learning Scheme). They must also be aware of local patient complaints procedures, 
have their own professional indemnity insurance and use complaints and compliments 
to identify learning needs and areas for improvement (as part of CPD portfolio). 
 
1.8.6 Liability 
Pharmacist prescribers are expected to use their professional judgement and work 
within their professional competence. They are accountable for and must be able to 
justify their actions. They must ensure that all activities they undertake are covered by 
professional indemnity arrangements.112 
When a pharmacist prescriber is employed by an NHS organisation, that organisation 
has vicarious liability for the pharmacist’s actions. This does not replace the 
pharmacist prescriber’s own professional accountability. In some circumstances, legal 
liability may be shared between the organisation and the professional. For the 
purposes of vicarious liability it is important that the prescribing role is reflected in 
the job description for the post.112 
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Indemnity providers currently require a declaration of activity as a pharmacist 
prescriber and a description of the scope of practice.  
In terms of liability, the definition of independent prescribing (p. 42), is important as 
it is likely that a lot of weight will be attached to this when courts have to decide 
whether independent prescribers are meeting standards.113 At a non-medical 
prescribing conference held in May 2006 a solicitor (Alison Gulliver) warned of the 
key exposure areas for independent non-medical prescribers:113 
 
 Failing to make an adequate assessment of the patient 
 Failing to make the right diagnosis 
 Failing to prescribe the appropriate medicine 
 Failing to monitor adequately (e.g. pick up an adverse drug reaction or 
deterioration of a condition) 
 Prescribing outside of their authority 
 
Ms Gulliver stated that: “With added clinical responsibility comes an increased risk of 
liability. The question is whose standards are independent prescribers going to be 
judged by when carrying out extended responsibilities? My instinct is that the 
standards will be the same as those of doctors who have been fulfilling the same role. 
Another issue for independent prescribers is the expectations of them if confronted by 
signs and symptoms that are obvious but that do not fall within their area of 
expertise”.113 
 
Ms Gulliver also stated that the key areas that non-medical prescribers need to check 
are: 
 
 Their employment contract- does it stipulate prescribing as an activity in the 
contract? Who will be responsible if a claim is made? 
 Ensure that clinical governance arrangements at the organisation are robust, 
that there are audits, risk management plans and CPD arrangements in place. 
 Ensure you adhere to available guidance and use electronic prescribing 
systems where possible. 
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 Ensure that your patients are aware that you are a non-medical prescriber and 
of the limits of your prescribing, and note that you have told them this. 
 Ensure you keep extensive records and good notes about your consultations, 
including differential diagnoses that have been excluded.113 
 
So, what is the legal position if a supplementary prescriber prescribes outside the 
Clinical Management Plan? 
 
If a supplementary prescriber prescribes a Prescription Only Medicine (POM) outside 
a Clinical Management Plan they will be acting illegally under the terms of the POM 
Order, and could be subject to sanctions under the Medicines Act 1968. 
 
If something other than a POM is involved, supplementary prescribers have a dual 
accountability: 
 
 to their employer 
 to their statutory regulatory body, the Nursing and Midwifery Council 
(NMC) or the Royal Pharmaceutical Society of Great Britain (RPSGB). 
 
A supplementary prescriber who prescribes a non-POM without the agreement of a 
Clinical Management Plan could potentially be subject both to: 
 
 disciplinary proceedings by their employer  
 action by the regulatory body should a charge of professional misconduct 
follow.114 
 
 
1.8.7 The theme of risk in this research. 
 
Clinical governance is an extremely important aspect of prescribing. As prescribing is 
such a high risk activity, it is clear that the impact of risk upon the development of 
non-medical prescribing is an important aspect to consider in terms of different 
healthcare professionals opinion’s (doctors, pharmacists and nurses) and the end-user 
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of the service, i.e. the patient if it is going to be implemented and utilised fully. The 
research that was undertaken during this thesis was divided into three separate studies 
as follows; 
 
As shown in the timeline of research Table below (Table 1 p 54-55) when this 
research started, no legal model of prescribing was available for non-medical 
prescribing (2001). However, as discussed earlier, there were anecdotal reports that 
certain prescribing roles were being undertaken by pharmacists within secondary care, 
predominantly the role of discharge prescription writing (see p 45). Given the 
importance of clinical governance in the role of prescribing, information about 
clinical governance aspects of the prescribing activities being provided in secondary 
care were sought (via a questionnaire survey), such as training provision, audit and 
how prescriptions that were being written by pharmacists were being authorised. This 
represents the first study in this thesis. This information was going to be used to 
provide a baseline of what prescribing was being undertaken in secondary care and to 
investigate whether aspects of clinical governance were being adhered to. 
 
When the introduction of supplementary prescribing was being consulted upon 
(2002), it became clear from the output of the consultation, from anecdotal 
discussions with colleagues and from discussion in the press that there were concerns 
about this development. Therefore a second questionnaire survey was also used to 
collate clinical governance data upon the views of chief pharmacists and primary care 
pharmacists of some of the risks and concerns surrounding supplementary 
prescribing. This represents the second study in this thesis. 
 
Finally, qualitative interviews were undertaken with patients in order to enquire about 
their perceived concerns and risks regarding the development of independent 
prescribing by nurses and pharmacists. This represents the third study in this thesis. 
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TIMELINE OF RESEARCH 
 
Published consultations, legislation, 
announcements and associated 
documents available at time of 
research project development 
Timing of Research 
 
 Review of Prescribing, Supply 
and Administration of Medicines 
Final Report –March 199911 
 Pharmacy in the Future-
Implementing the NHS plan (Sept 
2000) 46 
 The Health and Social Care Act  
(May) 200147 
 
AUGUST 2001 
 
First questionnaire is distributed: 
 
Pharmaceutical input to the discharge 
process. A survey of Hospital Pharmacy 
Services. 
 
 
 A spoonful of sugar- Medicines 
management in NHS hospitals 
(Dec 2001)49 
 MLX284- Proposals for 
supplementary prescribing by 
nurses and pharmacists and 
proposed amendments to the 
prescription only medicines 
(human) order 1997 (April 
2002)15 
 The Royal Pharmaceutical 
Society of Great Britain 
Pharmacist Prescribing Task 
Group, First Report, 
Supplementary prescribing by 
pharmacists (July 2002)52 
 November 2002- Announcement 
that SP will be legalized. 
 Spring 2003: SP training starts 
 March 2004: First pharmacist SP 
prescription is written. 
 
MAY 2004 
 
Second questionnaire is distributed: 
 
A survey of chief pharmacists/ primary 
care trust pharmacist’s views upon 
supplementary prescribing by nurses and 
pharmacists in England. 
 
Table 1: Timeline of Research
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Published consultations, legislation, 
announcements and associated 
documents available at time of 
research project development 
Timing of Research 
 
 Consultation on proposals to 
introduce independent prescribing 
(IP) by pharmacists (MLX 321) 
(2nd March 2005-25th May 2005)55 
 Nurse and pharmacist prescribing 
powers extended- press release 
10th November 200545 
 
 
JANUARY-AUGUST 2006 
 
Patient interviews take place: 
 
Patient’s perceptions of pharmacists and 
nurses as independent prescribers within 
primary and secondary care 
 
Table 1: Timeline of Research cont. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 SEARCH STRATEGY 
Various databases have been used for the literature search: Medline, Embase, 
Healthstar, Pharmline, Ingenta journals, Web of Science, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), cited reference search and Bath 
University Library Catalogue.  
For the three studies, a total of 634 references have been retrieved to date. 
The following Table (Table 2) presents the search strategy used, a summary of the 
findings and what types of research were included in the literature review. 
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Table 2: Literature search strategy and outcomes 
Study Search terms used Outcomes 
First study- 
discharge 
prescription 
prescribing 
 
 
 
 
 
 
 
discharge planning pharmacist 
discharge liaison 
discharge medication primary care 
secondary care communication 
GP communication discharge, 
pharmacist discharge summary 
discharge prescription 
Terms used singly and in 
combination 
Research upon pharmacist prescribing tends to 
be of a poor quality and consisted mainly of 
pilot studies. There has only been one 
randomised controlled trial published in this 
area, which has its limitations. 75 
The majority of the studies that were reviewed 
were either non-controlled or before and after 
studies which have various weaknesses in their 
methodology and hence generalisability of the 
results. 
Further good quality research involving 
multiple sites is necessary to prove whether 
there are any benefits to this role extension and 
that it is at least as safe as prescribing being 
undertaken by doctors.  
First study- 
Other types of 
pharmacist 
prescribing 
 
Pharmacist,  
pharmacist-managed, anticoagulant 
clinic, warfarin,  
cost-effectiveness,  
patient satisfaction, economic,  
clinical pharmacist, diabetes, heart 
failure, cardiac, gynaecology,  
pre-admission, clinics,  
lipid clinic, hypertension, epilepsy,  
Prescription amendment, 
therapeutic substitution. 
Terms used singly and in 
combination 
 
Second study- 
Nurse literature 
 
 
 
 
 
 
supplementary prescribing 
prescriber, prescription, advanced 
practitioner, specialist nurse, 
independent, non-medical 
Terms used singly and in 
combination 
For the search of nursing literature, a wide 
range of literature was found which tended to 
consist of mainly surveys and interviews with 
patients and nurses themselves to establish their 
views and opinions on the services being 
provided. Some of these studies were 
methodologically flawed. No published work 
could be found which evaluates the clinical 
outcomes and appropriateness of the nurse 
recommendations, or evaluates the safety of 
their services. Limited evaluation of economic 
cost-effectiveness suggests comparable costs of 
those services provided by GPs. A lot of 
literature that was found tended to consist of 
commentary, review and reflection upon nurse 
prescribing as opposed to being primary 
research studies, such literature was excluded 
from the review. 
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Study Search terms used Outcomes 
Second study- 
Pharmacist and general 
supplementary 
prescribing literature 
pharmacist 
supplementary prescribing 
prescriber, prescription, 
non-medical 
Terms used singly and in 
combination 
As supplementary prescribing was only just 
starting to be practised in 2004 when the 
questionnaire survey was developed, there was 
very little literature found about supplementary 
prescribing for pharmacists. It tended to consist 
of commentary from people who were running 
or undertaking supplementary prescribing 
courses and documents about implementation 
of supplementary prescribing, as would be 
expected with such a new development. 
 
Third Study 
Independent prescribing 
 
 
 
 
 
 
independent prescribing 
pharmacist 
prescribing 
prescription 
Terms used singly and in 
combination 
Very little literature was found and it was all 
commentary as opposed to primary research 
studies. 
A literature review was also conducted in order 
to investigate qualitative methodology. General 
texts upon qualitative methodology were read 
on the techniques of Interpretative 
Phenomological Analysis (IPA) and grounded 
theory to establish which qualitative 
methodology would be the most appropriate for 
the final research project. Guidance was also 
sought from colleagues who were experienced 
in the field of qualitative research. 
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2.2 EVALUATION OF NURSE PRESCRIBING RESEARCH 
 
Literature review of nurse prescribing has found research that has been published in 
the following areas: 
  
2.2.1 Perceptions held towards nurse prescribing by patients 
 
In 1997, Luker et al115 undertook an early qualitative evaluation of the first eight 
nurse prescribing pilot sites in England where the nurses were prescribing from the 
Nurse Prescribers Formulary. The evaluation investigated one GP practice in each 
regional health authority. Interviews were held with a convenience sample of patients 
prior to nurse prescribing implementation (n=157) and with patients following 
implementation (n=148). One third of the patients interviewed post-prescribing had 
also been interviewed pre-prescribing. The patients viewed nurse prescribing as a 
success. Patients received treatment more promptly and found the service more 
convenient, especially with regards to prescribing by health visitors. In some cases the 
patients felt that the nurses were in an even better position to prescribe for them than 
the doctors. Few disadvantages were noted and when they did occur, appeared to be 
related to the fact that nurses had previously helped patients by bringing them their 
dispensed medications from the local pharmacy, whereas now they were left with a 
prescription by the nurse to go and get the medication themselves. Problems such as 
the nurse being limited to a formulary did not appear to cause misunderstandings with 
patients as to what a nurse could and couldn’t prescribe. None of the patients 
interviewed after the introduction of nurse prescribing were opposed to it and only a 
small number (7%) appeared neutral or did not express an opinion. The patients 
thought that the nurses’ prescribing ability was linked to the qualities of individual 
nurses. Patients could distinguish between nurses with different levels of experience 
or training. The patients felt that only experienced nurses should be prescribing. 
Interestingly, they found that patient’s positive evaluations of nurse prescribing were 
related to aspects of the nurse-patient relationship. These included the length of the 
relationship and regularity of contact, approachability, the nurses’ style of 
consultation and information provision within the consultation and the expertise of 
nurses in certain areas such as skin and wound care.115  
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It is interesting that for the patients, their view of this system being a success was 
expressed mainly in terms of the increased timeliness and convenience. It would 
appear that clinical outcomes such as risk and safety were not seen to be an issue by 
patients in this study, which should be further explored. It is unclear in this paper as to 
whether all of the patients interviewed actually experienced nurse prescribing. Neither 
is it clear in the results what the views were (or how they changed) from pre-
prescribing to post-prescribing. The sampling methodology is also unclear as it states 
that only a third of patients who had been interviewed pre-prescribing were also 
interviewed post-prescribing, but does not state how the rest of the sample post-
prescribing is actually derived. The method of analysis of the transcripts from the 
interviews is also not stated in the paper. There may also be some bias in the results as 
it is not clear whether the patients knew that they were being interviewed by a nurse 
about nurse prescribing. 
A further publication from this study focused upon the patient’s experience with the 
nurse prescriber compared to a GP. The continuity of care and a stable relationship 
with the nurse, rather than the GP, was raised by a number of patients and this was 
considered to be an advantage when the nurse was prescribing. The expertise of 
nurses in certain areas, such as skin and wound care was also highlighted. When 
distinguishing between the nurse and GP’s role, patients were more likely to cite 
convenience as the reason for seeking advice from the nurse rather than the GP. 
Nurses were also found to be more accessible than GPs and patients did not want to 
waste GPs time with minor conditions. Nurse prescribing was seen as alleviating the 
GP of more routine duties. In general, nurses were considered to have more time than 
the GP and more likely to listen to concerns raised by patients. This relaxed attitude at 
consultation is due in part, to the long-term relationship which often exists between 
nurses and patients.116 
 
Brooks et al undertook a series of qualitative interviews (during May to September 
2000), with patients (n=50) who had experienced nurse prescribing in one primary 
care trust in Leicestershire. This involved health visitors, district nurses and practice 
nurses (who were all experienced prescribers) recruiting five patients for whom they 
had recently prescribed. The participants ranged from mothers of under 5’s who were 
in their 20’s and 30’s to older people in their 80’s. All were white and spoke English 
as their first language. The researchers found that nurse prescribers were, in the main, 
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meeting the needs of participants with positive experiences identified in terms of the 
prescribing process and the outcome. These included the patients perceiving that 
nurse prescribing demonstrated more effective use of the GP’s and nurses’ time, that 
nurses know their professional limitations and when they need to refer the patient to a 
doctor, the expertise of nurse prescribers in certain types of care, the improved 
timeliness and convenience of nurse prescribing and that nurse prescribing was based 
upon an established nurse-patient relationship and this relationship allowed for an 
improved continuity of care.  Limitations of nurse prescribing that were perceived by 
patients included the training and competency of nurse prescribers and the limitations 
of the nurse prescriber’s formulary.  Suggestions made by participants for the future 
development of nurse prescribing included the need for education to maintain public 
safety and develop and maintain competence, the potential for the NPF to be 
expanded and the need to provide patient-centred services and renegotiate traditional 
roles so that the NHS workforce is used more effectively. 117 
However, this study had a methodological flaw of the nurses themselves choosing and 
approaching their own patients for recruitment, which could lead to coercion and it 
may have lead to positive bias from the patients about the service. It is also not clear 
whether the nurses recruiting patients were following any kind of recruitment criteria 
or whether they were choosing patients with no guidance which again could lead to a 
positive bias as they may have chosen patients that they got on well with. 
 
In September 2004 Berry et al undertook a self-completed questionnaire survey of the 
general public (a convenience sample, recruited from a waiting area at a London 
railway station n=74) to assess the views of people who had not yet experienced nurse 
prescribing, to determine their level of confidence in nurse supplementary prescribing 
as opposed to doctor prescribing, effects on likely adherence and concerns that they 
might have. Generally, participants felt that they would have confidence in the nurse 
having prescribed the best medicine and said that they would be very likely to take the 
medicine. Concerns identified did not specifically relate to the nurses’ status when 
compared to a doctor. Only 5 participants stated that they preferred to see a doctor or 
to see a doctor before the nurse. Another participant wanted to be checked by a doctor 
at regular intervals and two others questioned the nurses’ knowledge/competence.118 
This is a more exploratory study and hence the findings are not generalisable and are 
thus indications of the publics’ attitudes. 
 62 
The shortcomings of this study are that they did not use a random selection of people 
and instead used a convenience sample, and also the participants had no experience of 
nurse prescribing. The authors also state that in the initial verbal description of the 
study during recruitment, participants were positively biased by the description of the 
purpose of the study (whether participants would be willing to take part in a study 
looking at how best to support nurses in relation to nurse prescribing) although they 
dismiss how much this would have biased participants as they had to read more 
detailed guidance in an information sheet before participating. 
 
In 2004, Latter et al119 undertook a study to investigate whether nurses were practising 
the principles of concordance within their prescribing interactions (the nurses were 
independent nurse prescribers), in the nurses’ and patient’s opinion via postal 
questionnaires and observation of practice. Most nurses believed that they were 
practising concordance in their prescribing consultations and the majority of patients 
also reported experiencing concordance in practice. However, observation of practice 
highlighted that the shift from a professionally determined compliance agenda to the 
integration of concordance into nurses' prescribing consultations had not yet taken 
place. In particular, nurses were not always giving patient’s information about 
possible side-effects of the medicines they were prescribing, nor giving explanations 
about risks and benefits of treatment options or assisting patients in making informed 
choices about the management of their health problems. 
A positive bias may have been present in this study as patients who had their 
consultation with the nurse observed, then completed a post-consultation 
questionnaire and may have therefore felt some obligation to be positive about their 
experience. Also some nurses who had been observed in their consultations were also 
involved in purposively sampling their patients to post questionnaires to. 
 
So, in the limited amount of research into patients’ opinions of nurses as prescribers, 
the overwhelming opinion is that patients are happy with nurses in this role, and it is 
only a minority that have some concerns about it. However, patients can see the many 
advantages of the system. However, all of these studies have some methodological 
flaws and positive bias associated with them. 
It is interesting that patients did not express concerns in terms of clinical outcomes or 
competence yet the observational study did highlight that there were flaws within 
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nurse consultations. Therefore it could be suggested that the public do not know what 
they should be looking for in a good consultation or prescriber anyway. 
 
2.2.2 Perceptions and quantification of nurse prescribing by nurses and other 
healthcare professionals 
 
A review of the literature upon the effectiveness of nurse prescribing was undertaken 
(1993-2002) in the UK by Latter and Courtenay.25 They included 18 research-based 
publications in the review and found that patients were generally satisfied with district 
nurses’ and health visitors’ prescribing in the first phase of nurse prescribing. The 
nurses themselves were also generally satisfied with the role, although some concerns 
about the adequacy of their pharmacological knowledge were raised. The limitations 
of the Nurse Prescriber’s Formulary were also raised. They identified that some nurse 
prescribing outcomes remain unevaluated, such as its impact on the prescribing 
practices of doctors and the perspectives of certain patient groups. The authors 
concluded that the majority of studies are limited to self-report designs with limited 
“generalisability” of research findings to the myriad of practice settings.25 
 
In 2001 Luker et al120 undertook a postal survey of 164 community nurses who were 
qualified to prescribe independently from the Nurse Prescriber’s Formulary in order 
to investigate patterns of prescribing in three primary care trusts (PCTs) in the United 
Kingdom (UK). Although they received 129 (79%) responses, 35 nurses identified 
themselves as not actually actively prescribing (even though they had the 
qualification). Hence 93 (72%) questionnaires were analysed in the results. They 
found that prescribing costs ranged from £7.65 to £18,053 (median £2,023.64) for 
district nurses and £0.73 to £2,556 (median £42.77) for health visitors over a twelve 
month period. Nineteen per cent (n=28) of community nurses had decided not to 
prescribe even though they were trained to do so (the reasoning for this was not stated 
in the paper). Nurses perceived that their ability to prescribe was benefiting their 
patients and that they are providing better care. 
The authors comment that action is needed by PCTs to put structures into place to 
ensure that nurses take on board the further extension to nurse prescribing given that a 
quarter of nurses in their survey were not using their prescribing skills. 
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In 2002 a questionnaire survey was conducted of all health visitors and district nurses 
working in three trusts in southern England, with a 74% (n=91) response rate 
achieved.27 Most respondents prescribed for less than three patients per week, with 
district nurses prescribing significantly more than health visitors. Over two-thirds of 
the sample found nurse prescribing at least moderately helpful to their professional 
role and over four-fifths reported that they are more than moderately confident nurse 
prescribers. Over two-thirds of the sample found that the NPF did not cover their 
prescribing needs and most respondents said that their general practitioner team was 
at least moderately supportive of their prescribing role. 
 
In 2003 to 2004 Bradley et al121 undertook a self-report questionnaire of nurses who 
had completed an extended/supplementary prescribing course at one university in the 
West Midlands in order to gather data on demographics, expectations of nurse 
prescribing, personal and professional development and perceived education needs. 
They found that respondents thought that despite initial problems, the nurse 
prescribing initiative would ultimately prove to be a cornerstone of improved service 
delivery for service users. The majority of nurses were heavily involved in prescribing 
“by proxy” and the course merely formalized what they were currently doing. Some 
concerns were expressed about how supportive the current health climate in health 
care could be, given the multiple demands on time and energy required by so many 
other innovations. 
The authors conclude that the respondents were not indifferent to the many short and 
long-term problems that need to be resolved before it can be claimed to have become 
embedded in practice. They also suggest that the success of non-medical prescribing 
may depend on organizational support, coupled with a robust continuing professional 
development strategy for all nurse prescribers.   
 
In June 2005 an evaluation of extended formulary independent nurse prescribing was 
published.122 This study consisted of two phases. First of all a national survey of  
nurse prescribers (n=246) was undertaken and then an in-depth evaluation of ten case 
studies of practice settings in which nurse prescribers were working involving 
observation of their practice and investigating the views of a range of stakeholders in 
local practice contexts. The authors found that nurses were prescribing frequently and 
clinically appropriately in a range of practice settings. Clinical appropriateness was 
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judged by a sample of observed nurse prescribing consultations being sent to a panel 
of medical prescribing experts. The expansion of independent prescribing was largely 
viewed by nurses, patients and doctors who participated in the study as successful on 
a range of policy and practice dimensions.  
 
Finally, in January to February 2005, a questionnaire survey was sent out to a 
convenience sample of 1187 qualified independent extended/supplementary nurse 
prescribers, and 868 (73%) completed questionnaires were returned.123 The authors 
found that independent extended/supplementary nurse prescribers work 
predominantly in primary care and do prescribe medicines. These nurses are highly 
qualified and have many years of clinical experience (87.6% had >10 years post 
registration experience). Supplementary prescribing is used by a minority of nurses. 
Implementing the CMP was found to be a barrier preventing the use of this mode of 
prescribing, although detail upon this identified barrier was not established in the 
study. They also found that the continuing professional development needs of 
independent extended/supplementary nurse prescribers are frequently unmet. 32% of 
the sample was unable to access CPD but again further examination of this issue was 
not undertaken during the study. 
The limitations of this study are that as all qualified independent 
extended/supplementary nurse prescribers were sent the questionnaire, so it was not a 
random sample. A second limitation is that the length of time that participants had 
been prescribing was not taken into account which may have affected the responses.  
 
2.2.3 Differences in care provision between nurse practitioners and GPs 
 
In 1999, Kinnersley et al124 undertook a randomised controlled trial in order to 
ascertain any differences between care provided by nurse practitioners and GPs for 
patients seeking “same day” consultations in primary care in 10 general practices in 
south Wales and south-west England. Practices chose to randomise patients either by 
day or within the same day. The randomisation schemes used were supplied to them. 
1368 patients were recruited into the study and main outcomes measured were patient 
satisfaction, resolution of symptoms and concerns, care provided (prescriptions, 
investigations, referrals, recall and length of consultation), information provided to 
patients and patient’s intentions for seeking care in the future. These measures were 
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measured via two questionnaires- one administered during the consultation and one 
after the consultation about consultation satisfaction. Nurse practitioners would have 
been prescribing from the NPF9 as independent prescribers. Ten GP practices 
participated in the study, and n=716 patients were seen by a general practitioner and 
n=652 by a nurse practitioner. 
Generally, patients consulting nurse practitioners were significantly more satisfied 
with their care, although for adults this difference was not observed in all practices. 
Resolution of symptoms and concerns did not differ between the two groups. The 
number of prescriptions issued, investigations ordered, referrals to secondary care, 
and re-attendances were similar between the two groups. However, patients managed 
by nurse practitioners reported receiving significantly more information about their 
illnesses and, in all but one practice, their consultations were significantly longer. The 
authors conclude that the study results support the wider acceptance of the role of 
nurse practitioners in providing care to patients requesting same day consultations. 
A systematic review was undertaken in 2002125 to determine whether nurse 
practitioners working in primary care can provide equivalent care to doctors. This 
review had similar findings to the above study. This study also found that patients 
were more satisfied with care by a nurse practitioner, that they had longer 
consultations and made more investigations than doctors. No differences were found 
in prescriptions, return consultations or referrals. The authors conclude that there was 
no difference in health outcomes and that nurse practitioners in primary care were 
providing high quality care. This study does not clearly define what they mean by 
“equivalent” care and states that although all of the randomised trials found no 
significant differences between the doctors and nurse practitioners in health outcomes, 
the studies included used many different outcome measures, which reflects the 
difficulties in measuring changes in health outcomes after single consultations 
predominantly about minor illnesses. 
 
2.2.4 Cost-effectiveness of nurse prescribing compared to GPs 
 
Only one study could be found where the cost-effectiveness of nurse prescribing in 
the UK has been evaluated. Venning et al126 undertook a multi-centre randomised 
controlled trial of patients requesting an appointment on the same day across 20 GP 
practices in England and Wales. 651 general practitioner consultations and 641 nurse 
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practitioner consultations were compared in terms of length of consultation, 
examinations, prescriptions, referrals, patient satisfaction, health status, return visits 
over two weeks and costs. Costs were analysed in terms of the basic salary costs, 
costs of prescriptions, tests, referrals and the cost of return consultations in the 
following two weeks. The nurse practitioners prescribed from the NPF9 as 
independent prescribers. 
It was found that nurse practitioner consultations were significantly longer than those 
of general practitioners, nurses carried out more tests and asked patients to return 
more often. There was no significant difference in patterns of prescribing or health 
status outcome for the two groups. Patients were more satisfied with the nurse 
practitioner consultations even when length of consultation was controlled for. There 
was no significant difference in health service costs. The authors state that the nurses 
were paid less than the doctors, but as they took longer to see patients and more of 
their patients returned for further consultations the cost savings were cancelled out. 
The authors conclude that if nurse practitioners were able to maintain the benefits 
while reducing their return consultation rate or shortening consultation times, they 
could be more cost effective than general practitioners. 
 
In the systematic review discussed earlier,125 the authors also investigated economic 
analyses of the costs of care by nurses compared with doctors. They found five 
studies which provided data about costs. However, these studies used different 
approaches to the valuing of resources and were inadequately powered for economic 
analysis.   
 
Therefore evaluation of nurse prescribing has tended to consist of in the main, surveys 
and interviews with patients and nurses themselves to establish their views and 
opinions on the services being provided. There has not been any research undertaken 
which evaluates the clinical outcomes and appropriateness of the nurse 
recommendations, or evaluates the safety of their services. Limited evaluation of 
economic cost-effectiveness suggests comparable costs of those services provided by 
GPs, however the lack of good evidence about the economic impact of substituting 
nurse practitioners for doctors needs to be addressed in future research, otherwise 
changes may be introduced which are inefficient. As non-medical prescribing is in its 
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infancy, it would be expected that further research for this type of nurse prescribing 
will be forthcoming. 
Hence there is a big gap in the evaluation of nurse prescribing whilst further extension 
of prescribing rights continues. It is possible that the government’s agenda for 
continuing to extend non-medical prescribing at such a fast rate has hindered research.  
 
2.2.5 Nurse prescribing experience from other countries  
 
Development of nurse prescribing in the UK parallels practice issues in other 
countries such as USA, New Zealand, Canada, Australia and Sweden, which have 
implemented independent nurse prescribing rights to varying degrees.127 In the USA, 
advanced practice nurses (these include nurse practitioners, nurse midwives, nurse 
anesthetists and clinical nurse specialists who are registered nurses with advanced 
skills and knowledge, usually with a master’s degree in nursing) are able to prescribe 
medications in all 50 states.128 In 27 of these 50 states the nurse prescribing is 
independent, where there are no requirements for written agreements. In the other 23 
states, the prescriptive authority is linked to a collaborative agreement with a 
physician. However, advanced practice nurses are working towards independent 
prescribing status in all 50 states.128 
In Canada and several states of Australia, support for nurse prescribing has been 
primarily in rural areas where there are a shortage of doctors, and nurses work 
independently.127 
In New Zealand, the Government has changed (April 2004) their regulations to allow 
advanced nurses (these have a master’s degree and at least 4-5 year’s experience in a 
specialist area) to extend their prescribing rights to allow them to prescribe all 
prescription, pharmacy-only, restricted and general sale medicines within their scope 
of practice.129 
In Europe, Sweden was innovative in its development of nurse prescribing rights in 
1994, when they gave their district nurses with post-graduate qualifications a list of 
drugs that they could prescribe for specific conditions.130 
The introduction of this role for Swedish nurses was to enable patients living in 
remote areas access to medicines and also to reduce the workload of doctors.127 
Although prescribing training is available to nurses in Botswana and South Africa, 
there is an absence of literature with regards to its implementation or evaluation.127 
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Experience from countries such as this was drawn upon when the Crown Review was 
undertaken,11 and this has aided the development of non-medical prescribing in the 
UK. 
 
2.6 HOW THIS LITERATURE REVIEW HAS HELPED TO DEVELOP THE 
RESEARCH INTO NURSE PRESCRIBING (phase 2 and 3). 
 
As supplementary prescribing was introduced in 2003, published research upon this 
new model of prescribing could not be found in nursing journals when phase two of 
this research was being developed in 2004. This would be as expected for such a new 
development. However, being aware of the other legal forms of nurse prescribing 
(independent and extended formulary prescribing) that led up to the development of 
supplementary prescribing and what impact they were having was essential to 
understand how supplementary prescribing was fitting into their practice. 
It was therefore clear that in terms of the new development of supplementary 
prescribing for nurses, provision of baseline data upon implementation of SP within 
primary and secondary care by nurses and in which clinical areas they were intending 
to practice was important to establish. This was also important as pharmacists were 
also going to be starting their role as prescribers and it would be important to establish 
whether nurses and pharmacists were setting up their clinics in similar areas or 
whether their different skills led them towards niche clinics which were most suited to 
their abilities. 
 
The literature reviewed also highlighted what patients thought about nurses in their 
independent and extended formulary prescribing roles. The literature showed that 
patients were very positive about nurse as prescribers and quantified this in terms of 
its convenience and timeliness as opposed to the clinical appropriateness and 
effectiveness. Risk, safety and competence did not seem to be issues of concern for 
patients. Patients had such trusting relationships with nurses due to their stable and 
long-standing relationships with them. 
Therefore as Independent Prescribing (An extension from the limited NPF for nurses 
so they could prescribe ALL licensed medicines (except for controlled drugs until 
2007)) for nurses and pharmacists was due to be legalized in 2006, it seemed that a 
study was necessary in order to establish what patients thought about the impending 
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legalization of Independent Prescribing especially in terms of their concerns and 
safety of the system. 
The literature review also informed that although there had been some research 
undertaken comparing nurses consultations to that of doctors, there needed to be some 
investigation of what patients thought of nurses compared to pharmacists. Pharmacists 
had more recently been allowed to prescribe as supplementary prescribers, and further 
prescribing rights were due to be given as Independent Prescribers. The literature 
showed that there was acceptance by the public of nurses as prescribers when 
compared to doctors and that they were satisfied with their care. Therefore for the 
final research study patient’s opinions of pharmacists and nurses as independent 
prescribers was investigated, especially whom patients are most comfortable with and 
why. Also their concerns regarding independent prescribing will be investigated. 
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2.7 EVALUATION OF PHARMACIST PRESCRIBING RESEARCH 
 
A review of the research evidence surrounding pharmacist prescribing is followed by 
exploration of the legal issues surrounding pharmacists prescribing and a discussion 
of the development of the pharmacist’s role as a prescriber in USA and the rest of the 
world. This review was first undertaken during 2001 when the PhD was started. Since 
then, the literature available in this area has increased substantially. Therefore this 
review has been updated to include some research that is pertinent to the development 
of pharmacist research that has been published since 2001 as well. Where papers are 
being discussed that were published after 2001, this will be highlighted. Literature has 
been included from all over the world, but has focused where possible on UK 
research. 
 
A literature review upon the area of pharmacist prescribing has elicited the following 
areas in which types of pharmacist prescribing has been reported: 
 
 Anticoagulation 
 Specialist clinics (Primary and Secondary care) 
 Writing discharge prescriptions (Secondary care) 
 Prescription amendment/therapeutic substitution (Secondary Care) 
 
These areas of prescribing or “pseudo-prescribing” (depending on who actually signs 
the prescriptions produced) developed without a legal model being available (before 
the introduction of supplementary prescribing in 2003) for the pharmacist to prescribe 
in these scenarios. It is worth examining these areas to establish what has been learnt 
regarding pharmacist prescribing in terms of the outcomes such as its efficacy, safety, 
cost effectiveness and patient/doctor acceptability. 
 
2.7.1 Anticoagulation 
 
This is the therapeutic area that has the largest body of research to support it, and has 
been reported to occur as early as 1979 in USA,131 and 1985 in the UK.132 Of the 
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articles retrieved, the majority are American (n=32), with one Canadian article, and 
15 from the UK. 
Pharmacist prescribing within this area has been reported in the following settings:  
primary care clinics,85, 87, 133-135 in-patients90-92, 136-144 and mainly at outpatient 
clinics.83-86, 88- 89, 135, 145-159 
Several of the papers have either been audits of a service provided 87-88, 92, 152, 158 or 
descriptions of the service provided. 89, 135, 153  
The research has provided evidence that pharmacists can act as anticoagulant 
prescribers via the following outcome measures: 
 
2.7.1.1 Pharmacists successfully manage anticoagulation at least as effectively as 
doctors 
 
In order to measure this, several different endpoints have been used; time spent or 
percentage of patients within the target range, deviation from the target range, time 
spent or percentage of patients outside of target range.  
The most commonly reported method for examining anticoagulant control has been to 
assess the percentage of International Normalised Ratio’s (INR) within range.  
The majority of studies are non-randomised controlled studies or a comparison of care 
before and after a new pharmacist-led service has been put into place. 
There have been some papers that have compared the pharmacist service against the 
standard medical care for both in-patient90, 136-137, 139-142, 144 and out-patient 
management.83- 84, 145-147, 157  
In a UK non-randomised study based in five wards in Brighton General Hospital144 in 
2004, two wards were under pharmacist control of warfarin dosing and three wards 
remained under the care of the doctors. Data was collected for 11 months and a total 
of 33 patients were recruited into each arm. Pharmacists prescribed more appropriate 
loading and maintenance dosing according to protocols compared to doctors, which 
resulted in more patients reaching their target INR sooner. Documentation of 
indication, duration of treatment and target INR was also much improved compared to 
medical staff. However, more patients (73%, n=22/30) in the doctor’s group were 
within range on discharge and at the out-patient clinic (79%, n=19/24) compared to 
the pharmacists (68%, n=19/28 and 61%, n=13/21 respectively). Significantly fewer 
patients dosed by pharmacists had episodes of over or under-coagulation (91%, 
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n=30/33 vs 67%, n=22/33) (F (1,64)= 6.17, p=0.016) and fewer INR tests were 
requested (2.3/patient/week) compared to those dosed by doctors (2.7) (no statistics 
were quoted as to whether this difference was statistically significant). Patients under 
the control of pharmacists also had fewer adverse events (6%, n=2/33 vs 12%, 
n=4/33). Therefore it appeared that pharmacist dosing of warfarin for in-patients had a 
beneficial effect on most aspects of anticoagulation control which provides some 
evidence to support this extended role. However, it should be noted that the numbers 
of patients recruited into this study was poor as only 33 patients were recruited into 
each arm of the study over a period of 11 months. Further recruitment of patients may 
have allowed more explanation of why doctors managed to get patients into range 
more often on discharge and in out-patients than pharmacists did.  
This study also does not state who judged the appropriateness of the prescribing and 
whether there was any analysis of why the protocol was not adhered to in such cases. 
There is only one study (USA) that could be found which is a randomised controlled 
study (RCT),160 where the management of anticoagulant therapy for hospitalized 
patients by seven certified pharmacist prescribers and one physician was compared. 
Eighty-one consecutive patients referred to the anticoagulation service were randomly 
assigned to two groups. For patients in the pharmacist-prescriber group, the physician 
independently monitored laboratory results and recorded heparin and warfarin doses 
that he would choose to administer, whilst the doses that the pharmacist chose to give 
were administered to the patient. The roles of pharmacist and physician were reversed 
for patients in the physician-prescriber group. There were no significant differences in 
the mean heparin and warfarin doses administered to patients in the two prescribed 
groups. The authors concluded that while the results are not applicable to all 
pharmacists or all settings, the certified pharmacist prescribers in this study adjusted 
anticoagulant therapy as well as an experienced physician. 
More recent studies have been able to provide evidence that pharmacist-managed 
anticoagulation clinics are effective over a longer period of time. Willey et al158 
(2003) (USA) found that amongst patients that attended a pharmacist-managed 
anticoagulation clinic over the six-year period from when it first started that an 
estimated 40-60% of International Normalised Ratio (INR)s were within the targeted 
range, a frequency which is consistent with that achieved by non-pharmacist managed 
clinics.  
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2.7.1.2 Pharmacist anticoagulant services are safer than usual care 
 
To examine this aspect of care, bleeding complications and the safety of the therapy 
have been examined. This has been measured by numerous endpoints including, 
INR>6, sub-therapeutic INR, bleeding rates, readmission due to bleeding and 
incidence of sub-therapeutic and supra-therapeutic events. 
Chiquette et al (USA) compared newly anticoagulated patients who were treated with 
usual medical care (n=183) with those treated at a pharmacist-led anticoagulant clinic 
(n=145). They reported that the pharmacist group had lower rates (%/patient year) of 
significant bleeding (8.1% n=9.9 patient yrs vs 35%, n=36 patient yrs), major to fatal 
bleeding (1.6%, n=1.9 patient yrs vs 3.9%, n=3.9 patient yrs), and thromoboembolic 
events (3.3%, n=4.1 patient yrs vs 11.8%, n=12.0 patient yrs). The pharmacist-treated 
group also had a significantly reduced rate of warfarin-related hospitalisations.145 
Garabedian-Ruffalo et al149 (USA) describe a before and after study of 26 patients 
which found that patients who’s warfarin dosing was controlled by a specialist clinic 
ran by pharmacists had a reduced number of hospitalisations (39%, n=10 versus 4%, 
n=1) when compared to their previous, standard medical care. Also the percentage of 
prothrombin times outside of the target range were significantly lower (14.4% versus 
35.8%). However, this was a small study in terms of numbers of patients but did last 
for 30 months. Another problem is that the patients acted as their own controls and 
there was no blinding.  
Dager et al137 (USA) reported a comparison of a historical cohort of in-patients 
starting warfarin therapy prescribed by doctors versus a prospective cohort matched 
for treatment indication, on warfarin started by pharmacists. They found that the 
number of patients and patient-days with INR values>6.0 were reduced by pharmacist 
dosing from 20 patients and 50 days to 2 patients and 6 days, respectively (p<0.001). 
The design of this study would have been improved by having an active control group 
who were also observed prospectively at the same time as the intervention group. 
There may have been other external factors affecting the intervention group three 
years after the historical cohort making them non-comparable. 
Witt et al157 (2005) (USA) carried out a retrospective, observational cohort study 
where they compared a clinical pharmacy anticoagulation service (via the telephone) 
to standard doctor care. They found that those patients looked after by the clinical 
pharmacy services were 39% less likely to experience an anticoagulation therapy 
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related complication when compared to the control group. Additional analyses 
revealed that improved outcomes associated with the clinical pharmacy service were 
mediated largely through improved INR control. 
This study was not randomised and also the control group was composed of patients 
from two different settings and from two different time periods which could introduce 
some bias to the results as one group had paper records and the other had electronic 
records. It is also not clear whether the authors considered the issue of patient 
compliance with medication- the telephone service may have induced a “Hawthorn 
effect” where some people work harder and perform better when they are participants 
in a study- i.e. they comply with their medication more than usual. 
Locke et al155 (2005) (USA) undertook a retrospective cohort analysis in a 300 bed 
community hospital where they compared adverse events related to anticoagulation in 
patients assigned to a pharmacist-managed anticoagulation service versus those 
receiving usual care. There were more adverse events requiring hospitalisation in the 
control group (n=14) versus the pharmacist managed group (n=3) (p=0.0153)  
However, it should be noted that Rivey et al140 (USA)found that the only cases of 
major bleeding occurred in patients being treated by pharmacists following a protocol 
(n=4/151). 
The most significant research to suggest an improved safety for patients receiving 
pharmacist-managed anticoagulant services when compared to usual care was a 
retrospective cohort analysis of 717,396 Medicare patients treated in 955 hospitals in 
USA for conditions requiring anticoagulant therapy.154 They found that in hospitals 
without pharmacist-provided warfarin-management, death rates were 6.2% higher 
(p<0.0001), length of stay was 5.86% higher (p<0.0001), bleeding complications were 
8.09% higher (p<0.0001) and the transfusion rate for bleeding complications was 
22.49% higher (p<0.0001). The authors state that these findings are significant for the 
healthcare system considering that the study population represents 28.25% of 
hospitalized Medicare patients who should receive anticoagulants and that total 
Medicare admissions represent 35.02% of total admissions to US hospitals. Although 
the benefits reported in this study were considerable, there was only a 30% 
(n=1109/3701) response rate from eligible hospitals and the pharmacy-managed 
cohort comprised just over 10% (97/955 hospitals, 84,219/633,177 patients) of the 
patients and hospitals analysed. The participating hospitals were not categorized nor 
were other potential confounding factors discussed (e.g. patient demographics, 
 76 
availability of specialist physicians)156 It is not clear whether the differences seen in 
this study are actually due to the pharmacists themselves. The study design allowed 
determination of associations and direct relationships between variables but does not 
allow causality to be determined. Hospitals with pharmacist-led clinics may for 
instance, be more innovative and hence may have more confident specialists. 
Therefore further study would be required to see if these results can be replicated. 
 
2.7.1.3 Patient satisfaction with anticoagulant services 
 
In the study discussed earlier by Willey et al158 (2003) (USA) they also assessed 
patient satisfaction with the pharmacist-lead anticoagulation service. They sent 
satisfaction surveys to all 742 patients that had attended the clinic over the six years it 
had been operational and to 77 referring doctors. This elicited a response rate of 
n=355 patients (48%) and n=26 doctors (38%). The researchers rated satisfaction with 
the clinic via a 5-point Likert scale and found that both patients and doctors were very 
satisfied with the clinic. The patient’s greatest complaint about the clinic was the need 
to travel to the clinic to have a blood sample taken. The doctors stated that they were 
pleased with the level of care provided by the clinic and also believed that it 
decreased their workload. 
The response rate is poor for this study and the paper gives no information as to how 
the questionnaire was developed, validated and piloted. The paper states that many 
returned questionnaires were incomplete which would suggest that the design of the 
questionnaire had not been thoroughly developed. Therefore the level of confidence 
that could be attributed to this data would be low. 
Lodwick and Sajbel161 (USA) also assessed the satisfaction of their facilities’ 
pharmacist-managed anticoagulation clinic via a questionnaire sent to their patients 
and referring doctors. 34/44 patient questionnaires were returned (79%) and 21/41 
doctor questionnaires (51.2%). The researchers found that there were high levels of 
both patient and doctor satisfaction and both groups appeared to be satisfied with the 
pharmacist’s ability to provide accurate and timely information regarding coagulation 
status. It should be borne in mind that this study had a small sample size and the 
results are limited to this particular clinic and pharmacist. Also there may be some 
positive bias as one of the authors actually ran the clinic themselves, so patients and 
referring doctors may have felt this bias when answering the questionnaires. 
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Calcagno et al162 (USA) assessed patient satisfaction with a pharmacist-managed 
anticoagulant clinic (Response rate: n=156/217, 72%) versus a group of patients who 
saw their doctor for their warfarin (Response rate: n=66/128, 52%. However n=10/66 
only answered the comments section and so the results were not included in the 
statistical analysis). A significantly higher percentage of clinic patients (pharmacist-
managed) were more often “very satisfied” with the items on the survey, and a 
significantly higher percentage of patients in this group “strongly agreed” that their 
overall experience was excellent (n=117, 79% vs n=27, 55%). They conclude that 
traditional warfarin management can be improved by facilitating patient access, 
providing continuous patient education and offering efficient feedback. 
Therefore there is some evidence that indicates patient and doctor acceptance of 
pharmacists managing anticoagulation. However, the generalisability of these results 
to the UK and to our health system is doubtful. 
 
2.7.1.4 Pharmacist anticoagulant services are cost-effective 
 
Ten studies were found to have analysed cost-effectiveness of pharmacist-led anti-
coagulation. However, only two of these are UK studies (the rest are from USA), 
therefore the studies from USA are not discussed in detail as the results of the 
American papers are difficult to translate to the UK. 
The outcome measures utilised have included reduced total hospital costs, benefit: 
cost ratio, reduction in heparin costs and tests per 7 days, savings per 100 patients per 
year, cost avoidance and total costs of hospitalisation. 
 
Macgregor et al87 described their evaluation of a pharmacist-led anticoagulant clinic 
set up in a UK GP practice. The authors found that the direct costs to the practice of 
the clinic, including the cost of the pharmacist, the tests, and the cost of the 
coagulometer, were less than that charged to fund holders for each hospital 
appointment. Surgery attendance cost less for 48% of patients and more for 4%. 
Travelling time was less for 64% and greater for 20%. Most patients lived near the 
surgery, eliminating the need for an estimated 27 ambulance trips a year. However, 
these costs would have been made by any healthcare professional running the clinic in 
this setting. No methodology was reported for calculating these costs savings. Also 
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the author of the paper ran the clinic herself so there may have been some positive 
bias in the reporting of the results. 
The other UK study (2003) investigated the use of resources and cost implications of 
stroke prophylaxis with warfarin in non-valvular atrial fibrillation patients referred to 
a pharmacist-led anticoagulant outpatient service. The participants were interviewed 
in person at their first visit and then by telephone every 4 to 6 weeks by an 
investigator. They were asked about bleeding events and extra physician visits, 
procedures, or hospital admissions related to bleeding. They were also asked about the 
method and the cost of transportation to the anticoagulation clinic and the costs 
involved in days of work missed by the patient and caregiver. Costs of warfarin 
treatment consisted of the following: (1) cost of the drug, (2) cost of monitoring, 
international normalized ratio, travelling, nurse visits, work missed, postage) and (3) 
costs associated with complications (i.e., bleeding-related physician visits, hospital 
admissions, related procedures) admissions and related procedures. A total of 402 
patients were included. 
The mean cost of warfarin treatment per patient per month was £11.00 (95% CI, 
10.2–11.6) in patients with no bleeding and £11.90 (95% CI, 10.30–12.50) in patients 
with minor bleeding (p = NS). The cost was significantly higher in patients with 
major bleeding (£299.00; 95% CI, 74.60–538.90; P < 0.001). The total cost of 
warfarin treatment per patient per year was £159.40, and the cost to prevent 1 stroke 
per year was £5260.20 in 2003.163 Unfortunately these costs were not compared to 
usual care via a doctor to determine the cost effectiveness of using a pharmacist. 
Anderson159 (2004) (USA) undertook a retrospective analysis of data from patients 
who had attended a pharmacist-managed outpatient anticoagulation service with 
chronic atrial fibrillation (AF). The cost per patient per month was determined (n=97) 
as being $51.25, distributed as 27% in personnel costs, 36% for lab tests and 37% for 
anticoagulant drug costs. Unfortunately this study also did not compare costs to usual 
care via a doctor to determine the cost effectiveness of using a pharmacist. 
One study (2005) (USA) did not undertake an economic evaluation of the pharmacist-
managed anticoagulation service, but did note that as the control group of patients 
undergoing usual care accrued 64 more hospital days due to adverse events when 
compared to the pharmacist-lead care, this would result in costs savings.155 
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The large retrospective cohort study by Bond et al154 (2004) (USA) did state that 
Medicare charges were 2.16% higher ($234,275,490) in hospitals that did not have a 
pharmacist managed warfarin management service (n=633,177). 
A review of published literature (2006) (USA) regarding pharmacist-managed 
anticoagulation has concluded that with regards to the cost effectiveness of such 
services, it appears likely that pharmacy-managed services do provide financial 
advantages over other approaches but is critical of the research published in this area 
as well. This review states that you cannot extrapolate from small or flawed studies 
such as those available thus far.156  
 
2.7.1.5 Pharmacist anticoagulation improves patient knowledge   
 
There are only 2 articles that could be found that have investigated the effects of 
counselling by the pharmacist on patient knowledge regarding warfarin therapy. They 
are both UK research papers.  
Macgregor et al87 reported that they assessed patient knowledge via a questionnaire 
during their initial visit. Knowledge was then re-assessed after three months to see 
whether the counselling during the clinic appointments had improved the patient’s 
knowledge. The review did show improved knowledge. However, the study did not 
state any of the methodology used, or the results. Also, they used patients as their own 
controls so this does not provide evidence that it is pharmacists per se that have 
improved the patient’s knowledge, but just that by receiving information they have 
improved their knowledge. Also some bias may have been introduced as it is not clear 
whether the patient’s knew they were going to be assessed at the end of the study and 
so may have revised. 
Radley et al86 described the establishment and evaluation of a pharmacist-led 
outpatient anticoagulant service. A counselling standard was incorporated into their 
clinic documentation, in order to educate the patients. An audit was then undertaken 
of the effectiveness of their counselling programme. Patient knowledge of diagnosis, 
warfarin side-effects etc. was audited via an interviewer-administered questionnaire. 
The questionnaire was piloted amongst 15 patients. 100 patients were then 
interviewed over a 5 week period with the questionnaire to ascertain their knowledge. 
Several areas of knowledge were found to be lacking, including the signs of over-
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dosage and effects of other illnesses. However, no baseline data is available to 
ascertain how the patient’s knowledge had improved. 
 
In a review of published literature (2006) regarding pharmacist-managed 
anticoagulant clinics156 the researchers state that the evidence indicates the efficacy of 
pharmacy-managed in-hospital anticoagulation and that reported outcomes seem to be 
at least equal, if not superior to those obtained through standard (doctor) care. There is 
some suggestion that pharmacy-managed anticoagulation saves money and doctor 
time, however the quality of the design of these studies is poor. They also state that 
due to this, the apparent superiority of the pharmacist’s results in some studies may be 
a result of stricter adherence to guidelines and protocols as opposed to anything else. 
The authors therefore suggest that if this is the case, then the ideal method may not be 
to rely solely on either doctors or pharmacists but to adopt a multidisciplinary 
approach. 
Overall, as this is the pharmacist prescribing area which has the most substantial body 
of research to support it, it is encouraging that the performance of the pharmacists in 
this role has been found to be at least as effective as doctors. 
 
2.7.2 Pharmacist-led specialist clinics (non-anticoagulation) 
 
A total of 55 papers upon pharmacist-led clinics could be found. The majority of the 
research published is American. Published UK-based clinic descriptions/studies have 
included the clinical areas of diabetes, psychiatry, heart failure, cardiac, gynaecology 
and surgical pre-admission clinics. Quite a few of the published papers only describe 
the service that was provided as opposed to assessing the service provided in a 
meaningful way. 
The clinical areas which provide the most publications are for lipid clinics, 
hypertension clinics and diabetic clinics. 
 
2.7.2.1 Pharmacists prescribe at least as effectively as other health care professionals  
 
Twelve articles could be found about the role of the prescribing pharmacist in a lipid 
clinic. Effectiveness was based upon changes in lipid parameters. Six of these papers 
compared the lipid control by the pharmacist to that of a medic. 
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Bozovich et al164 (USA) compared the care of one group of patients with coronary 
heart disease who were treated in a pharmacist-managed lipid clinic (n=104), to a 
group of control patients with coronary heart disease who were provided with usual 
care via a cardiologist (n=101). A clinical protocol was drawn up by the pharmacist 
and agreed by a cardiologist (different from the cardiologist looking after the control 
group). The protocol aimed to reach National Cholesterol Education Program low-
density lipoprotein (LDL) goals. 
The patients were followed for at least 6 months. At the end of 6 months, 69% 
(72/104) of patients in the pharmacist-managed group achieved their LDL goal 
opposed to 50% (36/72) in the control group (p=0.016). Compliance with laboratory 
tests and also medication compliance improved in the pharmacist-managed group. 
The drawbacks of this study were that it was of a short duration, so long-term 
effectiveness cannot be assessed. 
 
Geber et al165 (2002, USA) also compared the effectiveness of pharmacist-managed 
care of patients with coronary heart disease via attainment of LDL goals with that of 
usual medical care. The researchers retrospectively reviewed the drug charts and 
blood results of 75 patients in each group. They found that there was statistically 
significantly lower LDL levels in the pharmacist-managed group compared to the 
medic group (92.5mg/dl compared to 112.5mg/dl in the medic group p<0.05). The 
authors suggested that this was due to a failure to titrate the statin dose appropriately. 
They also suggest that the lower LDL levels may have arisen from the fact that the 
patients in the pharmacist-managed group saw a health-care provider more often as 
the pharmacist-managed clinic was provided on top of the patient’s normal follow-up 
appointments. This may have biased the results considerably. 
 
A more recent American study (2006) evaluated the effect of a clinical pharmacy 
service on lipid control in patients with peripheral arterial disease, and had a longer 
follow-up (mean 17.1 months). The authors established a pharmacist-managed, 
physician-monitored algorithmic approach to the outpatient management of this group 
of patients. From a cohort of 691 patients, 90 patients were enrolled in the lipid 
service (study group) and 601 received standard (physician-led) care. Patients with 
validated peripheral artery disease but without clinically evident coronary artery 
disease at one (of sixteen) randomly selected regional medical offices were enrolled 
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into the intervention group. All the other patients received standard care (control 
group). Pharmacists were allowed to initiate statins in the intervention group. 
Screening fasting lipid profiles were found in 95.6% (86/90) of patients in the study 
group and only 66.9% of the standard care patients (P<0.0001). Low density 
lipoprotein cholesterol (LDL-C) control was improved in the pharmacist-managed 
group, with 79.1% (68/86) achieving an LDL-C of less than 100mg/dl in comparison 
to the standard care group (54.8% (219/400); p<0.0001). An LDL-C value of 
>130mg/dl was noted in 1.2% and 14.0% (56/400) in the treatment and control groups 
respectively (P<0.001). Statin use was present in 51.9% (312/601) of the control 
group patients and 84.4% (76/90) of the pharmacist –managed group (P<0.001). The 
authors conclude that the pharmacist-managed clinic provided improved compliance 
with national guidelines166 and hence would suggest better patient outcomes. 
The authors do not discuss why there is such a large control group compared to the 
intervention group. Therefore it is difficult to establish whether the results are over or 
under representative of the real impact that this intervention has. 
 
A similar study (2005) (USA) compared patient outcomes of patients with 
dyslipidaemia who either attended pharmacist-managed lipid clinics (n=115) or 
received usual care from their physician (n=115). The patients were followed up for at 
least 6 months from their initial visit. The researchers found that nearly two-thirds of 
patients diagnosed with dyslipidaemia and enrolled in a pharmacist-managed lipid 
clinic had LDL-C levels at or below 2001 National Cholesterol Education Panel Adult 
Treatment Panel III guidelines targets compared with 16% of dyslipidaemia patients 
who received usual care. The pharmacist-managed clinics were also twice as likely 
(83 vs 41%) to have attained the total cholesterol (TC) goal.167  
It is apparent that the studies reviewed have produced benefits in terms of reductions 
in LDL-C levels, TC level and statin use, but further studies are necessary to establish 
how these impact upon hard clinical end points such as coronary events and death 
rates and also cost-effectiveness.  
 
Seven articles were found upon hypertension clinics, and two of these were 
randomised controlled trials;  
Okamoto et al168 compared one group of patients receiving care from a pharmacist-
managed hypertension clinic (n=164) versus a group having the usual medical care 
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(n=166). Pharmacists had to determine the most appropriate antihypertensive regimen 
for the patient. Their assignment was to rationalise the patients’ medication in order to 
obtain similar or improved blood pressure control. The pharmacists had to contact the 
patient’s physician in order to obtain consent for the changes they proposed. The 
physicians were told not to change the drug therapy unless a lack of intervention 
would have been dangerous for the patient. They compared the blood pressure 
readings of the patients at baseline, and then after 6 months care at the clinic. The 
authors found that there was a statistically significant lower mean systolic and 
diastolic blood pressure in the pharmacist group versus the medic group (p<0.001). 
However this study is limited as it is of short duration and is based upon differences in 
two sets of blood pressure readings. It would also have been preferable to study 
patients that had been newly diagnosed with hypertension so that previous treatment 
did not affect outcome. 
 
Vivian169 (2002, USA) also compared hypertension management by a pharmacist-led 
clinic (n=27) versus physician management (n=29). The pharmacist made appropriate 
changes to medication, adjusted doses and counselled patients on their medication. 
They also found a statistically significant lower blood pressure outcomes in the 
pharmacist group- Twenty-one (81%) of patients in the intervention group attained 
their blood pressure goal of below 140mmHg at completion of the study versus eight 
patients (30%) in the control group (p<0.0001). However, this study included a very 
small number of patients and was of short duration. Also, it was conducted in only 
one clinical setting, which limits the ability to extrapolate the results to other settings, 
it was also un-blinded. Another factor which could have led towards better control of 
blood pressure in the intervention group was that the pharmacists spent on average 
30-45 minutes with each patient whereas the doctor spent only 20 minutes. 
 
Further evidence of the effectiveness of pharmacists as prescribers can be found 
amongst published studies of pharmacist-run diabetic clinics. Seven such papers could 
be found, two of which were randomised controlled trials;  
Jaber et al170 (USA) assessed the effectiveness of a pharmaceutical care model on the 
management of non-insulin dependent diabetes mellitus (NIDDM). Patients were 
randomised to either a pharmacist intervention (n=17) or control group (n=22 normal 
physician care) and followed for a 4-month period.  Patients in the intervention group 
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received diabetes education, medication counselling, instructions on dietary 
regulation, exercise, and home blood glucose monitoring, and evaluation and 
adjustment of their hypoglycaemic regimen (dosage increases, reductions and 
alterations were made by the pharmacist). 
To evaluate effectiveness of the pharmacist-prescriber, the primary outcome measures 
were fasting plasma glucose and glycosylated haemoglobin concentrations. The 
researchers found that there was a significant improvement in the glycosylated 
haemoglobin (p=0.003) and fasting plasma glucose (p=0.015) was achieved in the 
intervention group, and no change in glycaemia was found in the control group. 
However, this study was of a short duration and had a small number of patients in the 
study as well, hence sustained, long-term effectiveness of this model is unknown. The 
pharmacists involved had a large time allocation to their group of patients-the authors 
state that this may preclude management of a larger patient load. 
 
Scott et al171 (2006) evaluated the outcomes of a pharmacist-managed diabetes care 
service in an American community health centre. Patients were randomly assigned by 
the clinical pharmacist and nurse to the intervention group (n=76) who were enrolled 
into a pharmacist-managed diabetes care program or a control group (n=73) who 
received standard care (physician-led). The pharmacist undertook medication review, 
implemented changes and could initiate aspirin. The pharmacist did not adjust 
medications via a protocol. The study found that mean glycosylated haemoglobin 
(HbA1c) levels fell significantly (p<0.05) from baseline to nine months in both 
groups. A difference of 1.0 was reported between the group’s HbA1c levels (95% 
confidence interval, 0.08-1.78; p<0.05). Secondary outcome measures including 
systolic blood pressure, LDL-C levels and quality of life measures were improved 
compared to the control group and the patients met treatment goals more often than 
the control group. The authors do concede that as the intervention group was not 
blinded at the health centre, leading to a potential site-interaction effect which may 
have allowed other “usual care” providers to implement more aggressive care, leading 
to a reduction in HbA1c in the control group as well as the intervention group. As 
with the previous study, this study was of a short duration and had a small sample 
size. The extra feedback and monitoring that the intervention and control group 
received may have also caused a “Hawthorn effect” whereby both groups put more 
effort into controlling their diabetes, and hence led to an improvement of their 
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glycosylated haemoglobin levels.  The pharmacists involved also had a large time 
allocation to their group of patients-which may preclude management of a larger 
patient load. 
 
Coast-Senior et al172 reported of their before and after study of pharmacist 
management of  patients with NIDDM. The pharmacists provided diabetes education, 
medication counselling, monitoring and insulin initiation and/or adjustments. Patients 
were referred to 4 pharmacists in 2 primary care clinics over an 8 month period 
(n=23). The primary outcome measures were changes from baseline in glycosylated 
haemoglobin, fasting blood glucose and random blood glucose measurements. 
Glycosylated haemoglobin, fasting blood glucose concentrations, and random blood 
glucose concentrations significantly improved. However, the author’s state that the 
level of glycaemic control achieved was unacceptable for the majority of patients. It is 
suggested that this was due to the short mean follow up period of 27 weeks. Also the 
patients recruited to the study tended to be older men with multiple medical problems 
upon multiple medications, and therefore were more difficult to gain glycaemic 
control. Patient numbers in this study were very small and the study was not 
randomized or controlled. 
 
McCord173 (2006) undertook a retrospective chart review of patients referred to a 
pharmacist-managed diabetes mellitus drug therapy management service. This study 
had a more substantial sample size compared to other studies reviewed (n=316). It 
was found that the mean reduction in HbA1c was 1.4% (SD=1.94) (p<0.001) the 
percentage of patients whose HbA1c was at goal level at baseline (< 7%) increased 
from 14.8% to 43.2% (p<0.001). Mean LDL level reduction was 14 (SD= 41.1) 
(p=0.002), mean triglyceride level reduction 42 (SD=97.6) (p<0.001). The percentage 
of patients who reached goal for LDL level (< 100 mg /dl), HDL level (> 40 mg/dl), 
and blood pressure (< 130/80 mm Hg) did not increase significantly from baseline, 
whereas those who reached the triglyceride level goal (< 150 mg/dl) increased from 
36% to 55% (p<0.005). Frequency of annual dilated retinal examinations and 
monofilament foot examinations increased by 29% (p<0.05) and 12.5% (p<0.05), 
respectively. Daily aspirin use increased from 35% to 59% (p<0.05). 
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The service provided at this site was interdisciplinary and it therefore introduces a 
potential confounding influence of other providers and means that the clinical 
improvements found may not be attributed to the clinical pharmacist service alone. 
 
Therefore it is apparent from the literature reviewed in this clinical area that further 
randomised controlled studies are necessary, with larger sample sizes in order to 
establish the benefits of a pharmacist-led service and to establish its cost-
effectiveness. 
 
2.7.2.2 Pharmacist prescribing in specialist clinics is cost-effective 
 
Evidence to prove the cost-effectiveness of this type of prescribing was fairly limited 
with seven papers mentioning cost savings, although the majority of these provided 
no methodology.  
Okamoto et al168 (USA) evaluated the cost-effectiveness of a pharmacist-managed 
hypertension clinic. Total costs consisted of aggregate managed care costs for any 
health care service provided plus drug costs for each patient. Cost-effectiveness ratios 
were calculated using total costs/mmHg of blood pressure decreased. 
The authors found that in the pharmacist-managed hypertension clinic group, 
marginal cost-effectiveness ratios were lower for both systolic and diastolic blood 
pressures. However, the costs associated with clinic visits were statistically higher in 
the pharmacist-managed group (p<0.001). 
 
More recently, an American paper (2006) has been published in the clinical area of 
epilepsy which focused on economic outcomes. Bond and Raehl174 evaluated 
pharmacist-managed antiepileptic drug therapy in a study population of 9380 
Medicare patients diagnosed with epilepsy or seizure disorders treated in 794 US 
hospitals. They reported that for hospitals without pharmacist-managed antiepileptic 
drug therapy, Medicare charges were 11.19% higher, with $14,372,550 in excess total 
charges. Per patient, drug charges were $115 higher and laboratory charges were 
32.24% higher. The authors conclude that the increased costs in hospitals without 
pharmacist-managed antiepileptic drug therapy are substantial. Given the clinical 
improvements that are also made by these clinics in patient outcomes they advocate 
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that pharmacist-managed antiepileptic drug therapy should be an integral component 
of core services in hospitals. 
 
Another American paper (2005) focused on economic outcomes of a pharmacist-
managed aminoglycoside or vancomycin therapy service, where pharmacists 
monitored and amended doses of the aminoglycoside/vancomycin by following 
protocols. The service was evaluated in a study population of 199,082 Medicare 
patients treated in 961 hospitals. In hospitals that did not have the pharmacist-
managed service, total Medicare charges were 6.3% higher ($140,745,924 in excess 
total Medicare charges (p<0.0001), drug charges were 8.15% higher ($34,769,250 in 
excess drug charges (U=4.785 x 109, p<0.0001) and laboratory charges were 7.80% 
higher ($22,530,474 (U=4.860 x 109, p<0.0001). The authors conclude that due to 
these cost savings, pharmacy directors and clinical co-ordinators should develop these 
services as an integral component of their core services.175 
 
Therefore there is some evidence to suggest that certain pharmacist-led specialist 
clinics offer economic benefits over usual physician care. It is however, unclear 
whether any published evidence is translatable to the United Kingdom model of 
healthcare. It is also unclear whether these savings made are due to the fact that it is a 
pharmacist running these clinics or whether any other health care professional given 
the same amount of time could also produce such cost savings. 
 
2.7.2.3 Patient satisfaction with pharmacist-managed clinics 
 
Five studies evaluated patient satisfaction with the service, although three of these did 
not provide any methodology. The two studies that did discuss their methodology in 
detail are therefore discussed below. 
Vivian et al 169 evaluated patient satisfaction with a pharmacist-managed hypertension 
clinic via a questionnaire survey which had been previously developed in another 
study. They did not find any statistically significant differences in patient satisfaction 
between the intervention and control groups. In the intervention group, 88% (n=23) 
were satisfied with pharmacy services versus only 68% (n=18) in the control group 
(p=0.098). This was a very small study of only 56 patients in total. A critique of this 
study was discussed earlier (p 83). 
 88 
Capper et al93 assessed patient satisfaction with a pharmacist-led rheumatology drug 
monitoring clinic via a questionnaire. A response rate of 97% was achieved (n= 
61/63). Overall, 90% of respondents were satisfied with the service provided by the 
pharmacist, with the only negative comments being about the waiting time. This was 
only a small study, and did not have any previous data to compare the results with in 
order to establish whether satisfaction had improved. There was also no statistical 
analysis of the results. 
Hence there is a lack of evidence to allow rigorous assessment of pharmacist-led 
clinics. 
 
2.7.2.4 Evidence to support the role of the pharmacist in pre-admission clinics  
 
Another form of pharmacist prescribing which has been widely reported is that of 
pharmacist prescribing in pre-admission clinics.76-78, 80, 82, 176-179 Eight articles were 
found which reported the pharmacist role in surgical pre-admissions clinics. One of 
these was a non-randomised controlled study,78 one was a randomised controlled 
trial179 and the rest were descriptions of the activities occurring within the clinics. 
Where this review has been updated to include literature post-2002, (when the first 
phase of the research for this thesis was developed) the year of the paper will be 
highlighted. 
 
At these clinics, two different prescribing activities were performed. Pharmacists 
wrote the patients normal medication onto the in-patient drug chart, to be used when 
the patient arrives at hospital, and also wrote the patients discharge prescription 
during the clinic, so that it can be dispensed as soon as the patient arrived at the 
hospital. This avoids any delays that may have occurred in the previous system, when 
the patient waited for their discharge medication to be dispensed after the discharge 
decision was made. 
The randomised controlled trial was an American study (2007),179 in a single hospital 
setting which sought to measure the discrepancies associated with a combined 
intervention of structured pharmacist medication history interviews with assessments 
in a surgical preadmission clinic and a postoperative medication order form. Eligible 
patients were randomly assigned to the intervention arm (n=227) or to the standard 
care arm (n=237) (nurse-conducted medication histories and surgeon-generated 
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medication orders). The primary end-point was the number of patients with at least 
one postoperative medication discrepancy related to home medications. In the 
intervention arm, 41 (20.3%) of 202 patients had at least 1 postoperative medication 
discrepancy related to home medications, compared with 86 (40.2%) of 214 patients in 
the standard care arm (p<.001). In the intervention arm, 26 (12.9%) of 202 patients 
had at least 1 postoperative medication discrepancy with the potential to cause 
possible or probable harm, compared with 64 (29.9%) of 214 patients in the standard 
care arm (p<.001). These were mostly omissions of reordering home medications. The 
authors concluded that a combined intervention of pharmacist medication assessments 
and a postoperative medication order form can reduce postoperative medication 
discrepancies related to home medications. As this study was undertaken at one centre 
only, the generalisability of the results is limited. 
 
Hick et al78 recruited 100 elective general surgery patients, and separated them into 
two groups of 50 as part of a non-randomised controlled study. The groups were 
comparable for age, surgical procedure and use of medicines. The control group 
received standard ward pharmacist visits, and the intervention group were seen by the 
pharmacist in a pre-admission clinic. In the pre-admission clinic, the pharmacist took 
a patient medication history, wrote the patient’s normal medication upon the in-
patient drug chart, and any medications routinely needed for the procedure. The 
pharmacist also wrote the patient’s discharge prescription. Also the pharmacist 
assessed the appropriateness of the patient’s own drugs for use in the hospital, advised 
the clinicians on which drugs needed to be stopped pre-operatively, recorded any 
clinical interventions and counselled the patient. The doctor always co-signed the 
drug chart and prescription. Outcome measures included the number of interventions 
and clinical significance using a visual analogue scale. Peer review analysis from 
other pharmacists revealed a statistically significant higher intervention score in the 
intervention group (p=0.003). The authors commented that although this clinic 
released junior doctor time, the cost of a suitably qualified pharmacist to undertake 
this activity was greater than a junior doctor. They also note that although this was an 
effective method of preventing prescribing errors, cost-effectiveness still needs to be 
proven. 
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Several reports suggest the benefits of pharmacist-led pre-admission clinics (including 
avoidance of cancelled operations)77 but there is little quantitative evidence to support 
this.  
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2.7.3 Writing discharge prescriptions 
 
In the mid 1990’s it was apparent that there were many problems and inefficiencies 
with the way pharmacy services were being provided within secondary care.180 A new 
model of practice was published which suggested that pharmacists ought to write 
discharge prescriptions, earlier in the patient’s stay, so that when a discharge decision 
was made, the patient’s take home medication was ready.102   
A questionnaire survey by Sexton et al from 1999 sought to identify the services that 
hospital pharmacies were providing to facilitate seamless care upon discharge. It was 
the first survey to quantify how frequently pharmacists were involved in writing 
discharge prescriptions within secondary care in the UK. It established that in 
approximately a third of hospitals, pharmacists were involved in the task, but their 
overall impact was almost negligible.67 
Considering that Sexton suggests that a third of all hospitals in 1999 had pharmacists 
involved in discharge prescribing, there have been relatively few studies published in 
this area. All of the published research upon pharmacist prescribing has been reports 
from single hospitals (n=7), and only one of these was an American study, the rest 
originating from the UK. Three reports have been about pilot studies,72, 74, 99 one 
report was a before and after study,181 there were two controlled studies70- 71 and one 
randomised controlled study.75 
The studies have taken place mainly on medical wards, but also a couple of surgical 
wards and also one combination of both. The studies lasted between one to four 
months, and four of these studies compared the pharmacists providing this service to 
doctors. 
There have been several outcomes measured from these studies: 
 
2.7.3.1 Increased timeliness of the discharge prescription   
 
Five studies used timeliness of the prescription as an outcome measure, and the 
studies indicated that pharmacist-written discharge prescriptions were timelier than 
those written by doctors. 70- 74, 75, 99, 181 
In 2001, Cattell et al75 recruited 68 patients from one surgical and one medical ward at 
the Bristol Royal Infirmary. Patients were assigned to have their discharge medication 
organised either by a pharmacist (intervention group) or by the existing system 
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(control group). Information relating to a variety of prescription processing times, 
together with data on clinical interventions and use of patient’s own drugs, was 
recorded for each group. 
Sixty-eight patients were recruited from one surgical ward and one medical ward at 
the hospital. Wards were randomised into two 12-bed areas, and allocated as 
intervention and control sites. Data collection forms were collected over a period of 
eight weeks. 
The key findings were that median discharge prescription processing time (time from 
discharge decision to patient discharge) was significantly less in the intervention 
group than in the control group (322 vs 460 min p=0.056). The median discharge 
prescription dispensing time was significantly greater with the existing system than 
when the discharge pharmacist transcribed prescriptions (240 vs 177 min p=0.005). 
The authors conclude that the integration of a pharmacist into the discharge system 
improves the timeliness of discharge, benefiting hospital bed management. Significant 
reductions in drug wastage and release of medical time were also apparent using this 
process.75 
Although this study is the only randomised controlled trial that has been undertaken in 
this area, and was statistically validated, the sample size was small (n=68) and the 
study period was only 8 weeks. 
 
In April 2001, Hammersmith Hospitals NHS Trust published a report describing a 
pilot study of their discharge pharmacist service. The service ran from December 
1999 to March 2000. The discharge pharmacist post provided the service to five 
medical wards at the hospital. The discharge pharmacist was involved in 244 
discharges (36%). However, the pharmacist transcribed only for 102 discharges, the 
other discharge involvement was with counselling and scheduling of the prescription. 
The researchers found that the pharmacist-transcribed prescriptions were available for 
dispensing a median of one day in advance of discharge compared to 0 days in 
advance for a doctor written prescription.74 
 
Milliken et al described a controlled study that sought to evaluate the introduction of a 
pharmacist-led discharge prescription service.70 A clinical pharmacist was available 
an equivalent of two and a half days a week, and the system was used on one 27 bed 
general medical ward for two months. The clinical pharmacist entered the patient’s 
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medication onto a computer-based clinical information system in advance of the 
discharge of the patient, and when the discharge decision had been made, the 
prescription was printed. During the study, 54% (n=121) of discharge prescriptions 
were entered by a pharmacist and 46% (n=104) by medical staff. As they attached a 
time log label to each prescription, they were able to ascertain that on average, 
prescriptions arrived in the dispensary earlier when printed by a clinical pharmacist 
(9min vs 12 min). It was concluded that it was appropriate for a clinical pharmacist to 
enter drugs on discharge and to print discharge prescriptions.70 However, the 
significance of the time savings made is unclear. The study was also short at 2 
months. 
 
Barrett et al (2002) described a before and after study where they introduced a new 
pharmacist discharge service on one medical ward. The pharmacist led a junior doctor 
and nurse ward round, and was able to anticipate when the patients were being 
discharged, and hence write their discharge prescription, and have it dispensed and 
back on the ward before the patient was discharged. The authors state that the time 
spent by patients awaiting discharge was reduced from 4.5 hours to 40 minutes, 181 
however, this was not statistically validated. 
The study was fairly short (3 months) and also the design of the study (before and 
after) inherently leads to bias potential. 
 
2.7.3.2 Increased accuracy of the discharge prescription 
 
Four studies have evaluated whether the prescriptions that pharmacists write are more 
accurate than those produced by doctors. 
Boorman and Cairns72 attempted to implement a novel model of hospital based 
pharmaceutical care using a medical team based pharmacist. The study was carried 
out over two separate three-month periods. During the control period (July to 
September 1996), a traditional visiting clinical pharmacy service to review 
prescribing and provide advice was in place. 
During the study period (February to April, 1997) one clinical pharmacist was 
attached to a consultant medical team. This pharmacist attended the morning ward 
round each day for a 22-bed medical ward. The pharmacist wrote To Take Away 
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(TTA)s for patients scheduled for discharge, which were clinically validated by the 
doctor prior to dispensing. 
The impact of this new model was evaluated by analysis of three activities: clinical 
interventions, TTA provision and the re-use of Patient’s Own Drugs (PODs). 
Clinical interventions were collected by all pharmacists providing clinical services for 
medical, surgical and care of the elderly wards during the control period and by the 
study pharmacist only during the study period. 
During the control period, 556 interventions were recorded by eight pharmacists, 437 
(78%) of which were related to medical patients. There was no difference in the 
nature of interventions, the grade of doctor with whom the intervention was discussed, 
and whether the intervention was prospective or retrospective, between the study 
pharmacist and other pharmacists during the control period. 
The team-based pharmacist made 237 interventions in the study period compared with 
114 interventions in the control period. There was a significant shift in the grade of 
medical staff with whom the intervention was discussed to being a more senior doctor 
(p<0.001). In addition to a doubling of the number of interventions there were 
increases in interventions of a multiple nature, i.e. those that involved a number of 
problems and/or causes, and an increase in the number of interventions made 
prospectively.  
187 discharge prescriptions were available during the control period from a total of 
587 prescriptions written. Of these, junior house officers wrote 80%. Errors or 
omissions were found in 57 (30%) of the sample.  
During the study period, the pharmacist wrote 102 discharge prescriptions during or 
immediately after the morning junior doctor rounds of which 94 (92%) were validated 
by the doctor, with no errors omissions or alterations documented. All the alterations 
on pharmacist written discharge prescriptions were either additions arising from new 
medication being prescribed or existing medication being stopped after it had been 
written. 
The authors conclude that pharmacists can contribute more frequently to prescribing 
and management of medicines by working more closely with the medical team. The 
decreased prescribing errors on discharge prescriptions provide a safer system and 
improvements in pharmaceutical care of patients.72 
The study did not quantify the effect of the service upon junior doctor’s time. As the 
intervention data was self-reported, it could lead to potential bias from the observer. A 
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further source of potential bias is that the study has sequential control and study 
periods. Also the study was of short duration (3 months).  
 
Barrett et al181 (2002) also investigated the accuracy of the pharmacist-written 
prescriptions via the need for intervention by dispensary pharmacists. The authors 
found that the number of prescriptions needing pharmacist intervention at the 
dispensary decreased from 6.2% (n=8) for prescriptions written by the doctors, to 
0.9% (n=1) of prescriptions written by the pharmacist. However, this was not 
statistically validated, and was also a very small number of prescriptions involved. 
 
Jacklin et al74 stated that the pharmacist writing discharge prescriptions made 
additional interventions compared to a normal pharmacist service (n=38, 52%). 
However the significance of this is not clear, and also the pharmacist only transcribed 
a fairly low number of the overall prescriptions written. 
It was also reported in the Audit Commission’s report ‘A spoonful of sugar’49 that 
pharmacists are five times more accurate than doctors in writing discharge 
prescriptions, and hence it advocates that pharmacists undertake this role ( Although, 
this finding in the Audit Commission’s report is taken from a MSc thesis (Stevenson 
N, MSc thesis, Liverpool John Moores University, 1998) and hence  this implies it 
was probably a small and localised study and indicates that the strength of this 
evidence might be limited). 
 
2.7.3.3 Increased cost savings with pharmacist transcribing services 
 
Cattell et al75 suggested that the implementation of their pharmacist discharge 
prescription transcription service saved £6 per patient but this was due to re-use of the 
patient’s own drugs. The study has therefore not assessed what savings the service 
implementation itself has made due to e.g. increased timeliness of discharge 
prescriptions leading to earlier discharges. This same comment could be made about 
the purported savings made by Barrett et al, of £4 per patient.181 
Feil et al (USA) also reported cost savings when patients own drugs were used more 
often when pharmacists wrote discharge prescriptions.71 
No studies have assessed the potential costs savings made directly from 
implementing this service. Increased bed turnover, savings in doctor time involved 
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with writing prescriptions and nurse’s time asking doctors to write prescriptions. Also 
increased accuracy of prescriptions which lead to less prescribing errors, will all have 
a cost-saving impact. 
 
2.7.3.4 Increased patient and doctor/nurse satisfaction with pharmacist discharge 
prescription services 
 
Evidence to suggest that pharmacist discharge services are well liked by patients 
and/or staff is scarce. Jacklin et al report that a survey that was returned by 18/31 
nurses and doctors involved with the study wards indicated that they were positive 
about the service. The survey asked general questions such as “Is it a good idea to 
have a discharge planning pharmacist?”, “Do you think the discharge pharmacist 
should be transcribing discharge prescriptions?” and “Has the service been useful in 
freeing up time for doctors and nurses?”. However, the study does not indicate how 
the survey was validated, whether it was piloted and the response rate is not good.74 
 
2.7.4 Prescription amendment/therapeutic substitution 
 
Twelve articles could be found upon this prescribing activity. Eight of these articles 
focused on pharmacists being permitted to switch certain drugs within specific groups 
as a formulary substitution -most commonly statin substitution. Cost analyses of the 
savings made by these changes were also presented in the majority of the papers. 
Seven articles were American182-189 and there was one UK paper which did not 
present any data on cost analyses.190 
The earliest description of a pharmacist prescription amendment policy was in 1997 
by Glinn et al.98 This was a brief description of a policy, which enabled pharmacists 
to amend certain prescription items on in-patient drug charts without contacting the 
doctor at Treliske Hospital in Cornwall. It mainly included changing the timings of 
certain drugs, frequency of antibiotics and formulary substitution. 
Hughes et al97 described a non-controlled study that they undertook, which allowed 
pharmacists to undertake certain prescription amendments without reference to a 
doctor. The authors suggest that there were costs savings in a small number of the 
prescription amendments, and also increased patient satisfaction, but do not quantify 
this in any manner, or supply methodology.  
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Woolfrey et al96 evaluated the views of pharmacists, doctors and nurses about the 
implementation of a prescription amendment policy. Selected qualitative responses 
were presented, which suggested a positive reception to the scheme. 
In the only UK study found, pharmacists were permitted to substitute modified-
release isosorbide mononitrate (ISMN) for standard-release ISMN after completing a 
baseline study of frequency and timing of chest pain, the number of rescue doses of 
sublingual nitrates needed alongside an assessment of adverse effects experienced. 
These parameters were also assessed one month after the pharmacist substituted the 
patient’s therapy to the standard-release formulation. This was a small before and 
after study with only 8 patients participating. These participants did not experience 
any loss of control of chest symptoms, did not need to use any extra doses of rescue 
nitrates and did not experience an increased incidence of adverse effects. Therefore 
the authors concluded that therapeutic substitution of nitrates by pharmacists was 
successfully managed without any clinical deterioration of the patients’ symptoms. 
Finally, it should be noted that the American College of Physicians- American 
Society of Internal Medicine released a position statement about the scope of practice 
of pharmacists in 2002, in which they reiterated their support of pharmacist 
therapeutic substitution.191 In the statement they resolved to work with pharmacists in 
designing therapeutic substitution policies to ensure the highest level of patient care 
and safety. This statement also includes support for pharmacist therapeutic 
substitution from the American College of Clinical Pharmacy along with their 
guidelines for the process. 
There is not a large amount of literature about therapeutic substitution available. This 
might be because such changes may be viewed as being straight forward, and does not 
deviate too much from what pharmacists already do. For the medical profession, such 
changes are not very controversial on a local scale and still allow them to retain 
control over what pharmacists can and can’t do in a prescribing role. They might also 
represent very laborious and menial jobs that the medical profession wouldn’t mind 
not having to do anyway. Prescription amendment/therapeutic substitution represents 
a process that pharmacists can do at a local level if policies and protocols are 
developed in conjunction with medical staff agreement. 
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2.7.5 Electronic Prescribing 
 
One of the key elements of the government’s White Paper, “Information for 
Health”192 was the implementation of Level 3 electronic patient record within 100% 
of acute hospitals by 2005. However, progress on implementation of electronic patient 
records has been slower than expected and this target has not been met. 
When Level 3 electronic prescribing is implemented, there will still be a role for the 
pharmacist to decide upon the appropriateness of treatment on discharge and input the 
discharge prescription onto the computer. Some pharmacists are already using similar 
electronic prescribing systems in this manner, and have become more integrated into 
the healthcare team. 193, 194, 195  
 
2.7.6 Development of Pharmacist Prescribing in USA 
 
The development of the prescribing role for pharmacists parallels practice issues in 
other countries, notably the establishment of collaborative practice agreements in the 
USA. Pharmacist prescribing was first introduced in California in the late 1970’s, and 
since then has been extended to at least 16 states. In 1979, Washington changed its 
legislation to allow pharmacists to prescribe under protocols agreed with a physician 
and registered with the state board of pharmacy.196 197 Only one state (Florida) has 
introduced independent prescribing, where pharmacists are prescribing from a limited 
list of drugs.196 Collaborative drug therapy management has become the suggested 
model of pharmacist prescribing in America, whereby the pharmacist has a 
collaborative arrangement with a physician to dependently prescribe certain 
medications as agreed in a management plan.197,198 The development of 
supplementary prescribing has been informed by this collaborative drug therapy 
management model. In this model, the pharmacist has a collaborative arrangement 
with a physician to dependently prescribe certain medications as agreed in a 
management plan.197-199 In some cases, clinical pharmacy specialists are also 
prescribing independently, especially in veteran’s affairs medical centers, which allow 
greater freedom to prescribe under locally agreed protocols.196, 200 
The main differences between pharmacist prescribing in the USA and the UK are that 
in the UK, supplementary prescribing represents a more coordinated, centralized 
approach, where the same model is being used nationally, with an associated formal 
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training process and stipulated competencies (in areas including communication, 
consultation skills and diagnostic skills) that the pharmacist needs to achieve in order 
to qualify as a supplementary prescriber. Unlike the USA, where the pharmacist 
prescriber needs to be credentialed by their individual institution201to provide drug 
therapy management services, in the UK, once the pharmacist has attained the 
supplementary prescriber qualification, they can move to any secondary or primary 
care trust and the supplementary prescriber qualification will be recognized. However, 
the non-medical prescriber does always need to prescribe within the limits of their 
own competencies. 
Collaborative practice protocols are very similar to the CMP that is used in 
supplementary prescribing, but a CMP has to be written individually for each patient 
that is seen, and also has to be agreed by the patient and the independent prescriber. 
Therefore rather than a general protocol being produced which applies to all patients 
being seen with a certain condition, the CMP is very much a tailored document for 
each patient that is seen by the non-medical prescriber. 
Since some pharmacists in the USA have been involved in prescribing medications 
for patients as part of drug therapy management services for such a long time, much 
has been learnt from their experiences in the development of pharmacist prescribing 
in the UK.  Experience in the USA has also shown that even when legislation is in 
place for pharmacist prescribing to take place, certain barriers, such as establishing a 
working relationship with physician colleagues, have to be overcome in order for a 
successful service to be developed.201 
Within the pharmacy profession in the USA there is still disagreement about whether 
medication prescribing should be an independent or protocol-limited privilege, and 
about whether this responsibility is needed or even wanted by most practicing 
pharmacists.202 
There appears to be no published cases in which pharmacists have been sued in civil 
actions on the basis of the exercise of their prescribing authority in America.203 
Review of the published literature seems to suggest that the advent of pharmacists 
writing discharge prescriptions seems to be a role that is peculiar to the UK. Although 
pharmacists in certain US States have extensive prescribing rights in terms of 
initiating, modifying and discontinuing medication, especially in outpatient clinics, 
196, 204- 205 only one American abstract could be identified which concluded that 
pharmacists should write discharge prescriptions on the basis of less adverse drug 
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events and more cost-effectiveness when compared to those written by physicians and 
nurse practitioners.71  
 
2.7.7 Pharmacist prescribing in the rest of the world  
 
In the rest of Europe, New Zealand and Australia, pharmacists do not have the right to 
prescribe, and no literature could be found to suggest that any other countries have 
pharmacists which write discharge prescriptions. This could well be due to discharge 
prescription provision not being such a source of delayed discharge or error in these 
countries. Also primary care may be more involved in the discharge process. 
In many European countries, pharmacists are active in preventing and correcting 
drug-related problems (such as Belgium, France, Germany, The Netherlands, Norway, 
Sweden); however, pharmaceutical care is in its infancy in the majority of Europe. It 
has been suggested that European pharmacists have a lack of authority to take an 
active part in decision-making for drug prescribing, and lack support from some 
physicians to be part of the healthcare team.206 Training is not clinically orientated 
and focuses much more on the basic science of pharmacy as opposed to the clinical 
element. It is now recognised that there needs to be substantial changes made to most 
universities’ curricula in Europe in order to arm pharmacists with the suitable 
knowledge and skills to implement pharmaceutical care efficiently.206 
 
2.7.8 What this literature review highlights 
 
The research evidence presented here highlights the need for further research in order 
to quantify the benefits pharmacist prescribing and prove its safety for patients (N.B. 
The research reviewed in this section is that undertaken outside of the models of 
supplementary prescribing and independent prescribing that are now legalized). It is 
noted that there have been very few randomised controlled trials in the area of 
pharmacist prescribing, and the few that have been done have their limitations. Many 
of the studies were either non-controlled or before and after studies which have 
various weaknesses in their methodology and hence generalisability of the results. 
Most of the published studies are from individual organisations and the pharmacist-
prescribing activities that have been developed across primary and (mainly) secondary 
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care are based upon very poor, ungeneralisable studies and anecdotal evidence. This is 
much the same for nurse prescribing. 
The other areas which seem to lack supporting evidence in pharmacist prescribing in 
specialist clinics is the longer-term benefits to the patient, and also benefits in terms 
of effect upon mortality and morbidity. Also there is very poor evidence in the area of 
cost-effectiveness of pharmacist prescribing.  
There is an issue of commonality in prescribing skill and competency between nurses 
and pharmacists who will bring such different skills to the prescribing role. It is 
becoming apparent that there are certain areas of prescribing that will be more 
appropriate to nurse prescribers, such as single clinical areas, including asthma, 
hypertension and heart failure, and other areas that would suit pharmacist’s skills, 
such as medicines management in the elderly, and other areas where polypharmacy is 
commonplace, such as renal clinics and rheumatology clinics. 
The four different areas of pharmacist prescribing research provide evidence at 
different levels of complexity of prescribing. For example, anticoagulant prescribing 
is a very narrow speciality, which is very easily monitored via INR, and limited 
clinical experience is needed in order to undertake such a role. In the area of writing 
discharge prescriptions, a thorough review of the suitability and appropriateness of the 
medication should be undertaken by the prescriber, and therefore it isn't a case of 
simply copying a list of drugs from one chart to a prescription. A patient may be 
taking medication for numerous medical conditions and hence there is a much wider 
knowledge required of all of these conditions, how to treat them, monitor them and 
ensure that all the medications prescribed do not interfere with any other medications 
that are prescribed. Within some specialist clinics, such as medicines management 
and renal clinics, many different signs and symptoms may need controlling with 
medication as a result of the patient being elderly or having renal impairment, which 
may involve numerous drug changes.  
Therefore there are limitations to applying outcomes of one type of prescribing to 
another, and so it is difficult to generalize the evidence provided by the literature upon 
anticoagulation to other types of pharmacist prescribing.  
It is apparent that there will have to be a lot of care in choosing the complexity of 
prescribing by allied health care professional's as there is a grey area where diagnosis 
and prescribing merge (especially when asking who is going to monitor the 
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outcomes). So care will have to be taken when considering which models will work 
and their applicability.  
With respect to pharmacists writing discharge prescriptions, the literature review has 
shown that such services have reduced the error rate on the prescriptions when 
compared to those written by doctors, doubled the intervention rate by the pharmacist, 
and increased the number of prospective interventions that the pharmacist makes.72 
All of these findings fall into line with the recommendations of the Audit Commission 
report.49 
Realisation of the benefits and the developments that can arise from such service 
provision could also help pharmacists gain acceptance within the clinical team as a 
provider of pharmaceutical knowledge, and lead to further development of the 
pharmacist’s role. 
The disadvantages of such a service relate to resource issues. For the service to be 
implemented throughout a hospital, it would be necessary to maximize the technician 
role in order to release pharmacist time from the dispensary and other duties. 
Therefore although the PDPTS has its disadvantages, overall it would appear that it is 
a worthwhile service for pharmacy to be providing in terms of the benefits to the 
patients. 
 
2.7.9 How this literature review has helped to develop the first aim and 
objectives of the research 
 
Table 1 (p 54-55) shows the important consultations, legislation announcements and 
documents that were available when each stage of the research in this thesis were 
developed and undertaken. 
When the first questionnaire survey, “Pharmaceutical input to the discharge process, 
a survey of Hospital Pharmacy Services” was developed, there was a lot of 
speculation about pharmacists being allowed to prescribe in some format in the future. 
This was fuelled by the Review of Prescribing, Supply and Administration of 
Medicines Final Report (–March 1999)11 advocating the extension of prescribing 
rights to pharmacists and nurses and also in the Pharmacy in the Future-Implementing 
the NHS plan (Sept 2000)46 Report. There was also literature published about 
pharmacists writing discharge prescriptions in various hospitals,73-74, 195, 207 as well as 
informal discussion between pharmacist colleagues in different hospitals about 
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development of pharmacist discharge prescription transcription services (PDPTS). 
Although there have been many reports advocating the benefits of providing 
PDPTS49, 70-72, 74- 75, 99, 208- 209 there is no consensus view available upon the benefits of 
the process. It is also unknown how much influence these factors have upon the 
decision to provide a PDPTS service. It is important to establish these driving factors, 
as they will be applicable for other pharmacist prescribing roles and the impact of 
these factors upon service development could be considerable.  
Due to the legal status pre-2003 and responsibility for these prescriptions written by 
pharmacists being so unclear, these issues could be considered a potential barrier to 
development of PDPTS. Therefore authorisation requirements for pharmacist-written 
discharge prescriptions were also investigated, together with the prevalence of formal 
protocols for PDPTS within hospital pharmacy departments offering such a service. 
A survey conducted by Sexton67 (1999) identified that out of 162 hospital trusts, a 
third involved pharmacists in writing discharge prescriptions, but their overall impact 
on the total number of prescriptions being written was negligible. The survey did not 
attempt to suggest reasons for this, but did report that managers responding to their 
survey stated that there were continuing resource and staffing difficulties. The survey 
did not aim to describe the pharmacist prescribing services. 
Literature review undertaken before the survey was developed did not identify any 
research that provided quantitative data upon PDPTS provision in the UK. 
Although this literature review has emphasized the poor quality of the research into 
pharmacist prescribing, it also highlighted a need to establish a baseline of what 
pharmacist prescribing was being undertaken in the UK and how commonplace it 
was in 2001. As there were many more reports of pharmacist prescribing activities 
taking place within secondary care (and commonly in the area of writing discharge 
prescriptions) it was decided that a questionnaire survey ought to be undertaken of 
secondary care in the UK, focusing on pharmacists writing discharge prescriptions. 
This survey would be used to not only establish the prevalence of pharmacist 
prescribing in 2001 but also to provide detail upon the type of services being 
provided, the training requirements for the pharmacists involved, the prevalence of 
formal protocols for such services and the key factors influencing hospital’s decisions 
to initiate pharmacist discharge prescription transcription services.   
Alongside this data about the service being provided, it was also apparent that some 
of these services may not be provided within a legal framework (see section entitled: 
 104 
The issue of legal responsibility for pharmacist-written prescriptions before 
supplementary prescribing was legalised (pre 2004 p 44) and hence there was a 
clinical governance issue. Therefore data needed to also be collected upon how the 
prescriptions were being authorised and also what training provision there was for 
pharmacists undertaking this role. 
The methodology used in this first stage of this research is discussed on p112 in the 
methods section. 
 
Aim: 
 
To establish the prevalence of pharmacist “prescribing activities” within 
secondary care in the UK, & to describe in detail the provision of pharmacist 
discharge prescription transcription services (PDPTS). 
 
Objectives for phase 1 
 
The objectives of this survey were as follows: 
 To identify the frequency of PDPTS provided in the UK  
 To provide further detail upon the level and type of service provided and 
training requirements for pharmacists involved in such services.  
 To investigate authorisation requirements for pharmacist-written discharge 
prescriptions and to determine the prevalence of formal protocols for PDPTS 
within hospital pharmacy departments offering such a service.  
 To establish key factors influencing hospitals’ decisions to initiate PDPTS. 
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2.7.10 Consideration of developments in pharmacist prescribing by 2004.  
 
2.7.10.1 Supplementary prescribing for pharmacists 
 
This role has been viewed as a major step forward in the development of the 
pharmacist’s role. Although this was the first time that pharmacists would be legally 
able to prescribe, it has been acknowledged that pharmacists had already been 
“prescribing” and had circumvented problems that arose from the legislative controls 
upon prescribing, by asking doctors to sign prescriptions that they had written. 177, 210 
The model of supplementary prescribing may not be suitable for all of these 
prescribing roles, especially writing discharge prescriptions. 
 
2.7.10.2 How supplementary prescribing fits in 
 
There is no national strategy to guide which clinical areas supplementary prescribers 
should practice in, or where areas of expertise should be developed. Without this, 
development of supplementary prescribing will happen in an ad hoc way.211 This 
represents a missed opportunity to target these extra prescribing resources upon health 
areas that need improvement within the population, such as heart disease. However, it 
does enable Primary Care Trusts to develop services according to local needs in a 
targeted manner.  
It is important to establish which clinical areas pharmacists and nurses are using their 
supplementary prescribing qualification in, so that it may be possible to start 
considering whether the clinical areas are most beneficial from a strategic viewpoint. 
Chiropodists/podiatrists, physiotherapists, radiographers and optometrists will use 
their prescribing skills in very narrow, specialist areas, it is therefore not expected that 
there will be any overlap of their prescribing area with other non-medical prescribers. 
However, there might well be some overlap between nurses and pharmacists clinical 
areas. 
 
2.7.10.3 Attitudes and perceptions of supplementary prescribing 
 
The implementation of supplementary prescribing will be influenced by many 
external factors such as attaining funding of the service, funding for the training itself, 
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funding for backfill whilst the pharmacist is training and ability to recruit a designated 
medical practitioner (DMP) to supervise part of the training. It may also be influenced 
by the perceptions that the people who may be in overall charge of implementation 
have with respect to supplementary prescribing.  
During the consultation process for supplementary prescribing,15 many issues and 
risks with the proposed supplementary prescribing model were raised with the 
Department of Health.53 Although some of these envisaged problems were dealt with 
as part of the consultation process, some negative perceptions and issues that were 
raised may have had an impact on health care professional’s perceptions of 
supplementary prescribing. 
The literature review identified other pharmacist prescribing roles (NON-
supplementary/independent prescribing), which were taking place prior to SP being 
legalized. Previous experience of these types of prescribing within a trust may also 
influence CPs and PCTP’s opinions upon how successful SP will be.  
 
2.7.11 How this literature review has helped to develop the second research 
question and derive the aim and objectives. 
 
When the second questionnaire survey was being developed, supplementary 
prescribing (SP) had been legalized, some pharmacists were undertaking the SP 
training and the first prescription had been written by a pharmacist supplementary 
prescriber (2004). As there was now a legal framework available for pharmacists to 
use to prescribe, it was felt that it was important to establish how chief pharmacists 
intended to introduce supplementary prescribing within secondary care, and primary 
care trust pharmacists within primary care and within which clinical areas. As the first 
questionnaire survey had highlighted the poor adherence to clinical governance 
standards amongst some hospitals that were already allowing pharmacists to 
“prescribe”, it was also important to examine their thoughts upon the risks and issues 
surrounding supplementary prescribing. Reducing the risks and issues surrounding the 
role extension of prescribing (for full discussion see section entitled clinical 
governance, risk and prescribing p44) had been highlighted in The Royal 
Pharmaceutical Society of Great Britain Pharmacist Prescribing Task Group, First 
Report, Supplementary prescribing by pharmacists (July 2002).52 This report stressed 
the importance of clinical governance and established that there would be a need for 
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the development of a competency framework, criteria for demonstrating on-going 
competency and Continuing Professional Development (CPD) for supplementary 
prescribers. Anecdotally, pharmacist colleagues were also raising questions about the 
safety of certain aspects of non-medical prescribing and wanted to be sure that clinical 
governance procedures would keep the safety of the patient paramount. Hence, it was 
felt important to focus part of this questionnaire on the risks surrounding 
supplementary prescribing. 
 
Aim 
 
To investigate the views of chief pharmacists within secondary care and 
pharmaceutical advisors of primary care trusts in England upon the 
implementation, risks & issues surrounding supplementary prescribing.  
 
Objectives 
The objectives of this survey are as follows: 
 To establish how chief pharmacists in secondary care, and primary care 
pharmacists in primary care, were implementing pharmacist supplementary 
prescribing within their trusts and their reporting of how nurse supplementary 
prescribing was being implemented within their trust.  
 Collect quantitative data upon the numbers of pharmacists and nurses who 
were being trained as supplementary prescribers, which type of pharmacists 
and nurses were being trained and the therapeutic areas they would be working 
in.  
 Investigate the perceptions of chief pharmacists and primary care trust 
pharmacists upon the risks and concerns surrounding supplementary 
prescribing. 
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2.7.12 Consideration of developments in pharmacist prescribing by 2005.  
 
2.7.12.1 Evaluation of Supplementary Prescribing (SP) 
 
Those publications discussed which were published after the last research project was 
started (January 2006) will be highlighted as such. The evaluation of supplementary 
prescribing (SP) by pharmacists has been mainly reported as individual case reports, 
evaluating questionnaires and commentary. This is unsurprising as the first 
prescription was written by a pharmacist supplementary prescriber in March 2004.212 
There are many gaps in published literature which do not allow for full evaluation of 
SP services. No randomised controlled trials evaluating the outcomes of the 
consultations and the recommendations made have been reported in the literature. Nor 
have any studies which compare the care to that provided by doctors or which 
undertake an economic evaluation of the services being provided. There is also only a 
limited amount of data regarding patient’s opinions upon pharmacist prescribing. 
 
A qualitative evaluation of supplementary prescribing pharmacists sought to explore 
how the role was working in practice and the factors which contributed to successful 
and unsuccessful pharmacist prescribing practice213 (Published in 2006, whilst phase 
3 of research was being undertaken). This exploration found that the pharmacist 
supplementary prescribers found the role rewarding and perceived that there were 
clear benefits to patients in terms of the time they had for them in the consultations 
and the amount of information they were able to give them. During this two-phase 
research study, ten patients were interviewed about their experiences with the 
pharmacist supplementary prescriber. It was found that there was a general lack of 
awareness and understanding of the SP role and how the arrangement worked in 
practice by patients (and other healthcare professionals). They also did not see what 
the benefits of such an arrangement were for themselves, however some patients did 
admit that they felt that they received more information about their medications and 
that the pharmacist had more time for them. Numerous recommendations were made 
in order to more successfully implement SP.  
A questionnaire survey was undertaken of all qualified pharmacist supplementary 
prescribers in September to November 2005 (published in 2006) in order to explore 
their early experiences of prescribing and their perceptions of the prescribing course 
they undertook.214 48.6% (n=195) of the respondents self-reported that they were 
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actively practising and 79% (n=154) of these had written a prescription. Lack of 
organizational recognition of SP was given as the main reason for those not 
commencing practice (37; 18%). Better patient management was regarded as a major 
benefit by 139 (71.3%) of those engaged in SP whilst funding issues were identified 
by 71 (36.4%) as major barriers in implementing the practice. The authors concluded 
that pharmacists needed more support in terms of infrastructure and integration into 
the healthcare team to overcome barriers to implementing SP. 
Various abstracts have been published from on-going research where pharmacists 
undergoing training have been questioned about the training itself or problems they 
were facing with implementing their SP when they qualified215- 216 or pharmacists that 
had recently finished their training about implementation of SP.217 
An abstract has also been published regarding doctor’s opinions in secondary care 
about pharmacist SP218 which found that  although they were positive regarding their 
relationship with pharmacists, doctors were largely unaware of pharmacist SP and did 
not feel that pharmacists were the most appropriate healthcare professional to 
prescribe.  
A similar abstract by the same lead researcher of hospital nurses views on pharmacist 
SP found that although the nurses were very positive about pharmacist’s skills and 
knowledge regarding drugs, they had concerns regarding pharmacists being the most 
appropriate healthcare professional to prescribe.219 
Qualitative interviews held with doctors, nurses, pharmacists and business managers 
within one secondary care NHS trust (2006) found that although all of the 
stakeholders supported the introduction of non-medical prescribing within their trust, 
medical staff had reservations and thought that it should operate within controlled 
protocols. The medical staff disagreed with the concept of independent prescribing. 
Pharmacists were seen by both doctors and nurses as being experts in drug therapy but 
lacking diagnostic skills and knowledge of patients.23 
One paper could be found which evaluated patient’s opinions of a single pharmacist-
led SP hypertension clinic (2006).220 The authors conducted a closed question, self-
administered postal questionnaire of the patients that the pharmacist had seen. They 
concluded that the patients found the standard of care to be better than the normal 
doctor clinics and their understanding of their condition and involvement in treatment 
decisions had improved since attending the clinic. This was the only paper found 
which specifically sought patients’ views upon pharmacist prescribing. 
 110 
 
Research regarding patient’s opinions of nurse prescribing from the initial nurse 
prescribing formulary to extended and supplementary prescribing can inform how 
patient’s may regard independent prescribing by nurses and pharmacists. This 
research has been discussed previously (section 2.2.1, p 59) along with an evaluation 
of nurse prescribing research. The literature showed that patients were very positive 
about nurses as prescribers. Patients had such trusting relationships with nurses due to 
their stable and long-standing relationships with them. However, pharmacists 
(especially secondary care pharmacists) do not necessarily have these established 
relationships with patients. Pharmacists also do not have a recognized prescribing role 
in the eyes of patients which community nurses did before supplementary prescribing 
was legalized. Therefore, although it would appear that patients have been very 
accepting of nurses as independent/extended formulary prescribers, in the limited 
number of studies that have been undertaken, patients may not be quite as accepting 
of pharmacists as prescribers. 
 
Although evaluation of SP is in its infancy, the introduction of independent 
prescribing may limit the number of studies investigating SP. The uptake of SP has 
been much slower than the Department of Health had wanted (1000 qualified 
pharmacist SP’s by end of 2004, this figure was not achieved until November 2006) 
and the reasons for this are discussed in the discussion (section 5.2.2.1.5, p 286). 
  
The views and attitudes of Scottish community pharmacists were sought upon 
independent prescribing (2006).221 The authors found that there was high awareness 
of independent prescribing and perceived competence in diagnosing and selecting 
appropriate drugs for treating many common conditions. The authors concluded that 
prescribing training with emphasis on evidence-based medicine, generic issues of 
prescribing and diagnostic and consultation skills is warranted before independent 
prescribing is undertaken by Scottish community pharmacists.221  
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2.7.13 How this literature review has helped to develop the third research 
question and derive the aim and objectives. 
 
It is therefore apparent that when this part of the research was developed there was 
not a lot of research available about patients’ views upon pharmacists as prescribers.  
The interview schedule for the patient interviews was developed when the 
consultation for pharmacists and nurses becoming independent prescribers was 
published.55 In this role extension, the pharmacist would be responsible for their own 
actions (which they are as a supplementary prescriber) and would be an autonomous 
healthcare professional, not needing to depend upon a medical professional for a 
diagnosis or support (other than if they need to refer the patient to another 
professional). It was hypothesized that this represented a much greater change for the 
public to accept and that some patients would have very strongly-held beliefs 
surrounding the acceptance of non-medical professionals in this new role. It was 
therefore important to attempt to establish what patients thought about the role 
extension and what their concerns were (if any) about the development as well. 
Concerns regarding the risks of the new development and how they would be 
minimised would be of great importance to the patient as well, and it would be useful 
to understand these issues from the patient’s perspective. 
If patients do have concerns that are not addressed, the uptake of non-medical 
prescribing will be affected and patients will not have the increased access to 
healthcare that is needed.  
The use of qualitative research methods will provide a detailed description of the 
perceptions and beliefs that patients have, and how these inform their opinions on 
pharmacist and nurse independent prescribing. 
This research will allow the identification of factors that affect these beliefs and 
therefore pharmacists and nurses will be able to tackle any misconceptions and 
barriers that patients may have.  
 
Aim 
To investigate opinions of patients who have and haven’t experienced 
supplementary prescribing by pharmacists on the development of pharmacists 
and nurses as independent prescribers. 
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Objectives 
 
 To identify and describe patients’ opinions of whether pharmacists and 
nurses should become independent prescribers, whether they are perceived 
to be capable of providing such a service, and whether the patients think 
they would utilize the service. 
 To identify whether patient experience of pharmacists as supplementary 
prescribers affects their acceptability and opinion upon independent 
prescribing by pharmacists? 
    To identify and describe factors that affect whether patients would rather 
utilise a nurse or a pharmacist independent prescriber, and if there are any 
preferences, what is the basis of this belief? How does patients’ previous 
experience of contact with pharmacists and nurses inform this preference?  
 To identify patients’ perceived benefits of pharmacist independent 
prescribing. 
 To identify patients’ concerns about pharmacist and nurse independent 
prescribing and any perceived barriers to its development. 
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CHAPTER 3: METHODS 
 
 
This chapter presents the methodology used during this research. The methodology 
for each of the three separate studies will be presented one after the other. 
 
3.1 NATIONAL SURVEY OF PHARMACIST TRANSCRIBING OF 
DISCHARGE PRESCRIPTIONS (SECONDARY CARE) 
 
3.1.1 Selection of the survey tool  
 
A descriptive survey was used as the information is collected from the population of 
interest and descriptive measures are calculated. These surveys are also known as 
cross-sectional as the data is collected from the population of interest at one point in 
time.222 Statisticians often refer to descriptive, cross-sectional surveys as 
observational research because phenomena are observed rather than tested, but this 
shouldn’t be confused with observational research methods used by social scientists. 
It should be borne in mind that with these types of survey, it is not generally possible 
to draw conclusions about cause and effect from them.222 
In order to be able to survey a large sample of secondary care trust chief pharmacists, 
principal pharmacists or clinical services managers (according to whose name could 
be found in reference sources223- 224) in the United Kingdom (UK) (n=234 hospital 
trusts), the only feasible survey method that could be used was a postal questionnaire 
survey as opposed to a telephone survey or focus groups. 
Postal questionnaires have the advantage that a large sample of the population can be 
reached and that it is cost-effective as well.225 Postal questionnaires do have 
disadvantages such as that closed questions do not allow the respondents to fully 
explain their opinions and that the respondents cannot be probed about their 
responses. Response rates tend to be lower as well when compared with for example, 
telephone surveys.225 Furthermore, access to the sampling frame was relatively easy 
as hospital pharmacy departments could be identified in several publications (as 
discussed in sample selection section p113). 
A telephone survey of such a large sample of people by one researcher would have 
been unfeasible within the time frame for the study. This is because of the time it 
would have taken to do the survey via telephone. Especially when you factor in 
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having to often speak to secretaries before speaking to the chief pharmacist, and 
having to phone back again if they are busy. Hence a questionnaire survey was 
deemed to be the most suitable method for the purposes of the data collection. 
 
3.1.2 Sample selection 
 
In order to establish the baseline situation with regards to pharmacist prescribing, the 
questionnaire survey had to be sent to all acute hospital trusts in the UK (n=234). The 
total population of pharmacy departments was used, rather than a sample because the 
total number of pharmacy departments was not so large to have enormous resource 
implications. Surveying the whole population also negated any problems of sampling 
error or random error in subsequent statistical analysis. Primary care was not included 
as legally during 2001, they had no methods of pharmacist prescribing, and the 
literature review made it apparent that pharmacist clinics and reports of prescribing in 
other situations such as discharge prescribing were occurring in secondary care. 
Individual hospitals from each trust were identified using a combination of the UK 
Drug Information Pharmacists’ Group Directory223 and the Chemist and Druggist 
Directory.224 The questionnaire was sent to one hospital from each trust. The largest 
hospital in the trust was purposively chosen to send the questionnaire to where more 
than one hospital was within the trust. Some questions in the questionnaire asked 
about aspects of pharmacist prescribing across all of the trust. An assumption was 
made that the chief pharmacist of the largest hospital in the trust would be aware of 
pharmacist prescribing activities across all of the trust. Any hospitals that were found 
to have merged with another trust upon responding to the questionnaire were removed 
from the database.  
 
3.1.3 Stages of questionnaire development 
 
Several stages of development of this questionnaire were utilised: 
 
 Literature review 
 In-depth unstructured interviews and field visits 
 Questionnaire development for the purpose of piloting. 
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 Questionnaire adaptation and validation into a final version. 
 
3.1.4 Questionnaire development –Literature Review 
Construction of the questionnaire was aided by literature review. The review elicited 
the pharmacist “prescribing activities” that had been reported from various hospitals. 
These included PDPTS, transcribing in-patient drug charts, various prescribing 
activities in pre-admission clinics (which often includes transcribing discharge 
prescriptions77- 78) and prescription amendment policies.  
These reported activities were used in the survey to ask pharmacy department’s 
whether they were involved in such activities.  
Transcribing was one activity that had been identified from the literature review. For 
the purposes of this study, and in the absence of a recognised definition of 
transcribing, transcription was defined on the front of the questionnaire survey as “a 
process where a pharmacist copies a list of drugs that has been prescribed by a doctor 
from one chart to another chart or prescription”. In undertaking the act of 
transcription, there is an implied professional obligation on the pharmacist to review 
the prescribed medicines and act upon any errors and assure suitability for the patient. 
 
3.1.5 Questionnaire Development- Field Visits 
 
From local knowledge of the hospital region, the researcher was aware that two local 
hospitals had developed a pharmacist discharge prescription scheme, which appeared 
to be the most commonly reported form of pharmacist prescribing that was being 
undertaken at the time, from the literature review. Pharmacists from these two local 
hospitals were therefore visited to inform the development of the questionnaire.  
Detailed notes were taken about the pharmacist discharge prescription schemes that 
they were running, and this was used to help develop the questionnaire, which 
focused upon this type of pharmacist prescribing, but also enquired about other types 
of pharmacist prescribing that had been reported in the literature. 
The first four models of service that the PDPTS were based upon (as listed in Table 3 
(p 145)) were established from these visits to two other hospitals that were running a 
pharmacist transcription service, and the other categories reported in Table 3 were 
from the results of the “other” option, which was examined for common themes. 
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3.1.6 Questionnaire Development- Piloting and Validity 
 
By using the findings from the field visits and literature review a questionnaire survey 
was developed for piloting.  
In order to assess face validity of the questionnaire, chief pharmacists (n=2) were 
observed whilst completing the questionnaire and discussed any ambiguities that 
arose with the researcher (from hospitals with and without a PDPTS). These hospitals 
were chosen from the same region as the researcher was based for ease of travel. 
Although this process does not constitute full validation, face validity was further 
assessed in responses to the pilot questionnaire for both primary and secondary care. 
The questionnaire was then piloted in 20 randomly chosen hospitals from Wales, 
Scotland, England and Northern Ireland in July 2001. Minor adjustments to the 
instructions for completing the questionnaire were made. Advice on data analysis 
was sought from a statistician.  Data collected from the pilot questionnaires was not 
included in the final analysis. This was because some changes were made to the 
questionnaire after the piloting process was complete. For example, extra options 
were added into a couple of questions and also a question was added in about 
whether the pharmacy discharge service being offered had decreased out of hours and 
weekend work in the dispensary. 
 
3.1.7 Final Postal Survey 
 
The questionnaire was distributed at the end of August 2001 to each NHS trust 
providing acute hospital services in the UK. The questionnaire contained a mixture of 
open and closed questions. Open-ended questions were kept to a minimum to keep the 
questionnaire as simple and concise as possible. The questionnaire was divided into 
five sections (see appendix 3, p367): 
  Section A enquired about general demographic data 
 Section B enquired about different prescribing roles being undertaken. 
  Section C enquired about the extent of the service provision amongst those 
hospitals that offer a transcription service (i.e. directorates/wards covered and 
operating hours of the service), and the model of service used.  
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 Section D was about training issues (e.g. reassessment, types of training used)  
 Section E aimed to quantify the service provided (e.g. number of prescriptions 
written/day/pharmacist, advance notice required).  
 
Confidentiality was maintained by number-coding the questionnaires. The 
questionnaire was accompanied by a covering letter which emphasized that the 
questionnaire was confidential and anonymous to ensure respondents could be honest 
without fear of reprisal. This was intended to encourage a good response rate, as 
described by Oppenheim.225 The covering letter also included recognised descriptions 
of independent and dependent (now supplementary) prescribing,11 and the 
researcher’s description of transcribing, in order to clarify the recipient’s 
understanding of the different types of prescribing. 
The covering letter was addressed to either the Chief Pharmacist, Principal 
pharmacist or Clinical Services Manager according to which person’s name could be 
found in the reference sources used.223, 224 The covering letter emphasized that the 
questionnaire survey ought to be completed by the pharmacist that manages the 
prescribing services on a day to day basis. The recipient was therefore instructed to 
pass the questionnaire onto the most relevant person to complete it (if it wasn’t 
themselves). Clearly defining who should complete the questionnaire should have 
increased the reliability of the questionnaire. A freepost-addressed envelope was 
included for return of the questionnaire. 
No deadline for completion of the questionnaire was stated on the questionnaire or 
covering letter, but non-respondents were followed up by a telephone call after 3 
weeks and then again at 6 weeks. Further copies of the questionnaire were sent out to 
those who requested them. The final deadline for accepting returned questionnaires 
was 11 weeks after they had been originally posted. Information on deadlines was not 
included on covering letters with the questionnaires as it was thought that if the 
deadline was included it might deter some respondents from completing the 
questionnaire, if they think they have passed a deadline. 
A total of 234 hospital pharmacy departments were identified, of which 20 were used 
for piloting the questionnaire, leaving 214 hospitals for the main study. Those 
pharmacy departments included in the pilot were excluded from the main survey to 
reduce the possibility of “survey fatigue” which may result in a poor response and 
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thus less accurate data. In addition, responding to the pilot questionnaire may have 
raised awareness of the issues covered and so population data may have changed. 
Eight of these hospitals were removed after it was established that they had merged 
with another Trust (this was discovered either by them offering this information 
amongst comments they made on the questionnaire, or by the researcher finding out 
themselves via further investigation), leaving 206 hospitals eligible for the study. 
 
3.1.8 Management of Questionnaire Data 
Data obtained from returned questionnaires was coded and analysed with the 
Statistical Package for the Social Sciences (SPSS) version 10. The database was set 
up and data entry was performed by the researcher. Data entry was checked by the 
researcher using a “screen and clean”226 process and the significance of the 
association between variables was assessed using chi-squared, Kruskal-Wallis and 
bivariate correlations (spearman’s rho), where appropriate.  
 
3.1.9 Ethical Approval 
Ethical approval was not sought for this part of the research as it would not have been 
needed for a questionnaire survey of NHS staff at the time it was undertaken (August 
2001). 
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3.2 IMPLEMENTATION, RISKS AND CONCERNS ABOUT 
SUPPLEMENTARY PRESCRIBING: SURVEY OF PRIMARY AND 
SECONDARY CARE PHARMACISTS 
 
3.2.1 Selection of the survey tool  
 
In order to be able to survey a large sample of chief pharmacists within secondary 
care and primary care trust pharmacists in England, the only survey method that could 
be used was a postal questionnaire survey as opposed to a telephone survey or focus 
groups, as discussed previously (section 3.1.1, p112 (phase 1 methods)). 
 
3.2.2 Sample selection 
 
It was decided to only send the questionnaire survey to Chief Pharmacists and 
Primary Care Trust Pharmacists in England because although legislation permits the 
introduction of supplementary prescribing throughout the United Kingdom, Scotland 
Wales and Northern Ireland have to decide how they are implementing the model for 
the National Health Service in their own countries. Also, it was felt that the 
population sample for primary and secondary care in England was already a large 
sample to deal with. (n=424 in total, n=168 secondary care, n=303 primary care) 
Also, this sample would allow a national (England) description of supplementary 
prescribing implementation. 
In order to be able to establish a list of every chief pharmacist from each NHS 
secondary care trust in England which provides acute hospital services a combination 
of the Chemist and Druggist Directory224 and the Guild of Healthcare Pharmacists’ 
chief pharmacist mailing list227 were used. A random-number generator was used to 
randomly send a questionnaire to one hospital from each trust. This was done because 
an assumption was made that the chief pharmacist would have be aware of 
supplementary prescribing implementation across all of the trust sites, and hence 
would be able to answer the questionnaire on behalf of the whole trust. 
For the questionnaire survey sent to the Primary Care Trust (PCT) pharmacist or 
pharmaceutical adviser, the PCTs and their pharmacists were identified using 
Medendium.228 
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3.2.3 Stages of questionnaire development 
 
Several stages of development of this questionnaire survey were identified: 
 
 Literature review 
 Policy making and academic pharmacists in England were identified and 
asked key questions (via e-mail or telephone) with respect to supplementary 
prescribing. 
 Exploratory unstructured interviews to develop a more detailed perspective on 
the issues and risks surrounding supplementary prescribing. 
 A focus group to more clearly define the key areas that the questionnaire 
should cover.  
 Questionnaire development for the purpose of piloting. 
 Questionnaire adaptation and validation for the final version. 
 
3.2.4 An explanation of the research participants 
 
Pharmacists are employed by Primary Care Trusts (PCT) to control drug prescribing 
budgets. Some primary care pharmacists are entitled “pharmaceutical advisors” whose 
role also includes policy development. Most work with individual GPs to assist with 
drug audits and medication review. These pharmacists will have an important role in 
overseeing the development of supplementary prescribing within primary care trusts. 
Although implementation of supplementary prescribing by nurses will more than 
often be overseen by a different person within the trust such as a senior nurse, that 
person will need to liaise with the Chief Pharmacist (CP) or Primary Care Trust 
Pharmacist (PCTP) as these people have the expertise to advise upon issues such as 
medicines management and clinical governance concerning medicines and 
prescribing. 
Liaison between these health professionals will also ensure that the patients are 
receiving the supplementary prescribing service from the most appropriate health care 
professional.  
Therefore CPs and PCTPs will have an interest in the development of nurse 
prescribing within their trust (and vice-versa) and it is clear that development of 
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prescribing by non-medical health care professionals within a trust will benefit from 
input from both professions. 
 
3.2.5 Questionnaire development- Literature Review 
Construction of the questionnaire was aided by literature review. A discussion of the 
literature found and its influence upon the development of the questionnaire can be 
found in the section entitled “How this literature review has helped to develop the 
second research question and derive the aim and objectives” (p105) and “Clinical 
Governance, risk and prescribing” (p 44). 
 
3.2.6 Questionnaire development- Scoping exercise. Policy making and academic 
pharmacists’ opinions 
 
At first, it was thought that the questionnaire ought to be sent to clinical governance 
leads of trusts, to specifically ask about the risks and issues surrounding 
supplementary prescribing. 
 
Opinion was therefore sought from several health care professionals with important 
roles with regards to non-medical prescribing in order to establish what they thought 
were the main issues regarding this role extension. 
 
The people contacted were:  
 David Cousins, Head of Safe Medication Practices at the National Patient 
Safety Agency (E-mail contact 19/2/03).  
 Rachel Drago, a senior nurse lecturer who was involved in developing and 
teaching on a nurse supplementary prescribing course in Bristol (University of 
West of England) (E-mail contact and a meeting, 26/2/03). 
 Beth Taylor, (manager of the community services pharmacy team at 
Southwark PCT and regional principal pharmacist, community care 
London/South East regions) who had been involved in piloting of 
supplementary prescribing. (via e-mail 30/10/02) 
 Gul Root, the deputy to the Chief Pharmacist at the Department of Health 
(Telephone interview, 10/03/03). 
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Feedback suggested that the questions that were proposed for the questionnaire were 
too specifically process related and missed some of the bigger issues.  
The following topics were suggested to be included in the questionnaire: 
 
What are the expected benefits of supplementary prescribing to: 
 The patient 
 The independent prescriber 
 The supplementary prescriber 
 The Trust 
 
How will the implementation of the supplementary prescribing be evaluated? 
What are the risks associated with the introduction of the supplementary prescribing 
regulations and how will they be managed and monitored? 
Are the perceived risks associated with supplementary prescribers different and do 
they need to be managed differently? 
What are the drivers of this level of change? 
How they perceive clinical leads will react to and plan for these drivers of change? 
 How are clinical leads going to cope if no one wants to prescribe - force them? 
Which grade of nurse would clinical leads expect to undertake prescribing and what 
incentives would they offer?  
How would they tackle continuing education needs of pharmacist prescribers, 
alongside nurses? 
Is it likely that trusts would have to chose to train and support nurses or pharmacists,  
rather then both i.e. will there be competition for support? 
How will replacement costs for pharmacists be found whilst training? 
Are the issues involved in pharmacist supplementary prescribers similar or differing 
from nurse supplementary prescribers? 
What practical tools will be needed for both groups of supplementary prescribers for 
this to work in practice? 
 
These opinions that had been sought were used to aid the development of the 
questions to be used in the exploratory interviews. 
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3.2.7 Questionnaire Development- Exploratory Interviews 
 
For the exploratory interviews, a list of questions was developed from the results of 
the scoping exercise and also after discussions with the supervisor as per appendix 6, 
p 407.  
Three people were interviewed from one acute hospital trust as detailed below: 
 Chief Executive, Sonia Mills (Swindon and Marlborough NHS trust, 30/1/03) 
 Clinical governance co-ordinator, Keith Todd (Swindon and Marlborough 
NHS trust, 30/1/03) 
 Clinical governance lead for the trust (who was also a consultant anaesthetist), 
Dr Sean O’Kelly (31/1/03) 
 
The following issues were raised during these discussions: 
 
 Concern surrounding prescribing errors -any system that would improve 
safety of prescribing would be a big bonus for patients. So patient safety is 
paramount. 
 Concern regarding poor communication between different health care 
professionals which could lead to lapses in patient safety and also 
fragmentation of roles, where there may be too many people involved in each 
patient’s care. 
 There may be difficulty in actually “selling” supplementary prescribing to 
doctors, and getting trust board and individual consultants to agree to 
pharmacists and nurses prescribing in such a manner, as it represents such a 
major change in healthcare provision. 
 How the development would be funded as people who have trained to extend 
their role in this manner will deserve an increase in their salary if they are 
taking on this extra responsibility.  
 Concerns generally about responsibility, safety, practicality and training. 
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After these discussions, it became clear that clinical governance leads did not have a 
lot of knowledge (if any) about the supplementary prescribing model, and had not 
previously considered the implications of non-medical practitioners being prescribers 
in the trust. It was therefore considered that if opinions were being sought from a 
group of people who had a general understanding of the detail of supplementary 
prescribing the questionnaire ought to be aimed at the people who would be more 
directly involved with implementing supplementary prescribing, which would be the 
chief pharmacists (CP) in secondary care. 
 
Similar topics were discussed in face to face exploratory interviews with a nurse 
senior lecturer and a chief executive of a different hospital trust. These interviews 
were informal, one-to-one discussions. The interview with the chief executive 
confirmed the low level of awareness of this role development for non-medical 
practitioners, and the nurse lecturer was able to add a nursing perspective to the 
development. 
Output from all of these exploratory interviews was used to aid the development of 
the topic guide for the focus group. 
 
3.2.8 Questionnaire Development- Focus Group 
 
It was apparent that as the questionnaire would be better directed at chief pharmacists 
in secondary care, further development of the questions to be used in the survey was 
necessary. Therefore a focus group was arranged. The participants included a 
professor of pharmacy practice, a nurse senior lecturer who had developed a 
supplementary prescribing course, a chief pharmacist and a clinical governance leader 
(who was a surgeon). 
A topic guide was derived for the focus group using literature review, results of the 
exploratory interviews that had been undertaken and after discussion with academic 
colleagues. The topic guide can be found in appendix 10, p 419. 
The focus group discussed issues such as the risks and benefits of supplementary 
prescribing and its implementation, responsibility and accountability of 
supplementary prescribers and availability and quality assurance of designated 
medical practitioners. The focus group’s discussions were audio taped and transcribed 
verbatim. Conceptual categories and themes for coding were derived directly from 
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analysing the interview material as well as from the ideas the author had whilst 
conducting and reviewing the focus group recording. From the focus group material, a 
list of main themes that were derived from the group was discussed with academic 
colleagues in order to establish the main topics that chief pharmacists should be 
questioned about in the survey (appendix 11, p 420).  
Attitudes were surveyed using a series of statements compiled from the content of the 
focus group. Attitudes are complex and may incorporate several dimensions which 
cannot be covered with a single question.225 Therefore, it was necessary to use a 
scaling approach in which individual statements were devised to measure different 
dimensions. 
The attitude scale focused upon risks, concerns and limitations about supplementary 
prescribing that had been raised during the focus group. 
Each statement contributed equally to the attitude scale. A five-point Likert scale 
from “strongly agree” to “strongly disagree” was used to grade respondent’s level of 
agreement with each statement.225 Both positive and negative statements were 
included in the scale. According to convention, the high numbers indicated agreement 
and the scales were subsequently reversed for negative questions.  Twenty-two 
attitude statements were used in section C for piloting. It was also decided at this 
point to extend the questionnaire to survey primary care as well, in order to establish 
whether the views of pharmacists in Primary Care Trusts differed to that of Chief 
Pharmacists in secondary care about implementation of SP and its risks and issues for 
pharmacists, nurses and patients within their sector. Therefore some of the questions 
were adapted slightly for primary care, but the majority of the questionnaire was the 
same as the secondary care questionnaire (see appendix 5, p 394). 
 
3.2.9 Questionnaire Development- Piloting and Validity 
 
In order to assess face validity of the secondary care questionnaire, one Chief 
Pharmacist (CP) was observed whilst completing the questionnaire and discussed any 
ambiguities that arose with the researcher, and another CP completed the 
questionnaire and posted it back with written comments. Although this process does 
not constitute full validation, face validity was further assessed in responses to the 
pilot questionnaire for both primary and secondary care. 
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In order to validate the primary care questionnaire, one Primary Care Trust 
Pharmacist (PCTP) completed the questionnaire and provided feedback via the 
telephone and the other PCTP completed the questionnaire and provided written 
feedback. No changes were made to the questionnaire at this stage. 
 
During February and March 2004, the secondary care questionnaire was piloted in 17 
randomly selected hospitals from the sample (n=168). 
At the same time, the primary care questionnaire was piloted in 30 randomly selected 
pharmacists from the sample (n=303).  Participants were advised that it was a pilot 
questionnaire and were asked to make further comments if they felt it necessary to 
help improve any ambiguities in the questions or to suggest any topics that they 
thought should be asked about but were not covered by the questionnaire. Several 
amendments were made to the questionnaire after piloting.  
For section C of the secondary care questionnaire, 8 attitude statements were removed 
upon piloting as review and discussion with the supervisor indicated that they were 
asking factual questions rather than about respondent’s attitudes. Other statements 
removed were statements where all respondents would naturally agree with them. 
Overall, statements were removed as they did not enquire about the respondent’s 
attitude towards supplementary prescribing. 
Also, one new question was added after open comments on the returned 
questionnaires suggested that it would be useful to ask whether chief pharmacists 
were waiting for independent prescribing to be introduced rather than training their 
pharmacists as supplementary prescribers. Therefore 17 attitude statements were left 
in the final questionnaire section C. 
For section C in the primary care questionnaire, there were four questions that needed 
to be removed once piloting had been conducted because they didn’t work well as 
attitude statements. One question was converted to an open question as it was felt that 
it wasn’t a statement that you could either agree or disagree with and was instead 
multi-faceted which required an open response. 
For the rest of the questionnaire, some questions were removed which upon review 
with the supervisor were deemed to not be providing useful information and their 
inclusion would also have made the questionnaire less concise. Some questions also 
had extra options added or removed from them. Therefore, data collected from the 
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pilot questionnaires were not included in the final analysis as the final version of the 
questionnaire that was used was significantly revised.  
 
3.2.10 Final Postal Survey 
 
Following piloting, a total of 151 hospital pharmacy departments were included in the 
main study. Eight of these hospitals were removed from the study after it was 
established that they had merged with another trust or were not an acute trust, leaving 
143 hospitals for the study. 
For primary care, after piloting, 273 primary care trusts were included in the main 
study. Two of these trusts were removed from the study after it was established that 
they were not a primary care trust or did not have a pharmacist employed as a 
pharmaceutical advisor. This left 271 primary care trusts eligible for the study. 
Therefore, a total of 414 primary and secondary care sites were sent questionnaires. 
Both questionnaires were distributed in May 2004 (see appendix 4 and 5 for copies of 
the questionnaires). The secondary care questionnaire was posted to CPs within every 
NHS trust in England providing acute hospital services. Responding hospitals which 
had merged with another trust were removed from the study. 
The primary care questionnaire was sent to the named Primary Care Trust Pharmacist 
(PCTP)/pharmaceutical advisor within each primary care trust (a questionnaire was 
not sent to the primary care trust if they did not employ a pharmacist. –If the reference 
source Medendium228 did not have a named pharmacist for the trust in question, the 
trust was telephoned in order to confirm whether there was a pharmacist employed by 
them or not) in England. 
The questionnaire was sent to a named chief pharmacist or primary care trust 
pharmacist (PCTP) in order to achieve a good response rate.229 
The questionnaire contained mostly closed questions. Open-ended questions were 
kept to a minimum to keep the questionnaire as concise as possible. 
The questionnaire was divided into three sections as follows: 
  
 Section A inquired about demographic data about the respondents and their 
trust using closed questions.  
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 Section B inquired about the implementation of supplementary prescribing 
within the trust. It contained mostly closed questions and one open question 
about recruitment of designated medical practitioners.   
 Section C used Likert scales in order to measure the respondent’s attitude to a 
number of statements about supplementary prescribing. In total there were 17 
attitude statements in the final questionnaires (appendix 4 and 5) 
 
The questionnaires were accompanied by a covering letter to explain the study and a 
freepost envelope was included for return of the questionnaire. Confidentiality was 
maintained by number-coding the questionnaires. The covering letter emphasized that 
the questionnaire was confidential and anonymous to ensure respondents could be 
honest without fear of reprisal. This was intended to encourage a good response 
rate.225 
 
Follow-up was via a second mail shot to non-responders after 3 weeks, and then a 
telephone follow up after a further 4 weeks (secondary care) or another questionnaire 
mail shot (primary care). After a further 3 weeks a last mail-shot of the questionnaire 
was sent out to any remaining non-responders. A final deadline for accepting returned 
questionnaires was set at 13 weeks after the questionnaires had originally been posted. 
The larger sample size in the primary care group required the use of postal (rather 
than telephone) follow up. 
In the questionnaire, the chief pharmacists were asked whether they intended to 
implement supplementary prescribing by the end of 2005. This date was chosen in 
order to be able to assess how quickly supplementary prescribing was going to 
develop. 
 
3.2.11 Management of Questionnaire Data 
Data obtained from returned questionnaires were coded and analyzed using the 
Statistical Package for the Social Sciences (SPSS) version 11. The database was set 
up and data entry performed by the researcher. Data entry was checked by the author 
using a “screen and clean” process.226  
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3.2.12 Analysis of Questionnaire Data 
 
3.2.12.1 Section A & B Quantitative data 
The significance of the association between variables was assessed using the non-
parametric tests chi-squared, Kruskal-Wallis, Mann-Whitney U and bivariate 
correlations (Spearman’s rho), where appropriate (the data was not of a normal 
distribution to enable parametric tests to be used). Advice from a medical statistician 
was obtained. 
The data was also analyzed by region/strategic health authority that the hospital or 
primary care trust (PCT) was from in order to assess whether there were any poor 
responses from particular regions. 
 
3.2.12.2 Section C Attitude Scale  
 
3.2.12.2.1 Assessment of range of responses and plotting of scores for statistical 
normality 
Firstly, the frequency of responses to each statement was assessed to determine if any 
questions were avoided by many respondents (i.e. redundant). Also, the responses 
were assessed in order to establish whether there was a spread of opinion, as would be 
expected in a normal population, and hence the questions were discriminating 
between respondents.  
A total score was calculated for each respondent by reversing positive statements then 
totaling the score for each statement (-2 strongly agree to +2 for strongly disagree). 
Total scores were plotted for each respondent and the normality of the distribution 
assessed. 
 
3.2.12.2.2 Reliability of Attitude Scale 
Reliability is the extent to which a measure (the attitude scale) produces the same 
measurement in the same individual at different points in time. Reliability of the 
survey tool could not easily be tested (test-re-test reliability) as it would produce 
survey fatigue if re-tested in the same, limited, population.225  
Since attitudinal questions are more sensitive than factual questions to changes in 
wording, context, emphasis etc. it becomes impossible to assess reliability via asking 
the same question in another form- it will no longer be the same question. Sets of 
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questions are more reliable than single opinion items -they give more consistent 
results (as there are more questions asking about the same attitude). The underlying 
attitude will be the same in all items in a set or scale. 
It is difficult to assess validity of attitude questions due to the lack of criteria. One 
would need groups of people with known attitude characteristics to see whether a 
question distinguishes between them. E.g. members of a political party- However, 
people join groups for different reasons therefore membership of a group is not 
necessarily a reflection of inner attitude.225  
However, the reliability of section C can be tested via the internal consistency 
method. This assesses the extent to which similar items (attitude statements) gave 
consistent responses. Determination of Cronbach’s Alpha is used via this method to 
give the overall correlation between items within the scale. A reliability coefficient of 
0.7 or above is recommended,226 which would imply that seventy per cent of the 
measured variance is reliable and thirty per cent is owing to random error. 
The other measure of internal consistency used was the item-total correlations. This 
measure compared scores on individual statements with the total score of the scale. 
Statements were considered for rejection if their item-total correlation was below 
0.3.226 
 
Factor analysis was used to explore the relationships thought to exist between the 
items in section C of the questionnaire and to assess the degree to which items were 
measuring the same concept. This is an assessment of psychometric validity. For 
respondents to be given a single score to represent their attitude towards 
supplementary prescribing, the scale must be uni-dimensional for this score to be a 
valid representation of their attitude. Factor analysis is a statistical tool to enable the 
detection of underlying dimensions (factors) in a set of responses, in this case, 
responses to all the attitude statements.225 Factor analysis was undertaken using the 
Statistical Package for the Social Sciences (SPSS) version 11. The factor analysis is 
conducted in a series of steps. Firstly, factors are identified and the size of each factor 
is represented by an “eigen value”. A factor is only included if its eigen value is 
greater than 1. A factor matrix is then produced which indicates which factors occur 
in which responses. Factors are represented by an arithmetical figure called a factor 
loading. Factors at this stage are still arbitrary and lack meaning so the computer 
programme conducts a process called rotation which calculates statistical results from 
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different angles until an “angle” is found in which results are most meaningful. 
Advice was sought from a medical statistician and colleagues that had undertaken 
factor analysis before in order to ensure the best angle was found for the data at this 
stage. 
Principal components analysis (PCA) was used as the method of extracting the factors 
from the item population. The extracted factors were rotated obliquely using the direct 
oblimin method, interpreted and tested for internal reliability.230 
 
Therefore, attitude statements were included in the final attitude score if they met the 
following criteria:226 
 The item-total correlation was greater than 0.3 
 No individual response category was selected by >80% of respondents 
 The factor loading for the hypothetical factors was greater than 0.4 
 The Cronbach alpha of the final score was >0.7 
 
 
The significance of the association between the factors themselves and between the 
factors and responses to certain questions in sections A and B of the questionnaire 
was assessed using the non-parametric tests chi-squared, Kruskal-Wallis and bivariate 
correlations (Spearman’s rho), where appropriate.   
 
3.2.13 Ethical Approval 
Ethical approval for the study was obtained from the south-west multi-centre research 
ethics committee (MREC) (Ref no: MREC/03/6/76) for the secondary care 
questionnaire survey and from the Eastern MREC (Ref no: 04/5/002) for the primary 
care questionnaire survey (approval letters in appendix 2, p354). 
Research and Development (R&D) approval was not necessary for this study.
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3.3 PATIENTS’ VIEWS AND OPINIONS OF PHARMACISTS AND NURSES 
AS INDEPENDENT PRESCRIBERS 
 
Qualitative, semi-structured interviews with patients were undertaken in four NHS 
trusts. The therapeutic areas were pre-determined by the area that the recruited 
pharmacist supplementary prescribers worked within. These four sites were used to 
interview four different groups of patients: 
 
 Primary care, normal GP care (Hypertension) Site 1 
 Secondary care, normal consultant care (Oncology) Site 2 
 Primary care, supplementary pharmacist care (Hypertension) Site 3 
 Secondary care, supplementary pharmacist care (Oncology) Site 4 
 
3.3.1 Recruitment of sites 
 
In order to recruit a supplementary prescriber pharmacist in primary and secondary 
care, a letter was forwarded to the director of postgraduate studies at the University of 
Bath which ran an accredited supplementary prescribing course for pharmacists. The 
Director of Postgraduate Studies, Department of Pharmacy & Pharmacology 
forwarded the letter to all those pharmacists who had completed (or were nearly 
finished) the supplementary prescribing course (in order for their names to remain 
anonymous to the researcher). This letter explained the study that was being 
undertaken and asked anyone that was interested in participating to contact the 
researcher. From this letter, one supplementary prescriber (SP) from primary and one 
from secondary care expressed an interest in participation. The primary care 
supplementary prescriber specialized in the clinical area of hypertension (site 3) and 
the secondary care prescriber specialized in the area of oncology (site 4). The primary 
care pharmacist was already running a hypertension clinic but needed the doctor to 
co-sign her prescriptions until she qualified. The pharmacist supplementary prescriber 
from secondary care was about to qualify and was setting up her clinic. As 
recruitment occurred approximately 4 months before any patient interviews were due 
to start, it was envisaged that the pharmacists should be qualified and running their 
clinics by the time that the patient interviews were due to start. 
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However, when it was near to the time that patient interviews were due to start at site 
4, the pharmacist SP had to pull out of the study as she had many problems setting up 
her clinic and wasn’t actually running her clinic when recruitment of patients was 
necessary. 
It was therefore necessary to recruit another pharmacist SP in the clinical area of 
oncology and so colleagues were asked to pass onto the lead researcher any contact 
names of people who may be able to help. A colleague found an oncology pharmacist 
SP at a hospital and approached them about the study. The pharmacist oncology SP 
then contacted the researcher to express their interest in the study. 
 
Once these two sites had been recruited, the sites where “normal doctor care” 
occurred could be recruited. As the researcher is employed by an acute secondary care 
trust, the intention was to recruit an oncology consultant from this trust to allow the 
researcher to interview their patients. A letter explaining the study was forwarded to 
the oncology consultants within the trust by the oncology pharmacist on the behalf of 
the lead researcher. A consultant expressed an interest in participating in the study, 
and allowed permission for the lead researcher to interview some of her patients (site 
2). 
In order to recruit a GP practice with patients suffering from hypertension, a list of 
research practices in Bristol (the Bristol area was chosen for convenience)  that get 
paid to take part in and host research projects (Avon PCT consortium) was used to 
send a letter explaining the study (see appendix 13 for this list. -This list was obtained 
from a Bristol GP who was an associate of a member of staff within the pharmacy and 
pharmacology department, University of Bath). A GP from this sample contacted the 
researcher, expressing an interest in participation (site 1).  
 
3.3.2 Inclusion and Exclusion Criteria 
 
The patients that were selected for possible recruitment to the study needed to be 
medically fit enough in the prescriber’s opinion to: 
 
i.) Give informed consent 
ii.) Undertake an interview that will take up to an hour. 
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The principal exclusion criteria for the study were: 
 
• Patients under 16 years of age (Patients under 16 years of age will not be 
chosen to interview due to added difficulties of obtaining parental consent). 
 
• Those suffering from dementia or mental illness which affects their ability to 
give informed consent and participate in this research. (as assessed by their 
pharmacist SP or GP/consultant) 
 
• Those patients identified by the supplementary prescriber or doctor as being 
medically unfit for interview. (e.g. patients with end stage Chronic Obstructive 
Pulmonary Disease (COPD)) 
 
3.3.3 Patient Recruitment 
 
It was anticipated that up to 20 patients in total would be interviewed (5 from each 
site), although the precise number would depend upon the extent to which the relevant 
themes have been saturated within the context of the study’s objectives. 
 
It was decided to recruit and interview patients from the sites where “normal doctor 
care” occurred first of all, as there might be interesting comments made that may lead 
to new lines of questioning in the interview schedule (as per Interpretative 
Phenomological Analysis (IPA) methodology allows) for those patients who have 
consulted a pharmacist supplementary prescriber. Also this allowed extra time for the 
two pharmacist SPs to get their clinics established. 
The GP practice where patients with hypertension were going to be recruited (site 1) 
prepared a list of all patients being treated for hypertension under the care of the GP 
who had given consent for the study to go ahead in his surgery. The GP was asked to 
look at the list of patients that was generated and remove any patients that were 
unsuitable for interview as per the inclusion and exclusion criteria outlined above. An 
electronic random number sampler was used to generate a sample of 30 patients that a 
recruitment pack would be sent out to in order to generate approximately 5 patients 
for interview. Patients that were interested in participating returned an expression of 
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interest form, including any communication requirements they had (such as being 
hard of hearing or not speaking fluent English) back to the lead researcher with their 
contact details. The lead researcher then contacted them on a first come first served 
basis to arrange a suitable interview date and time. The patients were interviewed at 
the GP surgery. 
 
For the patients under “normal doctor care” at the hospital (site 2), a secretary of the 
consultant who had given permission for her patients to be interviewed prepared a list 
of patients that the consultant was currently seeing for regular appointments. The 
consultant then asked the oncology specialist nurse to go through the list and remove 
any unsuitable patients who were too ill to be interviewed. An electronic random 
number generator was then used to produce a random sample of 30 patients that a 
recruitment pack would be sent out to in order to generate at approximately 5 patients 
for interview. The rest of the recruitment was arranged as previously and all patients 
were interviewed in the oncology outpatients department of the hospital. 
 
For the patients under the care of the pharmacist supplementary prescriber in 
hypertension (site 3), the pharmacist was asked to generate a list of the patients they 
had seen, remove any patients that were unsuitable for interview (as per inclusion and 
exclusion criteria) and use an electronic random number generator that was supplied 
to them in order to produce a random list of approximately 30 of their patients, who 
they would send a patient recruitment pack to. Recruitment occurred as explained 
above and the patients were interviewed at the GP practice where the clinic is held. 
 
For the patients under the care of the pharmacist supplementary prescriber in 
oncology the same recruitment methodology was used as per site 3. The patients were 
interviewed at the education centre of the hospital. 
At this new site, the pharmacist supplementary prescriber had only prescribed for 
n=12 patients, therefore recruitment packs were distributed to all of these patients. 
 
3.3.4 Interview Schedule Development 
 
The semi-structured interview schedule (Appendix 14, p429) was developed by using 
literature review, textbooks on qualitative interview techniques and methodology,231 
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232 and discussion with pharmacists and other researchers experienced in using 
qualitative research methodology. Suggestions were made in order to improve the 
flow, structure, content of the interview and to ensure the schedule was collecting data 
of interest. 
 
3.3.4.1 Piloting 
In order to pilot the interview schedule and allow the researcher to practice her 
interview technique, pilot interviews were held with two patients who were known to 
the pharmacy practice research group to be interested in participating in research (One 
of these patients had hypertension). 
These interviews were transcribed verbatim and coded and analysed using the QSR 
NUD*IST VIVO (N-Vivo) version 2 software in order to practice using the software 
with real data. Piloting was undertaken to test how long the interview took, the 
researcher’s interview technique and would also allow for any topics that had not 
been included to be added if necessary. Small amendments were made to the schedule 
after the interviews in order to improve the flow and structure of the interview, but no 
further topics arose and the length of the interview was considered satisfactory. 
The pilot interviews were not used in the final data analysis. 
 
3.3.4.2 Training 
The lead researcher attended a course on interview techniques for qualitative 
interviewing and also a course on the use of the software tool QSR NUD*IST VIVO 
(N-Vivo) version 2 in order to proficiently use the software to input and analyse the 
data generated. 
 
3.3.4.3 Conduction of the interviews 
 
Immediately prior to interview the researchers ensured that the participants were clear 
about the purposes of the research, by discussing the patient information sheet with 
them, and allowing them to ask any questions they had. The participants were 
reassured that their anonymity would be maintained and were asked to sign a consent 
form, on which they agreed to participate in the research and to the audio tape 
recording of the interviews. 
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The length of the interviews varied depending on how talkative the interviewee was. 
Precise times were not noted however times approximately ranged from 20 minutes to 
an hour. The quality of the data not only depended upon the length of the interview 
but also how articulate the participant was. 
The interview schedule was not followed in a rigidly structured manner and some 
topics were covered as they arose in order to keep the interview informal and to 
maintain the flow of information. However, all topics on the interview schedule were 
covered, except for one interviewee who had to leave on time for his hospital 
appointment. 
 
3.3.4.4 Content of the Interviews 
 
The interviews investigated the following issues: 
 
Background of relationship with pharmacists and nurses 
• Participant opinion of pharmacists and nurses and their understanding of their 
role and training that they undertake 
• Perceptions and experience of consulting pharmacists and nurses 
 
Development of non-medical prescribing  
• Perceptions of the development of non-medical prescribing i.e. Is it 
necessary? Is it viewed as appropriate and useful? What impact could it have 
on healthcare provision? How could safety be maintained? Do they think 
pharmacists and nurses capable of diagnosis and prescribing (in terms of 
knowledge and expertise)?  
• Would they would be happy to utilize such a service?  
 
Nurses versus Pharmacists 
 
• Would patients rather be seen by a particular profession and why?  
o Issues such as access to medical records, responsibility for the 
prescribing and diagnosing, need for physical examination as part of 
the consultation and informed patient consent will be discussed and 
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any differences of opinion they would have according to whether they 
are consulting a nurse or a pharmacist. 
 
Benefits of pharmacist and nurse independent prescribing 
• Perceptions of the benefits of pharmacist and nurse independent prescribing 
o Will it increase access to healthcare for patients? 
 
Concerns and barriers to the development of pharmacist and nurse independent 
prescribing 
• Opinions on the barriers to development of pharmacist and nurse independent 
prescribing and their concerns in terms of issues such as clinical governance 
and training (These issues were explored in terms of whether they thought the 
system would be a “safe” one for patients and how they thought the 
performance of the non-medical prescriber would be assessed and how the 
non-medical prescribers ought to keep up to date) 
 
For those who had experienced supplementary prescribing: 
 Describe their experience of consulting a pharmacist supplementary prescriber 
 Has the experience influenced their opinions of pharmacists becoming 
independent prescribers? If so, in what way? 
 
 
3.3.5 Analysis of the interviews 
 
3.3.5.1 Transcribing recorded interviews 
All interviews were audio tape recorded and were then professionally transcribed. The 
researcher then checked the transcription by listening to each tape whilst reading the 
transcription. At that time, minor alterations were made such as adding or correcting 
words that the transcriber had not heard correctly and correcting any typing errors. 
 
3.3.6 Analysis Method 
Interpretative Phenomological Analysis (IPA) was the methodological approach used 
in this part of the research. IPA is concerned with the experiences of small 
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homogenous  groups and not with looking for variations and extremes, as in grounded 
theory.233 As such, it does not attempt to produce an objective statement. The overall 
aim of IPA is to translate the themes into a narrative account, highlighting the relevant 
parts.233 This approach also recognizes that the data collection is a dynamic 
process.231  
IPA is also used where it is recognised that the researcher will influence interpretation 
of the data due to their background. So this theory allows for the bias that can be 
introduced by the fact that the researcher is a pharmacist. (It should be noted however, 
that the patients were introduced to the person undertaking the interviews (and in 
letter explaining the study) as a researcher rather than a pharmacist) 
Data analysis was undertaken concurrently with data collection and systematic efforts 
to check and refine developing categories of data.  
Themes and hypotheses that were identified in early interviews informed questions in 
later interviews. For example, extra prompts were added into the schedule to allow 
fuller discussion of topics. Examples include: Do pharmacists in primary and 
secondary care have the same qualifications? Who do you have the better relationship 
with out of nurses, pharmacists and doctors? How would your doctor know what had 
been prescribed for you by the non-medical prescriber? Would there be demand for 
non-medical prescribing?  
The analytic process was both descriptive and explanatory.  
Identification of themes and patterns and the application of codes require some 
interpretation of the meaning of the data. As a validity check on these interpretative 
processes, the findings were discussed with a health psychologist. This offered a 
different insight into the data. Identification of themes was also undertaken in 
consultation with the health psychologist and the PhD supervisor.  
The account provided is the researcher’s interpretation of the narrative, and therefore 
could be interpreted differently by another person. However, the verbatim extracts 
provide evidence to support the thematic account and their inclusion hence provides a 
means of validation.233 
Extrapolating conclusions from qualitative data should be undertaken cautiously as 
the sample is not large and not drawn randomly. Instead it is chosen purposively to 
elicit interesting and varied responses from the interviewees.234 Suggestions can be 
made as to what affect the attribute has upon the participant’s opinions but this cannot 
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then be generalized to the whole population. Qualitative research does not aim to 
generalise but instead, aims to explain. It can be used to generate data to form the 
basis of quantitative assessment or to explain/understand views of a group to inform 
further policy or practice development. It can also be used to inform further 
qualitative work. 
 
3.3.7 Coding interview data 
Preliminary analysis began with an examination of individual transcripts using the 
qualitative data indexing software package, QSR NUD*IST VIVO (N-VIVO) version 
2, to help analyse the interview data into themes. N-VIVO allows large amounts of 
qualitative data to be reorganised to facilitate interpretation. Each transcript was 
coded. The coding system used was based around the topic guide headings with 
additional codes for commonly occurring topics. Each interview was coded on screen 
by reading the manuscript and applying the appropriate code using the N-VIVO 
programme. 
 
3.3.8 Analysis of interview data 
N-Vivo places all statements with the same code into a separate file so that you can 
either consider the comment as part of the interview it came from or with other 
comments from other interviews that have the same coding. Analysing all comments 
within the same code allows themes to be identified, which are gradually refined and 
renamed as patterns in the words and phrases began to emerge which are common to 
participants discourses. After this initial sorting of the data into themes, the themes 
were written onto cards and placed onto a large white board so that further analysis 
could be undertaken using input from the health psychologist and the research 
supervisor. This helped to refine the themes into the final data set presented.  
 
3.3.9 Post-analysis 
During the interview, participants were informed that when the research was finished, 
they could have a copy of the final report arising from the research work, if they so 
wished. Those participants expressing an interest were asked for details of where to 
send this information, which was stored separately from participant codes. 
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3.3.10 Ethics approval 
 
Ethics approval was sought and obtained for the patient interviews from the Essex 1 
Research Ethics Committee (REC ref no: 05/Q0301/39) (See appendix 2, p 354 for 
copy of approval letter). Research and development approval was then sought from 
each hospital or primary care trust where a prescriber had indicated an interest in 
participating in the study. An honorary contract was also sought and obtained for each 
trust site other than the hospital site where the lead researcher was employed. 
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CHAPTER 4: RESULTS 
 
4.1 NATIONAL SURVEY OF PHARMACIST TRANSCRIBING OF 
DISCHARGE PRESCRIPTIONS (SECONDARY CARE) 
 
4.1.1 Response rates and demographics of respondents 
Of the 206 hospitals, responses were received from 135 hospitals, giving a response 
rate of 66%. Of these, 68% (n=92) of responses came from District General hospitals, 
27% (n=37) from teaching hospitals and 4% from tertiary referral centres (n=5).  
The questionnaire was completed by clinical pharmacist/managers (26% n=35), 
Chief Pharmacists (26% n=35) Principal Pharmacists (25% n=34), Pharmacy 
Managers (7% n=10), Deputy Chief Pharmacists (5% n=7), MI manager/pharmacists 
(4% n=5), Discharge services pharmacists (4% n=5) and one interface pharmacist 
(1%).  
The size of the hospitals varied, with bed sizes ranging from less than 100 to >1500, 
with the most common range being 401-600 (33% n=44). 
 
 
4.1.2 Prescribing activities 
 
4.1.2.1 No prescribing activity 
Hospitals with no pharmacist prescribing comprised the largest group of respondents 
(n=59, 43.7%). 
 
4.1.2.2 Pharmacist Discharge Prescription Transcription Services (PDPTS) 
36% (49/135) of hospitals were currently offering a pharmacist discharge prescription 
transcription service.  
20/135 (15%) of departments reported that they transcribe in-patient drug charts. The 
majority of department’s that re-write in-patient drug charts also transcribe discharge 
prescriptions (17/20, 85%).   
 
4.1.2.3 Prescription amendment policy 
The second most common pharmacist prescribing activity was prescription 
amendment (n=39/135 29%) via a policy whereby the pharmacists can follow agreed 
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protocols to change timings and frequencies of drugs or change a non-formulary drug 
to a formulary alternative within the same pharmacological class. 
 
4.1.2.4 Pre-admission clinics 
24/135 (17.8%) of departments reported that they performed prescribing roles in pre-
admission clinics. 20/135 (14.8%) departments stated that they had pharmacists that 
wrote patient’s normal medication onto drug charts. 12/135 (8.9%) departments 
reported that they prescribed medicines onto a drug chart at pre-admission clinics 
according to set protocols including (e.g.) analgesia, antibiotics, Venous-
ThromboEmbolism (VTE) prophylaxis, and 8/135 (5.9%) departments prescribe 
discharge medication at pre-admission clinics according to set protocols. 6/135 (4.4%) 
departments performed 2 of these roles and 5/135 (3.7%) departments performed 3 of 
these roles.  
 
4.1.2.5 Other prescribing 
The most common “other” form of pharmacist prescribing that was reported was in 
anticoagulant clinics (n=13, 9.6%), and total parenteral nutrition (TPN) prescribing 
(n=4, 3.0%). Four hospitals reported that they have pharmacists that independently 
prescribe (before Independent Prescribing was legalized) however, upon follow-up, 
only one of these hospitals did have a pharmacist that independently prescribed. This 
hospital was involved in a pilot study commissioned by the Department of Health, 
where a specialist TPN pharmacist was independently prescribing TPN for patients 
that were referred to her as part of the nutrition team. Other pharmacist prescribing 
included chemotherapy, in cardiac rehabilitation clinics, migraine clinics, any 
Pharmacy (P) medicines and medicines that the patient had been taking before 
admission.   
 
4.1.3 Future Plans 
Of the departments not offering a pharmacist discharge prescription transcription 
service (PDPTS), 41.9% (n=36/86) indicated that there had been discussions about 
pharmacist transcribing, but no decision made as yet. 33.7%, (n=29/86) indicated that 
there were no plans for such a development, and 22.1% (n=19/86) said that they were 
currently developing such a service.  (2= missing data) 
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Eleven of the departments who said they were implementing a transcription service 
intended to implement the service in 2002, and 2 departments intended to implement 
the service in 2003 (5= missing data). One department intended to implement the 
service during December 2001. 
 
Of the 86 non-transcribing hospitals, 59/86 (68.6%) undertake no prescribing activity 
(Range= 0 to 3 prescribing activities). Transcribing hospitals offer a wider range of 
prescribing activities (Range= 1 to 8 prescribing activities). 
A weak relationship was found between the total number of pharmacists employed 
per hospital and the total number of prescribing activities undertaken (Spearman’s rho 
correlation coefficient= 0.208, p= 0.018). 
 
4.1.4 Prescribing systems 
Asked when the pharmacy departments started their transcription service, one hospital 
stated that they have been running such a service since the 1980’s; all of the other 
hospitals that had a PDPTS had started the service between 1995 and 2001. 
The majority (68.1% n=32/47) only operate the service during normal working hours 
Monday to Friday. A few other hospitals had extended to weekend, or evenings but 
this was an exception. 
The wards/directorates in which the PDPTS was offered is illustrated in figure 3 
below.  
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Figure 3: Directorates/wards where PDPTS operates. (n=49) 
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The most common directorate to have a PDPTS was the medical directorate with 51% 
(n=24/47) of hospitals running the service within this directorate. The next most 
common directorate was the surgical directorate 36% (n=17/47), followed by parts of 
these directorates, and care of the elderly. Only 11% (n=5/47) of hospitals had rolled 
out the service to ALL wards, plus one hospital provided the service to all wards 
minus those wards that stocked pre-packed drugs. One hospital operated PDPTS only 
in those wards where an electronic prescribing system (EPS) was in place. 
 
The pharmacy departments mainly funded the PDPTS (58% n=28/48). Some services 
were funded by the medical and/or surgical directorates (23% n=11/48) and some 
have received trust monies into the pharmacy budget (8% n= 4/48). 
 
The number of pharmacists providing PDPTS per hospital ranges from 1 to 89 (whole 
time equivalent). (Mean=8, Median= 5, Mode=2, 25% percentile= 2, 75% 
percentile=10). The total number of pharmacists per department that provides PDPTS 
ranges from 7 to 102 (Mean=19, Median=16, Mode=9). The percentage of 
pharmacists involved in PDPTS per department ranges from 3% to 100% 
(Mean=39%, Median=33%, Mode=33%). 
 
The model that the PDPTS is based upon is illustrated in Table 3 (p 145). The total is 
greater then 49 as some respondents ticked more than one option for this question. 
The most common model used was the ward pharmacist model (78%, n=38/49) in 
which pharmacists transcribe the discharge prescriptions for their own ward. 
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Model 
 
Frequency (%) 
Ward Pharmacist model 38 (78) 
Medical pharmacist attends whichever ward within the medical 
directorate bleeps them. 
8 (16) 
Surgical pharmacist attends whichever ward within the surgical 
directorate bleeps them. 
4 (8) 
Pharmacists attend whichever ward bleeps them 3 (6) 
Ward model plus only at specific times/Ward Round 2 (4) 
Ward model plus odd prescriptions written in pharmacy  1 (2) 
Ward model plus urgent bleeps 1 (2) 
 
Table 3: Model of PDPTS in use.(n=49) 
 
The majority of departments (79% n=37/47) reported using paper-based prescriptions 
for PDPTS. Nine departments have pharmacists producing prescriptions on electronic 
prescribing systems (Computer-generated prescriptions (n=6), paper and computer 
(n=3)). 
 
Table 4 illustrates how many discharge prescriptions a pharmacist transcribes per day. 
The majority of pharmacists are writing less than 5 prescriptions per day (52% n=25), 
35% (n=17) are writing 5-10 prescriptions per day.  
 
No. of prescriptions/day Frequency (%) 
<5 25 (52) 
5-10 17 (35) 
11-15 3 (6) 
16-20 2 (4) 
26-30 1 (2) 
Total 48 (100) 
 
Table 4: Number of pharmacist-written prescriptions / pharmacist / day. (n=49) 
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The advance notice required to produce a pharmacist-written discharge prescription is 
shown in Table 5. 
 
Advance notice required Frequency (%) 
Less than 1 hour 16 (33) 
No rule as such 13 (27) 
1-2 hours 6 (13) 
Only written whilst pharmacist is on the ward 6 (13) 
24 hours 6 (13) 
3-4 hours 1 (2) 
Total 48 (100) 
 
Table 5: Advance notice required to produce a prescription (n=49) 
 
4.1.5 Training 
Training requirements for pharmacists who transcribe discharge prescriptions were 
explored. Table 6 illustrates that the most common training requirement was the 
completion of an in-house training programme (55% n=27), followed by designation 
by a senior pharmacist (31% n=15), and then possession of a clinical diploma (20% 
n=10). The total is greater than 49 as some respondent’s ticked more than one option 
for this question.  
 
Training Frequency (%) 
In-house training programme 27 (55) 
Designation by senior pharmacist 15 (31) 
Clinical diploma 10 (20) 
Clinical certificate 8 (16) 
2 years ward experience 7 (14) 
No further training 7 (14) 
MSc in clinical pharmacy 1 (2) 
3 years ward experience 1 (2) 
At least 1 year of diploma completed 1 (2) 
Clinical diploma or 3 years experience 1 (2) 
Training programme in development 1 (2) 
Table 6: Training required for pharmacists to transcribe. (n=49) 
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Of the eight departments that had a formal training programme for PDPTS 
(1=missing data), five departments used tutorials, seven departments used 
observation, seven departments used supervision, and four departments used an 
examination (some hospital pharmacy departments used a combination of techniques). 
Of the 11 departments that did assess competency to transcribe, four did this via non-
ward based training/assessment, four departments did ward-based assessment and 1 
completed an annual competency review (2= missing data). 
Frequency of re-assessment of competency of the pharmacists who were transcribing 
is illustrated in Table 7.  
 
Frequency of reassessment Frequency (%) 
Not reached a decision 22 (48) 
Never reassess 15 (33) 
Once every 2 years 3 (7) 
On-going assessments 3 (7) 
Twice a year 2 (4) 
Once a year 1 (2) 
Total 46 (100) 
 
Table 7: Frequency of reassessment of pharmacists providing a PDPTS. (n=49) 
 
The nine departments that did undertake some form of re-assessment were asked how 
they did this. Three departments used observation, two departments used a total 
competency assessment programme, and one department used supervised 
transcription of discharge prescriptions, one department used an examination, one 
department used on-going assessment via an intervention programme, and one 
department completed an audit of completed prescriptions prepared by the 
pharmacist. 
 
4.1.6 Responsibility and accountability 
 
Although the majority of hospitals operating PDPTS had a formal protocol for the 
service in place, (57 per cent, n=27), a substantial number did not have a protocol in 
place (43 per cent, n=20) however, 6 of these hospitals were in the process of drawing 
one up. (2= missing data) 
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The majority of hospitals that offer PDPTS ask the doctor to counter-sign/authorise 
the prescription written by the pharmacist before the patient is discharged (65 per cent 
n=31/48) (1=missing data). However, seven hospitals reported that they sometimes 
asked the doctor to counter-sign/authorise the discharge prescription, and ten hospitals 
that they did not ask the doctor to counter-sign/authorise the prescription. 
Those pharmacy departments that did not ask the doctor to co-sign the prescription 
often asked the doctor to indicate in some other manner that they wanted the 
pharmacist to write the prescription and were satisfied that the current medication was 
suitable for the patient at discharge. Three departments used verbal authorisation, two 
departments asked the doctor to sign the in-patient drug chart, two departments 
“sometimes” asked the doctor to sign the in-patient drug chart and one asked the 
doctor to sign a separate form. Two departments did not ask the doctor to indicate in 
any other manner of his/her authorisation to write the prescription. 
Among the hospitals that “sometimes” asked the doctor to counter-sign the 
pharmacist-written prescription, only one hospital had an alternative method of 
authorisation, which was to sometimes ask the doctor to counter-sign the in-patient 
drug chart. 
 
All of the hospitals were asked if the doctor indicated in any other manner that he/she 
gave authorisation for certain drugs to be prescribed on discharge by the pharmacist 
(Table 8).  
 
Authorisation method Frequency (%) 
No alternative authorisation method used 27 (56) 
Doctor verbally authorises the discharge prescription 7 (15) 
Doctor sometimes signs the in-patient chart 6 (13) 
Doctor signs a separate authorisation form 4 (8) 
Doctor always signs the in-patient chart 4 (8) 
Doctor authorises discharge prescription in medical notes 3 (6) 
Doctor writes information on the in-patient chart about discharge 2 (4) 
 
Table 8: Methods of authorisation of pharmacist-written discharge prescriptions by 
the doctor (other than counter-signing the discharge prescription). (n=48) 
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The most common method used for indicating which drugs the patient was to be 
discharged upon was verbal authorisation (15 per cent, n=7), (1=missing data) 
followed by the doctor sometimes signing the drug chart (13 per cent, n=6). The 
twenty-six reported methods of authorisation other than countersigning were used by 
twenty-one pharmacy departments indicating that some departments used several 
different authorisation methods. The remaining twenty-seven pharmacy departments 
did not use any other methods of authorisation. 
 
4.1.7 Factors that influence the provision of a PDPTS 
 
Pharmacists in hospitals that do offer PDPTS (n=49/135) were asked their reasons for 
offering the service, via an open question. (1=missing data) The results are presented 
in Table 9.  
 
Reason 
Frequency (%) 
Speed up the discharge process 35 (73) 
Improve accuracy/decrease errors 24 (50) 
Reduce junior doctor time 16 (33) 
Increase efficiency in dispensing process 9 (19) 
Cost savings Re: use of Patient’s Own Drugs (POD) 7 (15) 
Enhance pharmacist role/job satisfaction 6 (13) 
Improve communication with primary care 5 (10) 
Decrease waste prescribing 4 (8) 
Increased counselling opportunities 2 (4) 
Decrease nursing time 2 (4) 
Risk management 1 (2) 
Improve patient care 1 (2) 
 
Table 9: Reasons FOR provision of a PDPTS (n=48) 
 
Most hospitals gave more than one reason for providing PDPTS. The most common 
reason for implementing PDPTS was to speed up the discharge process (73 per cent, 
n=35), followed by to improve accuracy/decrease errors/improve quality (50 per cent, 
n=24). Thirty-three per cent (n=16) stated that the service was implemented to release 
junior doctor time.  
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Of the departments not offering a pharmacist discharge prescription transcription 
service (PDPTS), 42% (n=36/86) indicated that there had been discussions about 
pharmacist transcribing, but no decision made as yet. 34%, (n=29/86) indicated that 
there were no plans for such a development, and 22% (n=19/86) said that they were 
currently developing such a service.  (2= missing data) 
The pharmacy departments that had no plans to implement PDPTS were asked, via an 
open question, for their reasons against introducing this service. The results are shown 
in Table 10.  
 
Reason Frequency (%) 
Insufficient resources 18 (62) 
Other services being developed preferentially 7 (24) 
No plans/Discussion as yet about providing PDPTS 6 (21) 
Lack of funding 4 (14) 
Electronic prescribing system under development, so not applicable 4 (14) 
Viewed as an administrative role 2 (7) 
Service would be for the doctor’s benefit only 1 (3) 
 
Table 10: Reasons NOT to provide PDPTS. (n=29) 
 
The most frequently cited reason for not implementing a transcription service was 
insufficient resources (58 per cent, n=18), followed by development of other 
medicines management services in preference to pharmacist transcription of discharge 
prescriptions (e.g. PODs and one-stop dispensing) (23 per cent, n=7, 4=missing data) 
At no point were legal issues suggested as a factor against the provision of PDPTS.  
 
At the end of the questionnaire, respondents were asked whether they had any further 
comments. In this section, amongst the hospitals that did not provide PDPTS, a total 
of 24 comments were made. 11 of these hospitals commented that they were currently 
considering the implementation of PDPTS, although 4 hospitals also commented that 
this did depend upon staffing/funding resources. 3 hospitals also positively 
commented that there were clear benefits of PDPTS. Only two comments suggested 
that there would be opposition of PDPTS implementation by medical staff: 
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1.) “Despite continuous problems with delayed discharges due to TTO’s not being 
ready, we are likely to meet resistance to pharmacists transcribing TTO’s from our 
medical director. He is of the opinion that pharmacists should not write on 
prescription charts at all, but should be educating and instructing the junior doctors 
on how to do it.” 
 
2.) “A pilot project run 2-3 years ago of a pharmacist writing discharge 
prescriptions for medical patients worried medical staff so much that they got their 
act together (temporarily). There were problems predicting discharge doses e.g. 
reducing steroid doses. The project was not continued.”  
 
As stated earlier, some hospitals were not introducing PDPTS due to other services or 
electronic prescribing being implemented preferentially instead (Table 9). Three 
similar comments were also made in the open comments section about the potential 
impact of electronic prescribing upon the need for PDPTS: 
  
3.) “This will be superseded by electronic prescribing”  
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4.1.8 Summary of main findings from national survey of pharmacist 
transcribing of discharge prescriptions (secondary care) 
 
 The response rate was 66% (135/206).  
 PDPTS was offered by 49/135 (36%) of hospital pharmacy departments, as an 
additional service to doctors writing discharge prescriptions. PDPTS was the 
most common prescribing activity undertaken by pharmacists, followed by a 
prescription amendment policy (29%), prescribing in pre-admission clinics 
(18%) and re-writing drug charts (15%). Fifty-nine department’s (44%) did 
not undertake any prescribing activity. 
 Of the non-transcribing hospitals, n=59/86 (69%) undertook no prescribing 
activity (Range= 0 to 3 prescribing activities). Transcribing hospitals offer a 
wider range of prescribing activities (Range= 1 to 8 prescribing activities). 
 A weak relationship was found between the total number of pharmacists 
employed per hospital and the total number of prescribing activities 
undertaken (Spearman’s rho correlation coefficient= 0.208, p= 0.018). 
 The most frequently used PDPTS model involved pharmacists transcribing the 
discharge prescriptions for their own wards (n=38, 78%).  
 The number of pharmacists transcribing discharge prescriptions per hospital 
ranges from 1 to 89. (Mean=8, Mode=2, Median= 5, 25% percentile= 2, 75% 
percentile=10).  
 The majority of pharmacists wrote less than 5 prescriptions per day (n=25, 
52%), (n=17, 35%) wrote 5-10 prescriptions per day. 
 The most common training requirement for pharmacists to start transcribing 
was an in-house training programme (n=27, 55%).  
 The majority of department’s do not re-assess the ability of their pharmacists 
to transcribe (n=37, 80%).  
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4.2 IMPLEMENTATION, RISKS AND CONCERNS ABOUT 
SUPPLEMENTARY PRESCRIBING: SURVEY OF PRIMARY AND 
SECONDARY CARE PHARMACISTS 
 
4.2.1 Response rates and demographics of respondents 
 
 
Of the 143 hospitals, responses were received from 97 (68% response rate) and for the 
primary care trusts (n=271), responses were received from 183 (68% response rate). 
No particular patterns emerged when assessment of response rate from different 
regions was undertaken. 
 
Sixty-two per cent of hospital responses (n= 58) came from Chief Pharmacists (CP) of 
district general hospitals, 35 per cent (n=33) from Chief Pharmacists of teaching 
hospitals and 3 per cent (n=3) from Chief Pharmacists of tertiary specialist hospitals. 
The size of the hospitals varied, with bed sizes ranging from 201-400 to >1500, with 
the most common ranges being 401-600 (25%, n=23) and 1001 to 1500 (25%, n= 23). 
Secondary care trust respondents had most commonly been pharmacists for more than 
25 years (44/94 (47%)) and chief pharmacists for more than 16 years (26/92 (28%)). 
The mean +/- standard deviation number of full-time equivalent pharmacists 
employed by secondary care trusts was 26+/-19 (range, 6-126). 
 
Primary care trust (PCT) respondents had most commonly been pharmacists for 11-15 
years (45/181 (25%)) and PCT pharmacists for 3-4 years (62/180 (34%)). Primary 
care responses indicated that the mean +/- standard deviation number of full-time 
equivalent pharmacists employed by PCTs was 3+/-2 (range, 0.25-12). 
 
4.2.2 Pharmacist Supplementary Prescribing 
 
4.2.2.1 Secondary care  
 
When asked about their intentions to implement supplementary prescribing by 
pharmacists, the majority of CPs (57%, n= 55) stated that they intended to implement 
the service by the end of 2005 and 14 per cent (n=14) stated that they were not going 
to implement supplementary prescribing by pharmacists by the end of 2005. Some 
CPs did not know what their intentions were (29%, n= 28).  
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The total number of pharmacists employed by the trust was significantly associated 
with the intention to implement supplementary prescribing by pharmacists (p=0.004, 
kruskal-wallis test, df=3). As the number of pharmacists employed by the trust 
increased, the more common the intention to implement supplementary prescribing.  
The CPs who intended to implement pharmacist supplementary prescribing planned to 
train between 0 to 14 pharmacists (mean, 3) during 2004, and between 1 to 24 
pharmacists (mean, 3) during 2005. 
There was a significant relationship between the number of pharmacists to be trained 
as supplementary prescribers during 2004 and the number of hospital beds in the 
hospital, with the highest mean rank being for those hospitals with 601-800 beds 
(p=0.012, Kruskal Wallis test, df=5). This was also found to be the case for 2005 
(p=0.003, Kruskal Wallis test, df=5). 
A moderate positive correlation was found between the total number of pharmacists 
employed by the trust and the number of pharmacists to be trained as supplementary 
prescribers during 2004 (Spearman’s rho correlation coefficient, r=0.54, p<0.001), 
and this was also found to be the case for 2005 (r=0.57, p<0.001). 
Teaching hospitals were significantly more likely than other types of hospitals to train 
pharmacists in 2005 (p=0.026, Kruskal-Wallis test, df=2). The majority of chief 
pharmacists (85%) stated that they intended to train D grade pharmacists as 
supplementary prescribers; 70% intended to use E grade pharmacists. The different 
clinical areas of supplementary prescribing targeted by chief pharmacists appear in 
Table 11 (p 155). 
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 No. (%) Respondents 
Clinical Area Secondary Care (n=53) Primary Care (n=75) 
Hypertension -b 40 (53) 
CHD or Hyperlipidemia - 35 (47) 
Diabetes Mellitus 5 (9) 27 (36) 
TPN or nutrition 19 (36) - 
Asthma - 25 (33) 
Oncology-Haematology 16 (30) - 
Heart Failure or Cardiology 13 (25) - 
COPD - 18 (24) 
HIV 12 (23) - 
Renal 12 (23) - 
Anticoagulation 10 (19) 7 (9) 
Surgery or orthopaedics 9 (17) - 
Gastrointestinal or PPIs - 12 (16) 
Pain Control 8 (15) 7 (9) 
Rheumatology 7 (13) 5 (7) 
Medication Review - 7 (9) 
Hospital Admissions 5 (9) - 
Care of the Elderly 5 (9) 6 (8) 
Cystic Fibrosis 5 (9) - 
Hospital Discharge Planning 5 (9) - 
Mental Health 5 (9) 4 (5) 
Paediatrics 4 (8) - 
Other 30 (57) 17 (23) 
 
Table 11. Clinical areas to be undertaken by pharmacists with supplementary 
prescribing authority
a 
 
aCHD= coronary heart disease, TPN= total parenteral nutrition, COPD= coronary 
obstructive pulmonary disease, HIV= human immunodeficiency virus, PPIs= proton 
pump inhibitors. 
bArea not offered on questionnaire or provided by respondents 
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Teaching hospitals were also more likely than other hospital types to offer more 
pharmacist supplementary prescribing activities (p=0.007, Kruskal-Wallis test, df=2). 
A moderate positive correlation between the total number of pharmacists employed 
by the trust and the total number of pharmacist supplementary prescribing activities 
being offered (Spearman’s rho correlation coefficient, r=0.59, p<0.001). 
A moderate positive correlation was also found between the total number of 
pharmacist supplementary prescribing activities being offered (i.e. the different 
clinical areas) and the total number of non-supplementary prescribing pharmacist 
prescribing activities being undertaken currently (Spearman’s rho correlation 
coefficient, r=0.53, p=0.001). 
The person who will assume responsibility for prescribing if the SP is away was most 
commonly a junior doctor (56%, n=30/54), followed by a consultant physician (39%, 
n=21/54) or another pharmacist supplementary prescriber (37%, n=20/54). Some CPs 
indicated that no cover would be provided for the service (24 per cent, n=13/54) or 
that they didn’t know how who would provide the service (13 per cent, n=7/54) 
(missing data=1). 
Additional training requirements (additional to the standard supplementary 
prescribing training) most commonly included a period of clinical experience in the 
clinical area that the pharmacist supplementary prescriber would be working in (89 %, 
n=49/55), followed by possession of a clinical diploma (73%, n=40/55) and the 
completion of continuing professional development (CPD) requirements from the 
Royal Pharmaceutical Society of Great Britain (RPSGB) (55%, n=30/55). 
 
4.2.2.2 Primary care 
 
The majority of Primary Care Trust Pharmacists (PCTP) intended to implement 
supplementary prescribing by the end of 2005 (56%, n=100) and 9 per cent (n=17) did 
not. Some PCTPs did not know their intentions (35%, n=63). 
The total number of pharmacists employed by the trust was significantly associated 
with the intention to implement supplementary prescribing by pharmacists (p=0.008, 
Kruskal-Wallis test, df=3). 
The PCTPs who intended to implement pharmacist supplementary prescribing 
planned to train between 0 to 6 pharmacists (mean, 2) during 2004, and 1 to 10 
pharmacists (mean, 3) during 2005.  
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When asked which type of pharmacist they were going to train as supplementary 
prescribers, the most common response was primary care based pharmacists (in 
PCT’s) (67%, n=68/102) followed by general practitioner (GP) practice-based 
pharmacists (55%, n=56/102) and community pharmacists (45%, n=46/102) (missing 
data=3). 
The different clinical areas in which primary care trust pharmacists planned to 
implement supplementary prescribing are presented in Table 10 (p150). 
The person most commonly listed to assume responsibility for prescribing in the SP’s 
absence was a GP (37%, n=38/102) followed by a nurse supplementary prescriber 
(21%, n=21/102) or a pharmacist supplementary prescriber (15%, n=15/102). A large 
percentage of PCTPs indicated that no one would provide the service in the 
prescriber’s absence (32%, n=33/102); 26% (n=26/102) did not know who would 
provide the service (missing data=3). 
Additional training requirements (additional to the standard supplementary 
prescribing training) most commonly included the completion of continuing 
professional development (CPD) requirements stipulated by the RPSGB (64%, 
n=65/101) followed by a period of clinical experience in the area that the pharmacist 
supplementary prescriber would be working (60%, n=61/101) and possession of a 
clinical diploma (50%, n=50/101) (missing data=4). 
 
4.2.3 Nurse supplementary prescribing 
4.2.3.1 Secondary Care 
 
When asked whether there were nurses already qualified as supplementary prescribers 
working within their trust, 58% (n=56) stated that they did have nurse supplementary 
prescibers, 41% (n=40) that they did not currently have nurse supplementary 
prescribers, and one chief pharmacist did not know. 
The different clinical areas of supplementary prescribing that nurse supplementary 
prescribers were providing within their trust are presented in Table 12 (p 158). 
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Number (%) Respondents Number (%) Respondents  
Clinical Area Primary 
Care 
Secondary 
Care 
 
Clinical Area Primary 
Care 
Secondary 
Care 
AandE/ MAU - 8 (15) Obesity 2 (2) - 
Anticoagulation 1 (1) 5 (10) Oncology - 4 (8) 
Asthma 52 (61) 14 (27) Ophthalmology - 1 (2) 
Care of the Elderly 2 (2) 1 (2) Paediatrics - 6 (12) 
COPD 19 (22) 14 (27) Pain Control - 8 (15) 
Dermatology 7 (8) 9 (17) Palliative Care 4 (5) 4 (8) 
Diabetes 41 (48) 12 (23) Rehabilitation - 1 (2) 
ENT - 2 (4) Renal - 3 (6) 
Epilepsy 1(1) 2 (4) Rheumatology 1 (1) 5 (10) 
Family Planning 10 (12) 3 (6) SCBU - 4 (8) 
Gastroenterology - 2 (4) Sexual health 1 (1) - 
Gynae/maternity - 2 (4) Smoking 
Cessation 
3 (4) - 
Heart Failure 37 (43) 12 (23) Stoma - 1 (2) 
Homeless 1 (1) - Stroke 1 (1) - 
Hypertension 24 (28) 1 (2) Surgery - 2 (4) 
Immunology - 1 (2) Thyroid 2 (2) - 
Infection 
control/Infections 
1 (1) 1 (2) Urology - 2 (4) 
Mental Health 5 (6) - Vaccinations 1 (1) - 
Minor Injuries 10 (12) -    
 
(N.B. missing data=11 for primary care, 1 for secondary care) 
Table 12. Clinical area currently being provided by nurse supplementary 
prescribers in primary (n=86) and secondary care (n=52) 
 
Abbreviations: 
 
Aand E/ MAU= Accident and Emergency/ Medical Admissions Unit 
COPD= Chronic Obstructive Pulmonary Disease 
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ENT= Ear, Nose and Throat 
SCBU= Special Care Baby Unit  
 
4.2.3.2 Primary Care 
 
When asked whether there were nurses already qualified as supplementary prescribers 
working within their trust, 75% (n=136) stated that they did have nurse supplementary 
prescribers, 20% (n=36) that they did not currently have nurse supplementary 
prescribers, and four PCTPs stated that they did not know. Interestingly, 5 primary 
care trusts reported that they had nurses who were trained as supplementary 
prescribers, but were not actually prescribing at the moment (2=missing data). 
The different clinical areas of supplementary prescribing that nurse supplementary 
prescribers were currently providing within their trust are presented in Table 12 (p 
158). 
The specialist area of nurses that the primary care trust pharmacists stated were 
training as supplementary prescribers are presented in Table 13 below. 
 
 
Nurse Number (%) of respondents 
Practice-based nurses 127 (89) 
District Nurses 66 (46) 
Health-Visitor 30 (21) 
Specialist Nurse 25 (18) 
Midwives 10 (7) 
Community paediatric nurses 7 (5) 
Community hospital ward nurse 6 (4) 
Walk in centre/ Emergency Nurse 6 (4) 
Mental Health Nurse 3 (2) 
PCT nurses 3 (2) 
School Nurses 3 (2) 
Prison Nurse 1 (1) 
Interface Nurse 1 (1) 
Don’t Know 9 (6) 
(N.B. missing data=1) 
Table 13: Specialist area of nurses training as supplementary prescribers –
primary care. (n=143) 
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The most common form of cover for the nurse supplementary prescribing service was 
to be provided by a GP (45%, n=64), followed by another nurse supplementary 
prescriber (30%, n=42) and then a pharmacist supplementary prescriber (5%, n=7). 
However, 35% (n=49) of primary care trust pharmacists did not know how cover was 
going to be provided and 21% (n=30) stated that no cover would be provided for the 
service (missing data= 2). 
 
4.2.4 Implementation of Pharmacist Supplementary prescribing  
4.2.4.1 Secondary care 
The factors affecting recruitment of designated medical practitioners are presented in 
Table 14 (p 161). 
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 No. (%) Respondents 
Factor Secondary Care (n=93) Primary Care (n= 
179) 
Time commitment  65 (70) 146 (82) 
Concurrent workload 57 (61) 140 (78) 
Benefit to mentor 53 (57) 110 (62) 
Relationship with the trainee 47 (51) 75 (42) 
Commitment and understanding 47 (51) 93 (52) 
Lack of funding 20 (22) 119 (67) 
None 2 (2) 4 (2) 
Other 0 7 (4) 
 
Table 14: Factors affecting recruitment of Designated Medical Practitioners in 
secondary and primary care.  (N.B. missing data=3 and 4 for secondary and 
primary care respectively) 
 
When asked whether if it would be easier to recruit designated medical practitioners 
(DMPs) for nurses rather than pharmacists. 44% of the CPs did not believe it would 
be, 22% believed it would and 30% did not know (missing data= 4%). The most 
common reasons given amongst those who agreed with the statement was that nurses 
already have an established working relationship with doctors (50%, n=8) and that 
nurses are already working as prescribers (31%, n=5). Pharmacists who did not 
believe it would be easier indicated that (1) the problems are identical for both 
professions (31%, n=8), (2) the ease of recruitment would be dependent on the 
relationship with the DMP and the benefit received by the DMP (27%, n=7), and that 
(3) pharmacists are highly specialized and well regarded (23%, n=6).   
 
4.2.4.2 Primary care 
 
The individuals charged with implementing pharmacist supplementary prescribing 
within each PCT are listed in Table 15 (p 162). 
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Person or Group  No. (%) Respondents 
Pharmaceutical Adviser 118 (65) 
PCT non-medical prescribing group 58 (32) 
Medicines management committee 36 (20) 
Clinical governance lead 7 (4) 
Community pharmacy development group 4 (2) 
Nurse prescribing facilitator 3 (2) 
Lead pharmacist for prescribing 2 (1) 
Head of workforce development 1 (1) 
Not yet decided 29 (16) 
Do not know 3 (2) 
No one 2 (1) 
(N.B. missing data = 2) 
Table 15. Person or group responsible for implementing supplementary 
prescribing (SP) by pharmacists within primary care trusts. ( n=181) 
 
When asked if it would be easier to recruit designated medical practitioners (DMP) 
for nurses rather than pharmacists, the majority of PCTPs agreed with this statement 
(47%, n=86) Twenty-eight percent (n=50) did not and 25% (n=46) did not know 
(missing data=1).  
Those who agreed with the statement indicated that nurses already have an established 
working relationship with doctors (87%, n=69), and that nurses are already working 
as prescribers (27%, n=21). Respondents also stated that (1) General Practitioners 
(GPs) do not understand pharmacists’ skills and have no relationship with them (15%, 
n=12), (2) it would be more difficult for employees of trusts (11%, n=9) and (3) 
pharmacists are viewed as being business focused or non-NHS employees(10%, n=8). 
The most common reasons given amongst those who disagreed with the statement 
were (1) the problems are identical for both professions (48%, n=13), (2) pharmacists 
have good working relationships with other healthcare professionals (26%, n=7) (3) it 
would be dependent on the relationship with and the benefit received by the DMP 
(15%, n=4), and (4) it depends on whether the person is a trust employee (15%, n=4). 
Therefore there seemed to be some confusion as whether being an employee of a 
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primary care trust for a pharmacist would make it easier or more difficult to recruit a 
DMP. 
 
4.2.5 Implementation of Nurse Supplementary Prescribing 
 
The person responsible for taking forward non-medical nurse supplementary 
prescribing within primary care trusts are presented in Table 16 below. 
 
Person or group Number (%) of Respondents 
Director of nursing 95 (52) 
PCT non-medical prescribing group 70 (39) 
Pharmaceutical adviser 56 (31) 
Medicines management committee 25 (14) 
Nurse prescribing lead 20 (11) 
Executive nurse/ professional development lead 6 (3) 
Clinical governance lead 5 (3) 
Senior nurse forum 3 (2) 
Assistant director of primary care 1 (1) 
CPD facilitator 1 (1) 
Head of workforce development 1 (1) 
Yet to be decided 6 (3) 
Don’t know 2 (1) 
No-one 2 (1) 
(N.B. missing data =1) 
Table 16: Person or group responsible for implementing supplementary 
prescribing (SP) by nurses within the trust (primary care). (n=182) 
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4.2.6 Section C attitude scale results 
 
4.2.6.1 Secondary Care 
The overall attitude scale results (Section C of questionnaire) are presented in 
appendix 7, p 409. 
 
4.2.6.1.1 General attitude score 
The mean attitude score overall was 0.35 (SD 6.87) and a histogram of attitude scores 
indicated a normal distribution (Kolmogorov-Smirnov significance >0.05) (Figure 4 
below). 
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Figure 4: Histogram of the attitude scores of the chief pharmacist respondents 
(secondary care) (Missing data n=9) 
(The reasoning for removing statements 30,21,32 and 35 from the total scale is 
discussed in the section “Testing the overall reliability of the scale-secondary care” 
(p 169)) 
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4.2.6.1.2 Years of qualification 
A one-way between groups analysis of variance was conducted to explore the impact 
of number of years of qualification as pharmacists of the chief pharmacists on their 
attitude towards supplementary prescribing, as measured by the total attitude score. 
Subjects were divided into five groups according to the number of years they had 
been qualified as pharmacists. No statistical difference was found between the five 
groups and their total attitude scores. 
 
4.2.6.1.3 Number of years as a chief pharmacist 
A one-way between groups analysis of variance was conducted to explore the impact 
of number of years as a chief pharmacist on their attitude towards supplementary 
prescribing, as measured by the total attitude score. Subjects were divided into six 
groups according to the number of years they had been chief pharmacists. No 
statistical difference was found between the six groups and their total attitude scores. 
 
4.2.6.1.4 Hospital type 
A one-way between groups analysis of variance was conducted to explore the impact 
of hospital type upon the attitude of the chief pharmacist towards supplementary 
prescribing, as measured by the total attitude score. Subjects were divided into three 
groups according to the hospital type they were from. No statistical difference was 
found between the three groups and their total attitude scores. 
 
4.2.6.1.5 No. of beds 
A one-way between groups analysis of variance was conducted to explore the impact 
of the size of the hospital upon the attitude of the chief pharmacist towards 
supplementary prescribing, as measured by the total attitude score. Subjects were 
divided into seven groups according to the size of hospital they were from. No 
statistical difference was found between the seven groups and their total attitude 
scores. 
 
4.2.6.2 Primary Care 
The mean attitude score overall was -1.0 (SD 4.64) and a histogram of attitude scores 
indicated a normal distribution (Kolmogorov-Smirnov significance >0.05) (Figure 5, 
p 166). 
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Figure 5: Histogram of the attitude scores of the primary care pharmacist 
respondents (Missing data n=13) 
(The reasoning for removing statements 23,30,31 and 33 from the total scale is 
discussed in the section “Testing the overall reliability of the scale-primary care” (p 
170)) 
 
4.2.6.2.1 Years of qualification 
A one-way between groups analysis of variance was conducted to explore the impact 
of number of years of qualification as pharmacists of the primary care trust 
pharmacists on their attitude towards supplementary prescribing, as measured by the 
total attitude score. Subjects were divided into six groups according to the number of 
years they had been qualified as pharmacists. (Six groups were used rather than five 
as per secondary care, as an assumption was made that a chief pharmacist would have 
at least five years experience. For primary care pharmacists a category was included 
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for having less than five years experience since qualification.) No statistical difference 
was found between the six groups and their total attitude scores. 
 
4.2.6.2.2 Number of years as a primary care trust pharmacist 
A one-way between groups analysis of variance was conducted to explore the impact 
of number of years as a primary care trust pharmacist on their attitude towards 
supplementary prescribing, as measured by the total attitude score. Subjects were 
divided into six groups according to the number of years they had been primary care 
trust pharmacists. No statistical difference was found between the six groups and their 
total attitude scores. 
 
4.2.7 Factor analysis 
Bartlett’s test of sphericity was significant (p<0.001) for both the primary and 
secondary care questionnaire. Also the Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy was adequate for both questionnaires. This verifies that the 
majority of items within the survey were sufficiently related to each other to proceed 
with factor extraction. More than half the items had a correlation coefficient of greater 
than 0.3, for both questionnaires, suggesting a strong correlation between the items. 
Six factors were extracted using Principal Components Analysis (PCA) with an Eigen 
value greater than 1 for the secondary care questionnaire, and on review of the scree 
plot, either three or five factors could be retained. However, after examining both 
models and seeking advice from a medical statistician, a three factor model was 
thought to be the most appropriate explanation of the data. This explained 40.5 per 
cent of the total variance.  
For the primary care questionnaire, seven factors were extracted using PCA with an 
Eigen value greater than 1. On review of the scree plot and discussion with a medical 
statistician, three factors were retained, which explained 37.0% of the total variance. 
The extracted factors were rotated using oblique rotational methods. 
For the secondary care questionnaire, item thirty-one did not load at all on the factors 
and therefore this item was dropped at this stage. Items 30 and 35 do not load 
significantly on any factor (significance= factor loading>0.4), and therefore these two 
items would be further assessed on the internal consistency of the extracted factors 
(see appendix 8, p 414). 
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For the primary care questionnaire, items 30 and 33 did not load at all on the factors 
and therefore these questions were dropped at this stage. Item 20 did not load 
significantly on any factor and therefore this item would be further assessed on the 
internal consistency of the extracted factors (see appendix 9, p 416). 
 
 
4.2.7.1 Testing the internal consistency of the extracted factors 
 
The internal consistency of items within a factor was ascertained. The reliability 
coefficient (Cronbach’s coefficient alpha) was calculated to indicate the strength of 
the relationship of each item within the factor. The consistency of the factor 
constructs are presented in Table 17 below. 
 
No. of items Coefficient Factor construct 
Primary Care Secondary Care Primary Care Secondary Care 
One 5 5 0.519 0.597 
Two 4 6 0.587 0.694 
Three 4 3 0.555 0.622 
 
Table 17: Reliability coefficients of the extracted subscales 
 
4.2.7.1.1 Secondary care 
 
Assessment of the individual reliability coefficient for each item in the extracted 
factors suggested that items 22, 32 and 35 needed to be removed from factor one, 
items 30 and 32 needed to be removed from factor two and item 25 from factor 3 as 
they adversely affected the internal consistency of the extracted factor. 
 
4.2.7.1.2 Primary care 
Assessment of the individual reliability coefficient for each item in the extracted 
factors suggested that items 23 and 31 needed to be removed from factor one, item 21 
needed to be removed from factor two and item 20 from factor 3 as they adversely 
affected the internal consistency of the extracted factor. 
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4.2.7.2 Testing the overall reliability of the scale 
Item-total correlations were assessed, which compares the scores on individual 
statements with the total score of the scale. Statements were considered for rejection if 
their item-total correlation was below 0.2. 
Also the overall correlation between items within the scale was measured using the 
Cronbach’s alpha score. A reliability coefficient of 0.7 or above is recommended 
which would imply that seventy per cent of the measured variance is reliable and 
thirty per cent is owing to random error. 
 
4.2.7.2.1 Secondary care 
The reliability scores as outlined above therefore suggest removing items 30, 31 and 
35 from the overall scale. As item 32 was removed from two of the three factors upon 
internal consistency measurement, the overall Cronbach’s alpha coefficient was also 
calculated for the scale minus this item as well. This produced the best overall 
Cronbach alpha for the scale =0.75, (minus items 30,31,32 and 35). 
 
4.2.7.2.2 Primary care 
The reliability scores as outlined above therefore suggest removing items 20, 30 and 
33 from the overall scale. However, the best overall Cronbach alpha score for the 
scale is with items 23,30,31 and 33 removed from the scale= 0.602. Therefore this 
overall reliability coefficient score coupled with the poor internal consistency of the 
extracted factors suggests that this scale is not reliably measuring the attitudes on the 
scale. 
 
4.2.7.3 Interpreting the factors 
Table 18 and Table 19 (p170-171) display the interpretation of the emergent 
constructs. The factor analysis process had grouped various statements from the 
questionnaire that were related to each other into each factor. The items within each 
of these emergent factors were then reviewed and the concepts underlying them were 
described and interpreted.  
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Factor one: Limitations of the 
SP training model  
High scoring respondents were being positive 
about SP, were willing to put more effort into the 
development of SP (if necessary) and they thought 
there would not be many limitations to the SP 
training model. 
Low scoring respondents were being negative 
about the SP training model, were less likely to put 
much effort into the development of SP and were 
agreeing that there were problems with it. 
 
Factor two: Professional 
competence/responsibility 
issues once trained 
High scoring respondents were being positive 
about SP and were suggesting that trained 
supplementary prescribers will not encounter 
issues that threaten their professional competence 
or responsibility. 
Low scoring respondents were being negative 
about SP and were suggesting that trained 
supplementary prescribers would encounter issues 
that threaten their professional competence or 
responsibility. 
 
Factor three: How commonly 
SP will be implemented 
High scoring respondents had more will to 
introduce SP and were suggesting that 
implementation would be a priority within trusts 
and that pharmacists in secondary care did want to 
take on this role. 
Low scoring respondents had less will to introduce 
SP and were suggesting that implementation of SP 
would NOT be a priority within their trust and that 
pharmacists did NOT want to take on this role. 
 
Table 18: Interpretation of the emergent factor constructs (Secondary Care) 
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Factor one: Professional 
competence/responsibility 
issues once trained plus 
limitations to uptake of SP 
High scoring respondents were being positive about SP 
suggesting that trained supplementary prescribers will 
not encounter issues that threaten their professional 
competence or responsibility. Also that issues such as IT 
provision will not be an obstacle and that IP will not be 
more useful. 
Low scoring respondents were being negative about SP 
and were suggesting that trained supplementary 
prescribers would encounter issues that threaten their 
professional competence or responsibility. 
They also thought that IT provision would affect 
implementation of SP and that IP would be of more use. 
Factor two: How 
commonly SP will be 
implemented plus 
limitations to uptake of SP 
High scoring respondents had more will to introduce SP 
and were suggesting that implementation would be a 
priority within trusts and that pharmacists in secondary 
care did want to take on this role. Also that reassessment 
and maintaining competency once qualified was not an 
issue. 
Low scoring respondents had less will to introduce SP 
and were suggesting that implementation of SP would 
NOT be a priority within their trust and that pharmacists 
did NOT want to take on this role. Also that 
reassessment and maintaining competency once 
qualified was an issue. 
Factor three: Limitations 
of the SP training model 
plus Professional 
competence/responsibility 
issues once trained 
High scoring respondents were being positive about SP, 
were willing to put more effort into the development of 
SP (if necessary) and that they thought there would not 
be many limitations to the SP training model. 
They also did not think that multiple prescribers would 
increase the prevalence of iatrogenic disease. 
Low scoring respondents were being negative about the 
SP training model, were less likely to put much effort 
into the development of SP and agreed that there were 
problems with the SP training model. 
They also thought that multiple prescribers would 
increase the prevalence of iatrogenic disease. 
 
Table 19: Interpretation of the emergent factor constructs (Primary care) 
 
 
4.2.7.4 Exploring the factor scores 
The distributions of the scores for the extracted factors are summarised in Table 20 
and Table 21 (p 172-173). Spearman’s rho was used to explore the relationships 
between the total scores for the extracted factors. Table 22 (p174) summarises the 
relationships between the factors. 
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Factor one: Limitations of 
the SP training model 
Normal distribution of scores 
The tendency towards lower 
scores indicates that the 
respondents agreed that there 
were limitations to the SP 
training model. 
Mean scale score: -1.73 
Std. deviation: 3.42 
Median scale score: -2.00 
Minimum score: -8.00 
Maximum score: 10.00 
Factor two: Professional 
competence/responsibility 
issues once trained 
Normal distribution of scores 
The small tendency towards 
lower scores indicates that 
respondents agreed that there 
were professional 
competency/responsibility 
issues post qualification. 
Mean scale score: 0.86 
Std. deviation: 4.09 
Median scale score: 1.00 
Minimum score: -7.00 
Maximum score: 11.00 
Factor three: How 
commonly SP will be 
implemented 
Skewed distribution of scores 
The higher proportion of high 
scores indicates that 
respondents were positive 
about the implementation of 
SP, that it would be a priority 
of trusts and that pharmacists 
wanted to take the role on. 
Mean scale score: 0.22 
Std. deviation: 2.23 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 6.00 
 
Table 20: Distribution of scores (Secondary care) 
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Factor one: Professional 
competence/responsibility 
issues once trained plus 
limitations to uptake of 
SP 
Skewed distribution of scores 
The higher proportion of lower 
scores indicates that 
respondents were being more 
negative about SP and were 
suggesting that trained 
supplementary prescribers 
would encounter issues that 
threaten their professional 
competence or responsibility 
and that IT provision would 
affect implementation of SP 
and that IP would be of more 
use. 
 
Mean scale score: -0.58 
Std. deviation: 2.54 
Median scale score: -1.00 
Minimum score: -7.00 
Maximum score: 6.00 
Factor two: How 
commonly SP will be 
implemented plus 
limitations to uptake of 
SP 
Skewed distribution of scores 
The higher proportion of high 
scores indicates that 
respondents were positive 
about the implementation of 
SP, that it would be a priority 
of trusts and that pharmacists 
wanted to take the role on. 
Reassessment and competency 
maintenance were not viewed 
as being an issue once 
qualified. 
Mean scale score: 0.29 
Std. deviation: 2.55 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 6.00 
Factor three: Limitations 
of the SP training model 
plus Professional 
competence/responsibility 
issues once trained 
Skewed distribution of scores 
The higher proportion of lower 
scores indicates that 
respondents were being more 
negative about the SP training 
model and were agreeing that 
there were problems with it. 
They also thought that multiple 
prescribers would increase the 
prevalence of iatrogenic 
disease. 
Mean scale score: 0.21 
Std. deviation: 2.55 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 7.00 
 
Table 21: Distribution of scores (Primary care) 
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 Spearman’s Correlation coefficient rho (n=169-174 primary care) (n=88-92 
secondary care)  
(P value) 
Percentage variance explained 
Factor One Factor Two  
Primary Care Secondary Care Primary Care Secondary Care 
Factor two 0.309 
(P=0.000) 
9.5 per cent 
0.511 
(P=0.000) 
26.1 per cent 
  
Factor three 0.415 
(P=0.000) 
17.2 per cent 
No significant 
relationship 
0.173 
(P=0.024) 
3 per cent 
No significant 
relationship 
 
Table 22: Correlations between the factors 
 
 
4.2.7.4.1 Secondary care 
There was a strong association between factors one and two (Table 22, above). 
Positive attitude towards limitations of the supplementary prescribing training model 
may be related to a positive attitude that trained supplementary prescribers will not 
encounter issues that threaten their professional competence or responsibility. 
 
4.2.7.4.2 Primary care 
There was a strong association between factors one and three (Table 22, above). The 
positive attitude that trained supplementary prescribers will not encounter issues that 
threaten their professional competence or responsibility. Alongside this, that issues 
such as IT provision will not be an obstacle and that independent prescribing will not 
be more useful may be related to a positive attitude towards limitations to the 
supplementary prescribing training model. Also that they did not think that multiple 
prescribers would increase the prevalence of iatrogenic disease. 
 
Therefore the same strong association was found amongst secondary and primary 
care. 
 
4.2.7.5 Exploring relationships between the factors and the respondents 
 
Table 23 (p175) presents the relationships between factor scores and relevant 
questionnaire responses. 
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 Correlation coefficient rho  
(P value) 
Percentage variance explained 
N 
Spearman’s Rho Factor One Factor Two Factor Three 
 Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Primary Care Secondary 
Care 
Total number of Whole 
Time Equivalent 
(WTE) pharmacists 
employed by trust 
No 
significant 
results 
0.303 
(P=0.008) 
9.2 per 
cent 
76 
0.267 
(P=0.000) 
7.1 per 
cent 
170 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
Total number of 
current pharmacist 
prescribing activities 
(NON-SP) 
No 
significant 
results 
0.300 
(P=0.021) 
9.0 per 
cent 
59 
No 
significant 
results 
No 
significant 
results 
0.441 
(P=0.008) 
19.4 per cent 
35 
No 
significant 
results 
Total number of 
current nurse 
prescribing activities 
(SP) 
No 
significant 
results 
0.359 
(P=0.011) 
12.9 per 
cent 
49 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
 
Table 23: Correlations between the factor scores and respondents 
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 Chi squared 
(P value) 
Df 
Highest mean ranking (Yes answer) 
N 
Kruskal Wallis Factor One Factor Two Factor Three 
 Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Intention to implement 
pharmacist SP by end 
of 2005 
No 
significant 
results 
20.523 
(P=0.000) 
3 
57.75 
92 
12.224 
(P=0.007) 
3 
96.95  
172 
No 
significant 
results 
No 
significant 
results 
14.128 
(P=0.003) 
3 
55.92 
96 
Intention to 
implement/train more 
nurse SP’s by end of 
2005? 
9.659 
(P=0.022) 
2 
126.88 (No 
answer) 
174 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
Do pharmacists 
undertake “prescribing-
type activities” (NON-
SP) in your trust? 
No 
significant 
results 
No 
significant 
results 
8.913 
(P=0.012) 
2 
106.64  
173 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
 
Table 23 continued: Correlations between the factor scores and respondents 
 
4.2.7.5.1 Secondary care 
There was a weak to moderate association between factor one and the total number of 
pharmacists employed in the trust. This suggests that as the total number of employed 
pharmacists increases the respondents had less concerns over the limitations of the 
supplementary prescribing training model. 
There was also a weak to moderate association between factor one and the total 
number of current pharmacist prescribing activities (NON-supplementary 
prescribing). This suggests that as the trust has more of these prescribing activities 
being undertaken, there are fewer concerns over the limitations of the supplementary 
prescribing training model. 
There was also a slightly stronger association between factor one and the total number 
of current nurse supplementary prescribing activities. Suggesting that as trusts have 
more experience of supplementary prescribing by nurses, the respondents have fewer 
concerns over the supplementary prescribing training model. 
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A relationship was found between factor one and the intention to implement 
pharmacist supplementary prescribing by the end of 2005. Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they did not have concerns over the supplementary prescribing training 
model. 
A relationship was also found between factor three and the intention to implement 
pharmacist supplementary prescribing by the end of 2005.  Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they thought that implementation of supplementary prescribing was 
going to be a priority within their trust and that pharmacists wanted to take on this 
role. 
 
4.2.7.5.2 Primary care  
There was a weak to moderate association between factor two and the total number of 
pharmacists employed in the trust. This suggests that as the total number of employed 
pharmacists increases the respondents thought that implementation of supplementary 
prescribing would be a priority within their trust, that pharmacists did want to take on 
this role and that reassessment and maintaining competency would not be an issue 
once qualified. 
A strong association was found between factor three and the total number of current 
pharmacist prescribing activities (NON-supplementary prescribing). As the number of 
current pharmacist prescribing activities (NON-supplementary prescribing) increases, 
the respondents had less concerns over the limitations of the supplementary 
prescribing training model and professional competency and responsibility issues. 
A relationship was found between factor two and the intention to implement 
pharmacist supplementary prescribing by the end of 2005. Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they thought that implementation of supplementary prescribing was 
going to be a priority within their trust, and that pharmacists did want to take this role 
on. Also that reassessment of the trained supplementary prescriber and maintenance 
of competency would not be an issue. 
A relationship was found between factor one and the intention to implement or train 
more nurses as supplementary prescribers within your trust by the end of 2005. 
Respondents were more likely to state that they were intending to implement 
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supplementary prescribing by nurses if they thought that supplementary prescribers 
would not encounter issues that threaten their professional competency or 
responsibility once qualified. They would also not consider that IT provision would 
be a problem or that independent prescribing would be more useful than 
supplementary prescribing. 
A relationship was also found between factor two and whether pharmacists currently 
undertake “prescribing-type activities” (NON-supplementary prescribing) in any 
format within the trust. Respondents who answered yes to this question were more 
likely to think that implementation of supplementary prescribing would be a priority 
within the trust and that pharmacists did want to take this role on. Also that 
reassessment of the trained supplementary prescriber and maintenance of competency 
would not be an issue. 
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4.2.8 Summary of main findings of survey of primary and secondary care 
pharmacists; Implementation, Risks and Concerns about supplementary 
prescribing 
 
 The response rate was 68% for both surveys.  Both sectors intended to 
implement supplementary prescribing by pharmacists by the end of 2005 
(57%, n=55 and 56%, n=100 respectively). 
 The majority of the chief pharmacists did not believe that it would be more 
difficult to recruit designated medical practitioners (DMPs) to supervise 
supplementary prescribing training for pharmacists as opposed to nurses (67%, 
n=43), whereas the largest group of primary care trust pharmacists did think 
this would be the case (47%, n=86). Reasoning included “GPs do not 
understand a pharmacist’s skills/ do not have an established relationship with 
them”, “Pharmacists are viewed as being business focused/ non-NHS” and 
“pharmacists are seen as a threat.” 
 Within secondary care, the clinical areas in which pharmacists were intending 
to work as supplementary prescribers were those where they already had 
established roles. Within primary care, the main clinical areas for pharmacists 
were influenced by those areas in the new General Medical Services (GMS) 
Quality and Outcomes Framework (QUOF) for general practitioners (GPs). 
 The survey tool was subjected to factor analysis and reliability testing. For 
both sectors, the three factors that were extracted described concerns over the 
training model for supplementary prescribing, concerns about the professional 
competency/responsibility of the supplementary prescribers once trained, and 
positivity about the implementation of supplementary prescribing. 
 For both sectors, as trusts have more experience of supplementary prescribing 
by nurses, the respondents had less concerns about the supplementary 
prescribing training model. 
 For secondary care, as the total number of pharmacists employed within the 
Trust increases, the respondents had less concerns over the limitations of the 
supplementary prescribing training model.  
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4.3 PATIENT’S VIEWS AND OPINIONS OF PHARMACISTS AND NURSES 
AS INDEPENDENT PRESCSRIBERS 
 
4.3.1 Demography of Interviewees 
The number of participants recruited for interview was 18. Five patients were 
recruited from a GP practice (primary care) who had received usual (GP) care for 
their hypertension (site 1), five patients from a GP practice (primary care) who saw a 
pharmacist supplementary prescriber for care of their hypertension (site 3). Five 
patients were recruited from an acute hospital NHS trust oncology outpatient’s clinic 
(secondary care), who received normal (consultant) care for their gastro-intestinal 
cancer (site 2), and three patients were recruited from a acute hospital NHS trust who 
saw a pharmacist supplementary prescriber for care of part of their treatment for 
gastro-intestinal cancer (oral capecitabine clinic) (site 4). Details of the participants 
are given in appendix 12, p424 and details of the sites and the patients’ prescribers are 
found below in Table 24. 
 
Site number Patient’s prescriber Address 
Site 1 Dr W House, GP St Augustine’s Surgery, 4 
Station Road, Keynsham, 
Bristol BS31 2BN 
Site 2 Dr C Blessing, Consultant 
Oncologist 
The Great Western 
Hospital, Swindon & 
Marlborough NHS Trust, 
Marlborough Road, 
Swindon SN3 6BB 
Site 3 Dr R Britton, SP Seymour Medical Practice, 
Charlotte Keel 
Healthcentre, Seymour 
Road, Easton, Bristol BS5 
OVA 
Site 4 Mr K Wildman, SP Royal Sussex County 
Hospital, Brighton & 
Sussex University 
Hospitals Trust, Eastern 
Road, 
Brighton, 
BN2 5BE 
 
Table 24: Site demographics 
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4.3.2 Layout of this section of results 
 
The findings reported below describe the participants’ experiences of prescribing by 
either a medical professional or a pharmacist supplementary prescriber, and their 
views upon the extension of the prescribing role of pharmacists and nurses to 
independent prescribers. Extracts from their narratives are shown in italics in the text. 
Those participants who had experienced pharmacist supplementary prescribing have 
SP written after their participant number so that the quote from them can be read in 
context. 
 
The results have been separated out into specific sections of discourse, as follows;  
 
 Section 1: The first section (p182) contains discourse regarding issues that 
equally affected nurses and pharmacists regardless of their profession. These 
have then been spilt into themes which were found to be supportive of non-
medical independent prescribing, followed by themes regarding necessary 
controls for non-medical independent prescribing and then themes regarding 
concerns that participants had regarding non-medical independent prescribing.  
 Section 2: The second section (p206) reports those themes that are specific to 
pharmacists alone.  
 Section 3: The third section (p225) regards those themes that are specific to 
nurses. 
 Section 4: The fourth section (p236) reports themes that were specific to 
participants who had experienced supplementary prescribing by 
pharmacists. 
 Section 5: This section (p249) further explores the differences of opinion 
between participants who had experienced supplementary prescribing and 
those who hadn’t, differences of opinion between participants who had 
hypertension versus those who had gastro-intestinal cancers, the influence of 
background experience upon participants’ opinions and differences of opinion 
upon nurses and pharmacists as independent prescribers. 
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Section 1 
4.3.3 General discourse supportive of Independent Prescribing by non-medical 
healthcare professionals regardless of the type of professional. 
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SUPPORT 
 Drs are not God 
 IP positivism 
 Physical examination positivism 
 Records Access 
PERCEIVED BENEFITS 
 Using HCP’s full potential 
 Increased access to healthcare 
and decreased pressure on doctors 
 Limitations 
NECESSARY CONTROLS 
 Personal Characteristics 
o Knowledge of pharmacists and nurses 
o Importance of training 
o Importance of experience 
 Risk Management 
o Close supervision by Dr 
o Importance of referral 
CONCERNS 
 Poor perception of nurses and pharmacists 
o Minor/basic ailments only 
o Questioning ability to diagnose 
 Intrinsic Barriers 
o Age Issues 
o Covets traditional doctor model 
o Dr is god 
o Issue of change/acceptance 
 Extrinsic Barriers 
o Location of IP 
Related 
Related 
Figure 6: Summary of discourse applicable regardless of type of healthcare professional. 
(Section 1) Emerging Themes  
 
 185 
4.3.3.2 Support for Independent Prescribing 
 
4.3.3.2.1 Dr’s are not God. 
 
A few participants recognised that although doctors tend to have a lot of status and 
power, looking at the roles they perform, they do not all have to be undertaken by a 
medically-trained professional. With appropriate training, other healthcare 
professionals could undertake some of the roles. 
 
There always seems to be this great myth about what GP’s are and 
do and I realise that from recent years that they are human beings 
especially when you see them out of the surgeries so to speak and 
also seeing in other contexts discussing stuff. I also realise that 
actually some of these things other people are quite capable of 
doing given the suitable training.  So I cannot think of any reason 
why not. (Participant 10) 
 
This realisation that other health care professionals are capable of taking on some 
roles traditionally performed by the doctor is part of the change process that the public 
will need to go through. They need to accept that healthcare provision is going to 
change and that you may not always see the doctor when you are ill.  
 
There appear to be a lot of people who want to see the top person 
and aren’t prepared to work their way up through the system, 
…personally I’d be quite happy to deal with the nurse or 
pharmacist rather than in the same way when you go to the doctor 
and they think maybe you’ve got something wrong they then refer 
you to a specialist. (Participant 8) 
 
4.3.3.2.2 Independent Prescribing positivism 
 
Some participants thought that as long as independent prescribing was introduced 
appropriately with controls in place, it would be a useful addition to improve the 
accessibility of healthcare. 
 
Obviously half the time with routine cases it is just not necessary to 
see a doctor really and I think I would be very much in favour of it 
really. (Participant 18 SP) 
I think then if it’s introduced properly it could be very beneficial. 
(Participant 6) 
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One participant felt that in order to maintain accessibility to healthcare this was the 
route that the NHS had to go down. Available resources of doctors in the future will 
mean that the current model of healthcare provision would not be viable.  
 
I think there are certain conditions that a pharmacist should be 
able to diagnose and prescribe; you don’t need the doctor to be the 
authority/ give the authority for it. I know it’s a lot of responsibility 
but I think in trying to deliver appropriate care or alternative 
pathways of care for patients then this is a route that I think the 
NHS should go down. (Participant 15 SP) 
 
The majority of the participants had no concerns about nurses becoming independent 
prescribers and were quite supportive of the development. They also stated that they 
would be happy to use such a service. 
 
I can see it would be quite useful.  When I was sitting one day in 
day-therapy unit and I had some kind of side-effect that I was 
talking to the nurse about she said ‘oh well maybe a bit of 
something or other would be useful’ and then she had to scurry 
round to find the person to write the prescription so if she had been 
able to do it, that would have been helpful, for example and it was 
quite unnecessary for somebody else to be brought in to have a 
look at me. (Participant 10) 
From experience I’ve had in hospitals I think if nurses can 
prescribe, if they’re trained up to be able to prescribe then I think 
it would be a good thing (Participant 17 SP) 
 
4.3.3.2.3 Physical examination positivism  
 
Most participants were very positive about pharmacists undertaking physical 
examinations. Participants understood the importance of doing this in order to monitor 
conditions and establish diagnoses. 
 
Oh yes that wouldn’t worry me at all, no. (Participant 8) 
Yes my body is nothing special. (Participant 13 SP) 
Well if you felt desperately ill you would be so grateful whoever 
was doing it, that they were trying to find out what is causing you 
to feel as you feel, so I think any patient will probably not resist at 
all. (Participant 3) 
 
However, some people were more cautious and felt that they would only be happy 
with a pharmacist undertaking a physical examination if they had sufficient training to 
do so. 
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If they’re appropriately qualified yes then no problem. (Participant 
17 SP) 
Yeah why not, I mean as long as they know what, they know what 
they are doing then (Participant 11 SP) 
 
A couple of participants recognised that the NHS is undergoing change and as such, 
different healthcare professionals will need to undertake physical examinations and 
therefore patients should be prepared for this as part of their consultation. 
 
Yeah I don’t see any problem really people go through 
chiropractors, herbalists and funny things and feeling all over you 
so people are happy to do that so yes I think they can be sort of not 
a problem with the pharmacist. (Participant 18 SP) 
They would have to been trained to know why they’re doing it and 
what they’re actually looking for and what’s within the normal 
span and what’s outside of that.  I suppose it’s base-line 
observations type of, which almost everybody needs to do 
(Participant 15 SP) 
 
One participant felt that they would only be happy for the pharmacist to do 
straightforward physical examinations. Some patients do have firm boundaries 
regarding their comfort zone for being physically examined by pharmacists. 
 
I think so yes, I mean it is not as if you know, you are having an 
internal examination or anything is it, it is high blood pressure its 
not too bad is it…... As long it is only like I say blood pressure or 
diabetes and checks like that, no I don’t think I would worry. 
(Participant 4) 
 
When participants were asked whether they would be happy for a nurse to physically 
examine them as part of the IP consultation they did not have any concerns. This is 
because nurses physically examine patients as part of their traditional nursing role. It 
is accepted that nurses can undertake quite intimate examinations of patients, and 
have to be present if a male doctor is undertaking an intimate examination of a female 
patient anyway. So as this does not represent a great change from the role they 
currently undertake this does not concern patients. 
 
4.3.3.2.4 Records Access 
 
With regards to non-medical health care professionals gaining access to patient’s 
medical records, participants made comments regarding how important this was in 
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terms of maintaining patient safety and maintaining communication between different 
healthcare professionals that see the patient.  
 
Yes so it’s sensible and that I’m not being prescribed things that 
I’m allergic to or whatever…… I think the more information they 
have on you the more likely they’ll make the correct decisions…… 
Well if it’s for your own good which obviously it’s intended to be 
then it’s necessary unless they’ve got this information they 
wouldn’t be able to make mistakes. (Participant 8) 
…there would have to be some information about the condition 
how it’s been treated up to date from the GP or doctor or whoever 
is treating it that it’s shared with the pharmacists and that they can 
see, well come to a more informed decision as to what direction to 
go. (Participant 15 SP) 
Well I would hope there would be liaison between the pharmacist 
and your own GP in the same way on the other side of the coin I 
mean I’ve been here in hospital and to Oxford in hospital, and the 
doctor has always known what is going on. (Participant 8) 
 
A couple of participants were rather sceptical about the ability of the NHS to actually 
provide pharmacists with access to medical records on-line, and they also had 
concerns regarding whether the system would be secure. 
 
I suppose the sort of thing that struck me was that if the electronic 
records system really functions effectively in some dim distant 
future so if people were really aware of whose getting what I would 
probably be a bit more confident that it really doesn’t matter 
whose doing what, to you anywhere in the country, they’ll be able 
to log on and get your records at the right sort of level, and that 
shouldn’t be a problem (Participant 10) 
 
Patients will need to be convinced that the computer records system is a secure system 
before they will trust a service provided by non-medical professionals, especially 
those being provided at non-NHS sites such as community pharmacies. 
 
…until proved wrong I would be happy provided that the system is 
properly secure I would be perfectly happy to see what’s what. But 
then I don’t have a very exciting history that anybody would find 
terribly interesting.  But that’s if the system works, but it has to be 
otherwise its not going to work is it?  (Participant 10) 
Well it is down to security isn’t it, system security as long as only 
the pharmacist have got access to the system to enable them to see 
your records fine, I would rather them have access and give you 
the right prescription rather than not have it and make some 
mistake.  So it’s we’ll have to trust people like receptionists ...so 
yes I think again we have to accept that there will be checks and 
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balances in place which restrict access to the records to only those 
people who need access.  (Participant 5) 
 
The majority of participants seemed to have no objections to nurses having computer 
access to medical records, but a couple of participants still had reservations regarding 
the location of the access by the nurse. They were happy as long as access was via a 
GP surgery and not in a community pharmacy or supermarket nurse clinic. 
(Reasoning for this is further explained in Extrinsic Barriers: Location of IP p 204) 
 
I think from a nurse really and the conditions that they would work 
in, they are not going to work necessarily are they in a chemist 
shop but……I would assume the nurses have the same sort of 
obligations as doctors so yes I don’t have any problems with it. 
(Participant 18 SP) 
I expect so because they’ll be specially trained nurses they will not 
be the run of the mill.  I don’t think they’ll go round and gossip 
about my entrails, will they? (Participant 13 SP) 
 
4.3.3.3 Perceived Benefits 
 
4.3.3.3.1 Using healthcare professional’s full potential. 
 
There was some expression that the system that is implemented should allow full 
utilisation of a pharmacist’s knowledge and skills in order to optimise patient care. 
 
I think if you are going to do it, do it, don’t start saying you can 
prescribe aspirin but you cannot prescribe some, another 
painkiller.  I think if you are going to do it, do it and we will take it 
that that’s common sense if it’s on there (Participant 7) 
 
Some participants also recognised that by non-medical healthcare professionals taking 
on this extension in their role, they may have increased job satisfaction and be able to 
use their skills more extensively. It was recognised that there were circumstances 
where nurses were “held back” in their job by having to ask the doctor for signatures 
at the end of a decision-making process that they had undertaken. It was also 
recognised that nurses’ skills were being under-utilised in some respects as well. 
 
Well yes I think it would save a lot of time within the health service 
if they were able to do this because you go along to see the nurse 
and the nurse will say ‘oh yes I think you’ve got so and so but 
you’d better see the doctor to get the prescription’ whereas they 
could quite happily do the job. (Participant 8) 
I don’t think that nurses have been given as much credit and it’s 
good to see how things have changed fairly recently in what 
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they’re being allowed to do, so it’s going in the right direction. 
(Participant 15 SP) 
Also for the nurses too with the training that they go through and I 
think it’s- it would be nice for them to take on more responsibility, 
some would like to. (Participant 17 SP) 
 
 
4.3.3.3.2 Increase access to healthcare and decrease pressure on doctors 
 
Participants perceived that the introduction of independent prescribing would bring 
benefits in terms of taking the pressure and strain off doctors, (which would enable 
them to be available to see the more complicated cases) and to increase the 
accessibility of healthcare to the public. 
Participants placed an enormous amount of importance upon any new system having 
benefits to doctors in terms of reducing their workload, and this links in with their 
perceptions of doctors having a “god-like” status. 
 
If they came to a practice as you say if they had a clinic here say 
once a week or once a fortnight or something like that, I can see 
the advantage in that especially for the doctors to relieve the 
pressure on them. (Participant 2) 
Well I know the poor GP’s are under such pressure that they need 
to have some relief. I’m not saying that entirely cynically because 
no doubt they are. (Participant 10) 
 
There was also recognition that once that the doctor’s workload had been reduced, 
they would be able to prioritise seeing those patients with more complicated problems 
which may reduce the likelihood of GPs making mistakes and it may generally have 
beneficial effects on all staff in the GP surgery.  
 
Well it certainly relieves the doctors (of) all the people sitting there 
with coughs and colds, all the people sitting there with in-growing 
toe-nails and what have you if you can go to the pharmacist and I 
think it would certainly speed up the waiting lists and recovery of 
people from different things, I cannot see that it would be a draw-
back I should think it would be a bonus. (Participant 17 SP) 
I think not just doctors, everybody in a surgery these days they’re 
under great pressure and the number of, if you sit in the waiting 
room, the number of people that flow in and out, it is quite 
staggering.  There are lots of us older people now who need more 
attention than we used to.  (Participant 2) 
 
The participants were also clear that the new system would help to increase their 
accessibility to healthcare. 
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Probably availability assuming that the doctors were busy and 
fully occupied you may not be able to get in for a day or two 
whereas you might be able to get more immediate treatment (with 
independent prescribing). (Participant 8) 
…it just increases the supply of expertise so as I said before, I think 
the only reason that I can see that there is a need for it is to ease 
the bottle necks, provide a quicker response to patients so it is like 
if you do it one-fold for pharmacists it will help so far but if nurses 
can do it as well it helps that bit more just a bigger supply of 
expertise in the market place. (Participant 5) 
 
One participant commented that for him, accessibility of healthcare was paramount 
and that he didn’t want choice of where he wanted to go, he just wanted to be seen 
quickly when he needed to be seen.  
 
I’d go anywhere where that was quick and easy, readily 
accessible…… I’d go anywhere.  I’ve got a problem it’s a bit like 
choice OK I don’t really want to know if there are four hospitals I 
can go to, I hurt, I want something done just tell me where I can go 
to get it sorted and I’ll go there.  I think that’s it …I don’t mind 
where I go if somebody can prescribe something quickly and easily 
and get it done I don’t really mind. (Participant 10) 
 
 
4.3.3.3.3 Limitations 
 
Participants commented how important it was that pharmacist independent prescribers 
operated within clear, strict guidelines as you do not recognise what you do not know. 
They also felt strongly that they should keep within their area of expertise as well.  
 
…I mean you will always get a grey area or one that goes wrong 
but I think in the general nature of things and providing there are 
strict guidelines and people are very professionally qualified and 
that you know they are good people, observant people.  I mean 
observant not only in observing things but observing the rules 
really. (Participant 18 SP) 
…if it was quite clear that that pharmacist was a specialist in that 
field.  But I’d be a little bit concerned if they were dealing with 
other things that they had not necessarily had experience with. 
…but from a patient’s point of view I would have thought generally 
the whole thing would be very favourable as long as it’s quite clear 
within the limits of which it would be practised.(Participant 8) 
…There has to be a limit they cannot just totally become 
independent. … It’s knowing your own limitations but how do you 
know? Well exactly and this is it and this is why I’m saying that 
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nurses and pharmacists they need to be given guidelines, they need 
to be given the indication... (Participant 15 SP) 
 
Similarly, participants did not have any concerns about nurse independent prescribing 
as long as appropriate limitations, checks and balances were in place. There was also 
a presumption that professionalism of the nurse involved would ensure the safety of 
the service.  
 
…if they’re giving you treatments and I’m sure this would happen 
if you were prescribing drugs they always check and they come and 
ask you your name but there are certain checks that are made 
before you are administered any drugs and I’m sure that would be 
exactly the same with the prescription. (Participant 6) 
No so again it’s just how the policing system works again from my 
professional point of view, all this needs to be adequate, normal 
and adequate and as long as that works then fine. … As long as the 
parameters are there and people are aware of what those 
parameters are, you know so they have to be clear then the 
observing is down to the professional discipline of the people 
involved. (Participant 9) 
 
 
For nurses, some participants thought that they ought to be limited to prescribing in 
single clinical areas that they specialised in, which wasn’t suggested for the 
pharmacists. 
 
Does this mean that people like a district nurse will be able to 
prescribe within a limited range or whatever they know I suppose? 
(Participant 13 SP) 
…as long as they’re working within their specialized area and in 
some ways that would probably need to be one specific area 
(Participant 15 SP) 
I think if the restrictions are in place about areas of specialism in 
independent prescribing then that is fine as well….. the restrictions 
will clearly play a part in what they can and cannot do (Participant 
5) 
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4.3.4 General discourse about necessary controls for Independent Prescribing by 
non-medical healthcare professionals regardless of the type of professional. 
 
4.3.4.1 Personal Characteristics 
 
4.3.4.1.1 Knowledge of pharmacists and nurses 
 
Some participants described pharmacists as being the expert on medicines, as being 
very knowledgeable and appreciated that they have gone through extensive training 
and have appropriate qualifications. The participants trusted the advice that they were 
given by pharmacists, and supported the extension of their role into prescribing. 
…pharmacists have got quite good experience and they, I mean 
they just don’t become pharmacists overnight and I think they are 
great and it should be used. (Participant 7) 
They are I suppose in their own right in the field the expert, 
obviously they’ve gone through the necessary training to become a 
pharmacist and to carry out their duties to the best of their abilities 
so therefore yes, they’re experts in their field…… I feel that they 
are probably the most qualified to advise which drug should be 
taken for what condition in my opinion. (Participant 15 SP) 
 
A few comments were made that were positive about nurses knowledge with regards 
to prescribing.  
…they build up a lot of knowledge over the years so they know that 
in a certain condition that this would normally be the appropriate 
course of treatment to follow. … I don’t want to discredit them 
because a lot of them have a lot of knowledge.  (Participant 15 SP) 
…my understanding of the training they go through, the 
qualification that they have to get, a nurse is somebody I would 
have complete trust in their advice and their guidance. (Participant 
5) 
 
4.3.4.1.2 Importance of training 
 
Some participants commented that as long as the pharmacists have had the 
appropriate training and maintain their competency, they had no concerns about 
pharmacists in a prescribing role. Although one participant commented that they 
would want community pharmacists trained to the same level as specialist hospital 
pharmacists, suggesting there is a perception that hospital pharmacists are more 
knowledgeable than community pharmacists.  
 
If you are going down this route then we need to ensure that we 
have the appropriate qualified personnel… but if these pharmacists 
were and I know they would have to be accredited to be able to 
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deliver that service you know, and if there was some certificate 
saying qualified then great and it’s down to them to build up that 
practice……if they are given a remit to prescribe and the 
responsibility is upon them solely they need to be made 
comfortable in being able to do that and if you need the 
appropriate training and if you haven’t got that then it’s going to 
be dangerous. (Participant 15 SP) 
Well I think the devil is clearly in the detail, and as long as those 
parameters are set then again I wouldn’t have a problem and from 
what you say, there are specialist pharmacists in hospitals and if 
the training and the what ever qualification is required are going 
to be the same for the high street pharmacist as they are for the  
hospital pharmacist, then I would feel more comfortable…… if they 
have had the training and then why not, there is nothing special 
about somebody who even the GP that suddenly they can diagnose 
if they have had the training and as long as the person has the 
training and has qualified in what ever way they have to show their 
proficiency and that is fine. (Participant 5) 
 
Participants thought that extra training was necessary if nurses were taking on the 
extra responsibility of independent prescribing.  
 
Well it’s the same matter of how much training they’ve had…. If 
they’re trained to do what it is they’re prescribing for, I’m quite 
happy.  (Participant 13 SP) 
I think that they should be able to be in control of what they 
prescribe as long as they are properly qualified. (Participant 17 
SP) 
 
4.3.4.1.3 Importance of experience 
 
Some participants explained that they would only want experienced pharmacists to 
undertake prescribing.  
 
I think it should be someone with the experience you know, you 
cannot say that a chap starts work and after 4 years… it’s got to be 
someone with a certain amount of experience (Participant 7) 
I think that the training that pharmacists have gone through 5 
years nurses at least 3, they have built up a good amount of 
knowledge and coupled with the experience during their training 
and as they are forming their clinical duties then they are building 
up their experience which will allow them to pass on I think 
relevant information and advice to the patients that will assist them 
in their well being. (Participant 15 SP) 
 
A couple of participants felt that it should only be more experienced, senior nurses 
undertaking independent prescribing: 
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…like I said before, the head nurse and as long as she checks out 
how the junior nurse is doing, I don’t think it would be a junior 
nurse’s job to prescribe drugs but if its a head nurse yeah. 
(Participant 4) 
 
4.3.4.2 Risk Management 
 
4.3.4.2.1 Close supervision by Doctor 
 
A lot of the participants thought that the patient’s normal doctor would be 
“supervising” what the pharmacist did in the clinics by somehow reviewing what 
happened during the consultation. 
 
I would hope that information what they’d been prescribing is 
forwarded to my GP at some point so that they can be checked on 
in that way. (Participant 8) 
…maybe you need a flag on the system once a pharmacist 
prescribes there is a flag on the system that this customer has been 
treated by a pharmacist so that it should be fairly easy then for the 
GP to just occasionally flash through and pick out all these cases 
and just have a general overview of that really. (Participant 18 SP) 
I should hope that Doctor X if he has got spare time he would look 
it up and go oh yeah, yeah that’s alright, double check it, that is 
what I would hope (Participant 11 SP) 
 
A couple of participants though that other methods such as a further consultation with 
their GP or a “repeat prescription” –type system would be used to supervise the 
pharmacist prescribing. 
 
…whether there would be a consultation afterwards with the 
doctor I don’t know. (Participant 2) 
I think probably it will be something like the surgery now where 
you like get your repeat prescription, and then on that repeat 
prescription you have to be reviewed by the doctor in six months 
time or whatever you know. (Participant 4) 
 
When participants were asked about clinical governance arrangements for ensuring 
the safe performance of nurse prescribers, a lot of participants assumed that the doctor 
in the GP practice would be closely supervising the nurses’ practice, and be there to 
give advice when they need it as well. There also seemed to be an assumption that the 
nurses would recognise when they needed help, which may not always be the case. 
Participants did not seem to have considered how poor performance would be 
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identified, and did not seem to be that concerned about it either, as they assumed that 
the nurses would be well supported by the GPs and the information on the computer. 
 
I think it would have to be the doctor or some sort of body that 
would have a check up to see that she is not prescribing anything 
that she shouldn’t be and giving patients something that they 
shouldn’t be taking.  But if they have got the family history on the 
computer you know I cannot see any problem. (Participant 4) 
…although it’s doctor x on this practice, he is always there in his 
room and if anything she cannot answer sort of thing she will go 
and see doctor x and he will probably have me in, but I haven’t 
done that very often. (Participant 11 SP) 
Well if they are not sure they can always pop in and ask the doctor 
couldn’t they? (Participant 1) 
 
4.3.4.2.2 Importance of referral 
 
The participants identified several areas which they thought were important in order 
to risk manage the introduction of independent prescribing. One of these areas was 
ensuring that the independent prescribers were able to refer patients to appropriate 
alternative care where necessary, and also they recognised when a patient needed 
referral elsewhere. 
 
…and if a pharmacist wasn’t happy hopefully then they would say 
‘I’m sorry this is out of my area, you need to go and see a doctor. 
(Participant 6) 
If there was any doubt, then I would expect and hope to be referred 
to a doctor. (Participant 8) 
Yes there has to be a responsibility that number one if you’re not 
sure that they are referred to a GP… (Participant 15 SP) 
 
A couple of participants discussed that they felt it was important with the system that 
nurses were able to refer to doctors when they felt they needed advice. This issue may 
not have been raised by many participants as it may have been presumed that the 
nurses would have and use this facility anyway. 
 
No not really because if they’re going to prescribe something that 
they feel could be a danger to the patient hopefully they would be 
very cautions about it and perhaps go back to the doctor and say 
‘well what do you think’. (Participant 6) 
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4.3.5 General discourse of concerns regarding Independent Prescribing by non-
medical healthcare professionals regardless of the type of professional. 
 
 
4.3.5.1 Poor perception of nurses and pharmacists 
 
4.3.5.1.1 Minor/Basic ailments only 
 
Participants had a poor perception of the pharmacist’s role, knowledge, training and 
professionalism and hence believed that independent prescribing should just be used 
to treat very minor and basic ailments. This is what the public are used to consulting 
pharmacists for and hence are more comfortable with pharmacists dealing with their 
minor complaints. 
 
Things like a skin rash they can see that, minor things I would 
imagine like eczema or anything like that they can prescribe 
steroids for them small things… (Participant 6) 
 …on the other hand for things like the everyday colds and flu’s 
and things of that nature well then I don’t see any problem. 
(Participant 8) 
I would for lesser illnesses if I thought there was anything radically 
wrong I’d go to the doctor.... …If I thought I got a bit of bronchitis 
or flu coming on I’d try the chemist first. (Participant 13 SP)  
 
Some participants felt that if they had previously seen their doctor about the 
complaint or it was an appointment to continue a treatment they were already having, 
they would be more confident to then see the pharmacist about it. 
 
I mean if it was an experience I’d had before and knew what the 
treatment had been and the pharmacist then says ‘yes this is what 
you ought to have’ and I think to myself yes that’s what I had 
before I’d be quite happy with that. (Participant 8) 
I think it is ok if it is probably like me or like a lot of other people 
that just have a drug that you have every, you know …Every day as 
a regular sort of thing you can take, I think that is probably fine 
with pharmacists, you know they can do that. (Participant 4) 
 
Some participants mentioned that they specifically felt that they felt comfortable with 
pharmacists dealing with hypertension, which may be because patients do not get any 
symptoms with hypertension and may not fully understand the complications that 
could occur if it is not well controlled. They therefore feel it is a “minor” condition. 
 
Yeah I mean it’s a fairly basic thing taking blood pressure and 
temperatures and things like that, I am sure they -within limited 
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restrictions of course, you cannot talk about my sort of complaint 
to a, but normal run of the mill blood pressures, temperatures, 
ankle hurts or your knee hurts, I can understand it. (Participant 7) 
I think if it is like blood pressure they are checking, if it was 
anything serious then no I think I would prefer to see a doctor as 
long as they keep a check on your blood pressure I cannot see why 
not. (Participant 4) 
 
Some participants were very clear about conditions or treatments that they did not feel 
that pharmacist independent prescribers should be dealing with. Those patients that 
had hypertension mentioned that they did not want a pharmacist independent 
prescriber prescribing them chemotherapy. 
 
If it is controlled properly, yeah I mean I cannot see -I mean I 
don’t know about chemotherapy, you know if there is a controlled 
thing then yeah I can see it. (Participant 4) 
I suppose generally, my only issue would be at the more extreme 
end you know talking about chemotherapy cancers this sort of 
thing. …if it were a case of saying no the pharmacist has only the 
ability to prescribe within this list or these parameters which are 
outside life threatening… …if we are talking about chemotherapy 
we are talking about life threatening disease as well (Participant 5) 
 
 
However, one participant illustrated that the public can perceive some very acute and 
serious conditions as being “minor” (due to it being a flare up of a chronic condition) 
and therefore poor knowledge about health can lead to misconceptions about what 
non-medical practitioners can safely deal with. 
 
I’ve got Crohn’s Disease so that possibly could have been 
controlled by a chemist you know when you have flare ups and stuff 
without having to go to the doctor you could go to the chemist 
instead and say ‘I’ve got a flare up, it looks as though it’s the same 
thing’ perhaps give me some steroids and they could prescribe 
them. (Participant 6) 
 
Some participants were very clear that they would only want to use the nurse 
independent prescribing service for what they deemed to be “minor ailments”. This 
included getting repeat prescriptions from them, blood pressure, diabetes, coughs and 
colds and thrush. If the condition was new and needed a diagnosis, they wanted to see 
the doctor first. 
 
Yes.  For minor things.  If I was really concerned then obviously I 
would want to see a doctor, he may say you can see the nurse.  If it 
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was a rash any minor ailments I would probably go to see the 
nurse or a pharmacist because you feel you can spend a little bit 
more time. (Participant 6) 
I don’t imagine she prescribes if you had an unusual illness or 
something like that but if it’s a follow on from run of the mill 
things, yes yes. I’d be happy enough about that. …if it was for an 
illness or condition that had been a long standing thing, yes I 
would (use the service).  I don’t know if I came I wouldn’t see the 
nurse if I wished to be diagnosed if you had something new, you 
would then see the doctor.  (Participant 2) 
 
4.3.5.1.2 Questioning ability to diagnose 
 
Participants expressed concerns about independent pharmacist prescribers actually 
diagnosing conditions. These concerns were centred on questioning whether 
pharmacists having the ability to diagnose proficiently. Some participants felt that 
pharmacists were not skilled enough and wanted their doctor to be responsible for 
diagnosis, and were more comfortable with the pharmacist prescribing for them and 
monitoring their condition after the diagnosis had been made.  
 
I would be a little wary of them doing the primary prescribing.  
When it wasn’t necessarily clear to the patient what the diagnosis 
was or likely to be but it’s only if there is a doubt as to what the 
correct procedure might be.  I think it would be a question of the 
patient and the pharmacist knowing and agreeing that yes that is 
what your problem is and this is the way to treat it. (Participant 8) 
…if there are minor things then it is ok pharmacist but if there is 
anything like risky things then the doctor should diagnose and then 
after that pharmacist they can monitor, they can check progress 
and see how the patient is coping… (Participant 12 SP) 
Well I think initially I would like to see a doctor you know for 
diagnosis and then I would be happy for X (Supplementary 
prescriber) to take the follow-up. (Participant 11 SP) 
 
The reasoning for the doubts and concerns about pharmacists’ ability to diagnose 
stemmed from the training that pharmacists would have received to undertake 
diagnosis. Many compared the training of pharmacists to that of doctors and felt that 
pharmacists would not have had sufficient training in this area when compared to 
doctors. 
 
…I have probably got some questions and maybe lack of 
understanding about, you know how far their training will have 
gone to enable them to diagnose life threatening diseases.  Umm so 
there is just a question mark in my mind there. (Participant 5) 
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Well you see, the doctors are trained in diagnosis whereas the 
chemists are presumably not. ………I’m not sure how well trained 
they’ll be in diagnosing that’s all…(Participant 13 SP)  
…they haven’t gone through the same training as a doctor for 
diagnosis and that could be dangerous. (Participant 6) 
 
The major concern that participants had about their perception that pharmacists would 
not be sufficiently trained to undertake diagnosis was that this would result in 
misdiagnosis occurring. 
 
If I would have gone to a pharmacist because I’ve had a pain in my 
back she may have given me some muscle relaxants whereas it was 
the cancer returning, so that would have been a dangerous 
situation to be in. (Participant 6) 
Well presumably if they misdiagnose and give the wrong medicine, 
if it is too strong or too much of the wrong sort if I say it like that, 
then presumably some other symptoms will appear.  If it works the 
other way, presumably whatever caused the consultation to take 
place in the first place will not be cured.  Whether people seek a 
second opinion from the pharmacist or go back to the doctor I 
don’t know. (Participant 9) 
 
Some participants expressed concern regarding whether nurses had the ability to 
diagnose as well as prescribe safely. This was also based upon a comparison of their 
length and depth of training with that which a doctor receives. It was also based upon 
the fact that they hadn’t seen a nurse in that type of role before. 
 
I’m a little bit wary -I do think especially on the treatment that I’m 
having now, the nurses there probably know as much as the 
doctors on the drug side, prescribing and diagnosing I’d be a bit 
wary because they haven’t gone though the same course you know 
training as a doctor for the diagnostic side. (Participant 6) 
I don’t know that I would accept diagnosis and things like that 
from a nurse. (Participant 2) 
Well because it would be something new that I hadn’t had before 
and I would rather have a doctor’s opinion really you know I mean 
as I am at the moment I am quite happy with everything I get in this 
clinic but if something new comes up you know… I would rather 
see a doctor and then refer me back to the nurse and then the 
nurses take over again.  (Participant 11 SP) 
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4.3.5.2 Intrinsic Barriers 
 
4.3.5.2.1 Age Issues 
 
Strongly linked to the issue of change or acceptance was participants views that 
elderly people would struggle more with accepting healthcare provision from a non-
medical practitioner. This was because older people have little experience other than 
doctor led healthcare and have an expectation that it is your right to see a doctor when 
you want to see one. All of the changes will be more difficult for older people to 
accept because they feel comfortable with their doctor and this development is 
unknown and unfamiliar to them.  
 
It is the change of attitude really which I think probably is easier 
for the younger people than it is for the older people to accept.  I 
often see people speaking to the pharmacist so they must 
presumably ask his advice.  So maybe some people are more in 
tune to that than I am. (Participant 2) 
This is ageist but as I get older and GP’s appear to be younger I’m 
not sure that I have any great faith in somebody who looks like 
their just out of college, again it’s completely irrational I suppose. 
As long as they’ve had the training……… I guess that all of these 
things that are newly introduced are easier for people who have 
had less experience of whatever it was in the past.  What I mean is 
actually it may well be that for some people who are older who 
have more experience of a particular regime they may well feel less 
happy about something different and that isn’t an ageist comment I 
think it’s just the reality whereas for my daughter’s in their 20s if 
that’s what happens then that’s just what the future holds then 
they’ll get on with it.  (Participant 10) 
 
There was also some recognition amongst participants that older people can actually 
waste their medical practitioner’s time by seeing them with more minor conditions 
that could be dealt with by non-medical practitioners.  
 
Obviously you have got to say that I am sure that this older 
population of which I am a part these days, there are a lot of 
people who go for the slightest thing to their GP and probably do if 
we are honest waste an awful lot of time of the GP and if there is 
anything that can be done to really give them the assurance that 
they need that they are being looked after and maybe just a word of 
comfort… (Participant 18 SP) 
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When asked whether they would use a nurse prescribing service, one participant felt 
that she wouldn’t want to as it involved change to the healthcare system which “older 
people” did not like. 
 
Perhaps younger people might -not older people like me. …I think 
it’s just that when you get older you get, you do get a bit set in your 
ways, a bit narrow with your thoughts really. I think if you’re 
younger you accept change more easily and readily than when 
you’re older.  (Participant 2) 
 
4.3.5.2.2 Covets traditional doctor model 
 
It was clear that it was going to be difficult for some participants to accept a change in 
the provision of healthcare where they may not automatically see a doctor when they 
are ill. Some participants expected to see a doctor when they were ill and were 
adamant that they would see a doctor regardless of the severity of the condition. They 
could not visualise a pharmacist as an independent prescriber, because the pharmacist 
is viewed as being inferior to the doctor. (As discussed in “Prior experience of HCP’s: 
Comparison of pharmacists to Doctors” p208) 
 
It’s completely different to how we sort of treat our bodies isn’t it 
really? If you’ve got something wrong with you, you feel you’ve got 
to go and see a doctor. (Participant 6) 
…I’ve been on the same drugs for a number of years now it seems 
to suit me and therefore -but I would still rather come to the doctor 
I really would, I hope I am not maligning pharmacists! (Participant 
2) 
 
Participants also imagined it would be difficult for other people to accept this change 
in the provision of healthcare. 
 
There are all types of people.  Some people are very belligerent 
and want to see a doctor… (Participant 6) 
Umm... I suppose there will be some disadvantages and there will 
be some people who really don’t agree with not seeing a doctor as 
a lot of people are adamant that they do want to see a doctor 
rather than just see a pharmacist. (Participant 4) 
  
One participant pointed out that there may be specific issues around healthcare 
professionals actually diagnosing illnesses. 
 
I can see that a lot of people it’s engrained that the doctor 
diagnoses things…(Participant 6) 
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It was apparent that extending prescribing rights to pharmacists and nurses represents 
a major change that some patients will find incredibly hard to accept. Such a major 
change will therefore take some considerable time to establish itself and fully realise 
its potential. 
 
4.3.5.2.3 Dr is God 
 
The opinions that participants had about accepting other healthcare professionals as 
prescribers is also linked to their opinions of doctors. Doctors are held in extremely 
high regard and have status and due to this, patients said they trust them implicitly. 
Participants also appeared to be very submissive, never wishing to question what the 
doctor was saying or suggesting. 
 
…my philosophy is if the medical profession said that this is what 
needs to be done then we do it. (Participant 9) 
Well I am fine with doctors and the you know with all of it like, I 
never argue and they always seem to sort me out so you know… 
(Participant 11 SP) 
 
Participants also stated that they thought other people held doctors in high regard, 
especially if people saw their GP more frequently and hence built up a closer 
relationship with them.  
 
 Yes, you know I have paid my taxes, I have got to see the top man. 
(Participant 9) 
I think some people clearly have a different view about their GP 
because they see more of them and people learn to love a 
particular GP and they really want to go and see them. (Participant 
10) 
 
One participant also explained that he thought opinions may be different according to 
the area that you lived, inferring that in a rural area you would have a closer 
relationship with your doctor. 
 
If you live in a very urban area then you might have more recourse 
to a pharmacy than I do for instance living in a rural area where 
the GP is the king (Participant 8) 
 
It is therefore difficult for patients to accept that anyone else could possibly do as well 
as a doctor in the prescribing role and therefore such services would be a sub-standard 
or second-class. 
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4.3.5.2.4 Issue of change/acceptance 
 
As alluded to earlier, (Covets traditional doctor model p201) this development is a 
major change in healthcare provision and as such, participants were very wary of it. 
When asked what they thought about pharmacists being able to prescribe, participants 
described being worried about this development, as prescribing entails a lot of 
responsibility. They did not think that the development was necessary or that it would 
actually be of benefit. 
 
Worries me… Well there’s so many medicines like -and there is so 
many different patients, it’s a huge responsibility… we’re lucky 
here, we’ve got a very good practice but other people aren’t 
fortunate aren’t they, so I don’t know if my opinions are fair but I 
worry really a little bit about it. (Participant 3) 
 
Participants raised the issue that people do not like change and that there will need to 
be a culture change in order to achieve acceptance of this development, and for people 
to be confident about it as well.  
 
  …it’s a big big change to get people to think well I’ll go to the … 
…..It’s going to take a long time for people to go to a pharmacist.  
 …Changing the culture, getting people to accept that pharmacists 
and nurses can prescribe (Participant 6) 
Yes I mean people will resist change, people don’t like change, 
they are comfortable with what they have got, they may not like 
what they have got but it’s a comfort they know what they are not 
comfortable with. (Participant 9) 
 
However, some participants were more positive, stating that it was a case of 
acceptance that if a healthcare professional is qualified to prescribe then it does not 
matter which profession they are. Also it was suggested that time was needed for 
people to “acclimatise” to the new development. 
 
…but I think if people get used to the idea umm you know they 
would be more acceptable definitely. (Participant 4) 
I mean I think once you accept the principle that they are qualified 
to do what they do then there is no difference in that case coming 
into a GP surgery and having made an appointment to see Dr x 
and coming in being told for what ever reasons he’s unavailable 
you are going to see so and so and you just accept it. (Participant 
5) 
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One participant raised the issue that the development might involve more work for 
the doctors. 
But if a patient is not happy with what the pharmacist prescribes 
for them it could fall back on the doctor, it could be more work and 
more headaches for the doctor. (Participant 3) 
 
A suggestion was also made that the only way that some people may accept non-
medical prescribers was if they were already having an inferior service from their GP 
practice, and hence were not going to be concerned about having an equally sub-
standard service provided by non-medical prescribers. 
 
We don’t know the running of every organisation do we? There 
may be people that welcome this, because of treatment that their 
having or because of difficulty their having with their surgeries 
(Participant 3) 
 
 
4.3.5.3 Extrinsic Barriers 
 
4.3.5.3.1 Location of IP 
 
Participants clearly expressed that they felt that pharmacist prescribing clinics in 
community pharmacies and supermarket pharmacies were seen as being inferior in 
terms of quality when compared to those taking place in GP practices and hospitals. 
This is because they feel that having that attachment to a GP practice or hospital gives 
the pharmacist clinic approval and credibility from the doctors, and somehow makes 
them “official”. It also suggests to patients that the doctors can keep a close eye on 
what the pharmacist is doing. The participants also felt that clinics that were run in GP 
practices or hospitals would have better facilities and support available which would 
make the patients feel more comfortable to use them.  
 
……if there was an on-site pharmacy in the GP surgery, now fair 
enough, yes it would mean you having to come in to the surgery 
which may or not be an inconvenience, but it just may add that 
little bit of creditability, security to the pharmacists that this is 
somebody who is employed or attached whether their independent 
or not I need to have the feeling that they’re attached to the 
surgery and they’ve got approval from the GPs on site, so they 
should be trusted, but again not to take anything away from 
community pharmacists because they do build up that rapport with 
the patients that they see. (Participant 15 SP) 
I suppose because if you go to the hospital then you’ve got all the 
departments and that are there and you can be referred to straight 
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away rather than letters going backwards and forwards and with 
the doctor he’s got I should imagine, greater pulling-power than a 
pharmacist would have, I don’t know what the powers they would 
be given, pharmacists whether they could rush you through or 
whether they would have to refer you to a doctor to refer you to a 
hospital. (Participant 17 SP) 
 
The following participant felt strongly that supermarket pharmacies would not be a 
suitable location for a pharmacist prescribing clinic as he felt that the image and ethos 
of a supermarket negated their ability to provide quality healthcare. 
 
I don’t think I would go to Tesco’s to get, I just wouldn’t do it quite 
frankly, the power of supermarkets to me is a sore subject, I 
wouldn’t allow prescribing pharmacists really in Tesco’s. …but 
Boots you see you associate with healthcare and medicines and 
medical issues that I don’t have a problem with, but Tesco’s or 
Asda you know it is the image of cut price -cut this and cut that you 
know and I just wouldn’t like that at all really.  It is ok if they are 
going to make up prescriptions, but I don’t want them to be 
prescribing, mind you with customer loyalty and I’m probably not 
speaking for the general population maybe they feel that you get 
a…To me that brings medicine down to the tacky end but you know 
if people are prepared to go to Tesco’s and get a diagnosis and it 
saves their life well fair enough but I just don’t feel comfortable 
with that at all really. (Participant 18 SP) 
 
When asked whether they thought it would be useful for nurses to prescribe, a few 
participants expressed that they would only be happy to use nurse independent 
prescribing services if they were within the GP practice. As for pharmacists above, 
being within the practice infers that the GP is “supervising” the service and also that 
the nurse can quickly get medical help if necessary.  
 
…Yes I think so within the practice because they would be in 
contact with the doctor if they had any doubts the doctor would 
probably be around anyway so within the practice (Participant 6) 
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Section 2: 
 
4.3.6 Discourse regarding pharmacists as independent prescribers 
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Prior experience of HCP’s 
 Comparison of pharmacists to doctors 
 Comparison of pharmacists to nurses 
 Comparison between primary and 
secondary care pharmacists 
Poor understanding of pharmacists 
 Pharmacist training 
 Barrier-public education 
Intrinsic Barriers 
 Negativity re: physical examination 
 Negativity re: pharmacist image 
Extrinsic Barriers 
 Lack of privacy 
 Practicalities 
Support for IP 
 Accessibility of community pharmacies 
 Positive about traditional pharmacist role 
  Pharmacists are capable of diagnosis 
 Location of IP unimportant 
 Pharmacy care allows greater patient independence 
Risk Management 
 Clinical governance 
 Ethics 
 Safety Concerns 
 Importance of monitoring 
 Negative about access to medical records 
 
 
 
Relationships 
 History of relationship 
 Importance of patient experience 
 Importance of trust 
Figure 7: Summary of discourse applicable to pharmacists only. (Section 2) 
Emerging Themes  
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4.3.6.1 Prior experience of health care professionals 
 
4.3.6.1.1 Comparison of pharmacists to doctors 
 
The majority of participants made comparisons in terms of knowledge and training. 
Although there were a couple of positive comments made by participants when 
comparing pharmacists and doctors, 
 
………they’re knowledge of drugs -I suppose it could be that their 
knowledge of drugs is better than a Doctors……(Participant 2) 
……in fact I think sometimes they know just as much as a doctor 
really. (Participant 1) 
 
-the majority of participants felt that the pharmacists were inferior to the doctors in 
this respect. 
 
I presume a doctor gets a lot of training on what to prescribe for 
what a pharmacist wouldn’t get that sort of training would they? 
…The doctor knows a lot more about you generally by looking at 
you by feeling your pulse, temperature and can know a bit more 
about what’s wrong with you.  The chemist’s just ‘oh it sounds like 
you might have a heart problem’ or whatever…… (Participant 13 
SP) 
……..a doctor trains for years and years a lot longer than a 
pharmacist and I always believe the doctors are kept up to date 
with medicine. (Participant 3) 
 
It would seem that also the status of the pharmacist is considered to be inferior to that 
of the doctor as well, and it is recognised that this may be a considerable hurdle to 
overcome. 
 
 I suppose ones perception of the pharmacist is kind of shopkeeper 
whereas the GP is still held in some regard isn’t she or he -in a 
different kind of way which is likely to be quite a hurdle to get 
over………(Participant 10) 
They’re only one-step down from the doctor really aren’t they? 
(Participant 17 SP) 
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4.3.6.1.2 Comparison of pharmacists to nurses 
 
There were quite mixed opinions when comparing nurses to pharmacists, and 
opinions made differed according to past experience the participant had with the 
relevant health care professional. Some participants did not mind which of these two 
health care professionals they saw for prescribing services, stating that their level of 
training would be similar, and that it would be matters such as accessibility that would 
determine who they saw. 
 
It would be whoever you could get into more quickly. (Participant 
6) 
……you take blood pressure as an example and my experience is it 
is a relatively simple thing and they take their reading and then 
make a decision based on whatever reading they get.  The degree 
of training format I would suspect wouldn’t differ very much 
between the pharmacists and the nurses…… (Participant 9) 
 
Some participants preferred to see a pharmacist prescriber, and this was because it 
was felt that pharmacists would have superior drug knowledge for prescribing. 
 
…the pharmacist should have more experience on drugs that are 
being prescribed because a nurse will not have gone through that 
side of it she may see the ailments and be able to diagnose for 
minor ailments because she’ll have come into contact with a lot of 
people with minor ailments.  But prescribing the drugs may be out 
of their area. (Participant 6) 
…my perception is that pharmacists might be more knowledgeable 
and umm have a better understanding of some more serious areas 
of illness again only because what I know about the training but its 
my perception and I suspect maybe that I would feel more 
comfortable with seeing a pharmacist if my own feeling was that 
there was something seriously wrong with me…(Participant 5) 
 
Another participant had other requirements before they would make a decision as to 
which health care professional they saw. 
 
…it would depend on what the conditions were, it would be 
dependent on the condition and it would depend on the expertise of 
the nurse or the pharmacist. (Participant 15 SP) 
 
Most often, the nurse was the preferred prescriber and this was based solely upon the 
participant being more familiar and comfortable with the nurse in that role due to past 
experience of being seen by a nurse for appointments. However, participants did make 
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comments that if the GP surgery was closed, they would then have no problem with 
going to see the pharmacist instead. 
 
Again from my own experience in my own practice and the 
pharmacy that I use I think I’d prefer to see the nurse rather than 
the pharmacist but on the other hand if it was out of surgery hours 
and I needed advice on something I certainly wouldn’t object to 
that to having to go to see a pharmacist in the first instance. 
(Participant 8) 
…if I was here then I would probably come and see the nurse 
because I am used to seeing her but if the surgery was shut and I 
had to go to the chemist then I would go to the pharmacist yeah. 
(Participant 4) 
 
4.3.6.1.3 Comparison between primary and secondary care pharmacists 
 
Hospital pharmacists were considered to have much less contact with the public (or 
none at all) and to be more impersonal that community pharmacists, whom 
participants often felt they built up relationships with over time.  
 
They’re far more helpful than the hospital ones (Participant 6). 
……I don’t know I suppose in some respects in a hospital they’re 
more impersonal because you don’t know them because you only 
come- I’ve only ever used it once so really I don’t know whereas 
when I go to my local pharmacy I’m known. (Participant 8) 
I think I have come across a couple in hospitals when I have been 
to the eye hospital and that’s with you know treatment for my eyes 
umm and they are not so personal they just give you the 
prescription and off you go. (Participant 4) 
 
Although it was considered that community and hospital pharmacists had the same 
qualifications, participants either thought that there was no difference at all in the day 
to day jobs that the two types of pharmacists undertook ‘A pharmacist is a pharmacist 
isn’t it?’(Participant 3) or they recognised that hospital pharmacists dealt with more 
specialist and toxic drugs 
 
…my chemotherapy wouldn’t come from a local pharmacist it 
comes from the hospital pharmacist so they are dealing with 
probably more high toxic drugs and so they have to be more 
careful. (Participant 6) 
I wouldn’t think qualifications were any different but I would say 
that a hospital pharmacist unless they’re in the general pharmacy 
like x (the community pharmacist) they’d got a specialist subject 
which they would be trained to, whereas the pharmacist in the 
chemist shop was very much like a doctor more general…     
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……it’s just that it’s a broader spectrum that they have to cope 
with whereas those in hospitals like x (the supplementary 
prescriber) for cancer and other people they specialise in those, 
probably not so good at coughs and colds. (Participant 17 SP) 
 
Some participants felt that the service being provided by hospital pharmacists was 
superior to that which you get in a community pharmacy, as a result of their 
specialism. 
 
I know they’re a little bit better in the hospital, they’re more 
concerned what you’re taking and everything. (Participant 16 SP) 
I’m supremely impressed having suddenly needed chemotherapy 
that every Friday when I turned up my little package of stuff was 
there in the bag it just happened I didn’t know where but something 
was going on here and that was very impressive and clearly that’s 
a whole lot more than what goes on in the average high street 
pharmacist. (Participant 10) 
 
 
It was also recognised that a difference for community pharmacists was their 
managerial and retail responsibilities. 
 
 …suppose the main difference would be that in a shop many, on 
many occasions not on all as I understand it, they also manage the 
shop so they have a responsibility for the retail management side of 
the business, so that is the big difference I guess.  (Participant 5) 
…Not in relation to the prescription drugs, I think they get people 
in the, outside will probably have more diversion into the retail 
type of goods you know they become more salesmen perhaps of the 
non-prescription drugs. (Participant 9) 
 
 
4.3.6.2 Intrinsic Barriers 
 
There were commonly held beliefs that participants held which prevented them from 
accepting the development of non-medical prescribing. 
 
 
4.3.6.2.1 Negativity re: physical examination 
 
When pharmacists become independent prescribers they are going to need to 
physically examine patients. One participant felt very uncomfortable about a 
pharmacist having to do this because they were not used to pharmacists having a 
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“hands on” role. Again, it is a major change in the role that a traditional pharmacist 
has and therefore may take some time be accepted. 
 
No, I think if that was needed I would rather go to the GP. 
(Participant 1) 
 
4.3.6.2.2 Negative Pharmacist Image 
 
Some comments were made which suggest that the pharmacist is not held in very high 
regard by some people due to a lack of understanding of the job that they do. 
Dispensing medication is not viewed as being a very complicated task, and the public 
do not understand the “safety role” that pharmacists have of also ensuring that the 
medication that has been prescribed for the patient is appropriate and safe for that 
patient.  
But they’re kind of unknown to most people aren’t they  the person, 
probably not in a white coat, but hovers around in the background, 
who actually makes you wait 20 minutes for a prescription to be… 
(Participant 10) 
 
 
4.3.6.3 Poor understanding of pharmacists 
 
4.3.6.3.1 Pharmacist Training 
 
Although some people correctly presumed that pharmacists received degree-level 
training for quite a few years in order to qualify as a pharmacist,  
 
I would imagine about 7 years.  Going from University then into 
training I would imagine it’s going to be a fair time… It’s not 
something you do in 2 years. (Participant 6) 
 
It was apparent that there was also a deficiency in a lot of people’s understanding 
about the training and knowledge of pharmacists, and this affects their confidence to 
consult a pharmacist in a prescribing role.  
 
I don’t know to be honest I don’t know a pharmacist.  …I don’t 
know beyond the fact that they make up prescriptions……… I still 
wouldn’t have the confidence but probably I think because I really 
don’t know what a pharmacist’s job is.  What his knowledge is 
really or her knowledge. (Participant 2) 
Some medicines are probably much more dangerous to prescribe 
than others and presumably you need special training to know 
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when they should be used, would a pharmacist know that?  
(Participant 13 SP) 
 
Once that participant’s were told the length of training that a pharmacist has, they did 
concede that over such a length of time, their knowledge must be substantial.  
 
I didn’t realise it was such a long, long training.  So they must 
learn a lot in 5 years. (Participant 2)  
 
4.3.6.3.2 Barrier- Public Education 
 
Some participants were very aware of the need for public education to occur in terms 
of the public understanding the expertise and experience that pharmacists have and 
the code of ethics they are bound to. They suggested that current levels of public 
education were a major barrier to the development of non-medical prescribing. 
 
So I think really you would have to do an awful lot of public 
education convincing people of the professional expertise of the 
people and the fields in which they are acting in and secondly their 
codes of professional conduct rules…. (Participant 18 SP) 
Biggest barriers -well public education number one -my experience 
has been that people are really extremely ignorant and its not 
surprising, about how the entire system works, so most people have 
complete misconceptions just like I do about who these people are 
and what they do (i.e. pharmacists). (Participant 10) 
…it’s all going to come down to information or education and if 
this is the route we’re heading towards the public need to be 
informed of the service of the qualifications that these individuals 
have and the experience that they’ve developed and they need to 
sell it. It needs to be sold positively so that we know that if we go 
and see a prescribing pharmacist or nurse that we know we’re 
going to somebody who is qualified to do it and that they’ve had at 
least 5 years experience or whatever the job spec. says. (Participant 
15 SP) 
 
 
4.3.6.4 Extrinsic Barriers 
 
4.3.6.4.1 Lack of privacy 
 
One of the barriers to community pharmacies developing successful pharmacist 
prescribing clinics is the commonly-held perception that there is not enough privacy 
in a community pharmacy.  
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…also I think there is no privacy in a pharmacy is there? I don’t 
think there is anyway…  You kind of chat over the counter for all 
and sundry to hear.  (Participant 2) 
We’ve got the pills and everybody’s ears are flapping aren’t they?  
But in your local pharmacy you’re quite likely to meet your 
neighbours and they know as well and they’re ‘oh you’ve still got 
the same old trouble with the? 
 (Participant 10) 
 
4.3.6.4.2 Practicalities 
 
Participants discussed how community pharmacies were going to cope with running 
pharmacist prescribing clinics, and many practical issues were raised.  
 
…you don’t want to be put out in the store room to be examined, 
providing it is professional, no it wouldn’t, the only analogy I can 
draw is that basically opticians these days, they are set out to do 
vision express or something like that.  They are set up in a very 
clinical way with consulting rooms and that and the whole thing 
looks professional and feels professional providing it was like that, 
then I wouldn’t have any problem but if you were asked to sort of 
you know step into the broom cupboard while I sort of look in your 
tonsils then no, it has got to be properly licensed, I think licensed 
premises for consultation really so standards.  There are hygiene 
factors and all sorts. (Participant 18 SP) 
But many of them are mighty cramped by the time you’ve waded 
through the rubber gloves and other stuff.  Yes ok people would 
need to be equipped to do the job and the premises need to be 
adequate for the purpose that they are going to be used... 
(Participant 10) 
 
Participants also commented that if community pharmacies are going to become more 
like a GP practice with a waiting area for appointments and therefore they would have 
difficulties with having enough room for everyone. 
 
…they couldn’t possibly cope with numbers couldn’t possibly have 
everybody’s I don’t know how many patients there are in this 
practice, thousands probably.  (Participant 2) 
I don’t know whether a chemist shop would turn into a place like 
this with queues and waiting rooms or not. If it became a general 
service it might well do and then you’d have to have a waiting 
room as well, there isn’t much room in our chemist shop for more 
than 2 or 3 people. (Participant 13 SP) 
 
One participant commented that if extra prescribing clinics are going to run in 
community pharmacies then the pharmacies would have to take on more pharmacists 
to keep up with the workload. 
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…they could well find themselves in a position that the surgeries 
find themselves where you’ve got too many patients and when 
you’ve got a time constraint, I think it would mean that the 
community pharmacists are going to have to grow, you cannot 
have a one-man band can you? You’ve got to have a few of you 
because of the consultations and then you’re going to have those 
who are dealing with the prescriptions. (Participant 15 SP) 
 
Another practical issue that a participant brought up was how would the customers 
know what the community pharmacist specialised in? This would be an issue if a 
person wanted to see a pharmacist prescriber for a particular condition without being 
referred by their GP. The community pharmacy will have to advertise the prescribing 
clinic and what conditions the prescriber dealt with to let the public know about the 
service if it was run as a private clinic. Perhaps this also shows that patients are 
having difficulty in visualising healthcare provision in such a radically different way. 
 
…but how do we know, how do we know if a pharmacist is trained 
in say heart problems or rheumatology or whatever.  I mean if I see 
x she’s a specialist in that field but a chemist is a general person 
isn’t it.  How will you know what the specialities are?(Participant 
13 SP) 
 
4.3.6.5 Support for Independent Prescribing 
 
4.3.6.5.1 Accessibility of community pharmacies 
 
Participants expressed that community pharmacies are very accessible in terms of 
location on the high street and the hours they are open. It was also recognised that the 
advice of pharmacists themselves has always been very accessible. This was seen as 
an advantage with respect to them offering pharmacist prescribing clinics. 
 
…it is easier to drop into your local pharmacist (Participant 18 
SP) 
…pharmacists are open all day long presumably so you have got 
more time range to get over your problem. (Participant 7) 
…sometimes shops are a bit closer to where people live and a 
doctors surgery is a bit more maybe out of the way. (Participant 4) 
See you’ve always been able to ask for a chemist opinion haven’t 
you? (Participant 13 SP) 
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4.3.6.5.2 Positivism about the traditional pharmacist role 
 
Participants made plenty of positive comments about pharmacists in their traditional 
role, which provides some support for the extension of their role. Participants speak 
very warmly about their local pharmacist. They valued the advice that pharmacists 
gave them, how accessible they were and how helpful they have been. 
 
…the actual local pharmacist we have got is very good, you can go to her 
and ask for her advice. We’ve got a new lady in the house and she got a 
cold and we went and she was very, very good, what she advised. …and 
you do find that they do have more time for you and it would be very sad 
if we lost them. (Participant 6) 
I told you I have had asthma for 10 years and what with the morphine 
and the other things I need to have someone that I can trust and talk to 
and I have found them very helpful (Participant 7) 
I find on the whole they’re very good and very helpful to what they used 
to be.  I think they seem to be more trained and more up together with 
what’s going on than they used to be and I think it’s a good thing, it 
relieves the doctors of a lot of pressure and you can go down to the 
pharmacist and say I’ve got problem can you help and they can have a 
look and say yep I’ve got something here I can give you. (Participant 17 
SP) 
 
4.3.6.5.3 Pharmacists are capable of diagnosis 
 
Some comments were made that as long as prescribing pharmacists were working 
within clear guidelines, were able to refer patients and were trained appropriately they 
believed that pharmacists were capable of diagnosis in some areas. 
 
The diagnosis side I think again providing that they are very clear 
guidelines and the right referral procedures, I think yes many 
minor ailments could be looked after by pharmacists prescribing 
really… (Participant 18 SP) 
 
One participant felt that she already felt that pharmacists were already working in an 
extended manner and therefore felt that they would be capable of diagnosing. 
 
…I think pharmacists are quite competent in doing things like that, 
like I say they now their doing my blood checks, doing the diabetes 
tests in the local chemist and things like that so I should imagine 
that they would be able to pick up quite a few things from patients. 
(Participant 4) 
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4.3.6.5.4 Location of IP unimportant 
 
Some participants did not consider that the location of the pharmacist prescribing 
clinic was an issue, as long as the premises were properly equipped and the 
pharmacist was competent and professional, it should not matter. Interestingly, one 
participant, when considering what will be the most difficult location for patients to 
accept pharmacist prescribing clinics at, chooses a supermarket pharmacy as being the 
most extreme example. 
 
It doesn’t bother me at all, it’s almost as long as whatever is wrong 
with me is put right… (Participant 9) 
No I don’t think so no.  I’m assuming that people in this sort of 
position are equipped to do the job competently and professionally 
and the premises don’t really matter so it could be at Sainsbury’s. 
(Participant 10) 
No I mean clearly it wouldn’t be doing it over the counter, you 
have to presume there is going to be a private room somewhere so 
as long as there are adequate facilities there. (Participant 5) 
 
4.3.6.5.5 Pharmacy care allows greater patient independence 
 
One participant felt that in order to be more in control of your own healthcare, he 
would prefer to use a pharmacist prescribing clinic as care by a GP means that you 
loose control of your own care. This may lead to some patients relying on such 
services as a way of avoiding seeing their GP. However, it is envisaged that most 
services would be referral-based from the GP.  
 
We have got a chemist in the next village which I think it is a 
Lloyds pharmacy that does blood pressure and the cholesterol 
testing, you know I would probably be more inclined to drop into 
there rather than my GP funnily enough.  I suppose in a way now 
this is an interesting point to me anyway whether that is because 
you can go in and find out but still remain in control of the 
situation, now once they go on record and that goes through to 
your GP whether that, it is a silly thing isn’t it really but one feels 
that one should go into your doctors, into the sort of chain there 
really you tend to lose control of things because you are sort of 
coerced and not forced. (Participant 18 SP) 
 
 
4.3.6.6 Risk Management 
 
The participants discussed many factors which they thought would need to be in place 
in order to have a safe and effective system if pharmacists were prescribing. 
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4.3.6.6.1 Clinical Governance 
 
With regards to clinical governance, there was an expectation amongst participants 
that there will be appropriate checks in place in order to ensure that the new 
prescribing system is appropriately policed. Participants had various ideas of methods 
in which this could be done. There was also recognition that the patient themselves 
would also be responsible for flagging up poor performance. 
 
I suppose there has to be a governing body that makes sure that if 
you’ve got a pharmacist that was prescribing, prescribing and 
prescribing there’s going to be somebody that is going to say ‘hang 
on’ what’s this coming out if there were drugs going out then there 
would be a check on that I would imagine. (Participant 6) 
Well certainly I think random type of interviews with patients 
would be useful but certainly periodic examination of the patient’s 
medical records and progress would be important, I think that is 
basically the only way you could do it.  You cannot have somebody 
sitting there watching over your shoulder all the time that is a 
waste of resources, but I would have thought some form of random 
sampling of his patients. (Participant 18 SP) 
It’s only a patient who will know whether he’s feeling better or not.  
If he gets the wrong medicine but then if you’re dead you cannot 
complain about it. (Participant 13 SP) 
 
 
One participant brought up the Harold Shipman case and remarked that a proper 
monitoring system has to be in place in order to identify poor performers, and that the 
service needs to be transparent so that service users are aware of the way that 
performance is checked upon. 
 
…that it doesn’t become like a back-street secret society, you know 
what I’m trying to air towards, in that it is all open and above 
aboard all kosher that you don’t get individuals and I suppose 
what I’m thinking of and don’t take this the wrong way, it’s the 
Harold Shipman scenario where you may well get somebody who 
doesn’t -who underperforms and there would have to be a 
monitoring system for the pharmacists to ensure that they are 
prescribing the appropriate drugs and that if there are any adverse 
problems incidences with patients that weren’t being dealt with 
correctly. (Participant 15 SP) 
 
Some participants were aware that the system should have the same type of 
monitoring that doctors have as the pharmacist prescriber would be providing the 
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same type of service. They therefore asked questions about how doctor’s prescribing 
is monitored. 
 
Who checks on the doctors in a hospital? (Participant 6)  
Whether they’re prescribing the right stuff, well the same applies to 
GP’s -how are GP’s checked upon on a day to day basis they have 
to do their own thing? (Participant 10) 
 
One participant also commented that he thought that reassuring the general public that 
the new system is appropriately monitored and is therefore safe will be much more 
difficult. 
I expect there to be rigorous arrangements in place to make sure it 
is (a safe system) and reassuring the general public that that’s the 
case would be quite difficult I suppose (Participant 10) 
 
Another participant thought that it might be more difficult to risk manage a 
prescribing service in a community pharmacy where a pharmacist may be working in 
isolation. 
 
Unless there was somebody else qualified within the same 
establishment who could go in and have a quick chat and sort of 
check which might be possible in some cases if it is a large enough 
shop and they have got more than one pharmacist although the 
time that that would take, I suppose the only other way of doing it 
would be to do some sort of spot checking just to make sure that 
generally what the pharmacist is doing is correct (Participant 5) 
 
 
4.3.6.6.2 Ethics 
 
One participant brought up the issue that he didn’t know whether pharmacists had to 
conform to the same type of Hippocratic Oath as doctors do. It was felt that the 
general public would need reassurance that pharmacists are bound by a code of ethics 
which would prevent them from sharing any confidential data about the patient with 
anyone not involved with their medical treatment. There was also a lack of confidence 
that even if they did adhere to some form of ethical oath that it may not carry as much 
weight as that taken by a doctor. There was therefore a level of suspicion about 
whether a pharmacist would really keep patient information confidential. 
 
I suppose what many of the public may want reassurance on is 
whether a pharmacist is bound by the same rules of ethics and 
confidentiality as your doctor, so you tend to sort of assume that 
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with the doctor you know it, but I am not sure that I would I would 
assume that a pharmacist has a confidentiality patient 
confidentiality issue but I wouldn’t be sure and even if there was I 
am not quite sure that I would genuinely feel that it had the same 
sort of weight as a doctor is it the Hippocratic Oath or something 
that they take, I don’t know what pharmacists take, what oath they 
take …… I think that (that pharmacists adhere to a code of ethics) 
would probably need projecting in the public domain so that 
people are aware that there is a strict code for pharmacists. 
(Participant 18 SP) 
 
 
4.3.6.6.3 Safety Concerns 
 
Some participants had more general safety concerns about the independent 
prescribing system. Some participants were not very able to fully explain their 
concerns, but they centred on pharmacists prescribing the wrong things for the patient, 
especially for what were considered to be more “serious” conditions. 
 
Because they might prescribe the wrong thing mightn’t they? 
(Participant 16 SP) 
 
One participant had concerns about whether the pharmacist would have all of the 
information available to them that would be necessary to make safe decisions about a 
patient’s healthcare. 
 
…to what extent the pharmacist will be aware of any issues about 
your health which might impact on what they prescribe.  I guess 
there are some medicines, some medication which doesn’t 
necessarily go well with something that you might already be on if 
that’s the case, so other than asking the patient what medication 
are you already on then umm is there a danger that the pharmacist 
might find themselves in a situation where they are prescribing 
something which actually when it is taken in conjunction with 
something else that they are taking is dangerous? (Participant 5) 
 
Some participants recognise that the safety concerns are applicable to any healthcare 
professional who is prescribing. However, one participant felt that once a prescriber is 
experienced, this risk would be reduced. 
 
Well is any system safe really, I mean you go to the doctor and they 
prescribe you’re in their hands so if the pharmacist is clued up on 
a particular area then he’s really no different than a doctor in that 
respect, from my opinion anyway. So it should be the same. 
(Participant 17 SP) 
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Well doctors make mistakes don’t they? -and one would assume 
that unless they’ve had a lot of experience they would equally be 
prone to mistakes (Participant 8) 
 
4.3.6.6.4 Importance of monitoring 
 
The participants did not have a lot of comments about monitoring of conditions that 
the independent prescriber was prescribing for, but some did state that it was 
important for their on-going condition to be closely monitored by the independent 
prescriber. As the public are used to pharmacists recommending things over the 
counter without undertaking any monitoring or examination, they are wary as to 
whether the pharmacists would actually properly monitor the condition as a doctor 
normally would. 
 
…if the pharmacist was able to have that sort of system that they, 
despatch reminder cards or even if obviously if they are 
prescribing them say every now and again or every 6 months note 
on the prescription to say you know come in for a test. (Participant 
18 SP) 
Well I presume they’ll do the tests if they are suspicious of blood 
pressure.  They will not just sort of look at you and say ‘you need a 
bottle of this’. (Participant 13 SP) 
 
 
4.3.6.6.5 Negativity about access to medical records 
 
Participants brought up various issues surrounding pharmacists having access to 
medical records. 
One participant thought that pharmacists should only be given certain levels of access 
to a patient’s medical history and that they could be denied access for certain 
conditions that the patient had. However the patient did concede that that may not be a 
safe prescribing system, and upon further reflection concluded that it was probably 
that pharmacists shouldn’t be treating certain conditions as opposed to access to 
medical records that was the issue. 
 
…whether it is possible to have levels of disclosure, I don’t know it 
may not be possible because who knows, but I don’t know enough 
about medical conditions to know whether it is possible for 
instance in my condition, I am not sure that I would like my whole 
history of my cancer record to be down at pharmacy level but 
would it be dangerous to prescribe anything without knowing that?  
I don’t know?... I would have thought that certain conditions may 
preclude treatment by a pharmacist and again if you have got this 
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wonderful technology you should be able to flag up that if the 
pharmacist is looking flags up yours records and there is a bar on 
it saying you know refer to GP, that would be the other issue 
really. (Participant 18 SP) 
 
This participant also raised the issue of access to medical records in community 
pharmacies as being particularly disagreeable, along with other participants. This is 
because community pharmacies are viewed as being “non-NHS” with a lot of non-
clinical “shop staff” who may inadvertently see medical records without being bound 
to any code of ethical conduct. Also the participants were not confident about the 
security and confidentiality of their records in these premises. 
 
…if you are talking about -I call them chemists, there are a lot of 
people in there because there is a retail side to the business and 
there are non medical people in there obviously, the access to those 
records would be a problem, I think all NHS staff even volunteers 
are bound by strict codes of confidentiality when they are handling 
records, you would have to consider that I think for staff of and I 
am not sure that I would actually like, certainly I mean I live in a 
village and you sort of know these people, they work around the 
shops in the village you know, you wouldn’t really want your 
medical records even on a confidentiality basis, or confidential 
basis rather known by those sort of basically shop assistants.  So I 
think that would be an issue the protection of medical records 
within a pharmacy. (Participant 18 SP) 
I think the public will feel a lot more comfortable if they were 
going to be allowed access to your records, I think if the 
pharmacist was attached to the surgery. I would definitely feel 
more comfortable like that. (Participant 15 SP) 
 
Some participants had concerns as to whether there was enough information 
technology capability to provide medical records access in all community pharmacies 
and other clinic locations and whether the information technology system would be 
reliable enough as well. Some participants viewed the IT capability as being a major 
barrier to the development of the independent prescribing system. 
 
Presumably they must instruct the doctor that they have done 
something and if they have got this computer link up -this is the 
only thing that would worry me because we hear so many times 
about computers going down, both my sons work in computers and 
they are always saying oh its gone down and it has happened in 
here hasn’t it things have gone down. (Participant 7) 
The IT and systems implications in doing that and presumably as I 
say a place like x (town) the issue is how any one pharmacist in a 
little shop in a high street in x (town) can have access to records 
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which are held on servers in umpteen different GP practices 
around the area… And I think the bigger issue is the solution to 
that is that all GP’s locally have records that are on an IT system 
and somebody centralising some mega central data base run by 
who ever, that is the bigger problem because the access issues are 
more serious  (Participant 5) 
 
These concerns over the IT capability lead to one participant commenting that he 
would be concerned that the independent prescriber would have enough information 
about the patient to safely prescribe as well. 
 
…providing the information is available, this is I repeat myself 
don’t I? -but this is the only thing that really worries me or would 
worry me, is that they have got the information they need to 
prescribe this drug and it doesn’t affect the other drugs that I am 
taking. (Participant 7) 
 
Therefore there is considerable feeling that the current IT support for this 
development is not going to provide a workable system at the moment. 
 
4.3.6.7 Relationships 
 
4.3.6.7.1 History of relationship 
 
Participants suggested that the popularity of independent prescribing will take some 
time to increase whilst patients build up their relationship with their pharmacist 
prescriber. The public are not used to pharmacists being prescribers and there will 
need to be a period of relationship building in order to promote trust. Once these 
relationships are more established the independent prescribing clinics may be used 
more frequently.  
 
I think from my experience generally speaking, the better one to 
one experience you have with an individual the more you’re going 
to trust them and believe that they are actually making decisions 
for your welfare. (Participant 15 SP) 
I mean I think the only issue you might have is that because you 
have a particular problem and you have been seeing that same 
doctor for all the time you have had the problem you might want to 
come back another day and see him because he knows the problem 
(Participant 5) 
…and people hopefully will not be so frightened in going and 
asking, as people are a bit worried about going to the doctor, they 
could go to a pharmacist that perhaps they see because they get 
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their corn plasters and what have you they become a friend and 
then they can talk to them. (Participant 17 SP) 
 
 
One participant thought that community pharmacists would need to work harder than 
pharmacists within secondary care to develop their relationships with their patients, 
due to the community pharmacy being a business and the bias that comes with having 
to maintain a viable business.  
 
For those who work in the community I think they have to I believe 
build up a rapport with the patients that come to them in giving 
advice.  Because I mean, it’s a business so you have to be pleasant, 
you have to have the human skills and touches, good 
communication skills because you want those patients to build up 
that trust with you in return for further services. (Participant 15 
SP) 
 
However, one participant already had a good relationship developed with their 
community pharmacist, and thought that was better than the pharmacist relationship 
they had developed in hospital. 
 
…I think it is more personal with a one to one pharmacist that you 
know so you know if you go to that chemist all the time and the 
pharmacist gets to know you then they give you more of a personal 
touch.  Once you have built up the relationship with the pharmacist 
then they know you and they know you by name and you know it’s 
more personal than a hospital. (Participant 4) 
 
4.3.6.7.2 Importance of patient experience 
 
One participant discussed that if he used a pharmacist prescribing service, it would 
depend upon how that experience went as to whether he would continue to use such a 
service. 
…should I choose to go down that route when the system is up and 
running, I’m not going to know them.  It is going to be down to the 
one on one experience that I have with that individual.  It’s going 
to take time for it to become efficient and a lot of it is going to be 
down to the delivery of the service, how they make sure that it’s a 
pleasant one for the patients. (Participant 15 SP) 
 
Therefore it is apparent that first impressions of pharmacist prescribing services will 
be very important if the general public are going to be “won over” to using this new 
service. 
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4.3.6.7.3 Importance of trust 
 
Participants discussed how important it was to trust their prescriber. You need to trust 
their professionalism, their knowledge and you need to put your faith in them that 
they are going to do the best for the patient and not put them at any risk of harm. 
Participants talked quite generally about trusting people that are providing you with 
healthcare. 
 
You take a lot of trust when you go into hospitals it is like flying, 
when you go on a plane you don’t see the pilots driving license so 
you trust that the people that you are dealing with are you know 
the professionals that they are.  (Participant 9) 
Yes I do tend to have great trust and faith and maybe I’m naive but 
I always assume that if people are doing something they’ll be up to 
it and motivated and we’re on the same side until I have some 
evidence contrary. …I would hope that they knew what they were 
doing, if they didn’t they shouldn’t be doing it should they? You 
have to be trusting (Participant 10) 
 
Some participants were more specific about how they trust their pharmacists. These 
participants obviously have had a good history of dealing with pharmacists in the past 
and have been able to develop a relationship with them so that they are now in a 
position where they trust their judgement.   
 
Well I get on very well with x (community pharmacist) as long as 
he’s been trained in whatever it is I’d accept his judgement 
(Participant 13 SP) 
…it is a profession that I have no trouble in trusting.  If a 
pharmacist tells me something I believe them. (Participant 5) 
 
However, a couple of participants were more uncertain of whether they could trust a 
pharmacist as a prescriber. 
 
I mean it’s a vocation it’s a job of work isn’t it? But we’ve got to 
hope that they don’t make mistakes.  You have to put a lot of trust 
and faith in them and if they’re going to have more responsibility. 
(Participant 3) 
Because I thought I’d just injured myself with a grandchild, you see 
pulling her back from the recreation grounds, you see this 
apparently comes on quite suddenly but it took 3 visits to my doctor 
before it was diagnosed (not a back injury) because I convinced 
her that I’d done it myself.  Would you talk to the pharmacist like 
that? I don’t know. (Participant 3) 
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Section 3:  
 
4.3.7 Discourse regarding nurses as independent prescribers 
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Prior experience of HCP’s 
 Comparison to pharmacists 
 Comparison to doctors 
How patients feel about nurses 
 Nurse positivism 
 Sympathy for nurses 
 Development of the nurse role 
 Benefit: job satisfaction 
 Nurse negativity 
 Subordinate role of the nurse 
 Lack of understanding of nurses 
 Barrier: public perception 
 Negativity about drug knowledge  
Barriers 
 Negative about nurse IP 
Facilitators 
 History of relationship 
Support for IP 
 Nurses already prescribe 
Figure 8: Summary of discourse applicable to nurses only. (Section 3) 
Emerging Themes 
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4.3.7.1 Prior experience of health care professionals 
 
4.3.7.1.1 Comparison to pharmacists 
 
When comparing nurses and pharmacists there were a range of positive and negative 
comparisons, but they seemed to mostly favour the nurses. They tended to be more 
negative about pharmacists in terms of their qualifications, their status, them being 
viewed as being “non-NHS” and in terms of professional relationship. Participants 
really value nurses and have great warmth and affection when discussing their role 
and abilities. They view them as being very dedicated to their jobs and therefore 
participants felt that this would lead to a more easily established trusting relationship. 
Participants recognised that pharmacists have never traditionally had a “hands on” 
role with patients and perhaps have “distanced” themselves from patients by having 
the barrier of the counter between them. It was also noted that when you go into a 
community pharmacy you may never see the same pharmacist in there, which 
precipitates the difficulties in developing a relationship. Therefore it seems to be more 
difficult for the public to accept this major change in role for pharmacists rather than 
nurses.  
 
Well I suppose mine as well as other peoples perceptions, I guess is 
that the nurse sort of person is more likely to be more medically 
qualified to do whatever it is that they’re been asked to do 
(Participant 10) 
Well it sad really, it’s difficult because you don’t think a 
pharmacist who is someone just behind a counter, he is set aside -
but I think nurses have got a little more status in my opinion…… 
With the dedication to me whereas I think a pharmacist if they’re in 
a job, it’s just....... Well I think nurses are usually female and they 
have this dedication and feeling for everyone whereas a 
pharmacist it varies and it’s usually men isn’t it?  Their not going 
to have any personal contact with us. (Participant 3) 
I mean we know these nurses, we get to know them, but I mean 
pharmacists you don’t know them do you?  I mean it may not be the 
same one all the time in the shop. (Participant 1) 
 
One participant also made the assumption that the nurse would be able to get access to 
patient’s medical notes more easily than a pharmacist, which may be due to 
community pharmacists being viewed as being non-NHS as they are mostly not based 
within GP practices or hospitals. 
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…taking into consideration they will probably be able to get their 
information quicker than the pharmacist I don’t know… 
(Participant 7) 
 
One participant did not see any differences between nurses and pharmacists in terms 
of their ability, training and knowledge as long as they were qualified appropriately. 
 
I don’t think I have got really any, I don’t think I have got any 
differences in my opinion between nurses and pharmacists because 
again they have been through the training they are qualified they 
are knowledgeable, so I don’t think I have got any differences at 
all. (Participant 5) 
 
The area where pharmacists were deemed in a more positive manner was when 
participants discussed their drug knowledge. One participant felt that pharmacists 
would be able to specialise in several clinical areas due to their expert drug 
knowledge, whereas nurses ought to specialise in a single clinical area. 
 
I suppose where maybe a pharmacist could be qualified maybe in a 
couple (of clinical areas) although they would concentrate in 
maybe chemotherapy or whatever. I think with a nurse they would I 
believe they would have to be qualified for specialising in one area. 
(Participant 15 SP) 
…maybe I have got a perception that pharmacists have got a better 
knowledge of drugs themselves than nurses might have, I don’t 
know if that is the case or not but I guess that is a perception I 
hold.  (Participant 5) 
 
4.3.7.1.2 Comparison to doctors 
 
Nurses were held in very high regard when compared to doctors. This was in terms of 
them having more time for patients and having better relationships with their patients.  
 
Yes-you always feel that they’ve got- perhaps it’s wrong, but you 
can spend a bit more time with them, it’s easier. (Participant 6) 
I very often see the nurse and she is more of a contact with me than 
the doctor is. (Participant 4) 
 
It was also recognised that in hospitals, experienced nurses tend to support and guide 
doctors- especially the junior doctors. Also participants reported how nurses now have 
more autonomy and are taking on a more extended role. The nurse was seen as being 
the “central” health care professional in a patient’s care who liaised with other health 
care professionals and saw the “overall picture” in a person’s care. 
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I think now hopefully that now they are able to make decisions and 
do more for the patient, clinical as opposed to have to leave a lot of 
stuff to a doctor and I think it’s quite frustrating when you get the 
changeover of the doctors and you’ve got these young doctors 
which is probably their first posting they’re in Accident and 
Emergency or on the wards and it’s the nurses that are carrying it, 
it’s quite stressful for them at the time…… at least they are able to 
give advice not only to the doctors because they are they’re in 
communication with one with the doctors one with the patient and 
the patient’s relatives more that they will probably pick up and 
take on a lot more information than maybe and I’m not discrediting 
doctors, than maybe a doctor would do and will be able to give the 
appropriate advice or pass on the appropriate information to a 
doctor so that that patient gets the right treatment. (Participant 15 
SP) 
 
4.3.7.2 How patients feel about nurses 
 
The way that participants regarded nurses could be split into positive and negative 
issues that impact upon people’s opinions of nurses in an independent prescribing 
role. The following themes regarded the positive views about nurses. 
 
4.3.7.2.1 Nurse positivism 
 
When participants were asked their opinion of nurses, they overwhelmingly praised 
nurses, using terms such as “wonderful” “excellent” “very good” “first class” “kind” 
“great” and “marvellous”. They were regarded with the greatest of respect and 
participants thought that nurses were committed and dedicated to their jobs and 
worked very hard under difficult conditions.  
 
…I think they work extremely hard…. I wouldn’t basically question 
their commitment or their ability or their caring really, the 
experience I have had has been first class. (Participant 18 SP) 
…some nurses are just wonderful and have worked for years in 
that area and know everything inside and out. (Participant 15 SP) 
…I mean we have the best nurses in the world (Participant 14 SP) 
 
It was also recognised that nurses could develop quite intimate relations with their 
patients as well, depending upon what condition the patient had: 
 
…nothing is too much trouble and I have suffered with things like 
constipation and the sister I had dealt with it within sort of 20 
minutes, she came and held my hand. (Participant 7) 
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One participant mentioned that the nurses he came across in hospital hadn’t fallen into 
the “stereotypical” view held (and promoted by the media) of nurses, but instead were 
incredibly professional: 
 
Well, my personal experience has been about 99% fantastically 
good much of the time as a patient one is pretty vulnerable and 
most of the time I wasn’t called ‘dear’ or ‘love’ or ‘ducks’ or 
anything like that they mostly got my name right and they were all 
very nice, very professional and so that’s a huge generalisation 
and in the day-therapy unit which I’ve said to themselves in a 
variety of ways they were extraordinarily I don’t know how they 
remained so cheerful with people who were extremely unwell… 
(Participant 10) 
 
 
Participants also thought they were very professional and thought that they took 
workload from the doctors, had more time for you than doctors and were more 
efficient than doctors.  
 
Excellent it’s a wonderful service you never have to wait more than 
5 -I don’t think I have ever had to wait more than 5 minutes for 
anything for any appointment they seem to get you in and get you 
out.  If you go to a doctors if you want to see the nurse it’s far 
easier to get in they do seem to run their clinics better possibly 
‘cause they’re not dealing with dramatic illnesses. … Now the last 
few times I’ve been in hospital the nurses are always busy but they 
have always got time for you…. I can only praise the nursing that 
I’ve had here. (Participant 6) 
Well they do a damn good job taking a lot of workload off the 
doctors don’t they? (Participant 11 SP) 
 
 
So all of this positive opinion facilitates them being accepted as independent 
prescribers. 
 
4.3.7.2.2 Sympathy for nurses 
 
Alongside this positivism held for nurses, participants also “felt sorry” for nurses as 
they believed that they worked extremely hard, under difficult conditions for not very 
much money. 
 
I mean I am sure they need more nurses on a ward because their 
work never seems to stop (Participant 7) 
…a nurse’s job is one I have great sympathy for and I think they 
are poorly paid for what they do now. (Participant 5) 
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They get a very poor wage for what they do.  They work for 10 hrs 
a day for what £200-£300 a week. (Participant 14) 
 
4.3.7.2.3 Development of the nurse role 
 
One participant recognised that the role of the nurse has already been changing over 
the past few years, and they are developing a more clinical role. This recognition 
again means that it will be more acceptable for the public to accept them in a 
prescribing and diagnosing role. 
 
It’s not bed baths anymore is it?! -It’s changed so much whereas it 
used to be a lot of hands on building up that rapport with the 
patients and getting to know your patients and basically assisting 
obviously you’ve got your clinical skills you need to carry out and 
doing your checks and observations and changing the dressings 
and administering drugs and what have you, things are changing. 
(Participant 15 SP)  
 
4.3.7.2.4 Benefit: Job Satisfaction 
 
One participant recognised that nurse independent prescribers may acquire greater job 
satisfaction from undertaking this role as well. Which alongside the participant’s 
positivism for nurses and their sympathy for them, will provide public support for the 
nurse as an independent prescriber. 
 
…it will be interesting if, if it makes their job interesting and they 
get more job satisfaction out of it, out of doing it. (Participant 9) 
 
 
Although the participants held these positive views about nurses, they also held the 
following negative views about nurses, which could be detrimental towards their 
support in an independent prescriber role. There was however, a greater strength of 
feeling with regards to positive comments about nurses than the negative comments. 
 
4.3.7.2.5 Nurse Negativity 
 
There was not a great amount of discussion about nurses in a negative manner. 
Comments that were made were based upon the knowledge of nurses and hence how 
worthwhile their role is. 
 
You cannot say that nurses are going to get 5 years in a university.  
They wouldn’t be nurses after that would they; they’d be doing 
something a bit more worth while. (Participant 13 SP) 
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…they can be bossy sometimes, but it comes with the job. 
(Participant 9) 
 
4.3.7.2.6 Subordinate role of nurse  
 
Participants commented upon the current job role of the nurse. They referred to the 
nurse as being in a supportive role to the doctor, removing more menial tasks away 
from them. Participants thought that nurses did not have a lot of responsibility and 
were always responsible to someone else. If nurses are perceived as being subordinate 
it will negatively affect the public’s opinions of their ability to be autonomous 
independent prescribers. 
 
(Asked what the role of the nurse was) Dogsbody. (Participant 17 
SP) 
…it’s minor medical care that they give they don’t give any 
diagnostic care that wouldn’t be their job, but they will what the 
doctors prescribe for you or recommended for you they will fulfil 
that criteria. (Participant 6) 
…of course they have no responsibility other than give drugs that 
are there. (Participant 7) 
…whatever the doctor provides for the nurses to do they do. … But 
nurses are responsible to someone they’ve all got a boss 
somewhere haven’t they? (Participant 13 SP) 
 
 
4.3.7.2.7 Barrier- Public perception 
 
One participant thought that the acceptance of nurses as independent prescribers 
would depend upon how the public perceived their status and qualifications. 
 
I’m just thinking it all comes down to status I think the public may 
perceive you are just a nurse and you’re not qualified to do this. 
(Participant 15 SP) 
 
4.3.7.2.8 Negativity about drug knowledge 
 
One participant raised concerns about whether nurses had sufficient drug knowledge 
to prescribe: 
 
I’m not discrediting their training, they go through a lot but I just 
wonder how in-depth they go into the drugs make-up itself and 
their knowledge of the drugs and it’s difficult to answer that 
question because you don’t know what kind of training they would 
have received. Now fair enough, they may have a lot of  knowledge 
about diabetes or whatever the condition is but with regards of the 
drug itself and what is the appropriate drug to give, I don’t know 
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how in-depth at present they go into that or if they are going to be 
given a wider remit then what training and support they will be 
given to be qualified to prescribe? (Participant 15 SP) 
 
 
4.3.7.3 Barriers 
 
4.3.7.3.1 Negative about nurse independent prescribing 
 
A couple of participants did not want to use nurse independent prescribing as they felt 
it represented too much of a change, and that they would still want to use their doctor 
regardless of how minor the complaint. Some participants also felt that the 
introduction of nurse independent prescribing was not absolutely necessary either. 
 
…I don’t say necessary but I think it would be an advantage to a 
practice.  (Participant 2) 
No I don’t think I’d use it if I had the choice of carrying on, I 
would continue (using the doctor). (Participant 3) 
 
4.3.7.4 Facilitators 
 
4.3.7.4.1 History of relationship 
 
Some participants stated that they would trust nurses in a prescribing role because 
they have developed a relationship over time and therefore they know them. 
Participants often reported that they had the better relationship with the nurse when 
compared with doctors and pharmacists. 
 
…the district nurses come in to clean the line and if I am in the 
middle of a course of chemotherapy they come and they take the 
blood samples ahead of the chemo, so again we build up a 
relationship with them, it tends to be the same 3 or 4 nurses that 
have been coming. (Participant 9) 
No I wouldn’t (have concerns about nurse IP) because I think they 
have the knowledge of the patients, or they can have. (Participant 
2) 
I’ve always got on well with the nurses because having your own 
children, my children would be born at home so you had quite a lot 
of contact in those days with your nurse…… I think the nurses are 
in contact with the patient, whatever they need a prescription for.  I 
think they would be involved with whoever it was. (Participant 3) 
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4.3.7.5 Support for Independent Prescribing by nurses 
 
4.3.7.5.1 Nurses already prescribe 
 
There was recognition amongst some participants that nurses were already prescribing 
in certain situations. They went on to describe situations where nurses were running 
clinics but needing to obtain a doctor’s signature on the prescription they had written. 
Participants were therefore viewing the process as prescribing even though it was the 
doctor that was authorising and taking responsibility for the prescription. 
 
Yes she dispenses it, she prescribes it and gets the doctor to sign 
the prescription, but she decides what level which should be the 
various types of medication to take. (Participant 5) 
…in fact 2 years ago I had a chest infection, I went round and the 
surgery was just closing and there was no doctor there and the 
nurse that deals with asthma happened to be there and she 
examined me and said yes you have got an infection and she 
phoned the doctor at the other surgery, made out the prescription 
and I was allowed to go down to the chemist and get it and the 
doctor okayed it over the phone (Participant 7) 
 
However, the same participant also recognised that in some circumstances, nurses do 
not have the legal right to prescribe. 
 
…in fact last year she (the nurse) recommended a change of drugs 
and she went and saw the doctor and came back and changed the 
drug.  I think if she’d have had the power at the time, she could 
have done it but she didn’t have the power. (Participant 7) 
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Section 4: 
 
4.3.8 Discourse from participants who had experienced pharmacist 
supplementary prescribing.
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Past experience of SP 
 SP positivism 
 SP positively affects opinion on IP 
 Importance of trust 
Change, recognition and acceptance 
 Surprise 
 Recognition that SP is a specialist 
 Lack of impact of SP 
 SP does not affect opinion of IP 
Psychological effect on patient’s health 
 No concerns that not seeing a doctor 
 Positive sign that you do not need to see a doctor 
Extended role of the pharmacist 
 Being monitored 
 Benefit of consistency 
 Expert knowledge 
 Letting the SP down 
 Professionalism expected 
 SP service is more in depth 
 Supportive role of SP 
Structure 
 Concern over consistency of quality 
 Importance of training 
 Minor ailments only 
Autonomy 
 Close supervision by doctor 
 Doctor supervision unnecessary 
 Doctor for initial diagnosis 
Benefits of SP 
 Concordance 
 Increased access to healthcare and decreased pressure on 
doctors 
Blurring roles of nurse/pharmacist/doctor 
 Comparable to nurse clinic 
Figure 9: Summary of discourse applicable to patients that had consulted a 
pharmacist supplementary prescriber. (Section 4)  
Emerging Themes 
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It should be noted that out of the 18 study participants, n=8 had seen a pharmacist 
supplementary prescriber. This section describes their experience of this process and 
how it has affected their opinion upon the role of the pharmacist and the extension of 
their role to become independent prescribers. (N.B. the initials SP are not added after 
the participant number for quotes in this section as all the quotes are from participants 
who had experienced supplementary prescribing). 
 
4.3.8.1 Past experience of supplementary prescribing  
 
4.3.8.1.1 Supplementary prescribing positivism 
 
Those participants that had seen a pharmacist supplementary prescriber did not have 
any negative comments to say about them. Instead, they remarked how helpful the 
pharmacist had been, how good the service had been and that they had received good 
advice. These participants were quite nonchalant about being seen by a non-medical 
prescriber and did not consider that their safety was being put at risk at all. 
 
…as far as I am concerned she did a good job and I was quite 
happy with it. …I am quite happy with X (supplementary 
prescribing pharmacist) and I don’t see any disadvantage and a 
tablet is a tablet and she is qualified to prescribe it for me up or 
down you know, I don’t suppose she is going to kill us. (Participant 
11) 
Well with x (supplementary prescribing pharmacist) we get on 
together like a team. …Well she’s done a hell a lot more than I 
would have ever thought possible. …Yes she’s given me a lot of 
advice and help. (Participant 14) 
 
4.3.8.1.2 Supplementary prescribing positively affects opinion on independent 
prescribing.  
 
When participants were asked whether their experience had affected their opinion 
upon pharmacists becoming independent prescribers, they commented that they did 
feel more positive about accepting pharmacists as independent prescribers. Their 
experiences had been positive and had therefore given them confidence about 
pharmacists being prescribers. 
 
Not really swayed me its probably could have slightly reinforced it 
yeah, yeah definitely. (Participant 18) 
He’s been very good.  I don’t really have a lot to do with other 
pharmacists. Yes I think it opens your eyes a bit to other 
pharmacists. (Participant 16) 
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4.3.8.1.3 Importance of trust 
 
Some participants talked about how they trusted the pharmacist supplementary 
prescriber they saw, and that if they are performing that role, they expected that they 
had the appropriate qualifications and were efficient at doing that job. 
 
I would assume that was her job and she knew what she was doing 
one has got to trust the medical people cause you don’t know do 
you? (Participant 13) 
It is quite alright I take her word for it, I mean I presume she 
knows what she is doing otherwise she wouldn’t be doing it, so yes 
I just take what she told me to take and she checks it, and I go back 
and see her and she says that your blood pressure is not down so 
she said I am going to double up these tablets, certain tablet.  And 
she said it might make you - things about it may make you feel 
dizzy and all this sort of thing and yeah I am in their hands really. 
… they know, I hope they know what they are doing so you have 
got to go along with it as far as I am concerned. (Participant 11) 
 
4.3.8.2 Change, Recognition and Acceptance 
 
4.3.8.2.1 Surprise 
 
One participant expressed that she was surprised that she was going to see a 
pharmacist prescriber rather than a doctor, but as she had not had much experience of 
hospitals, she thought it must be what is done in hospital. She therefore accepted it as 
it was the service being offered to her. 
 
It was a bit strange at first; I thought it was a natural thing for 
them to do. … I’ve never been in hospital before so I don’t  know 
what the procedures are you see, someone that’s always in there 
having an operations they get used to knowing what’s what but I 
didn’t know the first thing about it. … No I thought it was a bit 
strange but thought that was the way they work up there. 
 (Participant 16) 
 
4.3.8.2.2 Recognition that SP is a specialist 
 
One participant used an analogy of a GP and a consultant to compare a community 
pharmacist and a supplementary prescribing pharmacist. Therefore pharmacists with 
prescribing rights could be seen as being superior to a non-prescribing pharmacist by 
the public. 
…it’s like a GP they deal with anything from in-growing toe nails 
to strokes, heart problems, they are a doctor of all and that’s why.  
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The pharmacist in the village is the same and x (the supplementary 
prescribing pharmacist) is a specialist pharmacist and that makes 
a lot of difference. (Participant 17) 
 
4.3.8.2.3 Lack of impact of SP 
 
Some participants felt that the consultation with the pharmacist SP was quite 
unremarkable, nothing out of the ordinary. Therefore it was considered to be an 
effective and acceptable consultation that was not inferior to that which they would 
expect from a nurse or a doctor. 
 
Now when I went to see x (supplementary prescriber) it was a 
similar experience really, I just went and saw him and he basically 
asked me the same sort of questions as to my condition and taking 
the tablets.  I cannot remember whether there was any subtle 
difference in the fact that he suddenly produced the bag of drugs 
from his drawer or whether I… Or whether we had to go, I think 
they were ready actually, I think he had them there so it was a very 
sort of quick and uneventful experience really. (Participant 18) 
No he doesn’t do anything he just sits and listens and I tell him 
how I feel and he gives me the pills and I come away. (Participant 
16) 
  
 4.3.8.2.4 Supplementary prescribing does not affect opinion of independent 
prescribing 
 
A couple of participants felt that their experience of seeing a pharmacist 
supplementary prescriber did not affect their opinion upon pharmacists becoming 
independent prescribers. One participant felt that this was just the way that the NHS 
was having to go anyway and the other had a lot of confidence and faith in 
pharmacists beforehand anyway, so was fully supportive of this role extension. 
 
Personally no.  I just feel that this is just the way I think a move in 
the NHS into the 21st century. (Participant 15) 
No hasn’t affected my opinion on anything. (Participant 14) 
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4.3.8.3 Blurring of roles of nurse/pharmacist/doctor 
 
4.3.8.3.1 Comparable to nurse clinic 
 
A couple of participants commented that as they had experienced being prescribed for 
by a nurse prescriber, they had no concerns about seeing a pharmacist supplementary 
prescriber. So positive experience of other non-medical prescribers has developed 
confidence in patients to see other types of professionals as non-medical prescribers. 
 
…I would be automatically in favour of this from the point of view 
of what I know of nurse practitioners.…if I am honest there is not 
a, I didn’t notice a lot of difference between the visit when I saw x 
(supplementary prescriber) and when I saw a nurse.  (Participant 
18) 
Umm…the nurse you know the one I told you that was she was very 
professional yes that was…yes similar to the pharmacist 
(Participant 12) 
 
4.3.8.4 Psychological effect on patients’ health 
 
4.3.8.4.1 No concerns that not seeing a doctor 
 
Participants did not seem to have any concerns that they were seeing a pharmacist 
supplementary prescriber rather than a doctor. This links into the importance of trust. 
Participants had no concerns because they trusted the “organisation” that they were 
seeing the pharmacist SP within (i.e. G.P. surgery or hospital). Therefore this opinion 
may vary if the clinic was held in a community pharmacy. 
 
I was quite happy with that.  I took the view that he wouldn’t be there if 
he didn’t know what he was doing and they weren’t happy with him, so I 
was quite happy with that. (Participant 17) 
 
4.3.8.4.2 Positive sign that you do not need to see a doctor 
 
Within the clinical area of oncology, one participant made the very interesting 
comment that he felt that because he was being dealt with by the pharmacist rather 
than the consultant, his disease must be less severe, so he took this as being a positive 
message which made him feel better. Therefore the pharmacist is still being seen as 
inferior to the doctor, but the participant has correctly recognised that the whole point 
of this development is to free doctors’ time to see the more complicated cases. 
 
No, no in fact in many cases it, psychologically to me it was better 
because I felt as I was going along, you know you are in a sort a 
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state of wonderment after say you know what is the next stage, well 
the fact that you were only seeing a pharmacist and that almost 
gave you a relax that there is nothing going wrong really.  I say I 
had to have a blood test obviously before so the blood test results 
were in, so the fact that you were seeing a pharmacist you think oh 
crumbs, Doctor x will have looked at the results maybe the 
pharmacy and there is no problems with the blood tests so really 
psychologically I felt that it was better to see somebody else and 
say well if you are seeing the oncologist is there a problem sort of 
thing. …Psychologically I thought, that is me, I might be peculiar 
but I just felt that it was more relaxing to know that is who you 
were seeing really. (Participant 18) 
 
4.3.8.5 Extended role of the pharmacist 
 
Participants discussed the SP service that they had experienced and how it affected 
them. 
 
4.3.8.5.1 Being monitored 
 
One participant expressed that he was aware that the pharmacist supplementary 
prescriber was monitoring his progress, and was appreciative of this service. 
 
…if you slip then you know X is watching me, knowing that I have 
got to see her and that not only are you trying to prove to yourself 
or press yourself but you need to, you’ve got someone checking on 
you. (Participant 15) 
 
4.3.8.5.2 Benefit of consistency 
 
One participant felt that a benefit of pharmacist supplementary prescribing was that 
they were seeing one person throughout the course of their treatment, so therefore a 
professional relationship develops leading to increased trust. This consistency of 
seeing the same prescriber is liked by patients; it is felt that the prescriber knows the 
patient and their nuances. It might be that this consistency is more important for 
patients with more serious diseases such as cancer, who have more concerns about 
their wellbeing.  
 
…when I first went down to the oncology unit I was told that I 
would have a nurse, dedicated nurse allocated to me who would 
follow my progress right through and you know I suppose to get to 
know me a bit over that time, it didn’t happen and I saw a different 
one every time.  So if you are seeing a pharmacist, if you are 
giving, if that would guarantee consistency as well, apart from 
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holidays and so on, then I think that would be quite a good thing 
actually because I think the relationship over what 18 weeks, what 
about 36 visits, would be useful and probably make you feel more 
relaxed about going and talking really.  So I think the consistency 
would certainly help, I know you could get that if they dedicated a 
nurse but if it means that you are seeing a pharmacist you are 
likely to get more consistency then that will certainly be a benefit. 
…I think that sort of relaxed me more and I think as I said if you 
were, if there was a consistency as well with the person that you 
were seeing over the period that would enhance that relaxation and 
the freedom to talk and chat.  (Participant 18) 
 
 
4.3.8.5.3 Expert Knowledge 
 
One participant felt that her pharmacist supplementary prescriber (in oncology) was 
an expert in drugs in that clinical area, and felt that they actually knew more about the 
drugs than the doctor. So again this supports the suggestion that the public might view 
pharmacist supplementary prescribers as being superior to non-pharmacist 
prescribers. 
…Yes we went to see Dr x and she asked him (the pharmacist 
supplementary prescriber) whether I could have chemotherapy 
because I’d had a heart problem. …I think seeing a pharmacist 
they know more about the drugs that they’re giving you than 
probably a doctor does.  I don’t know because I haven’t had the 
opportunity to question Dr x about it, so how that compares I don’t 
know. …I would say from my personal thoughts that the pharmacist 
would probably  know more about drugs than the doctor even with 
cancer and that there are different forms of cancer so different 
drugs are needed and I think probably pharmacists would probably 
be the one that would know more about it than the doctor. 
(Participant 17) 
 
4.3.8.5.4 Letting the SP down 
 
One participant felt that as their pharmacist SP had set them targets of weight to loose, 
he did not want to let them down. The participant was grateful for the support and 
help that the pharmacist SP was offering him, which ties in with the benefits that were 
felt from participants of seeing the same pharmacist throughout the treatment. 
 
…you know also it’s amazing how you do feel if things haven’t 
gone in the right direction and it was really disappointing and 
embarrassing for me anyway, in knowing that here I am getting the 
support and I kind of felt and it kind of gives you that boost to do 
better next time. (Participant 15) 
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4.3.8.5.5 Professionalism is expected 
 
One participant clearly stated that he felt that if a pharmacist was in a prescribing role 
they would be expected by patients to be professional, and have the patients’ best 
interests at the forefront of their mind. 
 
…going back to what I said earlier they’re professionals she’s (the 
pharmacist SP) a professional and they will be acting 
appropriately in the interest of myself. (Participant 15) 
 
4.3.8.5.6 SP service is more in depth 
 
Some participants felt that the SP service they had received was very informative and 
more in depth than they had received before. 
 
…but they just doesn’t take blood pressure they sometimes they 
take, weight check your weight and other things like that. 
(Participant 12) 
…she’s talked about the drug itself, what the indicators are for it, 
what it would do for me and what the side-effects are, she’s been 
quite informative. (Participant 15) 
 
 
4.3.8.5.7 Supportive role of supplementary prescriber 
 
One participant expressed that he valued having the pharmacist supplementary 
prescriber there in a supportive role, helping him with his weight loss. 
 
…as I said it is more dietary, so it is a weight issue. Yes basically 
giving appropriate advice and support for me really in this issue.  
…as much as I have an idea as to what I need to do, it’s been 
advantageous to me in knowing that there is somebody there who is 
supporting me because some people are able to act independently 
some need a little bit of kick up the backside for their support, and 
I think it’s useful for me in having that there because you’re not 
just left… (Participant 15)  
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4.3.8.6 Structure 
 
4.3.8.6.1 Concern over consistency of quality 
 
One participant felt that although he had a good experience with his pharmacist SP, he 
was not sure whether it would be the same with other pharmacist SPs. Therefore there 
is still some concern present as to the abilities of some pharmacists to be prescribers. 
They are not totally convinced that the quality will be maintained across the board. 
 
Whether everybody is going to be the same I don’t know? 
(Participant 11) 
 
4.3.8.6.2 Importance of training 
 
The participants commented that as long as the appropriate controls were in place in 
terms of training and accreditation then they had no problems with pharmacists as 
independent prescribers. One participant does however emphasize that the training 
has to be an appropriate length in order to be of benefit. 
 
…providing that you can train people specifically with all the 
natural guidelines and controls then I think yes why not, why not 
obviously you don’t need to do 7 years doctors training to diagnose 
a sore throat really, you just don’t need it so I think in a lot of 
cases you are using sort of hammers to crack walnuts really, so yes 
I have a natural leaning towards that, always precursored by 
professional training and control and when that is done I think yes 
fine….. I don’t have any sort of problems with anyone seeing 
anyone who is adequately trained and professionally qualified in 
that field quite frankly. (Participant 18) 
 
4.3.8.6.3 Minor ailments only 
 
One participant was clear that he felt he knew what he would see a pharmacist 
independent prescriber for and what he felt was more serious would need to be seen 
by a doctor. 
…if I know what’s wrong with me and it’s not very serious I don’t 
think it matters.  If I thought it was anything that was dangerous I 
would want to see a doctor. (Participant 13) 
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4.3.8.7 Autonomy 
 
4.3.8.7.1 Close supervision by doctor 
 
A few participants felt that the service being provided by pharmacist supplementary 
prescribers would need to be closely supervised by doctors. This may infer that they 
also think that pharmacist independent prescribing needs close supervision as well. 
 
If I, if I see regularly x (pharmacist supplementary prescriber) 
instead of the doctor and then I am a little bit worried you know if 
because if there is a, I don’t know about pharmacists that how 
much they know about… Yes other conditions, but I still want to see 
the doctor as well and I want to see the doctor that  doctor had to 
check out everything is going, that everything is going ok then I 
will be more confident. (Participant 12) 
 
4.3.8.7.2 Doctor supervision unnecessary 
 
Participants did not however feel that doctor supervision was necessary during the 
supplementary prescribing process. Therefore they were happy for pharmacists to 
undertake the prescribing process but it is the diagnostic process which participants 
are not confident about. 
 
…she wasn’t seeing the doctor she wasn’t referring back, well as 
far as I know, and she was prescribing the medicine. (Participant 
11) 
 
4.3.8.7.3 Doctor for initial diagnosis 
 
One participant was not happy for independent pharmacist prescribers to undertake 
diagnosis. He still wanted to see the doctor for that. This is because diagnosis is still 
viewed as being part of the doctors’ realm. Prescribing by pharmacists is a large 
change for the public, but allowing pharmacists to diagnose as well may be too big a 
change for some patients to accept and be confident about. 
 
Well I think initially I would like to see a doctor you know for 
diagnosis and then I would be happy for X (pharmacist 
supplementary prescriber) to take the follow-up. (Participant 11) 
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4.3.8.8 Benefits of supplementary prescribing 
 
4.3.8.8.1 Concordance 
 
Some participants commented that during the consultation with the pharmacist 
supplementary prescriber, they are able to ask the pharmacist SP any questions they 
have about their treatment and they make decisions together about how their treatment 
should change. The participants seemed very satisfied that they were involved in their 
own healthcare and that the consultation was concordant.  One participant even 
thought the participation they managed to have in the consultation was better than 
what they would have if they had seen their doctor. 
 
If I want to know anything then I ask him, he tells me, we talk about 
-I asked him how my blood went from the check-up and he said that 
was fine (Participant 16) 
Yes she has put no pressure on me what so ever, it’s been my 
decision. …Yes and I suppose in some ways, airing towards us 
thinking seriously about going down that route again (i.e. using 
medication to control BP) there has been no added pressure it’s 
been a decision that’s left up to me to make. (Participant 15) 
 
4.3.8.8.2 Increase access and decrease pressure 
 
Participants could see that the SP system was beneficial in terms of being more timely 
for patients, in terms of the pharmacist SP having more time available than doctors to 
discuss issues with patients and also in terms of freeing up time for the doctors. 
 
Time saving for patients: 
 
Well it was much quicker you come in for an appointment and you 
go straight in sort of thing. (Participant 13) 
So yes I was informed that I was seeing a pharmacist which I 
actually thought was quite a good idea really, because it relieved 
time on the oncologist, I thought it was more efficient really.  
Particularly in my case where it was fairly straight forward and I 
hadn’t had any side effects or any problems with the medicines, I 
thought that the sooner I was in and out of these places the better 
really, so I thought it was an excellent idea. (Participant 18) 
 
The supplementary prescriber has more time for them: 
 
I can spend a little bit of extra time I can explain in more details 
what I have noticed from these medicines and what my condition is 
like, so I can talk to her in details other wise a doctor they have 
only got a small slot and they have a lot of patients waiting for 
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them so they cannot spare that much time, so they can  give 
additional advice and listening that they can find other things they 
can find the route of that disease where does it start and then it is 
very helpful. (Participant 12) 
 
Saves the doctors’ time: 
 
Well to save the doctors’ time really, I mean I don’t have to make 
an appointment with the doctor; she (the pharmacist SP) makes an 
appointment with me.  It is like the nurse next Wednesday, next 
week; I mean that will probably just come through the post from 
the nurse, so you bypass the doctor so you are saving them time. 
…I can see what it is all about, it is about saving the doctors time 
because they must have patients just walk in there just to prescribe 
a tablet, so X and what she is doing is saving the doctors time. 
(Participant 11) 
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Section 5: 
 
4.3.9 Differences of opinion between participants who had experienced 
pharmacist supplementary prescribers and those who had not. 
 
4.3.9.1 Summary of differences of opinion between participants who had experienced 
pharmacist supplementary prescribers and those who had not. 
 
Patients who had experienced supplementary prescribing by pharmacists: 
 
 Had less intrinsic barriers than those who had not experienced supplementary 
prescribing (e.g.  coveting traditional doctor model, negative pharmacist 
image, issue of change/acceptance) 
 Had more concerns regarding the importance of monitoring (i.e. risk 
management) 
 Were less positive about nurses as independent prescribers 
 Were less vocal about benefits of extended prescribing in terms of increased 
access to healthcare and decreased pressure on doctors 
 Were less vocal about the knowledge of nurses 
 Were less vocal about nurses already being prescribers 
 Did not discuss their past experience/relationships with nurses 
 Raised no concerns about the location of independent prescribing  
 
Opinions of these two groups of participants (those who had not consulted a 
pharmacist supplementary prescriber (SP) = participants 1-10, those who had = 
participants 11-18) have been compared in order to establish whether the experience 
of consulting a pharmacist in a prescribing role has any affect upon their opinions of 
nurses and pharmacists as independent prescribers.  
 
4.3.9.2 Pharmacists as prescribers 
 
4.3.9.2.1 Intrinsic Barriers 
 
Whilst the participants were discussing pharmacists becoming independent 
prescribers, those who had not experienced consulting pharmacists as supplementary 
prescribers more frequently expressed views that suggested they had more intrinsic 
barriers than those who had consulted a pharmacist supplementary prescriber. These 
opinions were more vocal in the areas of coveting the traditional doctor model, the 
issue of change/acceptance and a negative pharmacist image. 
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4.3.9.2.2 Covets traditional doctor model (Refer to p201 for further detail) 
 
For instance when discussing the traditional doctor model of provision of healthcare, 
the participants who had not consulted a pharmacist SP were much more conservative 
about pharmacists extending their role, and did not like the idea of not seeing their 
doctor when they were unwell, they used phrases such as “insist on your right to see a 
doctor” (Participant 9) and “I would expect him (the GP) to be my primary carer from 
that point of view”. (Participant 8) Only two participants who had consulted a 
pharmacist supplementary prescriber discussed this “coveting” of the traditional 
doctor model, and one of those said that he imagined other people would be unhappy 
about not seeing a doctor when they are ill, but was happy with the concept himself.  
 
4.3.9.2.3 Issue of change/acceptance (Refer to p203 for further detail) 
 
When the participants discussed the impact of these changes upon healthcare, none of 
the participants who had consulted a pharmacist SP voiced any concerns upon this 
development being a big change for the public. Those who had not consulted a 
pharmacist SP had much to say about the development being a big change in culture 
which would take people a long time to become accustomed to. They lacked 
confidence in the proposed system and could not even visualize how it was going to 
work in practice. Therefore the participants that had seen a pharmacist supplementary 
prescriber had any concerns addressed by the consultations they had experienced. 
 
4.3.9.2.4 Negative Pharmacist Image (Refer to p212 for further detail) 
 
Those participants who had not consulted a pharmacist SP tended to be more vocal 
regarding their negative opinions of pharmacists. These views focused upon their 
training being inferior to that of doctors that they do not really know what pharmacists 
actually do, that dispensing is not regarded as a very demanding or difficult job and 
that pharmacists are not regarded as being a very caring profession. 
Only one participant who had consulted a pharmacist SP made a negative comment 
about pharmacists, but this was directed at poor service he had received at a 
supermarket pharmacy when they dealt with an error they had made. 
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4.3.9.3 Risk Management 
 
4.3.9.3.1 Importance of monitoring 
 
None of the participants who had not consulted a pharmacist SP brought up the issue 
of on-going patient monitoring. However, three participants who had consulted a 
pharmacist SP stated how important it was to ensure that the pharmacist prescriber 
was monitoring the effects of the treatment(s) they had prescribed.  
 
 
4.3.9.4 Nurses as prescribers 
 
Overall, those participants who had not experienced pharmacists as prescribers made 
more positive comments than those who had experienced pharmacists as prescribers 
about nurses being independent prescribers. 
 
4.3.9.4.1 Perceived Benefits 
 
4.3.9.4.2 Increased access and decreased pressure (Refer to p189 for further detail) 
 
Although all participants had the same opinions upon how the development of nurses 
as independent prescribers would increase accessibility to healthcare for patients and 
help doctors to save time to see the more complex cases, the participants who had not 
seen a pharmacist SP were much more vocal about this and more frequently brought 
up this subject.  
 
4.3.9.5 Support for Independent Prescribing 
 
4.3.9.5.1 Knowledge of nurses (Refer to p192 for further detail) 
 
Participants who had not seen a pharmacist prescriber made more positive comments 
about how knowledgeable nurses were compared to those participants who had 
consulted a pharmacist prescriber.  
 
4.3.9.5.2 Nurses already prescribe (Refer to p235 for further detail) 
 
Participants who had not seen a pharmacist prescriber made more comments about 
nurses already being in a role where they can prescribe or nearly do.  
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4.3.9.6 Facilitators 
 
4.3.9.6.1 History of relationship (Refer to p223 for further detail) 
 
Participants who had not seen a pharmacist prescriber made more comments about the 
relationship that they had with nurses over the past. They discussed their previous 
relationship with them in a positive manner and that the relationship means that they 
really get to know their patients and hence this builds up trust. They used this 
relationship to illustrate their positivism for nurses as prescribers. 
Participants who had seen a pharmacist prescriber did not discuss their past 
relationship with nurses at all.  
 
4.3.9.7 Barriers 
 
4.3.9.7.1 Location of nurse independent prescribing (Refer to p204 for further detail) 
 
Participants who had not consulted a pharmacist prescriber were also more 
conservative about the location of the nurse prescribing clinic, in that they did not 
want to see such a clinic set up anywhere but within a GP practice. No such 
comments were made from those who had consulted pharmacists as prescribers.  
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4.3.10 Differences of opinion between participants who had hypertension and 
those who had gastro-intestinal cancers. 
 
Opinions of these two groups of participants (those who had hypertension = 
participants 1-5 and 11-15 (total n=10), those who had GI cancers = participants 6-10 
and 16-18 (total n=8)) have been compared in order to establish whether their medical 
condition had any affect upon their opinions of nurses and pharmacists as independent 
prescribers. 
 
Referring to the groups as a whole, the participants with hypertension seemed to be 
more vocal about their opinions than the group with GI cancers. This did not appear to 
be because the group with GI cancers were frailer physically than the group with 
hypertension. In all of the factors where the majority of opinions were expressed by a 
single group, it was always the group with hypertension that more frequently 
commented upon the issue being discussed.  
 
4.3.10.1 Pharmacists as prescribers 
 
The areas where participants with hypertension more frequently voiced opinion than 
the participants with GI cancers were as follows: 
 
4.3.10.2 Personal characteristics 
 
4.3.10.2.1 Knowledge of pharmacists (Refer to p192 for further detail) 
 
The participants with hypertension appeared to be much more expressive and positive 
about the knowledge that pharmacists had and talked about them being experts in 
medicines, who are highly trained and provide appropriate advice. However, this was 
in the context of the pharmacist in their traditional role. Only one participant with GI 
cancer discussed pharmacists’ knowledge in this manner. 
 
4.3.10.3 Intrinsic Barriers 
 
4.3.10.3.1 Negative Pharmacist Image 
 
Participants with hypertension made negative comments more frequently that 
pharmacists do not compare to doctors and that the role they currently undertake of 
dispensing is quite a menial one. They also commented that pharmacists are not felt to 
be a very caring profession, especially when compared to nurses. Therefore although 
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the group appreciated the pharmacists’ advice (as above) they did not value their 
dispensing role and did not value them in comparison to other healthcare 
professionals. 
Only one participant with GI cancer discussed the negative “shopkeeper” image of 
pharmacists’ in this manner. 
 
4.3.10.4 Nurses as prescribers 
 
4.3.10.4.1 Support for Independent prescribing 
 
4.3.10.4.2 Knowledge of nurses 
 
The participants with hypertension also made many more comments about the 
knowledge of nurses when compared to the group with GI cancer. 
The participants with hypertension commented that they particularly valued the 
advice and guidance that nurses gave them and recognised that over the years since 
their qualification, they build up a lot of knowledge. Again these comments were 
made in the context of nurses working in their traditional role. 
 
4.3.10.5 Risk Management 
 
4.3.10.5.1 Close supervision by doctor 
 
The participants with hypertension made more comments about nurses being 
supervised by the doctors whilst prescribing and that they would be able to “pop into 
see them” if they had any problems. Only one participant with GI cancer made a 
comment about the doctor being in overall charge. 
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4.3.11 Influences of background experience upon participants opinions 
 
4.3.11.1 Jobs/Relationships 
 
Some participants had a much closer affiliation with healthcare or had close 
relationships with pharmacists or nurses which may have affected their opinions that 
they expressed in the study. These circumstances are explained below. 
 
Participant 1 was a nursing auxiliary at a community hospital before retirement and 
therefore was very positive about nurses being prescribers. 
 
Participant 4 had been a counter assistant in a pharmacy for 9 years. Although she was 
cautious about pharmacist prescribing she was overall positive about it and was 
certainly positive about the pharmacists’ traditional role. 
 
Participant 5 had a brother-in –law who was a pharmacist and so had discussed his 
role in quite some depth and seemed to have quite a good knowledge about what 
pharmacists do. Although he was positive about pharmacists as prescribers he was 
also very positive about nurses prescribing as well, so it did not seem to bias his 
opinion that one profession was any superior to the other. 
 
Participant 10 was a member of the local PCT’s professional executive committee and 
a director of a local care of the elderly charity. So he was much more informed about 
healthcare issues and also was aware of how doctors work. This meant that he was 
very liberal in his views about non-medical professionals taking on roles that were 
traditionally performed by doctors (i.e. he was positive and supportive). However, he 
also had his misgivings specifically in terms of IT support for the developments. 
 
Participant 12 (SP) had a friend who was a pharmacist. Therefore as he normally 
sought advice from this friend, he was very positive about pharmacists in their 
traditional role. He was not however very well informed about pharmacists and their 
abilities. However it may have had some positive bias upon his opinions of 
pharmacists as prescribers. 
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Participant 15 (SP) was a clinical team leader for an ambulance trust, but it was 
unknown whether he had a nursing or a paramedic background. He was therefore very 
well informed about healthcare and was very opinionated about healthcare 
developments. However he had a very balanced opinion and did not seem to be biased 
towards nurses or pharmacists. He also brought up many problems with the 
development as well as reflecting upon the positive attributes of nurses and 
pharmacists. He did however seem to have more experience of working with nurses. 
 
Participant 18 (SP) had a friend who was a pharmacist and therefore had some insight 
to the level of training that pharmacists have and what they do. He also had a daughter 
who was a nurse. He was therefore also well informed about the level of training that 
they have and about what they do. He was therefore positive about both of these 
professionals in their traditional roles and about their training. Although these 
relationships informed his opinion, they did not seem to bias him in any way. 
 
4.3.11.2 Errors made by pharmacists and doctors 
 
Some participants described experiences of having doctors and/or pharmacists making 
errors with their prescribing or dispensing of their prescriptions. Regarding 
pharmacist errors, although the experiences may have put them off going back to a 
pharmacy that made the error, it did not seem to substantially affect any participants’ 
opinions of pharmacists. 
With respect to doctors’ errors, again even though one error in particular was quite 
major, it did not seem to negatively affect the participant’s opinions of doctors which 
were still held in very high regard. 
 
Participant 3 experienced a pharmacist’s error where they received a prescription item 
which had the wrong patient name on it. This error meant that the participant stopped 
using that pharmacy. This experience may have informed her traditional views of 
pharmacists being dispensers and not being comfortable about pharmacists 
developing their roles as prescribers. 
 
Participant 5 had experienced a serious doctor’s prescribing error. The doctor had 
prescribed his young daughter an overdose of a medicine to treat her colic, which his 
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brother-in-law informed him could have been fatal. It is therefore possible that as the 
pharmacist caught this error, that he has more respect and trust in the pharmacy 
profession.  
This participant had also experienced a pharmacist error, where his pharmacy 
dispensed him his wife’s antihypertensive tablets with his name on them. He spotted 
the mistake as soon as he opened the bag at home. He said that the pharmacy were 
horrified about the error and dealt with it very well. It seems that it is unlikely that this 
has biased his opinion on pharmacists. 
 
Participant 11 (SP) received the wrong quantity for a prescription he gave to a 
pharmacy, but this was a fairly minor error which did not seem to affect his opinions 
on pharmacists. 
 
Participant 14 (SP) experienced a pharmacist error where they dispensed him the 
wrong drug, but the pharmacist discovered the error quickly and phoned him on his 
mobile telephone whilst he was walking home. This experience did not seem to upset 
him as it was dealt with very efficiently and therefore did not bias his opinion of 
pharmacists as he was very positive about pharmacists being prescribers. 
 
Participant 15 (SP) had experienced a pharmacist’s error where the (supermarket) 
pharmacy had dispensed the wrong form of a medication for his child. He was not 
very impressed with the way that the pharmacist had dealt with the error, and had 
written a letter of complaint about it. This experience has meant that he does not use 
the particular pharmacy any longer, and it does seem to have negatively affected his 
opinion of supermarket pharmacies. 
 
Participant 17 (SP) also experienced a doctor error where the doctor had prescribed 
her the wrong medication, which the pharmacist noticed and sorted out. This did not 
seem to bias her opinions upon doctors or pharmacists in any way. 
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4.3.12 Summary of main findings of qualitative data upon patients’ views and 
opinions of pharmacists and nurses as independent prescribers  
 
 Participants shared common views upon the benefits of Independent 
Prescribing (IP) and necessary controls when providing such a service 
regardless of the type of professional.  
 They also had common concerns about IP, which included doubting their 
ability to deal with more than minor conditions and their diagnostic skills. 
Concerns were based upon issues of change and acceptance where some 
participants coveted the traditional doctor model which resulted in them 
considering the IP service inferior. 
 Nurse prescribing was more acceptable than pharmacist prescribing because 
nurses were considered to be trustworthy, caring and a devoted profession who 
are the central figure in an individuals’ healthcare, with which relationships 
are established. It was also noted by participants that nurses already prescribed 
for some participants. 
 Community pharmacists were perceived by some participants as being “non-
NHS”, not being a healthcare provider and as having a negative image. 
Practically, participants doubted the privacy of community pharmacies, 
whether they had the necessary space to provide a professional IP service and 
had clinical governance concerns. However, participants did acknowledge the 
expert drug knowledge that pharmacists have and their accessibility. 
 Participants that had experienced pharmacist SP were positive about the 
experience and it enforced views that pharmacists would be capable as IPs. 
Patients felt empowered due to increased concordance compared with doctor 
consultations. They also viewed SP pharmacists as being specialists compared 
to community pharmacists.  
 Participants that had not experienced SP tended to have more intrinsic barriers 
towards IP. 
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CHAPTER 5: DISCUSSION 
 
5.1 Methodological Issues 
 
During this research several different methods of data collection were used. The 
appropriateness, shortcomings, possible biases and confounding variables are 
considered for each section of the research in this section. 
 
5.1.1 (1) National Survey of pharmacist transcribing of discharge prescriptions 
(secondary care) (see section 4.1 p141 for results) 
 
5.1.1.1 Advantages and disadvantages of using questionnaire surveys and how these 
issues were addressed. 
 
The use of a national questionnaire survey for quantitative data collection was not 
only cost effective but also the possibility of sampling bias was reduced as the whole 
population was surveyed. However it is possible that non-responders may have had 
different opinions and perspectives from those who responded to the questionnaire, 
who may have been more motivated because of being more involved and interested in 
the subject matter. It is also possible that people who had extreme positive or negative 
views were more likely to have responded to the questionnaire. The extent that these 
outlying views have dominated the results is however minimized by the fact that a 
good response rate was achieved.  
 
The main disadvantages of questionnaire surveys have been reported as follows:225 
 
1. Generally low response rates and consequent biases 
2. Unsuitability for respondents of poor literacy; for the visually 
handicapped, the very old or for children below the age of say, ten; often 
unsuitable for people with language difficulties 
3. No opportunity to identify or correct misunderstandings or to probe, or to 
offer explanations or help; 
4. No control over the order in which questions are answered, no check on 
incomplete responses, incomplete questionnaires or the passing on of 
questionnaires to others; 
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5. No opportunity to collect ratings or assessments based on observation. 
 
To address point one, although the response rate is less than similar questionnaire 
surveys 67,235 it still represented the opinion and views of nearly 70% of the total 
population and hence this would have reduced the risk of extensive bias. Literature 
suggests that high survey response rates are desirable because they increase the 
precision of parameter estimates and reduce the risk of non-response bias.236 
The slightly lower response rate when compared to other questionnaire surveys may 
be due to the fact that the questionnaire was sent out in the summer. The questionnaire 
was sent out in the summer because the researcher is employed to teach and undertake 
research at the University of Bath. When teaching has finished for the academic year, 
there is more opportunity to devote time to research during the summer months. It is 
doubtful whether sending the questionnaire out at this time of year would have 
introduced any element of bias as the data collection period was for 11 weeks and so 
staffing bias was not anticipated.  
Point two is addressed by the fact that all of the people completing the questionnaire 
are healthcare professionals and as such, there would be no language difficulties, 
visual handicaps or literacy problems. 
Point three was addressed in part by the covering letter for the questionnaire having 
the contact details of the researcher with the offer of help if there were any problems 
that respondents had whilst completing the questionnaire. Also the piloting process 
should have reduced the possibility that parts of the questionnaire would have been 
misunderstood. However, this method does rely upon the respondent identifying that 
they have misunderstood a question, and so does not address the problem in full. 
Attempts were made to minimize the problems outlined in point four because the 
covering letter clearly stated who the questionnaire should be completed by and by 
having a space for open comments on the back of the questionnaire. However, it is 
impossible to determine in which order questions were actually answered in the 
questionnaire. It was intended that the questionnaire would have been passed onto the 
most appropriate person to complete it, which was clearly described in the cover 
letter. 
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Point five was addressed somewhat by the researcher visiting two hospitals that 
undertook PDPTS before developing the questionnaire. Observing the PDPTS process 
at the two hospitals allowed more insight to the process and detail of training and 
computer programmes used to support the pharmacist prescribing role. Also the 
research questions do not rely on observed data to answer them. 
Another flaw with questionnaire surveys is that you do not know whether the 
respondent does actually know the answers. There is a risk that the respondent might 
guess the answer to the question. In this questionnaire survey, a question where they 
might have guessed the answer in particular was question15: “On average/usually 
how many whole time equivalent pharmacists at each grade perform this role on a 
regular basis” and also section E of the questionnaire which enquired about numbers 
of prescriptions written per day, hours notice needed and impact upon the weekend 
services etc. Therefore you would report such results with more consideration of how 
accurate they actually were. 
Certain groups of healthcare professionals do tend to be targeted more often with 
questionnaire surveys and certainly for chief pharmacists (one of the target group of 
respondents) there may be some questionnaire fatigue, where they do not respond to 
the questionnaire due to the sheer number of questionnaires that they get regularly 
sent. The only way of combating this is to make use of evidence-based methods to 
enhance the response rate.229 
A criticism of the methodology used in the development of this questionnaire was that 
reliability and validity of the questionnaire were not assessed. Reliability refers to the 
purity and consistency of a measure, to repeatability, to the probability of obtaining 
the same results again if the measure were to be duplicated.225 A way to check on the 
reliability of the questionnaire is to ask the same question, with slightly different 
wording at different stages of the questionnaire. The percentage of respondents who 
answer the questions with the same answer gives you an idea of how reliable the 
questionnaire is. 
Validity tells the researcher whether the question, item or score measures what it is 
supposed to measure.225 In order to ascertain the validity of factual questions, external 
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checks are used, where a second, independent source of information is sought to 
check whether the answer given is actually correct. 
A problem with all questionnaire surveys is that they only record the opinions and 
views of respondents at the particular time that the survey was completed. As long as 
this is understood and clearly stated in any reports written from the results then this is 
generally accepted to not be a problem. 
 
This survey met its intended aim which was to provide baseline data upon the 
incidence of types of pharmacist prescribing within secondary care in 2001. 
 
Difficulties obtaining an up to date list of clinical pharmacists resulted in some 
questionnaires being directed to Chief pharmacists and Principal pharmacists (rather 
than pharmacist clinical services managers) to pass onto the most appropriate person 
to complete. This may have affected the response rate and also the information in the 
response, and so may have added some bias to the results. A manager such as a chief 
pharmacist or a principal pharmacist would be in-directly involved with the service as 
opposed to a clinical pharmacist who would be directly involved with the day to day 
running of a transcription service. Another problem was identifying hospitals that had 
merged trusts. Some of these were not identified until questionnaires were returned, 
and so these hospitals were then removed from the results. 
It would have been preferable to use a sampling method whereby the questionnaire 
was sent to every hospital in every trust as opposed to just one of them. This is 
because some hospitals had only recently merged trusts and therefore they may have 
had different pharmacist prescribing roles and transcription services in place from the 
other hospital(s) in the trust.  An assumption was made that single trusts would have 
trust-wide policies in place for such services, however if trusts had recently merged, 
this would have been unlikely to be the case. 
A question was included in the questionnaire entitled “What percentage of the total 
number of discharge prescriptions are written by pharmacists?” but this had to be 
removed upon analysis of the final questionnaire’s data as the question did not clarify 
whether the percentage was out of the total number of discharge prescriptions written 
in the trust/hospital or whether it was out of the total number written on the ward(s) 
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were PDPTS was active. It was unfortunate that this problem was not spotted until 
this late stage as the data would have been very useful. 
 
There are several areas where it has become apparent that further questioning would 
have been useful; 
 
 Is any other type of pharmacist assessment undertaken? Some hospitals 
commented that although they did not complete an assessment specifically for 
pharmacists’ transcription abilities, they did complete a whole competence 
assessment regularly.  
 Is the PDPTS regularly audited and if so, how?  
 Opinions upon the impact of electronic prescribing on PDPTS 
 Reasons for lack of further extension of PDPTS. 
 
The last question would have provided critical information as to why the services 
provided were not being used extensively throughout hospital trusts. Instead, the 
researcher was only able to speculate as to what these reasons were. This represents 
an acknowledged weakness in the design of the questionnaire.  
More extensive preliminary development work (such as semi-structured interviews 
with leading-edge practitioners and focus groups) would have lead to a more robust 
questionnaire being developed. This was acknowledged and the shortcomings in the 
design of this questionnaire were addressed in the subsequent questionnaire survey by 
more extensive development work being undertaken before piloting. 
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5.1.2 (2) Implementation, Risks and Concerns about supplementary prescribing: 
survey of primary and secondary care pharmacists 
 
5.1.2.1 Advantages and disadvantages of using questionnaire surveys and attitude 
scales and how these issues were addressed. 
As per the discussion for the first quantitative questionnaire survey that was 
undertaken (section 5.1.1), bias caused by extreme views/outliers is minimized by the 
fact that a good response rate was achieved. The response rate that was achieved 
compares with similar questionnaire surveys.67, 235, 237 
Addressing the main disadvantages of questionnaire surveys (section 5.1.1), for point 
one; the possibility of sampling bias was reduced as the whole population of England 
was surveyed. 
As per the previous survey, point two was addressed by the fact that it was health care 
professionals responding to the survey and point three by the contact details of the 
researcher being included in the cover letter and the piloting process. The limitations 
of the methods used to address these points have been discussed in the previous 
section (5.1.1). 
Point four was addressed via the cover letter as per section 5.1.1 and point five was 
not addressed for this survey. This was because supplementary prescribing had only 
recently been developed and was not being used extensively in England. This 
questionnaire was distributed only 2 months after the first prescription had been 
written by a pharmacist supplementary prescriber.212 This made it difficult to arrange 
to observe SP being done in practice. This would have provided insight to the process 
and helped the questionnaire development process. This omission represents a 
criticism of the methodology used in the development of this questionnaire. 
 
It is recognized as per section 5.1.1, that there is a limited “shelf-life” for 
questionnaire data as the data represents a snap-shot of views of respondents at the 
time that the questionnaires were completed. Hence it is important that the period of 
data collection is stated when reporting the data. 
 
For sections A & B of the questionnaire, construct validity should have been used to 
assess validity, by considering whether the responses to individual statements are 
consistent with other similar statements in the questionnaire. The similar statements 
should be planned into the questionnaire during the development stages. This was not 
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however done. Two similar statements were explored during data analysis to assess 
construct validity but one question used was part of the attitude scale and was not 
suitable to compare with questions used in the other sections. Also, using only two 
questions to compare to each other only addresses one aspect of construct validity for 
this issue and do not prove anything with regard to the other statements that were 
included in the questionnaire. Extensive assessment of construct validity is not 
achievable when assessing such a narrow frame of questions. Therefore further 
questions should have been put into section B which correlated more closely with 
other questions in section B, in order to test construct validity more effectively. 
A criticism of the methodology used in the development of this questionnaire was that 
reliability of the questionnaire was not assessed. Assessment of reliability of 
questionnaires was discussed in the previous section (5.1.1). 
 
Telephone follow-up of chief pharmacists was difficult as these people are extremely 
busy and therefore secretaries preferred to take a message rather than let the lead 
researcher speak with the chief pharmacist. This may have reduced the response rate. 
For PCTPs, it was noted that the list of named pharmacists in the spring 2003 guide 
for primary care trusts228 was often inaccurate. On subsequent mailings, the named 
pharmacist was therefore removed and changed to “Primary care trust pharmacist” in 
order to improve the response rate. 
Although it would have been preferable to use the same follow-up methodology for 
both surveys, due to the larger sample size of primary care trust pharmacists 
compared to secondary care pharmacists, telephone follow-up was not undertaken for 
the primary care pharmacists. Instead an extra mailing was sent because it would have 
taken more time than was available to complete the telephone follow up for such a 
large sample. As the same response rate was achieved for both questionnaire surveys, 
the slightly different follow-up methodology does not appear to have affected the 
response rate. 
It would also have been preferable to have surveyed directors of nursing about nurse 
supplementary prescribing implementation rather than pharmacists. However it was 
felt that as the respondents have overall responsibility for prescribing and drug budget 
issues within their trusts, they would be aware of what nurse prescribing services were 
available. 
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5.1.2.2 Attitude Scaling 
It has been stated that attitude scales are relatively overt measures which are not 
designed to yield subtle insights.225 However the use of such a scale allows the study 
of how the reported attitudes relate to other variables in the data set.  The attitude 
scale in this survey was used to relate attitude to demographic variables and service 
provision (i.e. supplementary prescribing services). This was not considered too 
subtle to relate to attitude via a scale. By using such attitude scales, generalisations 
cannot be made about the attitude of the group of respondents as a whole (as to 
whether their attitude overall is positive or negative about supplementary prescribing), 
instead more tentative comments can be made to suggest what their attitudes might 
be. 
A Likert scale was used in the attitude statements section (C) for the respondents to 
place their opinion on the scale. This type of scale was used as they are easy to use 
and hence are the most common scale used for attitude scaling. 
The most serious criticism of this type of scale is its lack of reproducibility: the same 
total scale score may be obtained in many different ways. This being so, it has been 
argued that such a score has little meaning or that two identical scores may have 
totally different meanings. Therefore the pattern of responses often become more 
interesting than the total score.225 
As the scale offers no metric or interval measures & lacks a neutral point, it is not 
known where scores in the middle ranges change from mildly positive to mildly 
negative. Scores in the middle region could be due to lukewarm response, lack of 
knowledge or lack of attitude in the respondent (leading to many “uncertain” 
responses) or to the presence of both strongly positive and negative responses which 
would cancel each other out. 
This study did not compare individuals’ scores on the scale for the above reasons.  
 
The reliability of section C was tested via the internal consistency method- This 
assesses the extent to which similar items (attitude statements) gave consistent 
responses. Determination of Cronbach’s Alpha was used via this method to give the 
overall correlation between items within the scale. A reliability coefficient of 0.7 or 
above is recommended.226 The attitude scale for secondary care did produce a 
statistically valid Cronbach’s alpha value for the overall scale, however, none of the 
Cronbach’s alpha values for the extracted factors demonstrated a high level of internal 
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consistency (as recognised in standard textbooks of what constitutes a reasonable 
level of consistency, reliability coefficient >0.7) (226) (Table 16). This would suggest 
that some caution is needed when interpreting the meaning of the factors and their 
associations. 
 
Unfortunately the scale for section C for primary care did not produce an overall high 
level of internal consistency (Cronbach’s alpha value), and neither did the individual 
extracted factors (Table 16). This suggests that the scale is not measuring what it was 
intended to for primary care. Since an almost identical scale for secondary care did 
have an overall high level of internal consistency (Cronbach’s alpha value), (and 
therefore was measuring what was intended reliably) it suggests that the scale items 
needed further development to make them more suitable for primary care. The poor 
Cronbach’s alpha values for the extracted factors were apparent in terms of 
developing an overall meaning for the factor (Table 18). Some of the individual items 
did not “fit into” the group as well as other items.  
Development of the attitude scale was not done according to recognised methodology. 
According to Oppenheim,225 usually after the pilot work (e.g. using sentence 
completion technique), a large number of attitude statements (probably between 60-
100) is assembled to form an item pool. These items are then analysed and submitted 
to a scaling procedure. The outcome is 1-2 dozen items which together have the 
properties of an attitude scale that can yield a numerical score for each respondent. 
More important than the number of attitude statements used is the fact that they have 
been scaled i.e. they have been selected and put together from a much larger number 
of statements according to certain statistical scaling procedures.225 In the attitude scale 
that was developed for this research, only 22 attitude statements were piloted, which 
was reduced to 17 statements in the final questionnaires. The poor internal 
consistency and lack of reliability of the primary care attitude scale was partly due to 
this flaw in the development process. 
Also, an original assumption was made that PCT advisers were a homogenous group, 
and it is apparent that this is not the case, as they may have very different pharmacy 
backgrounds, have very different job roles and influence within their PCT. Primary 
care trusts have also only been in existence since April 2002. Previously they were 
known as Primary Care Groups. Therefore these PCTs represent an organisational 
structure whose development is very much evolving. Also, the respondents were not 
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all entitled pharmaceutical advisers, so may have had roles with very different focuses 
within the PCT. Different PCTs will also have different healthcare provision pressures 
upon them, which will be affected by whether they look after a rural or urban 
population. These issues may have been anticipated if a primary care focus group had 
been held. Also, if there is a large proportion of dispensing doctors within a PCT, this 
may have a negative effect upon the development of pharmacist supplementary 
prescribing due to there being a previous history of disagreement between the two 
professions upon the need for separation of prescribing and dispensing. 
Representation of PCTs from a pharmaceutical adviser in the focus group and in the 
semi-structured interviews would have helped to improve the overall reliability of the 
scale for the primary care questionnaire. A representative from this sector was not 
initially used because at the time that the focus group was undertaken, it was only 
intended to survey secondary care. A late decision was made that it would also be 
useful to survey primary care. The decision to not include primary care until the late 
stage in development may have been due to researcher bias as the researcher was also 
employed as a secondary care pharmacist. 
 Upon reflection, it would have been preferable to have run another focus group with 
primary care participants in order to ensure that their opinions were considered in the 
development of the survey and attitude statements. 
 
Although the scale does not have a high level of internal consistency in terms of the 
Cronbach’s alpha value achieved, the results can be used to provide some insight into 
the views of primary care trust pharmacists upon the risks and issues surrounding 
supplementary prescribing in primary care, and to also highlight differences in those 
views between primary and secondary care.    
If either of these scales were used for further research they would both need further 
development to ensure that it was reliable and valid. 
 
It was noted that some respondents commented in the open comments section of the 
questionnaire that if the questions in section C were dealt separately for nurses and 
pharmacists, they would have answered the questions slightly differently.  
There were also some comments made that in some of the questions in section C, the 
term “primary care” was used, which can be misunderstood as just meaning PCT 
pharmacists. –It is only recently that PCT pharmacists have been more often 
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recognised as being their own specialist sector, separate from community pharmacy. 
Therefore the term “primary care” should no longer be used as a general term to 
collectively describe PCT pharmacists and community pharmacists, without further 
definition. 
Respondents also commented that they would like to be able to make open comments 
to explain their answers to each item in section C. Some respondents did this anyway, 
where they felt they needed to qualify their answer. This may suggest again that the 
scale is not measuring the respondents’ attitudes reliably if they feel it is necessary to 
further explain their answers.  
Although further explanation of answers is useful, it is not usual for attitude scales to 
allow extra space for explanation of their response. Also, the longer a questionnaire 
survey is, the more negative impact it will have on the response rate.229 However, the 
comments were taken note of, and are referred to in section 5.2.2.  
 271 
5.1.3 (3) Patients’ views and opinions of pharmacists and nurses as independent 
prescribers 
 
5.1.3.1 Sampling and sample size 
 
For the purposes of qualitative research, it is not necessary to select research 
participants via a random selection procedure. Purposive sampling is often used in 
qualitative research in order to ensure that the participants represent the views of a 
wide range of the population to be studied and that they target the group of interest. 
However it was considered that as some of the populations that met all of the 
inclusion criteria were rather large (e.g. group one- patients under the care of the GP 
for hypertension, total sample was >1000 patients) it was felt that a random selection 
would produce a group of participants that represented a wide range of backgrounds. 
Random sampling was not the most suitable sampling method for the groups of 
patients under the care of a pharmacist supplementary prescriber as the total number 
of patients they were looking after was small. Instead, a purposive method could have 
produced a more diverse sample. However, when the study was designed it was not 
known how many patients the pharmacist supplementary prescribers would be 
looking after and how well established their clinics would be by the time patient 
recruitment was being undertaken. It was therefore decided to use the same random 
method of selection for all sites so that there was a consistent approach to sampling. It 
is however recognised that the method of sampling that was used could have 
introduced some bias in the sample that was invited to participate. 
 
In terms of qualitative research, the overall total number of participants (n=18) is 
considered entirely reasonable. Statistics cannot be used to calculate an ideal sample 
size in qualitative methodology and instead the issue has to be dealt with 
conceptually: How many cases, in what kind of sampling frame, would give us 
confidence in our analytic generalizations?238 It also depends upon how rich and 
complex the within-case sampling is. With high complexity, a study with more than 
15 cases or so can become unwieldy with too much data to scan visually and too 
many permutations to account for. But with qualitative research, the aim is never to 
generalise the results on a population basis but is to inform thinking. 
As the number of cases (participants) increase to 20-30, the number of researchers 
may have to increase to analyse all the data and the data itself becomes thinner and 
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less rich. When using more than one researcher to undertake the data analysis regular 
communication needs to take place in order to ensure that changes and development 
of the topic guide used during interview is agreed by all members of the research 
team.  
However, it should be borne in mind that at this stage, the question has to be asked 
whether a questionnaire survey would have been a better method to use.238 It would 
appear that the number of participants was reasonable for the methodology utilised. 
However, the sample size may not have been suitable when the sample was analyzed 
in sub-groups (such as those who were under the care of a pharmacist supplementary 
prescriber) as the numbers did not allow discussion of the topics to be fully saturated, 
as discussed below. 
 
5.1.3.2 Why were patients of nurse supplementary prescribers not interviewed? 
Patients were not interviewed that had been under the care of nurse supplementary 
prescribers in primary and secondary care. It was felt that the main focus of this stage 
of the research was to investigate patients’ opinions and views of pharmacists as 
prescribers in particular which is a much more radical development for patients as 
they were expected to have more experience of seeing nurses as autonomous 
practitioners and prescribers. Patients were asked about their opinions of nurses as 
prescribers and how pharmacists compare to them.  
If time had permitted, the design of this stage of the research would have been more 
robust if this group of patients had also been interviewed. Had this data been 
collected, it would have allowed comparisons to take place between patients who had 
experienced nurses versus pharmacist supplementary prescribing and would have 
allowed more insight into what affect nurses undertaking a more extended prescribing 
role has on the publics’ opinions of nurses as independent prescribers. 
 
5.1.3.3 Limitations of the data collection regarding nurse prescribing   
 
Generally, it should be noted that because the initial discussions occurred with 
participants about pharmacist independent prescribers, participants were less verbose 
about nurses, as they often referred back to what they had already said about 
pharmacists. In hindsight, the interview schedule could have been re-designed in 
order for participants to consider both nurses and pharmacists at the same time when 
answering the questions rather than asking the same group of questions about 
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pharmacists and then nurses. This may have improved the quality and richness of the 
data collected regarding nurses. More care therefore has to be taken when interpreting 
the nurse data and when making assumptions and generalisations about it. 
 
5.1.3.4 Limitations of the interviews with participants who had experienced 
supplementary prescribing 
 
 
Only eight participants had experienced supplementary prescribing by pharmacists. 
Some participants in this group were not very vocal about their experiences and hence 
the data retrieved is not a very rich or detailed portrayal of how their experiences have 
informed their opinions upon pharmacists as independent prescribers. Sufficient 
numbers of patients should have been interviewed until the data had been saturated. 
This represents a flaw in the data presented. 
It would have been preferable to have interviewed further participants as the data was 
poor. However, recruitment at the centre where the participants had seen a pharmacist 
SP regarding their hypertension was difficult as it was a small population in total, and 
recruitment was poor. 
For the participants who had consulted a pharmacist SP in oncology, the pharmacist 
SP had only recently started prescribing and was very specifically prescribing the oral 
chemotherapy agent capecitabine as an adjuvant for treatment of advanced colon 
cancer following surgery. This meant that he had only seen 12 patients in his clinic, 
and after the original patient recruitment pack had been sent out to his patients twice, 
only four patients expressed an interest in participation.  
Also, due to restrictions upon the time available to do these interviews, it was 
untenable to try to find and recruit another site that had a qualified pharmacist 
supplementary prescriber working in such a narrow therapeutic area. 
 
The researcher had not undertaken qualitative interviews before, but hoped that the 
training course that was attended, the pilot interviews and the researcher’s 
professional experience would help these run smoothly. It is of no doubt that with 
experience, the researcher’s interview technique would have improved over time. 
However, the researcher did find that some of the interviews undertaken in the third 
group of patients interviewed (those under the care of the pharmacist SP for 
hypertension) were the most challenging, as some of the patients were not very 
articulate, perhaps due to the  deprived area of Bristol that the GP surgery was based. 
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 5.2 Consideration of research questions 
 
5.2.1 (1) National Survey of pharmacist transcribing of discharge prescriptions 
(secondary care) 
 
5.2.1.1 Prescribing activities 
The majority of departments had undertaken some form of pharmacist prescribing, by 
2001 with the most common type of pharmacist prescribing being that of transcribing 
discharge prescriptions. Those hospitals that offered a PDPTS also offered a wider 
range of other pharmacist prescribing activities than those hospitals not offering such 
a service. Also, teaching hospitals, which employ more pharmacists than District 
General Hospitals’ (DGH) were able to offer PDPTS more frequently. It could be 
suggested that staffing was a limiting issue in the provision of pharmacist prescribing 
activities. 
 
5.2.1.2 Prescribing systems 
The ward model of pharmacist transcribing was the most popular model in practice. It 
has been suggested that the most ideal method for pharmacist involvement in the 
discharge process is for the ward pharmacist to write discharge prescriptions whilst on 
the ward round, when medicine management issues can be discussed with the whole 
team as a collaborative process.197-198 The pharmacist could write the discharge 
prescriptions as the ward round is continuing, meaning that as soon as the discharge 
decision is made, the prescription can be written, and passed onto ward technicians to 
process.  
 
The majority of pharmacists that were transcribing discharge prescriptions are writing 
less than 5 prescriptions per day. As over half of the hospitals who offered such a 
service had less than 5 pharmacists who transcribe prescriptions, it can be assumed 
that the majority of hospitals were not having a large impact on the overall number of 
discharge prescriptions being written in the hospital. This agrees with the findings of 
Sexton’s survey of 1999, which found that pharmacists were involved in writing 
discharge prescriptions in about a third of hospitals, but their impact was considered 
to be negligible.67 
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Reasoning for the limited impact of the services was not investigated by the 
questionnaire survey. One could speculate that the reasoning could be due to poor 
support from the medical profession, poor IT support, insufficient staffing resources 
and perhaps that the pharmacists could not be or were not on the wards when the 
prescriptions needed to be written. 
The transcription services were operating during normal working hours Monday to 
Friday by the majority of departments. In light of the fact that Slee and Farrar 239 have 
shown that on weekdays 50% of inpatient and 18% of take home prescriptions were 
written outside the traditional 9-5pm working day, if a transcription service is going to 
have a significant impact, it needs to be operated over extended hours. The optimum 
benefit from this service provision may actually be from 5pm until midnight when 
junior doctors are working with minimal senior support. It could be hypothesized that 
this time would be the maximum risk for prescribing errors. 
 
5.2.1.3 Training 
Even though all pharmacists who are competent to practice within secondary care 
should be able to transcribe discharge prescriptions, for the purposes of Clinical 
Governance, the service should be accountable.62 Therefore all pharmacists providing 
the service should be assessed against key competencies, to provide an equivalent 
service of a suitable standard. However this requirement is superseded by legal forms 
of prescribing being introduced with accompanying training and CPD requirements. 
 
 The results show that a relatively low number of hospitals have a formalised training 
programme (n=8). This therefore suggests that when 55% (n=27) said that they ask 
their pharmacists to undertake an in-house training programme in order to be 
authorised to transcribe, some of these training programmes may be ad-hoc 
arrangements. 
The service should also be regularly audited to make sure that standards are being 
maintained. Principles of clinical governance are not being adhered to if these issues 
are not addressed.  
 
5.2.1.4 Responsibility and accountability 
Although PDPTS is widespread, the results of this study indicate that there is a lack of 
consensus on authorisation requirements for pharmacist-written prescriptions. The 
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Medicines Act 1968 100 does not define what a prescription is or what a hospital is. It 
is therefore not surprising that there is no authoritative interpretation of the legality of 
prescriptions written by non-medically qualified personnel.101 However, this position 
does not seem to be a perceived barrier to pharmacists when implementing PDPTS 
(perhaps because they had not considered it). 
 
 A few hospitals commented that although it was in their official policy that the doctor 
should always sign the prescription (and had indicated this in their questionnaire 
response), in practice this did not always happen. Some respondents indicated that 
they sometimes obtained a doctor’s counter-signature on their pharmacist-written 
discharge prescriptions. This approach is unlikely to be compliant with their protocols 
and raises a clinical governance issue. If there are mistakes on the prescriptions 
produced in this scenario, who is responsible and accountable for the overall quality 
of the prescription, shortcomings in care or even harm to the patient?  
Those hospitals operating PDPTS without having a formal protocol in place (43 per 
cent, n=20) are also not following the principles of clinical governance as they do not 
have an accountable, safe system in place and are not providing their employee 
pharmacists with formalized support.  
 
Another perceived problem in the provision of PDPTS is that prescribing and clinical 
checking roles are not separated thus creating a risk management issue. Some 
hospitals have overcome this issue by swapping the prescribing and checking roles 
with the doctor, so that the pharmacist writes the prescription and the doctor checks 
and signs it.70, 72 
However, it could be argued that due to time constraints upon the doctor, the 
prescription in this situation may be authorised, but the clinical check may not always 
happen.  
 
5.2.1.5 How does the writing of discharge prescriptions by pharmacists “fit” within 
the legalized versions of pharmacist prescribing? 
 
Regardless of the lack of quality or bulk of evidence available to support the 
development of pharmacists writing discharge prescriptions, with the development of 
legal frameworks (Supplementary (SP) (legalized in 2002) and Independent 
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prescribing (IP) (legalized in 2006)) there has been much discussion as to how 
discharge prescribing “fits” within these models available for pharmacist prescribers.  
There has been one descriptive report published (2005) where a cardiac specialist 
pharmacist has used the SP model to write discharge prescriptions for cardiac 
patients.240 However, it would seem that the need for an agreed clinical management 
plan for each condition that a patient has in order for a pharmacist to prescribe for that 
condition, would negate any benefits of a pharmacist writing a discharge prescription 
under this model. 
Within the consultation process for the IP model,55 it was specifically noted that 
“discharges from hospital may be expedited if pharmacists, who work as part of 
multi-disciplinary teams, can prescribe and supply appropriate medicines around the 
time of discharge, without having to wait for a doctor to sign a prescription.” 
Comment was specifically requested in the consultation upon IP about pharmacists 
using the IP model to prescribe discharge prescriptions. However, since independent 
prescribing for pharmacists has become legal,45 it is not clear yet whether pharmacists 
are using this qualification to legalise or develop their practice in writing discharge 
prescriptions. It could also be argued that undertaking an in-depth qualification and 
then not needing to actually diagnose (as the discharge prescription should be written 
after the patients’ problem(s) have been diagnosed and treatment commenced) or 
physically examine the patient in order to write their discharge prescription may be 
excessive and hence prohibitive.   
-A PGD would also not enable pharmacist prescribing of discharge prescriptions as 
the drugs and clinical situation need to be specified in the PGD. 
 
It is apparent therefore, that there are several unanswered legal issues surrounding 
PDPTS if the model of IP is NOT used to legalize pharmacist-written discharge 
prescriptions: 
  
• It is unclear whether the process itself is transcribing or prescribing. – Would a 
court of law view that a process whereby a list of medications was reviewed 
by a pharmacist and written on a document that was later accepted for 
dispensing at a pharmacy was not in fact prescribing but something else 
entirely? 
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• Who is legally responsible for the prescriptions that are written in this 
scenario? Therefore, who should authorise these prescriptions? 
 
Central guidance from the Department of Health and tailored provision of training and 
assessment from higher education institutions should be provided for this specific 
role, as per the supplementary and independent prescribing model. Without 
standardised guidelines for this process, it could be viewed as a disaster waiting to 
happen. 
 
5.2.1.6 Factors that influence the provision of a PDPTS 
 
The most frequent reason cited for providing a PDPTS was to speed up the discharge 
service. Published studies provide evidence to support this reasoning.70, 74- 75, 99, 181  
The system where medical practitioners write patients’ discharge prescriptions at the 
end of the ward round when the consultant has decided that the patient is medically fit 
to go home is flawed, and leads to long waiting times for patients.75  
The Department of Health’s current discharge document suggests that in order to 
improve and speed up the discharge process, the roles of junior doctors and 
pharmacists in taking medication histories on admission and writing up take home 
medication needs to be reviewed.104 It also suggests that the discharge process should 
be planned for at the earliest opportunity. Therefore by pharmacists writing discharge 
prescriptions in a timelier manner, the discharge process could be more efficient. If 
PDPTS was combined with a “one-stop” dispensing service241 the discharge 
prescription processing time could be even further reduced, with both the prescription 
and supply of medications for discharge being managed by pharmacy earlier in a 
patient’s stay.  
 
The next most commonly cited reason for providing a PDPTS was to reduce errors on 
prescriptions/improve accuracy (50 per cent, n=24). This reason is also supported by 
published literature,72, 74, 99, 181 and also by the Audit Commission report “A spoonful 
of sugar,”49 which has reported that pharmacists are five times more accurate than 
doctors in writing discharge prescriptions. Prescribing by newly qualified doctors is 
currently under particular scrutiny as a result of changes in junior doctor training.242 
It is apparent that extending prescribing rights to pharmacists would help towards 
meeting the Government targets of reducing serious medication errors by 40% by 
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2005 (It is unclear whether this target was actually met).63 The presence of a 
pharmacist on clinical ward rounds has also been shown to prevent further errors 
occurring,49 suggesting that pharmacists are also well placed to make interventions 
and review medication on the ward round as part of PDPTS.  
If these systems were in place the flow of work in the dispensary would also be 
improved as errors would be rectified before the discharge prescription was written.181  
 
Thirty-three per cent (n=16) of departments operating a PDPTS stated that one of 
their reasons for implementing the service was to release junior doctor time. Junior 
doctor time would not only be saved by not having to write the discharge 
prescriptions, but also from the reduced amount of time having to answer their bleep 
to rectify errors and omissions with the pharmacy department. The time saved by 
doctors from implementing such a service has been estimated as seven hours per 
doctor over a 3-month period,72 2 hours per doctor per week208 and also 45 minutes 
per doctor per day.99 Some pharmacy departments have managed to obtain funding 
for extra pharmacists to perform this role from resources provided to reduce junior 
doctors working hours.193 This may be an option for consideration by those hospitals 
that had not implemented PDPTS due to funding problems. 
 
One of the main reasons for not introducing PDPTS was lack of resources (n=18), 
and this claim is supported by the fact that the more pharmacists that are employed, 
the more pharmacist prescribing activities can be implemented.237 Although 
insufficient pharmacist resource is a major obstacle to PDPTS implementation, if 
pharmacy services are examined there are many ways in which departments can 
become more efficient in the way that they work, for example, by moving towards a 
pharmacist-free dispensary, and developing ward pharmacy teams of a pharmacist and 
technicians and assistants.64-66 This re-examination of the way that pharmacy 
departments work may release some pharmacist time for new roles including 
prescribing.  
The first and second comments made by questionnaire respondents in the results 
section (p151) illustrate potential difficulties some pharmacy departments may have 
in extending their role. Views upon the extension of the pharmacist role by medical 
staff may be due to individual personalities and beliefs of the medical practitioner, 
who may not fully understand the level of training that pharmacists receive. This 
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situation may improve if chief pharmacists are elevated to the equivalent of a clinical 
director, and are members of the trust’s management executive, as recommended by 
the Audit Commission report “A Spoonful of Sugar”.49 The chief pharmacist will then 
be in a stronger position to develop changes in pharmacists’ practice. Also the 
implementation of SP and IP will mean that this type of opinion will inevitably 
change.48 
 
When level 3 electronic prescribing is implemented, there will still be a role for the 
pharmacist to decide upon the appropriateness of treatment on discharge and input the 
discharge prescription onto the computer. Pharmacists are already using electronic 
prescribing systems in this manner, and have become more integrated into the 
healthcare team.48, 64-66, 193, 195 Therefore, the advent of electronic prescribing should 
not be seen as the end of the involvement of pharmacists in the discharge process, 
which was inferred in the third comment presented in the results section (p151). 
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5.2.2 (2) Implementation, Risks and Concerns about supplementary prescribing: 
survey of primary and secondary care pharmacists 
 
5.2.2.1 Section A and B 
 
5.2.2.1.2 Issues for community pharmacy 
The percentage of Chief Pharmacists (CPs) and Primary Care Trust Pharmacists 
(PCTPs) intending to implement supplementary prescribing by the end of 2005 was 
similar (CPs: 57%, n=55, PCTPs: 56%, n=100). Within primary care, it was most 
common for primary care trust and general practitioner (GP) based pharmacists to be 
trained as supplementary prescribers rather than community pharmacists. This 
observation suggests that there are some potential obstacles for community 
pharmacists when it comes to developing this role. These obstacles can include lack 
of on-line access to patients’ medical records, lack of a private area within the 
community pharmacy for the consultation to take place, difficulties in establishing 
funding for developing the service from the PCT and also lack of an established good 
working relationship with local GPs. It is therefore apparent that in order for 
community pharmacists to fully develop this opportunity to prescribe and develop 
services for patients, they have a lot more barriers to overcome than pharmacists in 
secondary care.  Subsequent research has corroborated this finding as practicing in a 
setting other than community pharmacy was found to be a predictor of pharmacists 
starting to practice supplementary prescribing.214 This research study utilized a 
questionnaire which was mailed to all RPSGB prescribers (n = 518), on June 1, 2005. 
They identified predictors of pharmacists starting to practice SP via univariate 
analysis, and significant variables were further tested in multivariate analysis. Their 
reasoning for development of supplementary prescribing being more problematic in 
primary care was due to lack of time, inadequate support staff, and insufficient 
awareness among other health professionals and the general public about the 
pharmacists' skills and attributes. They also noted a longer preparation time in setting 
up clinics in primary care, due to overcoming funding and organizational issues.214 
 A qualitative evaluation of supplementary prescribing found similar results, as one of 
its key findings was that community pharmacists wishing to practice as 
supplementary prescribers have particular obstacles to overcome including difficulties 
with medical record access, physical distance from the independent prescriber and 
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lack of funding provided for this service.213 It is not only pharmacists within the 
community that have these extra obstacles before implementing supplementary 
prescribing. A recent questionnaire survey of qualified independent 
extended/supplementary nurse prescribers has also found that nurses in general 
practice (as opposed to primary care trusts) have far more reasons preventing the 
implementation of supplementary prescribing.127 
One of the key recommendations from this piece of research was that community 
pharmacists may need additional support (financial, development of contracts and IT) 
from the local PCT to facilitate supplementary prescribing in the community 
pharmacy sector.213 
 
5.2.2.1.3 Service continuity 
Although most secondary care trust respondents indicated that junior doctors would 
provide cover for the supplementary prescriber in their absence, it has been suggested 
that provision of a pharmacist service would result in a superior prescription service 
in terms of safety and overall quality of the prescriptions.49, 72, 74, 99, 181 Is it therefore 
acceptable for annual leave, sickness cover and over-night/weekend cover to be 
provided by a more inferior service? It is not acceptable for patient safety. The 
pharmacy profession does not provide a 24 hour service unlike the medics and 
nursing professions. There is therefore an inference that pharmacy services are not 
essential and that other professions are able to continue without our services at 
weekends and in the evenings. The goal should be the provision of a 24-hour service 
for hospitalized patients; however, at the moment, the limited number of pharmacists 
would make this impossible for most hospital trusts. Instead, a more realistic approach 
at the moment would be to ensure that all prescribers, from whichever healthcare 
profession, provide the same standard of service. In order to ensure that everyone is 
providing a service of equivalent quality, as mentioned in the introduction (p30) it has 
been suggested that in the future, ALL health-care professionals who are going to 
prescribe ought to pass a “prescribing exam” before they start prescribing. (Personal 
communications, Professor Judy Cantrill, BPC 2003) This would seem to be a fair 
approach, and would help to avoid the situation described at a hospital in the Wirral 
where pre-registration house officers were not allowed to prescribe for their first six 
weeks of practice without close supervision.242 It would also avoid the perception of 
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increased medication prescribing errors being made when newly-qualified doctors 
start prescribing,243 as well as reduce opportunity for litigation. 
A more radical suggestion would be to vastly increase the numbers of pharmacists 
being trained so that in the future, within secondary care and in primary care a 24 
hour service could be provided so that pharmacists superior prescribing skills are 
available to patients at all times. 
Primary care respondents indicated that in the absence of the pharmacist 
supplementary prescriber, a nurse supplementary prescriber would provide the service 
if a GP was not going to be used. This may be because primary care has a large 
number of qualified nurse supplementary prescribers, and the therapeutic areas that 
most pharmacists are going to work in have clear, detailed guidance available (as 
discussed in following section), and are not as complex areas as some of the 
therapeutic prescribing areas in secondary care. 
However, it also suggests that no distinction is being made between the types of 
prescribing that a pharmacist in e.g. a cardiac clinic will undertake compared to that 
of a nurse. If the type of prescribing is identical for both professions then a nurse 
would be chosen to run a clinic in preference to a pharmacist because the salaries for 
experienced clinical pharmacists and community pharmacists are higher than nurses’ 
salaries. 
It may also be possible that as GPs are more familiar with working closely with 
nurses and hence have established working relationships with them. Most importantly, 
trust may have been developed in their relationships so they are more confident about 
using nurses as supplementary prescribers. In primary care, GPs tend to have less 
experience of working closely with pharmacists and hence they may be more hesitant 
about pharmacists developing supplementary prescriber clinics. This means that 
pharmacists will have to establish areas (such as more complex polypharmacy areas) 
for their more expensive clinical expertise, and a distinction will have to be made 
about what types of clinics the different professions are going to offer in each clinical 
area. The other important criteria for successful development of supplementary 
prescribing clinics will be the development of a closer working relationship with GPs 
so that trust can be developed as well. This will lead to acceptance of pharmacists as 
prescribers by the medical profession and hence patients. A good relationship between 
the SP and the independent prescriber (i.e. doctor) and a long standing existing 
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relationship of trust between professionals have also been identified as key success 
factors in the London Pharmacist Supplementary Prescribing project 2003-2006.244 
 
5.2.2.1.4 Therapeutic area  
The most common clinical areas served by supplementary prescribing pharmacists in 
secondary care reflect those areas where pharmacist prescribing input has already 
been established (Table 11, p155).  
The most common area that chief pharmacists were training pharmacists to be 
supplementary prescribers in was total parenteral nutrition (TPN), an area in which 
pharmacists are already working.245- 246 Pharmacists have a long established role as 
part of nutrition teams within most hospitals,247 and also have a key input in the 
individual composition of TPN prescriptions for patients. Pharmacists have also had 
established roles in the areas of oncology/haematology, cardiology and 
anticoagulation 83-86 246 248-254 which were also found to be areas where pharmacists 
were being trained as supplementary prescribers. Subsequent research upon 
pharmacist supplementary prescribers has confirmed that cardiovascular conditions 
are a common therapeutic area for these prescribers.214 
It is not surprising that pharmacists are being trained as supplementary prescribers in 
therapeutic areas such as renal, rheumatology, HIV and care of the elderly. 245- 246, 250, 
255 Again, these are areas where pharmacists have established clinical roles 93, 256 and 
pharmacist prescribing is well suited due to the polypharmacy, complexity of the 
medication (e.g. numerous drug interactions) and multiple concurrent conditions that 
are often associated with these patients.  
Some therapeutic areas that are being targeted for SP have associated National 
Service Frameworks and other published national guidance available.  
The publication of the NSF for older people 257 which sets standards in care, 
recommended that all elderly people should normally have their medications reviewed 
at least annually (every six months for those taking four or more medicines), and 
receive more help from pharmacists in using their medicines. Therefore this area 
provides a suitable target for pharmacist supplementary prescribing services.  
The NSF for Renal Services was published in January 2004,258 which emphasizes the 
extensive role that pharmacists can have in optimizing medication in this area. So 
again, this area should be targeted for supplementary prescribing by pharmacists. 
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Another therapeutic area that was commonly identified as being one in which 
pharmacists were being trained as supplementary prescribers was surgical/orthopaedic 
preadmission clinics. As described for the other therapeutic areas, pharmacists had a 
well developed role in this area before the advent of supplementary prescribing. 
Pharmacists were involved in taking medication histories, writing the patients current 
medication onto the in-patient drug chart during these clinics, and also following 
protocols for standard antibiotic prophylaxis and thromboprophylaxis to be written 
onto the in-patient drug chart as well.76-78, 80, 82, 176- 177, 259 
Indeed, since this research was undertaken, a review of the London Pharmacist 
Supplementary Prescribing project 2003-2006 has been published and this has  
confirmed the findings from this research, stating that one key success factor for 
supplementary prescribing was implementing it into an established pharmacist-led 
service such as total parenteral nutrition.244 
By training pharmacists as supplementary prescribers, doctors will no longer need to 
co-sign inpatient drug charts and pharmacists’ roles in these established areas of 
secondary care will become legitimized.  
 
Primary care has focused its supplementary prescribing training on quite different 
areas from secondary care. This may be due to the implementation of the new General 
Medical Services (GMS) contract in April 2004, for GPs.260 In this new contract, 
payment for services focuses upon improving the overall quality of clinical care for  
patients. Within the GMS contract, the QUOF specifies disease categories where 
more comprehensive service provision will be rewarded with more substantial 
payments. The top five clinical areas identified for primary care pharmacist 
supplementary prescribers (Table 1) are the same as those specified in the QUOF. It 
would appear that this has happened because GP practices are targeting the 
development of services in these areas in order to enhance their payments. These 
areas are also subject to detailed guidance published over the past few years in the 
form of NSFs, (the coronary heart disease NSF was published in March 2000, 261 the 
diabetes NSF in 2001262) and also specialist guidelines developed by the British 
Thoracic Society and the Scottish Intercollegiate Guidelines Network for Asthma, 263 
NICE guidelines for COPD264 and by the British Hypertension Society for 
hypertension.265 Therefore these clinical areas are extremely suitable for pharmacist 
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supplementary prescribing, as the clinical management plans can refer the pharmacist 
to such national guidelines. 
Subsequent research has recently reviewed Prescription Analysis and Cost (PACT) 
Data from community and primary care supplementary prescribers from 2004 to 2006 
and this has also shown that the most commonly prescribed therapeutic class of drugs 
for this group of supplementary prescribers was cardiovascular medicines.266 This 
finding supports the findings of this research where clinics in the therapeutic areas of 
hypertension and coronary heart disease/hyperlipidaemia were found to be most 
commonly reported for this sector. 
 
Pharmacist supplementary prescribing in mental health appears to be uncommon in 
both primary and secondary care. This is rather surprising considering that it is a 
clinical area identified in the QUOF, and that there is a NSF267 for this therapeutic 
area. 
The United Kingdom Psychiatric Pharmacy Group (UKPPG) and College of Mental 
Health Pharmacists (CMHP) have published a statement upon their position with 
respect to supplementary prescribing.268 They are advising their members that they 
believe that in order to be a competent supplementary prescriber in mental health they 
require membership of CMHP in addition to receiving the required supplementary 
prescribing training. This is the only specialist clinical pharmacy group to have any 
additional requirements. These additional requirements may have a negative effect on 
pharmacists wishing to become supplementary prescribers in this area. Alternatively, 
they may reflect an attitude within the mental health community that prescribing in 
this area is more complex than other therapeutic areas.  
Therefore this data upon therapeutic areas suggests that for secondary care, 
supplementary prescribing is not being used to drive forward non-medical prescribing 
for pharmacists, but instead is being used to legalize prescribing that is already taking 
place. It is therefore not being seen as a dynamic model that is being used to create 
new roles and is not providing a model that is really workable within secondary care. 
For primary care, it is being used to develop new services, but it is driven by the 
QUOF for medical services and by those PCTs who perhaps are more forward-
thinking in developing the pharmacists’ role. It is therefore leading towards 
development of non-medical prescribing in an ad-hoc manner where some 
geographical areas will have good access to non-medical prescriber services and other 
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areas will not. This development has therefore not led towards increased access to 
healthcare for all patients.  
 
5.2.2.1.5 Problems with implementation of supplementary prescribing 
Five primary care trusts reported that although they had nurses trained as 
supplementary prescribers, they were not prescribing at the moment. Although no 
reasoning was given for this, part of the requirements for training as a supplementary 
prescriber include support of their employer to confirm that the SP will have access to 
a budget to meet the costs of their prescribing and that their post is one in which they 
will have the need and opportunity to act as a SP.48 Therefore it appears that although 
these requirements for supplementary prescribing training have been implemented to 
avoid wasting resources they do not seem to be working in all cases. Recent research 
has found some reasoning as to why this might be. -A questionnaire survey of 868 
qualified independent/extended/ supplementary nurse prescribers found that 
supplementary prescribing was being used by a minority of nurses (n=304, 35%) and 
that the reasons for this included the inability to generate computer prescriptions and 
problems with implementing the clinical management plan.127 There has been 
research published about the practical difficulties that have been encountered with 
regards to independent nurse prescribing from the NPF which supports these findings 
regarding supplementary prescribing. The research suggests that issues such as 
organizational support, support from members of the team, communication issues, 
difficulties accessing medical information about patients and inability to produce 
computer-generated prescriptions, difficulties in coming to terms with this increased 
responsibility and fears of litigation, concerns about keeping up to date (CPD) and 
lack of confidence43, 122, 269- 270 have hindered development of nurse prescribing. Also 
more practical issues have been highlighted such as getting hold of prescription pads, 
lack of time in clinics, inability to prescribe for patients from other trusts, keeping 
records, situations requiring items from more than one prescriber and security 
concerns.271 It is likely that such problems will also face nurse supplementary 
prescribers as well. A recently published study sought to identify barriers that could 
either prevent community nurses from prescribing altogether or reduce the number of 
times that a nurse might prescribe and to determine how wide spread the barriers 
identified above were. Qualitative semi-structured interviews with nurse prescribers 
and Trust prescribing leads were undertaken and a postal questionnaire was sent to the 
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nurse prescribing leads in each Primary Care Trust across three strategic health 
authorities in England. Barriers identified in this study were those that (i) prevented 
prescribing included: roles with no patient contact, prescription pads not issued, 
opposition from general practitioners and lack of confidence; (ii) prevented some 
prescribing: included lack of time in clinics, inability to prescribe for patients 
registered with another Trust, security concerns, lack of access to patient medical 
records and the use of alternative methods of supply (iii) made prescribing more 
difficult included: keeping records, informing general practitioner of items prescribed, 
delivering prescribed items to housebound patients and situations requiring items 
from more than one prescriber.  
Indeed in the London Pharmacist Supplementary Prescribing project 2003-2006 
summary of project outputs and reflection on progress of pharmacist prescribing 
report244 it is highlighted that in order for supplementary prescribing to work, 
practical implications of setting up a prescribing service such as finding clinic space 
and time, administrative assistance and ordering prescription pads needs to be tackled. 
Subsequent research regarding pharmacist supplementary prescribing has also 
confirmed that similar issues face pharmacists. One study has found that funding 
issues were identified as major barriers in implementing supplementary prescribing 
and that lack of organizational recognition of supplementary prescribing was the main 
reason given for those not commencing practice once qualified.214 Another 
questionnaire study of pharmacists that had qualified as supplementary prescribers 
also found similar barriers to the successful implementation of supplementary 
prescribing, such as inadequate funding, no organizational recognition of 
supplementary prescribing, non-availability of prescription pads, difficulties in the 
referral process/identification of patients and poor recognition of pharmacy role by 
other health professionals.272 Other research has also found issues with administrative 
problems, lack of organizational recognition, funding, access to medical records and 
lack of resources as well.213, 216- 217, 273 
Alongside these practical issues, there have also been some concerns raised about the 
practicalities of using the clinical management plans in practice.213 -The Department 
of Health commissioned the National Prescribing Centre (NPC) to undertake a 
scoping study to find out how supplementary prescribing might work in practice in 
2005. The NPC brought together a range of nurses, pharmacists and the doctors they 
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work with, from different settings and specialties across primary and secondary care, 
to 'try out' supplementary prescribing. They invented some typical patients, and 
worked up Clinical Management Plans for them, identifying the information that 
would need to be included, and the best ways to reduce duplication of effort while 
ensuring patient safety. Their findings included that Clinical Management Plans 
(CMPs) have to be relatively simple and quick to complete - or supplementary 
prescribing will simply not be worth the effort. They should not duplicate a lot of 
information that is already recorded in the shared record. Also that supplementary 
prescribing might need to include team as well as one-to-one prescribing partnerships, 
when service delivery is organized in this way, and that for patients with multiple 
health needs, or multiple professional carers, supplementary prescribing may not be 
suitable at all: the independent prescriber can decide whether or not it is appropriate to 
implement supplementary prescribing for any patient.274 A recent review of literature 
upon supplementary prescribing273 has concluded that although having a standard 
format for the CMP offers consistency and procedural certainty, this is at the expense 
of having flexibility and an easy to use document. This is contrasted with protocol and 
collaborative prescribing models such as those used in USA where prescribing rights 
are arranged at an organisational level, which improves the flexibility of these 
arrangements. 
Therefore it would appear that there are some similar issues facing all new non-
medical prescribers. It is therefore essential that there is support from the medical 
profession and other healthcare organizations for this role if it is to be a success. One 
of the key recommendations from the qualitative evaluation of supplementary 
prescribers undertaken on behalf of the RPSGB213 was that if supplementary 
prescribing was to be effective, then there needs to be support for training and support 
for the practical processes that make supplementary prescribing work at ground level, 
including computer accessibility and prescription printing, -alongside having clear 
lines of responsibility and accountability (as outlined in the RPSGB’s clinical 
governance framework105). 
Trusts should monitor the prescribing of their non-medical prescribers, target 
appropriate support and encouragement to address problems with prescriber 
confidence, develop strategies to integrate their non-medical prescribers into the 
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healthcare team to improve access to patients’ medical notes, and improve the 
efficiency of the prescribing process. 
 
5.2.2.1.6 Nurse supplementary prescribing 
Primary care has many more trained nurse supplementary prescribers than secondary 
care. This is probably because nurses have been able to prescribe in primary care 
since 1998; therefore the prescribing role of nurses is well established in this sector. 
Another reason for secondary care having less nurse prescribers is that the model of 
supplementary prescribing is more tailored for treatment of chronic diseases and 
therefore its applicability to acute conditions in secondary care is more limited. There 
may also be reluctance amongst secondary care nurses to take on a prescribing role, 
due to their lack of familiarity with non-medical prescribing roles. However, further 
research would be necessary to confirm this. 
The Government stated that it was their intention to ensure that half the nursing 
workforce had prescribing rights by 2004,40 therefore there has been increased 
impetus to train nurses as supplementary prescribers than compared to pharmacists. 
 
5.2.2.1.7 Therapeutic areas 
The top clinical areas for nurse supplementary prescribing are very similar for 
primary and secondary care, with asthma, diabetes, COPD and heart failure all 
appearing in the top five clinical areas (Table 10). Respiratory medicine,275-278 
diabetes279 and heart failure280 281 are all clinical areas where specialist nursing input 
has been long established.  
Other clinical areas selected for nurse SP in primary care include areas where nurse-
led clinics are already taking place, such as family planning services,282 283 minor 
injuries services284 and smoking cessation clinics.285 286  
Similarly, nurses in secondary care have developed specialist roles, such as in 
accident and emergency medicine,287 palliative care288 pain teams289 and 
anticoagulation,290 so it is not surprising to see these clinical areas in the results. 
Therefore there is a lot of scope for nurses specializing in these areas to become 
supplementary prescribers.  
 
The fact that the most common therapeutic areas are the same for primary and 
secondary care reflects that nurses skills as prescribers are well targeted at chronic 
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disease areas, where drug therapy choices can follow national guidelines, and where 
polypharmacy is not such an issue. As discussed in the introduction (p28) concerns 
have been raised by nurses themselves,28 the medical profession,16 and amongst 
descriptive research, upon the pharmacological knowledge base of nurses.25 27 It 
would therefore seem appropriate that different healthcare professionals’ prescribing 
skills should be targeted at the most appropriate areas. For secondary care, nurses and 
pharmacists have already developed their own prescribing “niches” which are 
accepted by other health care professionals.  
Within primary care, the General Medical Services (GMS) contract for general 
practitioners260 may well have also influenced the top 5 clinical areas that nurse 
supplementary prescribers are currently working within. These clinical areas are also 
subject to detailed guidance published over the past few years in the form of NSFs261- 
262 and specialist guidelines.263-265 This makes these clinical areas very suitable for 
nurse supplementary prescribing in primary and secondary care, as the clinical 
management plans can refer to these national guidelines.    
Table 3 indicates that within primary care, nurses attached to individual GP practices 
are most commonly taking up SP, which may be due to more support and 
encouragement for them to take this role on in comparison to non-practice based 
nurses that work on their own in walk-in centres and schools.269  
 
5.2.2.1.8 Implementation of pharmacist supplementary prescribing 
Development of a standardized competency framework for pharmacists once they 
have qualified to practice, has only recently been developed.291 Although this will 
standardize the skills of e.g. senior clinical pharmacists from Trust to Trust, it will not 
differentiate the pharmacists who are supplementary prescribers. 
Currently, in most hospitals there is no differentiation between the skills necessary to 
practice as a clinical pharmacist versus a senior clinical pharmacist, making it difficult 
for doctors to be able to understand the knowledge and competency of different 
pharmacists when requesting advice. In 2004, the Government brought in a new 
single pay system for the NHS, entitled “Agenda for Change”.292 It applies to all 
directly employed NHS staff with the exception of doctors, dentists and some very 
senior managers. The remit of “Agenda for Change” was to evaluate all jobs within 
the NHS to ensure that staff was being paid at an appropriate rate for their services, to 
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harmonise terms and conditions and to also introduce a Knowledge and Skills 
Framework (KSF) that would allow progression and development of staff via annual 
review of performance. 
Although “Agenda for Change” was supposed to produce standardization of skills and 
pay for e.g. basic grade pharmacists versus senior clinical pharmacists, anecdotally, 
there has been much disappointment in the implementation of the system which has 
led to disharmony of the grading system from Trust to Trust.  
The development of non-medical prescribing might compound doctors’ confusion 
(and other health care professionals) when trying to distinguish among the skills of 
various pharmacists.  Published research involving nurse supplementary prescribers 
has already suggested that this development has caused such confusion. 6  
Community pharmacists will also have difficulty understanding which health care 
professional has which type of prescribing rights when presented with a prescription.  
The development of supplementary prescribing will also cause confusion to the 
general public, as some community pharmacies will have pharmacists that can 
prescribe medicines and others will not. Therefore it is important that the general 
public is well informed about this development. 
 
5.2.2.1.9 Recruitment of Designated Medical Practitioners (DMPs). 
Although both primary and secondary care trust respondents rated time commitment 
and workload as the two most important factors affecting recruitment of DMPs, 
primary care also highlighted the lack of funding for the role. Indeed another study 
has found that general practitioners that have been involved in supervising nurse 
prescribers had done so due to initial enthusiasm for enabling nurses to prescribe. 
However the doctors involved in the study did comment that there was a strong 
feeling that further involvement in supervision needs to take into account doctors’ 
time involved in doing so and also needed to address the lack of financial 
remuneration, especially if doctors are to be involved in supervising nurses and other 
health care professionals who are not closely associated with a GP or hospital 
consultant.293  For secondary care, this is not such an issue as all doctors are 
employees of the NHS. Also in the majority of cases, it will also help their own 
clinical area as well, by releasing the doctors’ time to deal with more complex cases, 
and improving access to services for patients. 
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For primary care, GPs receive payment individually based on the services they offer. 
To supervise a supplementary prescribing trainee, the GP may expect to receive 
payment for it, unless there is a clear business case presented to his or her practice, 
outlining the benefits that the service will provide.  
This may make it difficult for those nurses and pharmacists who are not employees of 
a practice to recruit a DMP to supervise their training, which has also been suggested 
elsewhere.293 
 Anecdotal reports from practice support this theory as they suggest that it does seem 
to be more difficult for community pharmacists to find a mentor to supervise their 
training compared to PCT and hospital pharmacists. The reason for this increased 
difficulty being that the GPs thought they ought to be paid to be a mentor, particularly 
if the pharmacist works in a different location to them.294 
 
When asked whether recruitment of DMPs would be more difficult for pharmacists 
rather than nurses, the majority of chief pharmacists disagreed with this statement, but 
the majority of primary care trust pharmacists agreed with it. Other than the reasons 
outlined above, in primary care, pharmacists also have less day to day contact with 
doctors than pharmacists in secondary care, which may mean that GPs do not fully 
understand the skills that pharmacists have, and therefore do not see the potential for 
development of pharmacist prescribing services. Upon examination of their reasoning,  
reasons such as “GPs do not understand a pharmacist’s skills/ do not have an 
established relationship with them”, “Pharmacists are viewed as being business 
focused/ non-NHS” and “pharmacists are seen as a threat” certainly illustrate the need 
for pharmacists in primary care/community pharmacy to develop closer working 
relationships with their local GPs to overcome these barriers. 
Speculation upon why recruitment of DMPs may present difficulties may not have 
been necessary if I had undertaken additional qualitative research alongside this study. 
By interviewing doctors in primary and secondary care about whether they would be 
happy to become a DMP more insight may have been established. 
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5.2.2.1.10 Commissioning of primary care supplementary prescribing services 
The people charged with implementing supplementary prescribing for pharmacists 
and nurses in primary care varied (Table 15 and 16). For primary care this array of 
different people will inevitably lead to different PCTs having different priority levels 
for implementation of this development and also extensiveness of implementation will 
vary considerably. Implementation of pharmacist SP will also be affected by the new 
community pharmacy contract.295 The first and second tiers of the contract are termed 
essential and advanced services, and these services will be funded via a national 
agreement. However, the third tier of enhanced services, which will include 
supplementary prescribing services, will be commissioned by PCTs meaning that if a 
PCT does not see a need for a particular service, pharmacists will not get paid for 
providing it.296  
Again, it is essential for community pharmacists to make their PCTs aware of the 
services they are capable of providing and the benefits that can be derived from such 
services for the local population. 
Further reorganization of PCTs started in 2004, whereby mergers of PCTs reduced 
their number from 303 to 100-150 across England. This happened because there was a 
growing belief that many trusts are perhaps ineffective organizations, unable to 
commission acute healthcare effectively and unable to fulfill public health 
responsibilities.297 During this reorganization, the commissioning of enhanced 
services such as supplementary prescribing for pharmacists and for nurses may have 
been even more difficult until PCTs settled any structural reorganization during 2007. 
The development of supplementary prescribing services will also need to make sense 
for community pharmacies. Although many multiple pharmacy businesses have been 
able to offer services such as cholesterol testing for free, smaller, independent 
pharmacies cannot offer such services without recompense. It is extremely important 
that pharmacy businesses maintain a united front when negotiating payment for 
supplementary prescribing services from PCTs.  
 
5.2.2.1.11 Is SP a “one-size fits all” model? 
The lack of national strategy to guide which therapeutic areas are more in need of 
pharmacist supplementary prescribers’ input may mean that some patient groups may 
still have reduced access to services, and that doctors working within these areas will 
still have unmanageable workloads and waiting lists. Conversely, it may allow 
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development of services in response to need and hence may produce better services. 
At the moment it seems that the GPs’ QUOF is having an influence on the therapeutic 
areas that supplementary prescribing is being undertaken in primary care, as explained 
earlier (p284). It might therefore seem sensible for the Department of Health to 
suggest target areas within the QUOF where this role development is more urgent (in 
terms of patient needs) than others in order to encourage GPs and PCTs to develop 
and utilize non-medical prescribing. 
 
The way in which supplementary prescribing is being implemented in primary and 
secondary care suggests that one model of non-medical prescribing may not be the 
“one-size fits all” answer that had been hoped for. Primary and secondary care is very 
different in terms of funding, inter-professional relationships and methods of working, 
which means that slightly different models of non-medical prescribing may be 
needed. Due to the necessity of producing a clinical management plan for the patients’ 
condition that is being treated by the pharmacist or nurse SP, supplementary 
prescribing is more suited for the management of chronic conditions in primary care 
rather than acute conditions that are seen in secondary care.  
The rationale for implementing supplementary prescribing must also be examined. It 
has been suggested that the main driver relates to resource issues within the NHS and 
the curbing of escalating healthcare costs6 rather than improving the quality of 
prescribing in terms of overall quality of prescribing will be crucial to prove that in 
the very least, the quality is not inferior to that of medical practitioner prescribing. 
 
The development of independent prescribing may well offer more flexibility for 
secondary care non-medical prescribers, and address some of the highlighted 
difficulties that community pharmacists will face with respect to supplementary 
prescribing. Supplementary prescribing may be viewed as being a transitional 
prescribing model and of value only in appeasing the medical profession alongside 
acting as a “training” prescribing model for newly qualified non-medical prescribers 
to start prescribing with, before starting Independent Prescribing.273 Independent 
prescribing rights may be more welcomed than the supplementary prescribing model, 
and hence may potentially undermine the success of supplementary prescribing.273 
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5.2.2.2 Section C 
 
5.2.2.2.1 Comments upon individual items in the scale  
For question 19 (secondary care)/ 20 (primary care) (Appendix 4 and 5), the majority 
of primary and secondary care disagreed with the statement that there is a risk that 
SPs’ may not appreciate the signs and symptoms that the patient declares to them 
during the consultation. Open comments were made that there is a risk for ANY 
prescriber that they will not appreciate the signs and symptoms being declared to 
them by the patient. Also, clinical governance should help to prevent this sort of 
problem occurring, thorough maintenance of competency from on-going continuing 
professional development and audit. Anecdotally, the close scrutiny of non-medical 
prescribing has inadvertently led to questions being raised about the quality of 
doctors’ prescribing training, by the medical profession themselves. It can only be a 
matter of time before the medical profession also has to use more rigorous training 
and assessment of prescribing skills of their newly qualified graduates.  
For question 20 (secondary care)/ 21 (primary care) (Multiple prescribers, arising 
from the introduction of SP, will increase the prevalence of iatrogenic disease), 
several open comments were made. As long as good communication between 
prescribers was maintained then this should reduce the risk of iatrogenic disease. 
Good communication and maintenance of medical records is therefore paramount for 
patient safety. The importance of good communication between different prescribers 
when supplementary prescribing is implemented has been highlighted as a key factor 
for success by healthcare professionals6 and by the London Pharmacist 
Supplementary Prescribing project 2003-2006 report244 and the qualitative evaluation 
of supplementary prescribing report on behalf of the RPSGB.213 This problem has 
also been highlighted in nursing research regarding supplementary prescribing, where 
it has been noted that communication with respect to medication was not as good as it 
should be and would need to be improved if supplementary prescribing was going to 
work.6 It should be noted that better communication should be facilitated when level 3 
electronic prescribing is implemented.192 
Open comments were made on some questionnaires about the issues surrounding the 
importance of good communication. Comment suggested that poor communication 
may be more applicable to nurse supplementary prescribers, especially those who 
prescribe in a very narrow, specialist area, who may not be aware of the impact that 
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their drug initiation may have on concurrent conditions that the patient may have. It 
was suggested that for pharmacists, this may not be such an issue due to their broad 
knowledge of pharmacotherapeutics. There may have been some bias in the 
comments made about this statement, as the respondents were all pharmacists. 
However, in practice it appears that prescribing nurses have been cautious about their 
extended role, and are very aware of their responsibilities.122 They are therefore likely 
to produce more detailed notes in the patients’ medical notes than doctors. The main 
problem that faces all types of healthcare professional is how do you know what you 
do not know? Being aware of your limitations is also going to be crucial in order to 
maintain patient safety. 
 
For question 25 (for both primary and secondary care), that “Lack of assessment of 
applied therapeutics in the prescribing area means that the training model for SP is not 
sufficiently robust” there were some comments made that they would agree that the 
lack of assessment of applied therapeutics in the prescribing area for nurses (not 
pharmacists) meant that the supplementary prescribing model was not robust. Again, 
the comments made may be biased as the respondents were all pharmacists. However, 
as discussed in the introduction (p28) the descriptive research regarding the 
pharmacological knowledge base of community nurses has consistently suggested that 
they may have knowledge deficits.25, 27, 298  
There are some SP courses available that run as a joint course for nurses and 
pharmacists. However, it is apparent that the different professions have very different 
needs and requirements from their training. For instance, initial evaluation of the 
supplementary prescribing training for pharmacists suggests that the trainees would 
prefer there to be more training in physical examination and consultation skills within 
the courses investigated, and less basic pharmacology and pharmacokinetics.215 It 
would therefore seem appropriate for profession specific courses to be utilised rather 
than generic supplementary prescribing courses. 
If the newly developed standardised competency framework for pharmacists291 was 
tied in with the requirements for pharmacist prescribers, it will make the prescribing 
role a safer one for both the prescriber and the patient, and would tackle some of the 
concerns about lack of therapeutics assessment within the SP training. Similar 
requirements would of course, be necessary for nurse supplementary prescribers.  
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It will therefore be very important, in terms of risk management, to ensure that the 
principles of clinical governance are adhered to. Trusts need to ensure that they have 
an accountable and safe system in place, with formalised support for their non-
medical prescribers, to ensure that patient safety is maintained. Undoubtedly, 
pharmacists should have a major part in the development of such a system. 
 
Although it was most common for primary and secondary care respondents to agree 
with question 29, that DMPs ought to undertake prescribing training themselves 
before assessing the prescribing competency of other health care professionals, there 
were comments made that this, however, would not happen, and that if it were a 
requirement, there could be even less medical practitioners willing to take on the 
DMP role. A requirement such as this is likely to be unworkable. Instead new 
requirements for prescribing training would need to be introduced for the medical 
profession at undergraduate level and upon qualification, and make an assumption 
that as qualified doctors are already prescribing, they are competent. 
 
Question 33/32 (secondary care/primary care) upon conflict within the pharmacists’ 
role with respect to being a prescriber and providing impartial advice to the public, 
was included after it had been suggested that this might be an issue for pharmacists 
especially in community pharmacies where it may not be possible to separate the 
prescribing and dispensing roles. However, the majority of respondents in primary 
and secondary care disagreed with this statement, and comments were made that the 
pharmacists’ professional and ethical duties would prevent this from happening. 
 
Question 34/33 (secondary/primary care) suggested that undergraduate pharmacy 
students should qualify as supplementary prescribers upon graduation. The majority 
of secondary care respondents disagreed with this statement whereas primary care 
respondents mainly agreed with it. For those who disagreed with this statement, the 
comments suggest that it was thought to be appropriate to teach the principles and 
theory of supplementary prescribing at undergraduate level, but that there was a 
period of practice as a pharmacist required before becoming a qualified 
supplementary prescriber. However, it had been the intention of the Department of 
Health to consolidate all of the supplementary prescribing training into the 
undergraduate course over a few years, so that pharmacists would qualify upon 
 299 
graduation.299 Whether this is still the case now that supplementary and independent 
prescribing is becoming established and there is now more experience of the 
requirements of non-medical prescribers is questionable. 
It is possible that primary care had less concerns about pharmacy graduates attaining 
the SP qualification upon graduation because newly-qualified pharmacists in primary 
care have much more autonomy upon qualification, and often manage their own 
pharmacies.  
 
Both primary and secondary care respondents agreed to question 35/34 
(secondary/primary care) upon whether independent prescribing would be more 
useful than supplementary prescribing (SP). For secondary care respondents, this may 
reflect that SP is for chronic disease management and therefore the SP model does not 
suit secondary care very well because it manages acute illness.  
Primary care respondents also agreed with the statement, which may reflect that for 
community pharmacists, independent prescribing may be more suitable and fit in with 
the majority of their premises not being located within GP surgeries. It would be 
especially suitable for their role in dealing with minor ailments and minor injuries. It 
was commented that for practice pharmacists, dealing with chronic conditions, that 
supplementary prescribing would be the prescribing model of choice. 
 
5.2.2.2.2 Factor scores 
The distribution of scores for the three factors in primary and secondary care illustrate 
that both sectors have a tendency towards negativity about the supplementary 
prescribing training model. For both sectors, the concerns included the paperwork and 
the clinical management plan that needs to be developed. These concerns have also 
been raised other studies. A questionnaire study of pharmacists that had completed 
supplementary prescribing training at Kings College London and Homerton College 
Cambridge found that half of the respondents anticipated problems in obtaining 
workable clinical management plans.215 A qualitative study involving interviews with 
pharmacists before and after supplementary prescribing training also found that in 
practice producing clinical management plans was very time-consuming.216 The 
qualitative evaluation of supplementary prescribing on behalf of the RPSGB also 
found that specifically within secondary care it was becoming clear that CMPs were 
not necessarily working in practice, as the research team found that in some secondary 
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care settings, they did not use CMPs at all,213 which is of course, illegal. So this 
evidence supports the concerns that chief pharmacists and primary care trust 
pharmacists had in this survey about the unworkable paperwork system for this model 
of prescribing.  
Another concern that secondary care had about the training model for supplementary 
prescribing were how reassessment of on-going competency of the supplementary 
prescriber would take place. It would seems that concerns regarding competency 
would be well placed with regards to nurses, as a recent survey of nurse 
supplementary prescribers found that 32% (n=277) of respondents to a questionnaire 
were unable to access continuing professional development.127 The National 
Prescribing Centre have developed a comprehensive competency framework for 
pharmacist supplementary prescribers in 2003, so as long as the pharmacist has 
support from their employer to allow them to have the time for CPD, there is a 
supporting framework for them to refer to in order to self-assess their competence.107 
Also, suggestions have been made that pharmacists are not allowed to remain 
qualified as supplementary prescribers if they have not practised for 2 years,213 in 
order to add a safety-net for the patient. However, this has not as yet been made a 
requirement by the RPSGB. 
 
Primary care had the same concerns over the paperwork involved but also had 
concerns over the lack of clinical assessment in the SP training and the risk of 
increased prevalence of iatrogenic disease due to poor communication between 
prescribers. It is likely that these issues are of more concern to primary care because 
there is less opportunity for community pharmacists to undertake further postgraduate 
clinical training in the form of clinical diplomas, whereas in secondary care, it has 
become embedded within the development of pharmacists to become senior clinical 
pharmacists. Working within a team of pharmacists in secondary care also allows for 
learning from colleagues in formal lunchtime teaching sessions as well as informal 
discussions with more experienced colleagues. 
Poor communication between different healthcare professionals is also likely to be of 
more concern to primary care pharmacists as they do not work as closely with doctors 
and nurses as secondary care pharmacists do. Within secondary care, ward 
pharmacists develop close working relationships with these professionals as they 
advise them every day when they visit the wards. They also have free access to the 
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patients’ medical notes, which of course, community pharmacists do not. It is 
therefore unsurprising that the primary care sector should have these understandable 
concerns. 
 
Both sectors were however, positive about the implementation of supplementary 
prescribing, and believed that pharmacists wanted to take this role on. People who 
scored highly on factor 1 (secondary care) or factor 3 (primary care) either did not 
perceive SP to require much effort on their part, or, if they did, that the effort was 
worth it.  
Therefore it would appear that although the profession has concerns about the training 
model and competency of supplementary prescribers once qualified (in terms of the 
lack of clinical assessment within the training programme and prescribers not 
understanding the significance of symptoms that are declared to them during the 
consultation), there is an understanding of the importance of this development, and 
that it needs to be taken forward within the constraints presented. 
A small survey of community pharmacists’ views upon supplementary prescribing 
would seem to support this finding of positivity about the implementation of 
supplementary prescribing. The survey found that a large majority wanted to become 
supplementary prescribers although only a few of them were currently in training for 
the role. Supplementary prescribing was being viewed very positively in terms of 
increased use of clinical knowledge, job satisfaction, responsibility and patient 
benefit.300 
It appears that early optimism for pharmacist supplementary prescribing has not 
converted into large numbers of pharmacists qualifying as supplementary prescribers. 
In 2002 when it was announced that new powers for pharmacists and nurses to 
become prescribers, the National Prescribing Centre (NPC) carried out a preliminary 
baseline survey of all PCTs in England to help identify early NHS thinking on new 
prescribing roles. At this stage, 71% of PCTs across England were expecting some 
pharmacists in their area to become prescribers by 2005.301 The survey that was 
undertaken during this research study found that by 2004, this percentage had 
decreased to 56%. In 2002, the Government announced that it expected that there 
would be 1,000 pharmacists trained as supplementary prescribers by the end of 
2004302 In reality this figure was only reached in November 2006 when there were 
1088 pharmacists qualified as supplementary prescribers. These figures perhaps 
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reflect the practical problems there have been with the supplementary prescribing 
model and also with its implementation. 
Alongside these practical issues, there are also issues regarding acceptance of this 
extended role by the medical profession. Recent research is now suggesting that 
although GPs still question community pharmacists’ motivation for prescribing and 
whether they will be compromised by commercial concerns, they are selectively 
accepting some aspects of pharmacist supplementary prescribing.10 It appears from 
this research that doctors are exerting their control over supplementary prescribing by 
defining the areas where non-medical prescribers might operate, so that they are 
working in therapeutic areas where there are clear treatment guidelines that can be 
followed.10 However, with the advent of IP, the medical profession is not going to be 
able to have controls over what the non-medical prescribers do and will be able to 
merely accept the practice and embrace it within their day to day working pattern or 
shun the development. The more experience develops with non-medical prescribing, 
the more it will be accepted into normal practice both by the medical profession and 
patients. 
   
5.2.2.2.3 Exploring relationships between the factors and the respondents   
The results suggest that as respondents had more experience of non-medical 
prescribing within their Trust (such as pharmacists writing discharge prescriptions) 
they were less likely to have concerns over the SP training model (see p176). 
Therefore the concerns that respondents had about training may not turn out to be an 
issue in practice.  
 
5.2.2.2.4 Reflection on findings in an international context 
On the basis of the UK experience, consideration should be given to the introduction 
of prescribing into the education programmes of pharmacists at an early stage if the 
supplementary prescribing model is to be developed in other countries. Where 
specialisation exists, for example the hospital pharmacy specialisation programmes in 
France and Spain, training in prescribing in secondary care could be included 
relatively easily. This issue should be discussed on a wider level, and perhaps 
European initiatives such as the Bologna Agreement could be used as a means of 
introducing prescribing practice into the undergraduate pharmacy curriculum. 
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5.2.3 (3) Patients’ views and opinions of pharmacists and nurses as independent 
prescribers 
 
5.2.3.1 Non-medical prescribing generally 
 
5.2.3.1.1 Benefits 
The results of this study do confirm that the benefits of the introduction of non-
medical prescribing are apparent to the participants. They can see that not all patients 
actually need to see a doctor for every condition they have, and that the doctors 
workload needs prioritising so that they see the more complex cases. They can also 
see the benefits in terms of it using the full potential of healthcare professionals,  
increasing the accessibility to healthcare for the public and decreasing the pressure on 
doctors, which concurs with findings from Luker et al and Brooks et al about nurse 
prescribing from a limited formulary.115, 117 
 
5.2.3.1.2 Controls- Knowledge, Communication and Autonomy 
There are also controls that the participants thought were necessary regardless of the 
type of healthcare professional that was prescribing. The healthcare professional 
should be very knowledgeable, and they did recognise the level of knowledge that 
nurses and pharmacists had. They also recognised how important training would be 
for individuals to take on this extended role and they wanted to ensure that individuals 
were very experienced as well. Patients that were interviewed by Luker et al who had 
experienced nurse prescribing from a limited formulary also thought that nurses that 
were prescribing had to be suitably trained and experienced.115 
They also recognised that communication between healthcare professionals was going 
to be very important to avoid any errors occurring and that it was very important that 
the individuals could refer the patient to the appropriate professional if they needed to, 
and indeed knew when they needed to refer patients as well.  
However, even with these controls in place, the participants had an assumption that 
the patients’ doctor would be closely supervising the prescribing that was being done 
by the non-medical prescriber. It is therefore not quite clear to them that the non-
medical prescriber will be autonomous and independent from the doctor, and although 
the doctor can certainly question the non-medical prescribers reasoning for making 
their decisions, they will not be closely supervising every move they make. These 
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findings are consistent with the findings of Berry et al118 who also found a sub-section 
of their sample who wanted closer supervision of their medical care and either 
preferred to see a doctor rather than a nurse prescriber, or wanted to see a doctor at 
regular intervals. 
 
5.2.3.1.3 Concerns- the model and diagnosis 
The participants also had concerns about the independent prescribing model. Due to 
their poor understanding of the training and knowledge of pharmacists and nurses, 
they did not feel comfortable with them dealing with anything other than very minor 
ailments and conditions, which would be a waste of specialists’ expertise. The level 
that they believe is appropriate for non-medical prescribers to work at is much less 
than what is expected from the professions themselves. 
The participants also had doubts over the ability of the nurses and pharmacists to 
diagnose conditions. This stems from their beliefs that the nurses and pharmacists do 
not have sufficient training to do this and they have concerns over them 
misdiagnosing conditions. These concerns may be appropriate from members of the 
public who do not know the detail of the professionals’ training. As long as the 
professional is working within their specialist area and has plenty of support, the risk 
of misdiagnosis would be minimal. Any prescriber is at risk of misdiagnosing 
conditions, so there will always be an element of risk. In order to relieve concerns that 
there are amongst the public about this, education and promotion is needed so that 
they understand the level of training non-medical prescribers undergo. 
A lot of their other concerns are derived from the issue of change and acceptance of 
such a large change in healthcare provision. This was especially apparent for older 
people in the group. -Younger people also thought that older people would not like 
the changes.  Participants coveted the traditional doctor model. Doctors have a very 
high status (higher than nurses and pharmacists) and are very well respected. Some 
people thought that the only people that would accept and use the new system were 
those who already had a poor service from their GP and therefore were happy to 
accept a “second-class” system. 
 
5.2.3.1.4 History of relationship 
For both nurses and pharmacists the importance of the history of the relationship 
between the healthcare professional and the patient was emphasized, however for 
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nurses it was discussed in terms of that relationship already being established and for 
pharmacists it was in terms of the relationship needing to be developed in order to 
promote trust. 
For nurses, the participants trusted them as they had already consulted them about 
healthcare issues and received NHS care from them. However, for pharmacists the 
participants commented that they do not have this established relationship and they 
also thought that for community pharmacists this relationship was even further 
undeveloped due to potential bias that comes from also being businessmen. Therefore 
again, this shows that nurses already have an advantage when compared to 
pharmacists in the public accepting them as an independent prescribers. 
 
5.2.3.1.5 Importance of trust 
Although the participants discussed generally how important it was to trust the 
healthcare professional you were consulting for pharmacists there were some positive 
comments made to support some relationships the participants already have with their 
pharmacist as well as some negative comments made that they were not certain that 
they could trust a pharmacist independent prescriber. Therefore there was some 
uncertainty about trusting pharmacists whereas the issue of trust was only raised very 
generally by one participant discussing nurse prescribing. 
Again this highlights that pharmacists still have some way to go when convincing the 
public of their ability to be independent prescribers. 
 
5.2.3.2 Nurses vs Pharmacists 
 
5.2.3.2.1 Opinions of nurses as prescribers 
Nurses have a definite advantage over pharmacists when it comes to the public 
accepting them as prescribers. Nurses are seen as having a higher status than 
pharmacists, and are viewed extremely positively by the public. They are thought of 
as being a central figure in a persons’ healthcare when compared to doctors. It was 
also perceived that they “guide” junior doctors in secondary care when they start their 
new jobs.  
When participants discussed nurses being independent prescribers, their discussions 
seemed to be based upon how they perceived nurses and what they felt about them on 
a personal level. The public are very comfortable with nurses, and have a much more 
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established relationship with them. This relationship leads to the public trusting them. 
The participants had a lot of sympathy for nurses and viewed them as being a very 
caring and devoted profession. One participant commented when discussing the 
extension of prescribing rights to nurses that “it would be nice for them”. The public 
want them to be happier in their role and to feel that they are using their skills more 
extensively. This perception may be fuelled by the media portraying nurses as the 
underdogs, who work very hard for little reward. 
 
This support and confidence in nurses as prescribers has also been reported by other 
researchers who have evaluated patients’ views of nurse prescribing from the nurse 
practitioners formulary and the extended formulary.115, 117- 118 
Part of this comfort that the public have with nurses also stems from the perception 
that nurses are easier to speak to and have more time to listen to patients,303-306 and it 
has been shown that having more time to speak to patients (i.e. longer consultation 
times) leads to greater patient satisfaction.307 It has been noted that nurses have a 
particular ability to form warm and friendly relationships with patients,308 even more 
so than with general practitioners. A qualitative study of stakeholders from one NHS 
trust has also identified that the close patient contact that nurses have would benefit 
them in relation to prescribing.23 
 The reasoning for their close, friendly relationship with patients has been attributed to 
the nurses having an “equal social footing” with the patient.309 This lack of social 
distance between nurses and patients has been found to be highly valued by women 
especially.305 Drury et al cite the relative status of doctors and nurses in society as the 
reason why some patients find it easier to relate to the nurse rather than the doctor.303 
The vast majority of nurses are females (89.24% 2006-0730) and qualities that have 
been attributed to “femaleness” (caring, gentleness, nurturing and warmth) are 
attributes that patients value in a doctor.310 
A qualitative evaluation of the impact of nurse prescribing in the community upon 
patients found that patients valued nurses for both their accessibility and 
approachability, which led them to discuss health issues which would not otherwise 
have been brought to the attention of the general practitioner.116  
The participants recognised that nurses already prescribed under certain 
circumstances and had experienced those running clinics. Even if the nurse was not 
actually signing the prescriptions they recognised that they had already been going 
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thorough the motions. Hence the extension of the nurses’ role from a practitioner who 
undertakes consultations, to a practitioner who consults and prescribes is not very 
remarkable in the eyes of a patient, as the nurse consultation is something that they 
are already extremely comfortable with. This is a big advantage for nurses. For 
pharmacists this recognition does not exist- even though supplementary prescribing 
has been used by a minority of pharmacists to prescribe since 2004 it has not reached 
the public psyche yet.  
The participants understood that the role of the nurse was very much under 
development and hoped that they would get more job satisfaction from this extension 
of their prescribing rights, as it would “be nice for them”. Importantly, it would 
appear that nurses therefore have the support of the public already, which pharmacists 
in community practice, do not. 
 
5.2.3.2.2 Negative opinions of nurses 
-The only negative points made about nurses were that the respondents felt they 
currently have a subordinate role where they are always being supervised and do not 
necessarily take on responsibility in their role. They also felt that the nurses had 
inferior drug knowledge compared to doctors and pharmacists, which has also been an 
issue raised by patients in the research undertaken by Berry et al118 as well as the 
nursing profession themselves and the medical profession (discussed in more detail on 
page 28). However, negative comments about nurses were made infrequently 
compared to the many positive comments made. 
 
5.2.3.3 Opinion of pharmacists as prescribers- Intrinsic Barriers 
 
This expression of feeling towards nurses was not expressed by participants towards 
pharmacists. The participants did not seem to have such a “close” relationship with 
pharmacists and therefore seemed to be far more cautious and even analytical about 
the finer detail of how the development would work than when compared to nurses. 
 
Pharmacists were deemed to have an inferior status to nurses and doctors, were 
viewed as being “non-NHS” due to their community pharmacy business ties, but were 
seen as having better drug knowledge than nurses. Pharmacists were viewed as being 
inferior to doctors in terms of their knowledge and training and their status. These 
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findings are corroborated by other research which has also shown the poor perception 
that the public have of pharmacists in the health professional hierarchy. Salter and 
colleagues reported of many examples where patients “call on the higher authority of 
the doctor” as a means to challenge the advice given by the pharmacist.311 
This is a key factor in the success of pharmacist prescribing. The public need to be 
educated as to the knowledge that pharmacists have in order for them to trust 
pharmacists more. The RPSGB should produce such an educational campaign for the 
public in order to highlight the pharmacists’ knowledge and skills. 
 
The low professional status of pharmacists is a view commonly held by other health 
professions as well. In the past, pharmacists enjoyed a high status because of their 
understanding of an exclusive field of knowledge, subsequently, pharmacists 
appeared to become overqualified for their roles and “overeducated” distributors of 
medicines.312 However, more recently, with the role extension into more clinical 
activities, there will be a positive shift in the status of pharmacists once that patients 
recognise their more demanding role.  -A minority of the participants in this research 
did concede that pharmacists may have the same or superior knowledge to doctors in 
terms of their knowledge of drugs. 
 
The big difference between how participants felt about pharmacists and nurses 
becoming prescribers was that when participants discussed pharmacists as prescribers, 
they often discussed the barriers that were present for pharmacists. 
 
5.2.3.3.1 Physical Examination 
Some participants did not want pharmacists to undertake physical examination as part 
of their prescribing role and this is because pharmacists do not currently have a 
“hands on role” in their traditional work. This is a big change for patients to accept 
pharmacists physically examining them. At no point did any participants say this 
about nurses because nurses already physically examine patients in their current role. 
However, for some participants this change to a pharmacists’ role was one step too far 
as they have never seen pharmacists have such a “hands on” role in the past. 
Again, the developing role of the pharmacist as a prescriber and as a member of the 
healthcare team needs to be highlighted to the public by an educational campaign by 
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the RPSGB. It needs to highlight that as a prescriber, the pharmacist will need to 
undertake physical examination when necessary.  
 
5.2.3.3.2 Image 
Pharmacists also have to fight a negative view of their image, which is not widely 
held, but some people do still consider them to be the person in the white coat hiding 
in the dispensary, popping out to sell some photos. These views stem from a lack of 
understanding of the pharmacists role and training they undertake. Pharmacists are not 
viewed as being a healthcare provider by some people. This view can be hard to 
dispel when it is also a view held by some general practitioners as well. An editorial 
in the British Medical Journal313 has recently highlighted to its readers the 
unfavourable impact upon patient outcomes of community pharmacists’ interventions 
in two studies that were published that week by Salter311 and by Holland.314 This 
editorial represented a rational and critical discussion of the methodology used, and 
suggests that the agenda for research into the impact of pharmacists on health should 
be refined.313 
A qualitative study sought to explore the barriers between pharmacists and GPs in 
relation to closer interprofessional working and the extension of prescribing rights to 
pharmacists. This study found that the “shopkeeper” image of community pharmacy 
emerged as the super ordinate theme, with subthemes of access, hierarchy and 
awareness. The shopkeeper image and conflict between business and health care 
permeated the GPs discussions and accounted for their concerns regarding the 
extension of prescribing rights to community pharmacists and involvement in 
extended services.315 –Therefore this opinion is also held by doctors themselves which 
has a huge influence upon the public as they hold doctors with such high regard. How 
can pharmacists redeem themselves if the doctors themselves have these views as 
well? 
It is interesting that negative comments about the nurses’ image were not made by 
participants. –This reinforces the high regard with which they are held by the public. 
 
5.2.3.3.3 Training 
The lack of understanding that some participants illustrated when discussing the 
training that pharmacists have does not help to dispel the intrinsic barriers that some 
people hold. Some participants recognised how important it was that the public 
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understood the training and qualifications that pharmacists have in order to gain their 
confidence and acceptance of pharmacists as prescribers. It has also been suggested in 
medical literature that if the Department of Health is to provide pharmacists with a 
more expansive role in public health in the UK, that a campaign is needed to educate 
the public and the medical community about the harms of inappropriate use of 
medication and how pharmacists can be a potential resource for patients who take 
medicines.313  
In May 2003 “Health Which?” surveyed >1,500 people across Great Britain for their 
views and experiences of community pharmacy services (the methodology used is 
unclear in the publication).316 They found that only 11% of pharmacy users surveyed 
had asked their pharmacist to help diagnose a medical problem or consulted a 
pharmacist about the need to see a doctor in the last two years. When the respondents 
were asked about their thoughts on supplementary prescribing, over a third was not 
keen on the idea. It appeared that patients regularly taking medicines were more 
resistant to the idea, with 41% not liking the idea at all. The reports authors suggest 
that this means that the Government has some way to go to convince the public that 
pharmacists are able to fulfil part of the role traditionally performed by GPs. Although 
surveys such as this may have less rigour than an academic survey, it does suggest 
that an educational campaign is necessary if the public are to accept prescribing by 
pharmacists on the high street. 
The model of the pharmaceutical care practitioner317 could be used as a strategy to 
increase the publics’ exposure to pharmacists’ working in primary care, reviewing 
medications and in a prescribing role as opposed to the traditional dispensing role.313 
As community pharmacists start to do more Medication Usage Reviews (MURs), this 
will also help the public start to accept the pharmacists’ role as more than just a 
glorified dispenser. It is however, noteworthy that none of the patients that were 
interviewed during this research had experienced a MUR. 
It would be even more useful to the patient and the general practitioner if all 
community pharmacists had full access to the patients’ medical notes so that a full 
clinical review of medication could take place.  
Although for nurses there was some comments made regarding their drug knowledge 
and whether it was sufficient to prescribe, (as discussed in the introduction p28) the 
participants did not seem to comment about their background training in a negative 
manner or suggest that lack of understanding of their training would form a barrier in 
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the implementation of nurse independent prescribing. This might be because the 
participants have a greater trust and familiarity with nurses in the first place and 
therefore their background training is not a concern to them.  
 
5.2.3.3.4 Opinion of pharmacists as prescribers- Extrinsic Barriers 
 
5.2.3.4.1 Facilities 
Community pharmacists in particular cause great concern to the participants with 
regards to holding prescribing clinics within their pharmacies. Participants had 
concerns about the level of privacy that would be provided to them, and the 
participants wanted to ensure that the clinics were held in a clean, spacious “clinical 
environment” –like a GP surgery. Participants were dubious whether all community 
pharmacies could provide such surroundings. This highlights the importance of image 
and that if a facility does not look clean, tidy and professional the public will not use 
it. 
The issue of community pharmacies having enough space to run prescribing clinics 
has been raised previously.318 Community pharmacies would need to have a 
consulting room facility if they were going to run their clinic within the pharmacy 
premises, and being able to create such a facility may be one of the biggest hurdles for 
some community pharmacies, when you consider the costs and finding the space to do 
this.318 
 
 
5.2.3.4.2 Professionalism 
Alongside the barriers mentioned above, participants also specifically mentioned for 
pharmacists that both the pharmacist and their clinic needed to be professional. This 
was not mentioned for nurses. This suggests that the participants had not always 
experienced professionalism from pharmacists they had come across in the past (or 
their premises) and hence did not necessarily trust the profession. For nurses, the 
participants inferred that they had no concerns about their professionalism as they did 
not mention how important this was in the context of nurses at all. 
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Another big difference found in participants’ opinions of nurses and pharmacists 
being independent prescribers was that participants undertook much more in depth 
consideration of risk management issues with pharmacists compared to nurses.  
 
5.2.3.4.3 Clinical Governance 
Although many of the issues regarding clinical governance are fairly generic in terms 
of recognising poor performance and monitoring, participants did have the opinion 
that it may be more difficult for clinical governance frameworks to flag up poor 
performance in community pharmacy, as the pharmacists tend to work in isolation. 
For comparison, in the fifth report of the Shipman Inquiry, the issue of GPs working 
in single-handed practices was considered, and it found that there was no good 
evidence that the clinical performance of single-handed GPs was inferior to that of 
their colleagues in group practice.319 It was also found that there is a considerable 
body of evidence to suggest that patients like single-handed or small practices. It has 
been found that smaller practices were regarded as being more accessible and 
achieved higher levels of patient satisfaction.319 There is other evidence suggesting 
that continuity of care leads to high levels of patient satisfaction. The Audit 
Commission Report entitled ‘A focus on general practice in England’,320 confirms that 
continuity of care tends to be better in small practices and is valued by patients.  
However, the report also outlined the disadvantages for patients stemming from a 
continuous one-to-one doctor/patient relationship. First, the patient may come to place 
unwarranted trust and confidence in the doctor. Secondly, there is a quite different 
type of problem that may be associated with continuity of care. This is the danger of 
overlooking a disease of insidious onset, where the doctor sees the patient regularly 
and fails to notice and take heed of gradually developing signs. Thirdly, patients who 
repeatedly see the same doctor and no other have no experience against which to 
compare their consultations. Fourth, patients do not have any ‘yardstick’ by which to 
measure the competence of their GP, if they do not see how their health and illnesses 
are managed by other doctors.319 
Problems can also arise where the less good doctors are in single-handed practice; the 
lack of peer contact can mean that they are unaware that their clinical and managerial 
standards are slipping. Also there are issues regarding clinical governance where 
some activities such as review of prescribing data and significant event review can 
only operate effectively within a group. The numbers of single-handed practices are in 
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decline and reasoning for this includes poor working infrastructure, premises, 
management, computerisation and recruitment arrangements.319 
It was concluded that although there were problems with single-handed practices, they 
should still be supported and encouraged. It was suggested that more should be asked 
of them in terms of group activity and mutual supervision.319 
It could therefore be concluded that pharmacists working alone in community 
pharmacies should also not be discouraged from running single-handed prescribing 
“practices” either, but should be mindful of the problems that can arise from such 
practice. They should therefore develop their own links with other local prescribers to 
support their own practice and should invite scrutiny of their practice from an external 
professional to support the clinical governance process at their practice as well. 
Having these processes in place will help to ease the anxieties that the public have 
because community pharmacy is not part of an NHS organisation with the close at 
hand support. 
This issue of clinical governance was not brought up when discussing nurses as 
prescribers at all by the participants. This may indicate the higher level of trust that 
participants have with nurses compared to pharmacists and also the fact that the 
majority of nurses will run their prescribing clinics within NHS organisations. 
 
5.2.3.4.4 Importance of monitoring 
A couple of participants raised the issue of pharmacists properly monitoring the on-
going care of the patient. This was raised because the public are used to seeing 
community pharmacists recommending products to patients without undertaking any 
on-going monitoring and there was some concern that this was going to be the case 
for pharmacist prescribing. This highlights another area where public education is 
necessary. 
Again, this issue was not raised for nurse prescribing. This may well be because 
nurses running clinics already undertake on-going monitoring of patients and 
therefore was not a concern for participants. 
 
5.2.3.4.5 Negativity about access to medical records  
This was another issue raised that was only discussed with respect to pharmacists. 
One participant was concerned about pharmacists having access to more sensitive 
aspects of peoples’ medical history but did concede that this would not make for a 
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safe prescribing system. An aspect of access to records that particularly concerned 
some participants was access within community pharmacies due to them being 
viewed as “non-NHS” with non-NHS staff that may not be held to the same data 
protection regulations. It is recognised that the issue of who should have access to 
highly sensitive information such as medical notes is of great concern to the public.316 
There have been high-profile leaks of sensitive information recently (e.g. Two 
compact disks containing personal details of 25 million people were lost by Her 
Majesty Revenue and Customs in October 2007321), and therefore the public are very 
sceptical of how secure sensitive information on computer systems is. This level of 
scepticism has possibly been exacerbated by excessive media reporting.  However, 
this will be a crucial factor in getting the public to use pharmacists for more general 
medical care and advice. 
There were also concerns over the IT capability to run such a system at the moment. 
Again this was not an issue for participants discussing nurse prescribing as nurses 
already have access to patients’ medical records and therefore already have a track 
record for maintaining confidentiality. Also nurses do not commonly run clinics in 
non NHS premises either so it is not considered to be an issue for nurses. 
 
5.2.3.4.6 Ethics 
Patients also questioned whether pharmacists had some kind of ethical “contract” that 
they were bound to like doctors. They did not know whether pharmacists had to 
conform to some kind of Hippocratic Oath as doctors do. This issue arose as the 
participant was concerned about his medical data being kept confidential by 
prescribing pharmacists. This again illustrates the lack of trust and lack of 
understanding that the participants had with regards to pharmacists prescribing as this 
issue did not arise with nurses. It also highlights the possible misunderstanding that 
the public have about what ethics are (as the respondent seemed more focused upon 
confidentiality issues as opposed to ethical issues) and hence another area where 
public education is necessary.  
 
5.2.3.4.7 Safety Concerns 
This was the only factor where safety was also mentioned in discussions about nurse 
prescribing as well. This is because maintenance of patient safety is paramount. One 
participant generally mentioned that anyone prescribing has to do so with care.  
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For pharmacists the participants had concerns about the pharmacists prescribing the 
right drug for the patient especially for more serious conditions and also about them 
having access to all the necessary information about the patient in order to prescribe 
safely. 
The participants also recognised that some safety concerns were applicable to any 
healthcare professional that was prescribing and that with experience the risk would 
be reduced. 
Therefore there are still a few concerns held by participants about the safety of the 
system specifically for pharmacist prescribers, which stems from a lack of trust in 
pharmacists abilities.  
 
5.2.3.4.8 Importance of patient experience 
One participant mentioned that the first consultation was extremely important in 
helping them decide whether they would continue to use the service. This was not 
mentioned for nurses and perhaps reflects that the participants are much more 
cautious about pharmacists being independent prescribers. 
 
5.2.3.4.9 Positive aspects for pharmacists 
For pharmacists, the accessibility of their community shops and hours they are open 
was seen as a big positive for pharmacists. Also, they valued the traditional role of the 
pharmacist. So there are good foundations for developing the role of the pharmacist. 
Some participants felt that pharmacists were capable of diagnosis, supported by 
appropriate training. This is interesting as the participants did not specifically state 
this about nurses. It might be that because the participants already trust nurses in a 
prescribing role they did not feel the need to have to specifically state that nurses are 
capable of diagnosis. 
Another benefit of community pharmacies not being linked to GP surgeries was that 
for some people, they felt empowered to look after their own healthcare and make 
their own decisions about who they see and when. At the moment the vast majority of 
nurse prescribing will be closely linked to GP practices or hospitals and there may not 
be many openings for nurse-run clinics to function within community pharmacies or 
supermarkets for instance. So this may be an advantage that community pharmacists 
have over nurses in some participants’ opinions. 
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These points highlight that the participants do not have confidence in the extension of 
this role (and even less confidence in community pharmacists in particular) to 
pharmacists and do not accept this role either. –They have lots of unanswered 
questions on how it will work in practice which they do not have with pharmacists or 
nurses that run their clinics within GP practices or hospitals. This highlights that this 
is a very big change in healthcare provision and the public do not necessarily have the 
trust or confidence in the pharmacy profession to support such a change. 
 
The only barrier that was raised to do with nurses was that for some, more 
conservative people, they did not accept or support nurse independent prescribing as 
they would still prefer to see their GP. There will always be a certain minority of 
people who prefer the status quo and do not wish to change systems etc. so this kind 
of comment is of no surprise. 
 
5.2.3.5 Pharmacist Supplementary Prescribing (SP) 
 
No negative comments were made about SP by those who had experienced it. For 
some participants the experience had enforced the view that pharmacists were capable 
of being independent prescribers and for others it had no affect on their opinion as 
they believed healthcare was headed in this direction anyway, or they were happy 
with the idea of pharmacist being independent prescribers anyway. 
Although for some, consulting a pharmacist prescriber was a novelty and a bit of a 
surprise, as the clinics were all held in NHS premises (a hospital or a GP surgery) the 
clinics were accepted because the organisation they were being held within obviously 
accepted them. So because of this, some participants felt that the experience of seeing 
a pharmacist SP did not have any impact as the consultation itself was no different to 
what they have experienced with doctors or nurses. This shows that in the future, once 
non-medical prescribing becomes established there may be a blurring of roles 
between the pharmacist, nurse and doctor in patients’ eyes and it may be difficult for 
them to understand the differences between them. 
The participants had no concerns that they were not seeing a doctor and indeed one 
participant actually saw it as a positive sign as it meant his illness was “run of the 
mill” and did not need to be seen by a doctor. This is probably peculiar to more 
serious, life-threatening diseases (this participant had gastrointestinal cancer) but is a 
 317 
patient benefit that would not be necessarily thought of by the professionals running 
the clinics. 
There were many positive comments about the SP clinics that participants had 
attended. They recognised that the SP themselves were specialist in the area that they 
were prescribing in and that they had an expert knowledge in the clinical area. They 
also appreciated that they were being monitored by the SP and valued the consistency 
of seeing the same prescriber each time for that particular problem. They felt that the 
service provided was more in depth and informative compared to what they would 
have normally received which concurs with research on a single pharmacist 
supplementary prescribing clinic undertaken by Smalley and the qualitative 
evaluation of supplementary prescribing.213, 220 Participants also acknowledged that 
the SP provided a support for them in their on-going illness. 
They also felt that they had more of a concordant consultation with the SP than they 
did with the doctor and hence felt more empowered in looking after their own 
healthcare. Smalley also found that patients at her supplementary prescribing clinic 
reported that they felt more involved in making decisions regarding their treatment 
since attending their clinic.220 This finding was also consistent with interviews held 
with patients as part of a qualitative evaluation of supplementary prescribing.213 An 
increase in patient involvement in their own healthcare is something that patient 
groups will welcome. 
Participants also recognised that it increased accessibility to healthcare and decreased 
pressure on doctors, which has also been reported by Weiss et al in patient interviews 
about pharmacist supplementary prescribing.213 
 
The participants stated that certain controls were however necessary. They stated that 
they expected the SP to be professional, they had concerns as to whether they would 
get consistent quality in the consultations of they saw a different pharmacist SP. They 
stated how important the training was, and that the SP was clearly responsible for 
their decisions. 
There was some mixed opinion over how autonomous the SP should be, with some 
wanting more close supervision of their practice than others, and some still thought 
that the doctor ought to do the initial diagnosis when it comes to independent 
prescribing. This opinion has also been voiced in a qualitative research study of the 
opinions of GP mentors and pharmacists who were about to start a supplementary 
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prescribing course. Both groups expressed concern about further extension of 
prescribing rights, particularly in relation to the role of pharmacists in diagnosis and 
independent prescribing decision making.322 Lack of adequate training, uncertainty 
over diagnosis and decision making and excessive responsibility were seen as barriers 
to the involvement of pharmacists in independent prescribing.322 
 
5.2.3.5.1 Affect of SP experience on opinions of pharmacists ability to be independent 
prescribers 
 
The participants that had not experienced SP brought up more often intrinsic barriers 
to pharmacists prescribing independently such as the issue of change and acceptance 
of the new development, negative pharmacist image and coveting the traditional 
doctor model. For those who had experienced SP, they were more aware of the 
importance of the on-going monitoring of the patient, so raised issues regarding that. 
This may be because this group had more insight to consultations with non-medical 
practitioners and had already considered “how is my on-going care going to be 
monitored?” 
Those participants who had consulted a pharmacist SP saw themselves as being more 
open to these new developments and willing to embrace change. It would appear that 
experience of consulting a pharmacist as a prescriber positively affects their opinion 
of pharmacists generally. 
 
For nurse prescribing, those who had not experienced SP were much more positive 
about nurses as prescribers, mentioning the benefits of the development, how 
knowledgeable nurses are, that they already prescribe and already have established 
relationships with nurses. Those who had experienced SP were much less vocal 
regarding positive factors about nurses as prescribers. It is possible that as nurses tend 
to be more closely associated with healthcare provision than pharmacists and are 
traditionally seen as a more caring and devoted profession participants who had not 
experienced pharmacist as prescribers were more comfortable with the idea of nurses 
prescribing for them and hence were much more vocal and positive about it. There 
was much more recognition of the nurse having a role that is currently more 
identifiable with that of a doctor, and hence the extension of this role to include 
prescribing is not such a big change for the participants to accept. Hence the 
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participants who had no experience of pharmacists as prescribers were much keener 
and hence vocal about the experience that nurses already had with regards to 
prescribing. 
When discussing the history of their relationship with nurses, the group of participants 
that had seen a pharmacist supplementary prescriber were less concerned with 
personal previous experiences and how this informs their opinions and instead were 
more focused upon the practicalities of prescribing and ensuring that the professional 
involved was capable.  
 
Therefore it would appear that SP prepares the patients for pharmacists to take on an 
extended prescribing role. It is an unthreatening introduction to pharmacists taking 
responsibility for their prescribing. It would also appear that it positively affects their 
opinions of pharmacists’ ability to be prescribers as well. However, these opinions are 
based upon a participants’ individual experience of seeing a single SP and whether 
that individual experience is transferable to other pharmacist prescribers is unclear. 
 
Overall, it is apparent from the results that pharmacists, especially those setting up 
prescribing clinics within community pharmacies, have many more barriers to deal 
with before the public will readily accept and use their prescribing services. 
Pharmacists also have a more difficult challenge in gaining public confidence in their 
prescribing skills when compared to nurses as well. This is because the public do not 
visualise pharmacists as healthcare providers at the moment. They also do not 
understand their therapeutic value and the knowledge and skills that they have. 
 
5.2.3.5.2 Differences between participants that had GI cancer and Hypertension 
 
Participants with GI cancers may not have considered the nurses’ level of knowledge 
in their traditional role as much as they are becoming more familiar with nurses 
working in more specialist areas.  
The group of participants with GI cancer may be better educated about the healthcare 
system as it might be that if you are faced with a potentially life-threatening 
condition, you may do your own research about your condition and who you would 
expect to treat you etc. It might also be that patients with GI cancer are exposed to 
nurses that are working at a much “higher level” more frequently. For example they 
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may see nurses working at consultant level and may spend more time with nurses in 
the day therapy centre if they receive intra-venous chemotherapy. Therefore they may 
have a better insight to the high level that nurses work at and therefore are less 
concerned about them being closely supervised by doctors. 
 
Generally, patients who have GI cancer may be more appreciative of pharmacists that 
they have come across in that specialist area than compared to those who have seen 
pharmacist prescribers for hypertension. This is because they may believe that cancer 
is a much more complex clinical area than hypertension. Therefore they may have 
been less interested in commenting on pharmacists’ knowledge in their traditional 
dispensing role. 
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5.3 The aims reviewed 
 
In sections 2.7.9, 2.7.11 and 2.7.13 the aims and objectives were outlined for this 
research. These aims are now reviewed. 
The aim for phase one of the research was as follows: 
 
To establish the prevalence of pharmacist “prescribing activities” within 
secondary care in the UK, & to describe in detail the provision of pharmacist 
discharge prescription transcription services (PDPTS). 
 
The findings of the research were as follows: 
 The questionnaire survey that was undertaken established that in 2001, PDPTS 
was being provided by 36% (n=49/135) of hospital pharmacy departments that 
responded, and this was the most common form of prescribing activity being 
undertaken. 
 The most common model being used to provide PDPTS involved pharmacists 
transcribing for their own wards (78%, n=38/49). 
 The number of pharmacists transcribing discharge prescriptions per hospital 
ranged from 1 to 89. (Mean=8, Mode=2, Median= 5, 25% percentile= 2, 75% 
percentile=10).  
 The majority of pharmacists wrote less than 5 prescriptions per day (n=25, 
52%),  (n=17, 35%) wrote 5-10 prescriptions per day. 
 The most common training requirement for pharmacists to start transcribing 
was an in-house training programme (n=27, 55%).  
 The majority of (pharmacy) departments do not re-assess the ability of their 
pharmacists to transcribe (n=37, 80%).  
 The majority of pharmacy departments required a medical practitioner to 
counter-sign the pharmacist written prescription (65%, n=31, 1=missing data) 
and had a formal protocol for their PDPTS (57%, n=27, 2=missing data). 
 The most common reasons for implementing PDPTS was to reduce delays in 
the discharge process (73% n=35), and decreased errors (50% n=24).  
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 Amongst pharmacy departments not providing PDPTS, the main reasons given 
for not developing PDPTS were insufficient resources (60% n=18), and 
preferentially developing other services (23% n=7).  
 
The aim was met in terms of describing the services being provided, and showed that 
PDPTS services were not being run extensively throughout those hospitals that were 
providing such services and were having minimal impact. Principles of clinical 
governance were also not being met in terms of training provision and re-assessment 
of pharmacists undertaking the service. 
 
The aim for phase two of the research was as follows: 
 
To investigate the views of chief pharmacists within secondary care and 
pharmaceutical advisors of primary care trusts in England upon the 
implementation, risks & issues surrounding supplementary prescribing.  
 
The findings of the research were as follows: 
 The questionnaire survey that was undertaken established that both sectors 
intended to implement supplementary prescribing by pharmacists by the end 
of 2005 (57%, n=55 and 56%, n=100 respectively). 
 The majority of the chief pharmacists did not believe that it would be more 
difficult to recruit designated medical practitioners (DMPs) to supervise 
supplementary prescribing training for pharmacists as opposed to nurses (67%, 
n=43), whereas the largest group of primary care trust pharmacists did think 
this would be the case (47%, n=86).  
 Within secondary care, the clinical areas in which pharmacists were intending 
to work as supplementary prescribers were those where they already had 
established roles.  
 Within primary care, the main clinical areas for pharmacists were influenced 
by those areas in the new General Medical Services (GMS) Quality and 
Outcomes Framework (QUOF) for general practitioners (GPs). 
 For both sectors, the three factors that were extracted described concerns over 
the training model for supplementary prescribing, concerns about the 
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professional competency/responsibility of the supplementary prescribers once 
trained, and positivity about the implementation of supplementary prescribing. 
 For both sectors, as trusts have more experience of supplementary prescribing 
by nurses, the respondents had less concerns about the supplementary 
prescribing training model. 
 For secondary care, as the total number of pharmacists employed within the 
Trust increases, the respondents had less concerns over the limitations of the 
supplementary prescribing training model.  
 
The aim of this research study was met as chief pharmacists and primary care trust 
pharmacists’ views upon SP were established by the survey results. It was also 
discovered that there were many more barriers to the establishment of supplementary 
prescribing within primary care than secondary care. The SP model is being used to 
legitimize non-medical prescribing within secondary care, but within primary care is 
being used to develop clinics as targeted by the GPs’ QUOF. 
 
The aim for phase three of the research was as follows: 
 
To investigate opinions of patients who have and have not experienced 
supplementary prescribing by pharmacists on the development of pharmacists 
and nurses as independent prescribers. 
 
The findings of the research were as follows: 
 Participants shared common views upon the benefits of Independent 
Prescribing (IP) and necessary controls when providing such a service 
regardless of the type of professional.  
 They also had common concerns about IP, which included doubting their 
ability to deal with more than minor conditions and their diagnostic skills. 
Concerns were based upon issues of change and acceptance where some 
participants coveted the traditional doctor model which resulted in them 
considering the IP service inferior. 
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 Nurse prescribing was more acceptable than pharmacist prescribing because 
nurses were considered to be trustworthy, caring and a devoted profession who 
are the central figure in an individuals’ healthcare, with which relationships 
are established.  
 Community pharmacists were perceived by some participants as being “non-
NHS”, not being a healthcare provider and as having a negative image. 
Practically, participants doubted the privacy of community pharmacies, 
whether they had the necessary space to provide a professional IP service and 
had clinical governance concerns. However, participants did acknowledge the 
expert drug knowledge that pharmacists have and their accessibility. 
 Participants that had experienced pharmacist SP were positive about the 
experience and it enforced views that pharmacists would be capable as IPs. 
Patients felt empowered due to increased concordance compared with doctor 
consultations. They also viewed SP pharmacists as being specialists compared 
to community pharmacists.  
 Participants that had not experienced SP tended to have more intrinsic barriers 
towards IP. 
  
The aim was met in terms of establishing views of patients upon pharmacists and 
nurses as independent prescribers, but due to saturation not being reached for the 
patient group who had experienced supplementary prescribing by pharmacists, the 
impact of this experience upon their opinions of pharmacists as independent 
prescribers is less clear.  
The study results also highlight the extra barriers that community pharmacists have 
with respect to the public accepting pharmacists as independent prescribers. The 
public do not currently visualise pharmacists as healthcare providers and do not 
understand the knowledge and skills that they have. 
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CHAPTER 6: CONCLUSION  
 
In 2001, 36% (49/135) of pharmacy departments had developed a pharmacist 
discharge prescription service. However, the services being offered tended to be 
rather ad-hoc and only available in certain wards or single directorates. Training and 
competency assessment of this pharmacist role appeared to not meet the requirements 
of clinical governance. Interpretation of requirements for medical authorisation of 
pharmacist-written prescriptions was variable. Furthermore, a substantial number of 
hospitals with a PDPTS had no formal protocol for the service.  
Literature supports the valuable patient benefits of such a service in terms of reduced 
waiting time for medicines on discharge,99,75,74,70 reduced error rates49,9,72,74, and the 
service also falls into line with the requirements of the Audit Commission report.49  
In order to extend this valuable service throughout hospitals, a workable legal model 
for this service needs to be established alongside funding, resources and skill-mix 
maximisation. The introduction of independent prescribing is the only legal model 
which will allow for this type of prescribing, but pharmacists would be somewhat 
over-qualified if this was the only type of prescribing that they undertook. Therefore a 
better use of resources would be for qualified independently prescribing pharmacists 
to not only prescribe discharge prescriptions in hospitals but also to run clinics in their 
chosen specialist areas and attend ward rounds in their area(s) as well. Alternatively, a 
separate qualification could be designed to allow pharmacists to write discharge 
prescriptions alone. This could be viewed as a “training” stage for pharmacists in 
secondary care, before they start to develop their own specialist clinics.   This will 
enable patients to gain the maximum benefit from this development in secondary care. 
  
Although the intentions of CPs and PCTPs were very similar in terms of 
implementation of supplementary prescribing, the results illustrate that there are 
significantly more barriers to its establishment within primary care, than secondary 
care settings.  
Within primary care, supplementary prescribing appears to be implemented in order 
to develop new services. However, within secondary care, the results suggest that the 
model is being used more often to legitimize services that are already being provided. 
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Nurse supplementary prescribing is taking longer to establish within secondary care, 
as this sector has less experience of nurse prescribing and because the current models 
of non-medical prescribing are less suited to the acute care environment in hospital. 
 
It would appear that although the Department of Health may feel that the training 
model and patient safeguards that have been put into place for supplementary 
prescribing are sufficient, there are still concerns within both primary and secondary 
care about the supplementary prescribing model (such as the lack of clinical 
assessment during training), professional competence and responsibility once trainees 
qualify. It is apparent that in order for supplementary prescribing to be a safe system 
for patients, pharmacists will have a central role in the development process in terms 
of risk management and the safe use of medicines. The Department of Health may 
need to provide more support for this role, showcase examples of good practice, and 
support research into the role in order to provide an evidence-base that supplementary 
prescribing is providing patients with at least an equivalent service to doctors, and is 
also increasing access to healthcare for patients, without compromising safety. 
Pharmacists also need more support in terms of infrastructure and integration into the 
healthcare team as it was apparent that there were many practical issues that needed to 
be overcome before SP could be implemented successfully. Although CPs and PCTPs 
have these concerns, overall there was a positive attitude towards supplementary 
prescribing and there was a belief that pharmacists wished to take this role on. 
 
Since this research was undertaken, it has become apparent that supplementary 
prescribing is not being taken up by pharmacists as much as was originally expected. 
The issues with the SP model being difficult to use as well as not being suitable for 
acute conditions has meant that in practice it is not very user-friendly. In practice, the 
independent prescribing model may be much more useful for both secondary care and 
community pharmacists working in isolation. In the future, supplementary prescribing 
may be viewed as a “training stage” for non-medical healthcare professionals to 
develop their prescribing and consultation skills with closer supervision before 
becoming independent prescribers. In secondary care, the writing of discharge 
prescriptions could also be used as a “training stage” in the development of the 
pharmacist as an independent prescriber. 
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With regards to the introduction of independent prescribing, the public are aware of 
the benefits of the introduction of this service and the nursing profession have support 
from the public for this role as they already have an established relationship with 
them, they trust them and because they have a good position in the hierarchical status 
of healthcare professionals. 
For pharmacists, this support from the public still needs to be developed. The public 
do not necessarily trust the profession, nor think of them as being members of the 
healthcare team. This is partly derived from them not being part of the NHS (apart 
from their contract) and also being businesses. The public are far more accepting of 
pharmacist as prescribers when they are employed by hospitals or work within GP 
practices. 
Community pharmacists in particular are suffering from image problems and the 
remedy for this is an extensive educational programme for the public in order to teach 
them about the training and knowledge that pharmacists have, the professionalism of 
the profession, the code of ethics that pharmacists are bound to, the rigorous clinical 
governance procedures that they have to adhere to and the assurance that their 
condition will be appropriately monitored by pharmacist prescribers. Public 
promotion of pharmacists’ skills will be essential to gain public confidence in IP. 
Alongside this, money needs to be invested into community pharmacies to help them 
provide appropriate clinic room facilities within their pharmacies.  
 
The other main hurdle is access to medical records. If independent prescribing is 
going to be extensively used by community pharmacies in order to provide minor 
ailment services as well as more specialist services, then access to a patients’ medical 
records is essential. Security of highly sensitive information such as this will be 
paramount if the public are to agree to community pharmacists having access to their 
records. This may well represent the main stumbling block preventing extensive use 
of extended prescribing within community pharmacy. 
 
Community pharmacy also needs to emphasize the recognised benefits that such a 
role would bring to the public and to healthcare commissioners, such as the 
accessibility of community pharmacies and that this development leads to the 
empowerment of patient choice in healthcare. 
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The evaluation of supplementary prescribing by pharmacists has shown that patients 
benefit in terms of receiving more information, having longer consultations, having a 
more concordant consultation and increased accessibility to healthcare. Patients that 
see a pharmacist supplementary prescriber also are more positive about non-medical 
prescribing and have less intrinsic barriers towards independent prescribing. 
Therefore good examples of supplementary prescribing could be used to facilitate 
public acceptance of independent prescribing. 
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CHAPTER 7: RECOMMENDATIONS 
 
From the results of this research, it is clear that there are several recommendations 
that can be made: 
 
 Central guidance from the Department of Health and tailored provision of 
training and assessment from higher education institutions should be provided 
for the specific role of pharmacists writing discharge prescriptions, as per the 
supplementary and independent prescribing models. 
 The Department of Health could suggest target areas within the QUOF where 
the role development of non-medical prescribers is more urgent (in terms of 
patient needs) than others in order to encourage GPs and PCTs to develop and 
utilize non-medical prescribing. This would help to support community 
pharmacists in particular who are finding it more difficult to develop non-
medical prescribing. 
 Doubts regarding pharmacists’ abilities to diagnose need addressing through 
education and promotional activities if independent prescribing is going to be 
fully utilised by the public. It also needs to be highlighted that patients under 
the care of a pharmacist prescriber for certain conditions will be closely and 
regularly monitored by that prescriber. Also this new development itself needs 
promoting to the public alongside the level of training and knowledge that 
pharmacist and nurse prescribers receive. Some of this promotion should be 
specifically targeted at older people to improve their acceptability of the role 
extension. 
 Communication and teamwork between different healthcare professionals is 
extremely important to maintain patient safety. It is therefore important that 
the new extension of prescribing is promoted to doctors so that they are aware 
of the development and include such prescribers in their network.  
 Primary Care Trusts could help provide a support network for prescribing 
pharmacists, in terms of helping new prescribers get into contact with 
established pharmacist prescribers, to help with CPD and clinical governance 
requirements. Examples of good practice should be highlighted to other 
pharmacist prescribers within PCTs and nationally via e-mail newsletters. 
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 The image of pharmacists, especially community pharmacists needs to be 
improved. A publicity campaign highlighting good examples of pharmacists’ 
practice and of community pharmacies with very high quality clinical facilities 
needs to be undertaken by the RPSGB. This should also emphasize the 
professionalism of pharmacists. It should also be highlighted that pharmacists 
who own their own business will not let business needs influence their practice 
and that all pharmacists are bound by a code of ethics to prevent this 
happening.  
 Clinical governance arrangements in particular need highlighting to the public 
especially with regards to prescribing clinics being held in community 
pharmacies. 
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7.1 Further research  
 
Even though pharmacists writing discharge prescriptions is becoming more 
widespread,323 it is possible that as the pharmacist becomes accustomed to this daily 
task, they may become less effective and make more mistakes if they are busy and 
being interrupted. Hence a longer-term study ought to be undertaken to establish 
whether the accuracy of the prescription that is written decreases over time. The 
pharmacist-written prescriptions ought to be compared to that written by doctors in 
order to provide evidence of which professional would be the safest to write discharge 
prescriptions for patients over a prolonged period of time. 
 
The different models of non-medical prescribing have been brought in without being 
based upon evidence from controlled studies. It is therefore apparent that evidence 
now needs to be sought in order to prove that this type of prescribing is at least as safe 
for patients as the normal care given by doctors. Therefore a clinical study would 
need to be undertaken to measure clinical outcomes, mortality and morbidity, quality 
of life, hospital readmission rates, number of prescribing errors and patient 
satisfaction. Alongside this, an economic study needs to be undertaken in order to 
investigate the cost/benefit ratio of providing such services versus standard doctor 
services.  
The study would need to be a multi-centre trial which could also assess the impact of 
this service development upon the pharmacy department, in terms of staffing and 
efficiency in order to enable hospitals that are not currently offering pharmacist-
prescribing services to introduce the optimum service model.  
Also, it needs to be established whether the introduction of non-medical prescribing is 
actually increasing accessibility to healthcare for patients, by comparing appointment 
times for patients under standard doctor care versus non-medical prescriber care.  
Qualitative work needs to be undertaken in order to establish whether patients are 
satisfied with the treatment they receive from non-medical prescribers, and how it 
compares to “traditional” care. 
Qualitative interviews with doctors would also be useful in order to establish their 
opinions of non-medical prescribing in practice and whether their role would change 
when non-medical prescribing becomes more wide-spread. 
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The other element of non-medical prescribing that needs to be investigated is whether 
the service being provided by nurses and pharmacists is equivalent in terms of 
providing a minimum level of patient care and safety which is at least equivalent to 
that provided by the traditional doctor model. Also an economic study should be 
undertaken to again look at the cost/benefit ratios of nurse versus pharmacist clinics. 
This type of study is necessary because the average pharmacist costs per hour more 
than the average nurse. The pharmacy profession can suggest that our more expensive 
services are more suitable for clinics in clinical conditions where polypharmacy exists 
and that nurses skills are better tailored at clinics where prescribing for a single 
clinical condition closely follows guidelines. Evidence is needed to prove that this is 
the case if GP practices are going to pay more for a pharmacists’ services.  
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research*** 
 
MREC Conditions of Approval. 
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• You must complete and return to the MREC the annual report form (progress of study) that is 
enclosed, and the final report form when your research is completed. (use the progress of study 
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research; 
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conduct ofthe trial. 
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You are not required to wait for confirmation from the LREC before starting your research. 
 
Local NHS Management 
The local clinician must inform his/her NHS organisation of their co-operation in the research project 
and the nature of their involvement. Care should be taken to ensure with the NHS organisation that 
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Legal and Regulatory Requirements 
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ICH GCP Compliance 
The MRECs are fully compliant with the International Conference on Harmonisation/Good Clinical 
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Yours sincerely 
 
Anne Burnley 
For Dr S Evans, Chairman. 
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MREC. Response form/ Progress of study form can be downloaded ftom the COREC website, but hard 
signed copy only may be submitted. 
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Email: liz.wriqhton@essexsha.nhs.uk 
 
 
13 October 2005 
 
Mrs Rachel Hobson 
TeacherlPractitioner Pharmacist 
University of Bath 
Pharmacy & Pharmacology Department 
Claverton Down 
BATH BA27AY 
 
 
Dear Mrs Hobson 
 
Full title of study: A qualitative analysis of patients perceptions of pharmacists as 
independent prescribers within secondary and primary care. 
 
REC reference number: 05/Q0301/39 
 
Thank you for your letter of 04 October 2005, responding to the Committee's request for 
further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Ethical review of research sites 
The Committee has designated this study as exempt from site-specific assessment (SSA. 
There is no requirement for [other] Local Research Ethics Committees to be informed or for 
site-specific assessment to be carried out at each site. 
 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully. 
 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Application- Page 11 only  24 August 2005 
Application  24 August 2005 
Investigator CV  23 August 2005 
Protocol 2 04 October 2005 
Letter from sponsor  15 August 2005 
Peer Review   
Compensation Arrangements  10 August 2005 
Interview Schedules/Topic Guides 2 04 October 2005 
Letter of invitation to participant 2 04 October 2005 
Participant Information Sheet 3 04 October 2005 
Participant Consent Form 1 23 August 2005 
Response to request for further information  04 October 2005 
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Other- Supervisor CV  01 June 2005 
Other- Expression of Interest Form (no version 
number) 
 
Other- Prescriber’s selection criteria 1 10 August 2005 
Other- Emails from Pharmacists, GPs & 
Consultant agreeing to participate 
 27 August 2005 
 
 
Research governance approval 
 
You should arrange for the R&D department at all relevant NHS care organisations to be 
notified that the research will be taking place, and provide a copy of the REC application, the 
protocol and this letter. 
All researchers and research collaborators who will be participating in the research must 
obtain final research governance approval before commencing any research procedures. 
Where a substantive contract is not held with the care organisation, it may be necessary for 
an honorary contract to be issued before approval for the research can be given. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
05/Q0301/39                                     Please quote this number on all correspondence 
 
With the Committee's best wishes for the success of this project 
 
Yours sincerely 
 
 
Hugh Bliss 
Chair 
 
 
Enclosures: Standard approval conditions 
 
Copy to: Professor Anthony Smith 
University of Bath 
Pharmacy & Pharmacology Dept 
Claverton Down 
Bath BA27AY 
 
An advisory committee to EssexStrategic Health Authority 
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Wolfson Centre 
Royal United Hospital 
BATH BA13NG 
Tel: 01225824121 
e-mail: m.perkins@bath.ac.uk 
Mrs Rachel Hobson 
Teacher/Practitioner Pharmacist 
University of Bath 
Pharmacy and Pharmacology Department 
Claverton Down 
Bath 
BA27AY 
 
 
Dear Mrs Hobson 
 
A qualitative analvsis of patients' perceptions of pharmacists as independent 
prescribers within secondary and primary care 
 
I am pleased to tell you that the above project has been approved by Bath and North 
East Somerset Primary Care Trust, subject to the conditions below, to recruit General 
Practitioners from this Trust. Please could you make it clear to the GPs that although 
the PCT has approved the study, this does not imply that the PCT will pay for their 
time to take part. BANES PCT is a member of the Pan-Bath and Swindon Primary 
Care Research Consortium. 
R&D approval is separate from ethics approval and is also essential for the conduct 
of research within NHS trusts. It is subject to the following requirements: 
 
1. It is a condition of the approval that the project is carried out according to Good 
Clinical Practice and with the guidelines of the NHS Research Govemance 
Framework (downloadable from 
 www.doh.aov.uklresearch/rd1/researchgovernancelresearchgovindex.htm). You 
have responsibility for ensuring that all participants give informed consent and that 
yourself and any co-workers adhere to the protocol agreed by the ethics committee. 
 
2. If there are any alterations to the protocol after the study has started, you must 
informe the LREC and the R&D department. 
 
3. It is my duty to remind you that as Principal Investigator that you will be required to 
provide us, at least annually, with project monitoring and outcome information. 
 
If you need any further support or information, please do not hesitate to contact me at 
the above address. 
 
Yours sincerely 
 
MARY PERKINS 
Research and Development Manger 
Cc: Rosie Rowe 
Bath and North East Somerset Primary Care Trust - Swindon Primary Care Trust 
West Wiltshire Primary Care Trust - Kennet and North Wiltshire Primary Care Trust 
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Bristol North Primary Care Trust 
Bristol South and West Primary Care Trust 
King Square House 
King Square 
Bristol 
BS2 BEE 
Tel: 0117 976 6600 
Fax: 0117 9766601 
Minicom: 0117 9002675 
Date: 21st October 2005 
 
Mrs Rachel Hobson, 
Department of Pharmacy and Pharmacology, 
University of Bath, 
Claverton Down, 
Bath, 
BA2 7AY 
 
 
Dear Mrs Hobson, 
 
A qualitative analysis of patients' perceptions of pharmacists as 
independent prescribers within secondary and primary care 
 
Thank you for your correspondence regarding the "A qualitative analysis of patients' 
perceptions of pharmacists as independent prescribers within secondary and primary care" 
research study and the subsequent information you have sent to us. 
 
We are pleased to inform you that Bristol North Primary Care Trust has approved your study. 
 
This approval is granted on the understanding that the Principal Investigator will follow the 
requirements identified in the Research Governance Framework for Health and Social Care, 
2nd edition, 2005, in particular with relation to confidentiality and data protection. Please find 
details on research governance at the Department of Health Governance website:. 
http://www.dh.gov.uk/PolicyAndGuidance/ResearchAndDevelopment/ResearchAndDevelopm
entAZ/ResearchGovernance/fs/en 
Any changes to the study protocol will need to be approved by the research ethics committee. 
Please send an amended protocol and approval letter to inform us of any changes. If any 
adverse events occur during the study, please follow the standard procedures for the 
particular PCT in which this occurs. 
 
Please note that your study is logged onto a PCT Research & Development Database 
(covering a collaborative of four PCTs). Any information stored is for internal and external 
use. Information will be used in reporting to the Department of Health and is in the public 
domain. 
We are continually assessing the impact of any research being conducted in our area, and we 
ask that you send us a copy of your final report on the project, or if your study extends over a 
year, interim annual reports. If publications arise we would also be grateful for copies. This 
will allow us to consider and share your findings with other PCTs in the Research 
Collaborative, which will enable the PCTs to improve services to our patients. 
 
We wish you well with your study and if you have any further queries, please do not hesitate 
to contact us. 
 
Yours sincerely, 
 
Mike Lacey 
Research & Development Co-ordinator 
Avon Primary Care Research Collaborative 
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Telephone: 0117 900 2686 
Fax: 0117 900 3409 
E-mail: Mike.Lacey@bristolnorth-pct.nhs.uk 
Web: http://www.apcrc.nhs.uk 
 
cc Professor Anthony Smith, Department of Pharmacy and Pharmacology, University of 
Bath 
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Swindon and Marlborough NHS Trust 
 
RESEARCH & DEVELOPMENT 
Great Western Hospital 
Marlborough Road 
Swindon SN3 6BB 
 
T: 01793 605565 
 
30th November 2005 
Mrs Rachel Hobson 
Teacher/Practitioner Pharmacist 
Pharmacy Dept 
GWH 
 
 
Dear Rachel 
 
APPROVAL OF RESEARCH PROJECT: A qualitative analysis of patient's 
perceptions of pharmacists 
 
Thank you for returning the completed R&D Project Form. As you have successfully 
obtained Trust and Ethical approval, please accept this letter as confirmation that you 
may proceed with your research project within this Trust. 
 
In accordance with the Research Governance Framework all researchers must be 
aware of their obligation to comply with the Data Protection Act and the Health & 
Safety Act. You are also required to inform the Data Protection Officer of your 
intended project prior to the start of research. 
After 6/12 months into your trial (depending on the duration of research) you will be 
asked to complete a short form in order to report progress and any changes to your 
project. Please also note that the R&D department will conduct a random audit of 
10% of all research trials/projects being conducted within the Trust each year and 
your research may be included. 
 
Please notify the R&D department when your research has been completed and of 
any resulting publications. 
 
Finally good luck with your research and please contact the R&D department again if 
you have any further queries. 
 
Thank you for your co-operation. 
 
Yours sincerely 
 
 
KATH BROWN 
Research & Development Manager 
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R&D Manager: Seott Harfield Tel: 01273 696955 ext. 7497 
E-mail: seott.harfield@bsuh.nhs.uk 
R&D Administrator: Paul Riehardson Tel 01273 696955 ext 7513 
E-mail: pauld.riehardson@bsuh.nhs.uk 
 
Brighton and Sussex NHS 
University Hospitals 
NHS Trust 
Research & Development Management Team 
Royal Sussex County Hospital 
South Point Building 
Eastern Road 
Brighton 
BN2 5BE 
REC Ref: 05/Q0301/39 
Date: 16th June 2006 
 
Mrs Rachel Hobson 
Pharmacy & Pharmacology Department 
University of Bath 
Claverton Down 
Bath 
BA2 7AY 
 
Dear Rachel 
 
RE: A qualitative analysis of patients perceptions of pharmacists as independent prescribers 
within secondary and primary care. 
 
Thank you for receipt of your completed NHS R&D Application Form for the above named study. 
I can confirm that the Trust's Research & Development Management Office have approved the study. 
Your study has been allocated the following reference: 06/062/HOB. Please quote this in all future 
correspondence. 
 
It would be appreciated if you could inform me when the study is complete. 
 
Yours sincerely, 
 
 
 
 
Paul Richardson 
Research & Development Administrator 
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Pharmaceutical input to the discharge process. 
A survey of Hospital Pharmacy Services. 
Instructions for completion: 
 
A senior clinical pharmacy manager or the pharmacist in charge of the pharmacist 
discharge service should complete this questionnaire (if you have such a service in 
place). 
 
This questionnaire should take approximately 15 to 30 minutes to complete. 
 
Please tick one box for each question unless otherwise specified. If there is 
insufficient space provided for you to answer some of the questions then continue on 
a separate piece of paper indicating the question number clearly.  (Please note the 
figures beside the tick boxes are for office use only.) 
 
All answers will be treated in the strictest confidence. When the questionnaire is 
completed please return it in the enclosed pre-paid envelope. 
 
For the purposes of this questionnaire, the following definitions are applied: 
 
Dependent prescribing- Refers to a pharmacist that has been authorised to prescribe 
certain medicines for patients whose condition has been diagnosed or assessed by an 
independent prescriber, within an agreed assessment and treatment plan1. 
 
Independent prescribing- Refers to a pharmacist who is responsible for the initial 
assessment of the patient and for devising the broad treatment plan, with the authority 
to prescribe the medicines required as part of that plan1. 
 
Transcribing- Refers to a process where a pharmacist copies a list of drugs that has 
been prescribed by a doctor from one chart to another chart or prescription. 
 
References: 
 
1.) Review of prescribing, supply and administration of medicines, Final Report 
March 1999 Department of Health. 
Section A : General Information: 
 
1.) What is your job title? (Please specify below) 
 
………………………………………………………………………………………… 
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2.) What type of hospital are you based at? 
 
 1        Teaching hospital 
 2        District General Hospital 
 3        Other (please specify) .………………………………………. 
 
3.) How many in-patient beds are there in your hospital? 
 
 
 1         100 or less  5         601-800 
 2         101-200  6         801-1000  
 3      201-400    7         1001-1500   
 4      401-600     8         greater than 1500  
 
 
4.) How many whole time equivalent pharmacists are employed at each job grade in 
your hospital? 
 
     A  ……………                     E  …………                    Other…………………… 
     B   ……………                     F  ………… 
     C   ……………                     G ………… 
     D   ……………                    Vacant positions (grade)  ………………………. 
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Section B: Pharmacist prescribing and transcribing: 
 
5.) Do you currently employ pharmacists that undertake the following activities as 
part of their role? -Tick more than one box if necessary. 
 
See instructions for completion at the beginning of the questionnaire for descriptions 
of transcribing/ dependent prescribing etc.  
 
 1       Transcribing discharge prescriptions which are then signed by the 
doctor at a later stage 
 2       Transcribing discharge prescriptions which are not then signed by the 
doctor at a later stage       
 3       Transcribing in-patient drug charts which are then signed by the 
doctor at a later stage 
 4       Transcribing in-patient charts which are not then signed by the 
                           doctor at a later stage     
 5      Transcribing patients normal medication onto in-patient drug-charts at 
pre-admission clinics which is then signed by a doctor 
 6      Transcribing patients normal medication onto in-patient drug-charts at 
pre-admission clinics which is not then signed by the doctor    
 7      Prescribing medication at pre-admission clinics according to set 
protocols  (dependent prescribing) 
 8  Prescribing discharge medication at pre-admission clinics according to 
set protocols (dependent prescribing) 
 9   Amend in-patient charts and discharge prescriptions via a prescription 
amendment policy (dependent prescribing/following agreed 
protocols) 
 10       Independent prescribing 
 11       Any other prescribing role (please provide more detail below) 
 
……………………………………………………………………………….. 
……………………………………………………………………………….. 
……………………………………………………………………………….. 
 
 0         None of these roles 
 
 
 
 
 
6.) Are there any special circumstances when your pharmacists have prescribed 
medication on discharge prescriptions. (You may tick more than one box) 
 
 0          No 
 If you have answered “none of these roles”, or do not transcribe discharge 
prescriptions  →  GO TO QUESTION 6 
 
 Otherwise → GO TO QUESTION 9 
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 1      To assist junior doctors at very busy times (such as bed crises or  winter 
pressures).         
 2    When items are missed off the prescription or a mistake has been made 
by the doctor/ improvement in chosen therapy etc. with the doctor’s 
permission. 
 3       Other (please specify) 
………………………………………………………………………………….. 
………………………………………………………………………………….. 
 
7.) If you do not currently employ pharmacists who transcribe discharge prescriptions, 
are there any plans within your hospital or trust-wide policies being developed to 
involve pharmacists in this role? If so, please estimate when you propose to 
implement this role. 
 
 1        The issue has been discussed but no decision has been made 
 2         There are no plans for such a development at the moment 
 3           We are currently investigating the development of this role and, 
we estimate that this role will be implemented at the hospital  by                         
(please provide an estimate date): 
……………………………………………………………………………. 
…………………………………………………………………………….   
 
 
 
 
 
 
 
8.) What are your reasons for not providing such a service at your hospital? 
 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
Section C: Transcribing discharge prescriptions 
 
9.) What were your reasons for implementing a pharmacist discharge prescription 
service at your hospital? 
…………………………………………………………………………………………
…………………………………………………………………………………………
 If you have answered there are no plans to develop a pharmacist transcribing 
discharge prescriptions service → GO TO QUESTION 8 
 
 Otherwise → GO TO THE FINAL PAGE. 
 
 GO TO THE FINAL PAGE. 
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…………………………………………………………………………………………
………………………………………………………………………………………… 
 
10.) Is there a formal protocol at your hospital for pharmacists transcribing discharge 
prescriptions? 
 
 1      Yes 
 0      No 
 2      In process of being drawn up 
 3      Other (please provide more detail) 
 
………………………………………………………………………………   
 
 
 
 
 
 
 
11.) When did you implement pharmacists transcribing discharge prescriptions at 
your hospital? (Month/Year) 
…………………………………………………………………………………………. 
 
12.) Please tick the days and state the times when the pharmacy transcription service 
is available: 
 
Days of the week: Times service is available: (e.g. 9.00-5.00) 
 1    Monday  
 2    Tuesday  
 3    Wednesday  
 4    Thursday  
 5    Friday  
 6    Saturday  
 7    Sunday  
13.) Which directorate(s) does your pharmacist discharge service cover? (tick more 
than one box if necessary) 
 
 1      Medicine 
 2      Surgical 
 3      ALL wards in the hospital 
 4      Only on certain wards, not a whole directorate –please specify below 
        ………………………………………………………………………………… 
             ………………………………………………………………………………… 
             ………………………………………………………………………………… 
If you do have a protocol, I would be grateful if you would send me a copy.  Even though the 
policy may identify your trust and/or people who have written the policy, please be assured that 
the information will be treated in strictest confidence. Please enclose the copy in the envelope 
when you return the questionnaire. 
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             ………………………………………………………………………………… 
 5        Other (please specify below) 
             ………………………………………………………………………………… 
             ………………………………………………………………………………… 
             …………………………………………………………………………………     
 
 
14.) Who funds the discharge service pharmacists? 
 
Funding Department(s) No. of 
pharmacists 
% funding by each department 
 1 Pharmacy department alone  100% 
 2 Medical directorate alone  100% 
 3 Surgical directorate alone  100% 
 4 Medical directorate and Pharmacy 
department 
 / 
 5 Surgical directorate and Pharmacy 
department 
 / 
 6 Medical/Surgical/ Pharmacy 
department 
 /     /     
 7  Other (please specify below)   
…………………………………………………………………………………………
…………………………………………………………………………………… 
 
15.) On average/usually how many whole time equivalent pharmacists at each grade 
perform this role on a regular basis? 
        
        A    ………                 E    ………   
        B     ………                 F    ……… 
        C     ………                 G   ………  
        D     ………         Other    ………………………………        
16.) Which “model” do you base your pharmacist discharge service upon? (tick more 
than one box if necessary) 
 
 1        Discharge pharmacists attend whichever ward bleeps them to write the   
discharge medication prescription 
 2       The ward pharmacist writes the discharge medication prescription for their 
own ward(s). 
 3       Medical discharge pharmacists attend whichever medical ward bleeps   
them to write the discharge medication prescription 
 4     Surgical discharge pharmacists attend whichever surgical ward bleeps 
them to write the discharge medication prescription   
 5          Other (please specify) 
 
…………………………………………………………………………………. 
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…………………………………………………………………………………. 
…………………………………………………………………………………. 
 
 
 
 
 
 
 
17.) Does the pharmacist who is writing the discharge prescription attend the doctor’s 
ward round? 
 
 0    No, never  3 Occasionally (not necessarily each week) 
 1 Yes, consultant AND junior 
doctors rounds 
 4    Other (please specify below) 
 2    Yes, consultant rounds only  
 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
18.) What medium is used by pharmacists to transcribe the discharge prescriptions? 
(tick more than one box if necessary) 
 
 1    Paper-based prescriptions 
 2 Computer-generated prescriptions (Please specify the name of the computer 
programme/system) 
……………………………………………………………………………………………………………………………………
………………………………………… 
 
 3    Other (Please specify details below) 
……………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………… 
 
 
19.) Does the doctor co-sign/clinically check the prescription prepared by the 
pharmacist at any time before the patient is discharged? 
 
 If you follow the ward pharmacist model → GO TO QUESTION 17 
 
 Otherwise → GO TO QUESTION 18 
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 1      Yes, always 
 2    Yes, sometimes  
 0      No 
 
20.) Does the doctor sign the in-patient chart to indicate which drugs the patient 
should be sent home on? If not, please state whether the doctors indicate in any other 
manner which medication the patient is to be discharged upon. 
 
 0     No 
 1   Yes, always 
 2     Yes, sometimes    
 3     Other (please specify) 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
Section D Training: 
 
21.) What further training, if any, do you stipulate for a pharmacist to perform the 
discharge service role? (please tick more than one box if necessary) 
 
 1 Post-graduate clinical certificate  6   2 years clinical ward experience 
 2 Post-graduate clinical diploma  7   3 years clinical ward experience 
 3 MSc in clinical pharmacy  8   In-house training programme 
 4 Designation by a senior pharmacist 
 5 Other (please specify below) 
 0   None 
 
 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
22.) Have you designed a formal training programme to train pharmacists to write 
discharge medication prescriptions? 
 
 0    We have no formal training programme 
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 1    We are currently developing a formal training programme 
 2    We have a formal training programme 
 
 
 
 
 
 
 
23.) Do you currently assess a pharmacist’s competency to transcribe discharge 
medication prescriptions before the pharmacist starts this role? 
 
 1  Yes 
 0  No 
 
 
 
 
 
 
 
 
 
24.) If you do assess the pharmacists competency, how do you do this? 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
25.) What type of training does your formal training programme involve? (Tick more 
than one box if necessary) 
 
 1       Tutorials  4 Supervised transcribing/prescribing of 
discharge prescriptions 
 2 Observation of pharmacists already 
performing the role 
 5  Examination or test 
 3      External courses  6   Other (please specify details below) 
 
………………………………………………………………………………………
……………………………………………………………………………………… 
 
 If you do not have a formal training programme or are currently developing a 
training programme → GO TO QUESTION 23 
 
 Otherwise → GO TO QUESTION 25 
 
 If you have answered yes → GO TO QUESTION 24 
 
 Otherwise →GO TO QUESTION 27 
 
 GO TO QUESTION  27. 
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26.) Is your training programme implemented throughout your trust or is it only used 
in your own hospital? 
 
 1 The training is used throughout the trust (at more than one hospital site) 
 2 The training is used in one hospital of the trust 
 3 Our hospital is the only acute hospital in the trust 
 
 
 
 
 
27.) Do you currently re-assess the competency of pharmacists that are transcribing 
prescriptions on a regular basis, and if so, how often ? 
 
 1   Twice a year 
 2   Once a year 
 3   Once every 2 years 
 4   Never re-assess pharmacists competency 
 5   Not reached a decision yet 
 6   Other (please specify below) 
 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
 
 
28.) If competency is re-assessed, how is this done? 
 
 0 Complete whole of training 
programme again 
 4 Supervised transcribing/prescribing of 
discharge prescriptions 
 1       Tutorials  5  Examination 
 2 Observation of pharmacists already  6   Other (please specify details below) 
If you do have a formal training programme, I would be grateful if you could send me a copy. 
Even though the policy may identify your trust and/or people who have written the programme, 
please be assured that the information will be treated in strictest confidence.  Please enclose the 
copy in the envelope when you return the questionnaire. 
 
 If you do re-assess pharmacist’s competency → GO TO QUESTION 28 
 
 Otherwise → GO TO QUESTION 29 
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performing the role 
 3      External courses ………………………………………………… 
 
 
Section E: Facts and figures: 
 
29.) Approximately, how many discharge prescriptions does a pharmacist write per 
day? 
 
 1     less than 5  5     21-25 
 2     5-10  6     26-30 
 3    11-15  7     31-35 
 4     16-20  8     36 or above 
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30.) a.) What percentage of the total number of discharge prescriptions are written by 
pharmacists? 
 
 1     1-10%  6      51-60% 
 2    11-20%  7     61-70% 
 3    21-30%  8     71-80% 
 4    31-40%  9     Greater than 80% 
 5    41-50%  10  Don’t know 
 
 
30.) b.) Was this figure derived from known data or was it an estimate? 
 1 Known data 
 2 Estimate 
 
31.) Has the introduction of the pharmacy discharge service caused a reduction in the 
dispensing requirements out of hours and at weekends? 
 
 1     Yes 
 0     No 
 2    Don’t know 
 
 
 
 
 
 
 
 
32.) a.) If you have found that the pharmacy discharge service has decreased out of 
hours and weekend dispensing requirements, by how much has the workload  
decreased? 
 
 1     10% or less  5     41-50% 
 2    11-20%  6     51-60% 
 3    21-30%  7     61-70% 
 4    31-40%  8     Greater than 70% 
 
 
32.) b.) Was this figure derived from known data or was it an estimate? 
 1 Known data 
 2 Estimate 
 
 If you have answered yes → GO TO QUESTION 32 
 
 Otherwise → GO TO QUESTION 33 
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33.) How many hours advance notice does the pharmacy department require prior to 
providing a pharmacist to write a discharge prescription? 
 
 1    Less than 1 hour  5     7-8 hours 
 2    1-2 hours  6     24 hours 
 3    3-4 hours  7   Other (please specify 
below) 
 4   5-6 hours  
 
…………………………………………………………………………………
………………………………………………………………………………… 
 
 
34.) I would be very interested to know whether your hospital has completed any in-
house study or data collection to show whether pharmacist transcribed prescriptions 
improve error rate, timeliness or completeness of prescriptions when compared to 
those written by doctors. If you have, what did your results show? 
 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTINUED ON THE NEXT PAGE……….. 
Comments/ Other information: 
 
Thank you for taking the time to complete the questionnaire. If you have any 
other comments upon pharmacist prescribing/transcribing of discharge prescriptions, 
then please write them in the space below. 
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…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
Would you like a copy of the questionnaire results sent to you when it is 
published?   (Please delete as applicable) 
                                
                                                                                                                        Yes / No 
 
If so, please provide an e-mail address (if possible): 
………………………………………………………………………………………… 
 
 
Please check that you have included (where appropriate): 
 
• Copy of pharmacist discharge service protocol 
• Copy of training programme 
  
 
Please contact me if you have any enquiries: 
 
Rachel Hobson, 
Teacher/Practitioner pharmacist, 
Pharmacy Practice Research Unit, 
Dept. of Pharmacy and Pharmacology, 
University of Bath, 
Claverton Down 
BATH  
BA2 7AY 
 
Tel: 01225 323107 (Monday to Wednesday) 
        01793 426095 (Thursday and Friday) 
E-mail: prxrjh@bath.ac.uk  
 
 
STUDY NUMBER:    ………..  (Office use only) 
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A survey of Chief Pharmacist’s views upon 
supplementary prescribing by nurses & pharmacists in 
England.  
Instructions for completion: 
 
This survey should be completed by Chief Pharmacists working within hospital trusts.  
 
I would estimate that this questionnaire should take between 15 to 20 minutes to 
complete.  
 
Please tick one box for each question unless otherwise specified. If there is 
insufficient space provided for you to answer some of the questions then continue on 
a separate piece of paper indicating the question number clearly.  (Please note the 
figures beside the tick boxes are for office use only.) 
 
• Confidentiality for those participating in the survey & for those who wish to 
withdraw will be maintained at all times.  
• Data processing will comply with the Data Protection Act 1998. All data will be 
held securely and access to the data will only be available to the researcher 
working on the project. All results and comments will be anonymised and 
although the aim is for the results to be published, no individuals will be 
identified. 
 
When the questionnaire is completed please return it in the enclosed pre-paid 
envelope. Thank you. 
 
For the purposes of this questionnaire, the following definition is applied: 
 
Supplementary prescribing: “A voluntary partnership between an independent 
prescriber and a supplementary prescriber, to implement an agreed patient-specific 
clinical management plan with the patient’s agreement”[1] 
It is proposed that this type of prescriber will have responsibilities including: 
 Monitoring & assessing the patient’s progress as set out in the clinical 
management plan, & as appropriate to the medicines prescribed, including the 
reporting of any adverse reactions 
 Contributing to the clinical management plan 
 Prescribing for the patient in accordance with the agreed clinical management 
plan 
 Changing the medicine prescribed, within the limits set out in the clinical 
management plan, if monitoring of the patient’s progress indicates that this is 
clinically appropriate[2] 
 
STUDY NUMBER: …………… 
Please turn over 
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References: 
 
1. Supplementary prescribing. 2003, Department of Health. (WWW) 
http://www.doh.gov.uk/supplementaryprescribing/ (February 12th 2003) 
2. Proposals for supplementary prescribing by nurses and pharmacists and 
proposed amendments to the prescription only medicines (human use) order 1997. 
2002, MCA: London. p. 1-19. 
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Section A : General Information 
 
1.) How many years has it been since you gained your original professional 
qualification (MRPharm S)? 
 
 1  5-10 years ago  4   21-25 years ago 
 2  11-15 years ago  5 > 25 years ago 
 3  16-20 years ago  
 
 
2.) How many years have you been a Chief Pharmacist? 
 
 1 Up to one year  4 6-10 years  
 2 1-2 years  5 10-15 years 
 3 3-5 years  6 16 years and above 
 
 
3.) What type of hospital are you based at? 
 
 1        Teaching hospital 
 2        District General Hospital 
 3        Other (please specify) .………………………………………. 
 
 
4.) How many in-patient beds are there in your trust? 
 
 1         0-200  5        801-1000   
 2         201-400    6        1001-1500    
 3      401-600     7         greater than 1500  
 4      601-800      
 
 
5.) How many whole time equivalent pharmacists are employed by your trust at 
each grade? 
 
A ……………………………………… E ……………………………………….. 
B ……………………………………… F ……………………………………….. 
C ……………………………………… G ………………………………………. 
D ……………………………………… Other ………………………………….. 
 
Please turn over 
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6.)a.) Do pharmacists currently undertake “prescribing-type activities” in any 
format within your trust? (i.e. where the pharmacist is writing prescriptions for 
patients which may or may not be co-signed by a doctor)  
 
 1Yes  0 No 
 
b.) If yes, in what capacity? (e.g. writing discharge prescriptions, warfarin clinics, 
prescribing in outpatient clinics) 
………………………………………………………………………………………….. 
.…………………………………………………………………………………………. 
.…………………………………………………………………………………………. 
 
 
 
Please turn over 
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Section B: Implementation of supplementary prescribing 
 
Part A: PHARMACIST supplementary prescribing 
 
7.) Do you intend to implement supplementary prescribing (SP) by pharmacists within 
your trust by the end of 2005? 
 
 1   Yes  0   No  2 Don’t know   3 Yet to decide 
 
 
 
 
 
 
8.) How many pharmacists do you intend to train/ will be trained as 
supplementary prescribers within your trust? 
(or if you don’t know tick the box: ) 
 
During 2004:…………………..                        During 2005…………………… 
 
 
9.) What grades of pharmacist(s) are you considering training as supplementary 
prescribers? Tick all that apply  
  
 1 Grade B  4  Grade E 
 2 Grade C  5 Grade F & above 
 3 Grade D  6 Other (Please specify below) 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
10.) Describe the therapeutic area in which the supplementary prescribing by 
pharmacists will take place, & the conditions within that area for which the 
pharmacist will prescribe? (or if you don’t know tick the box: ) 
 
Therapeutic area & condition(s) 
e.g. Rheumatology, DMARD clinic 
 
 
 
 
 
 
 
If you have answered no/don’t know/yet to decide, go onto question 13, If 
you have answered yes go to question 8. 
Please turn over 
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11.) How would these service(s) be covered when the pharmacist is on annual 
leave/off sick? (Tick more than one option if necessary) 
 0 By another pharmacist 
supplementary prescriber 
 4 The service would not be covered 
 1 By a junior doctor (SHO)  5 Don’t know 
 2 By a consultant  6 Other (please specify below) 
 3 By a nurse supplementary prescriber  
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
12.) Pharmacists taking on the supplementary prescribing role are taking on an 
increased risk & responsibility. As there is no applied therapeutics assessment within 
the SP training (e.g. A pharmacist who will be a supplementary prescriber in an 
asthma clinic will not be assessed upon their knowledge of asthma), do you have any 
additional requirements of pharmacists to become SP’s (other than the SP course)?  
(Tick more than one box if necessary) 
 
 1 A period of experience in the clinical 
area chosen to prescribe in 
 4 I have no other requirements 
 2 A general clinical postgraduate 
qualification (e.g. clinical diploma) 
 5 CPD as per RPSGB 
requirements 
 3 A specialist postgraduate 
qualification in the area they are going 
to prescribe in. (e.g. psychiatric 
diploma) 
 
 6 Other (please specify below) 
………………………………………………………………………………………….. 
…………………………………………………………………………………………. 
 
 
 
Part B: NURSE supplementary prescribing 
 
13.)a.) Do you already have qualified NURSE supplementary prescribers working 
within your trust at the moment? 
 
 1   Yes  0   No  2 Don’t know (go to Q.14)  
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b.) Describe the therapeutic area in which the supplementary prescribing by nurses is 
currently taking place & the conditions within that area for which the nurses are 
prescribing: (or if you don’t know tick the box: ) 
 
Therapeutic area & condition(s) 
e.g.Cardiovascular Disease,  Hypertension clinic 
 
 
 
 
 
 
14.) Do you intend to implement supplementary prescribing (SP) by nurses within 
your trust by the end of 2005? (extended nurse prescriber + supplementary 
prescriber course &/ or separate supplementary prescriber course) 
 
 1   Yes  0   No  2 Don’t know   3 Yet to decide 
 
 
 
 
 
 
 
15.) Describe the therapeutic area in which the supplementary prescribing by nurses 
will take place, and the conditions within that area for which they will prescribe? (or 
if you don’t know tick the box: ) 
 
  
Therapeutic area & condition(s) 
e.g.Palliative Care, Pain Control 
 
 
 
 
 
 
 
 
 
If you have answered no/don’t know/yet to decide go to question 
17, if you have answered yes go to question 15. 
If you need more space to describe other services please continue 
on the back of the questionnaire. 
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16.) How would these service(s) be covered when the nurse is on annual leave/off 
sick? (Tick more than one option if necessary) 
 1 By another nurse supplementary 
prescriber 
 4 The service would not be covered 
 2 By a junior doctor (SHO)  5 Don’t know 
 3 By a pharmacist supplementary 
prescriber 
 6 Other (please specify below) 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
17.) What factors (if any) will affect the recruitment of designated medical 
practitioners (DMP)? (Tick more than one option if necessary) 
 
 0 DMP’s workload  5 Commitment & understanding of 
the SP role (by the DMP) 
 1 Perceived benefit to the DMP  6 Lack of funding for the role 
 2 Time/availability to do the DMP 
role 
 7 There are no factors that affect 
recruitment 
 3 Is there an established good 
working relationship between SP 
& DMP? 
 8 Other (Please specify below) 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
18.) a.) In your own opinion, do you think it will be easier to recruit designated 
medical practitioners to mentor nurses rather than pharmacists? 
 
 1   Yes  0   No  2 Don’t know    
  
b.) Please explain your answer below: 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
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Section C: Views on supplementary prescribing 
 
 
 
 
 
  (Please tick the appropriate box) 
  Strongly 
agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not 
Applicable 
 
19 There is a risk that SP’s may 
not appreciate the 
significance of signs & 
symptoms that the patient 
declares to them during the 
consultation. 
 
      
20 Multiple prescribers, arising 
from the introduction of 
supplementary prescribing, 
will increase the prevalence 
of iatrogenic disease. 
 
      
21 Amongst other developments 
being undertaken within the 
NHS, development of SP by 
PHARMACISTS will be a 
priority within our trust. 
 
      
22 Amongst other developments 
being undertaken within the 
NHS, development of SP by 
NURSES will be a priority 
within our trust. 
 
      
23 Insufficient pharmacist 
resource will be a major 
limitation to development of 
pharmacist SP within 
secondary care. 
 
      
24 Lack of 24-hour opening of 
pharmacy departments will 
be a limitation to 
development of pharmacist 
SP. 
 
      
Please indicate your views upon the following issues concerning 
supplementary prescribing (SP). 
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  (Please tick the appropriate box) 
  Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not  
Applicable 
 
25 Lack of assessment of applied 
therapeutics in the prescribing 
area means that the training 
model for SP is not sufficiently 
robust. 
 
      
26 The paperwork & development 
of individual clinical 
management plans will be 
prohibitive to the development 
of SP.  
 
      
27 The majority of pharmacists in 
secondary care do not wish to 
take on the SP role. 
 
      
28 Reassessing and maintaining 
competency of SP pharmacists 
will limit the uptake of SP. 
 
      
29 The designated medical 
practitioner should undergo 
prescribing training themselves 
before assessing the 
prescribing competency of SP 
trainees. 
      
30 Pharmacists who currently 
transcribe discharge 
prescriptions should be trained 
as SP’s to continue this role. 
 
      
31 An employee SP should have 
their own indemnity insurance, 
as the trust’s own vicarious 
liability may not be sufficient. 
 
      
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  (Please tick the appropriate box) 
  Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not  
Applicable 
32 Non-SP pharmacists will 
regard themselves as 
“second class citizens” 
compared to prescribing 
colleagues. 
 
      
33 The SP role will cause 
conflict with the 
pharmacist’s role of 
providing impartial advice 
to patients upon medicines. 
 
      
34 In the future, I believe that 
it will be appropriate for 
undergraduate pharmacy 
students to qualify as SP’s 
when they graduate. 
 
      
35 In secondary care, there 
will be more extensive 
uptake & use for 
pharmacists as 
INDEPENDENT 
prescribers rather than as 
supplementary prescribers. 
      
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Comments/ Other information: 
 
THANK YOU FOR TAKING PART IN THIS STUDY, YOUR TIME IS MUCH 
APPRECIATED. 
 
Any other comments upon supplementary prescribing? 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
If you would you like a copy of the questionnaire results sent to 
you when it is published, then please complete the enclosed 
reply slip. 
 
 
 
Please do contact me if you have any enquiries: 
 
Rachel Hobson, 
Teacher/Practitioner pharmacist, 
Pharmacy Practice Research Unit, 
Dept. of Pharmacy and Pharmacology, 
University of Bath, 
Claverton Down, 
BATH,  
BA2 7AY. 
 
Tel: 01225 384081 (Monday to Wednesday) 
        01793 605029  (Thursday and Friday) 
 
E-mail: prxrjh@bath.ac.uk  
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A survey of Primary Care Trust Pharmacist’s views on 
supplementary prescribing by nurses & pharmacists in 
England. 
Instructions for completion: 
 
This survey should be completed by Pharmaceutical Advisor Pharmacists working 
within primary care trusts.  
 
I would estimate that this questionnaire should take between 15 to 20 minutes to 
complete.  
 
Please tick one box for each question asked unless otherwise specified. If there is 
insufficient space provided for you to answer some of the questions then continue on 
a separate piece of paper indicating the question number clearly.  (Please note the 
figures beside the tick boxes are for office use only.) 
 
• Confidentiality for those participating in the survey & for those who wish to 
withdraw will be maintained at all times.  
 
• Data processing will comply with the Data Protection Act 1998. All data will 
be held securely and access to the data will only be available to the researcher 
working on the project. All results and comments will be anonymised and 
although the aim is for the results to be published, no individuals will be 
identified. 
  
Please return the completed  questionnaire  in the enclosed pre-paid envelope. Thank 
You. 
 
For the purposes of this questionnaire, the following definition is applied: 
 
Supplementary prescribing: “A voluntary partnership between an independent 
prescriber and a supplementary prescriber, to implement an agreed patient-specific 
clinical management plan, with the patient’s agreement” 324 
It is proposed that this type of prescriber will have responsibilities including: 
 Monitoring and assessing the patient’s progress as set out in the clinical 
management plan, and  as appropriate to the medicines prescribed, including 
the reporting of any adverse reactions 
 Contributing to the clinical management plan 
 Prescribing for the patient in accordance with the agreed clinical management 
plan 
 Changing the medicine prescribed, within the limits set out in the clinical 
management plan, if monitoring of the patient’s progress indicates that this is 
clinically appropriate15 
STUDY NUMBER: …………… 
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Section A: General Information 
 
 
1.) How many years has it been since you gained your original professional 
qualification (MRPharm S)? 
 
 1  <5 years  4  16-20 years ago 
 2  5-10 years ago  5   21-25 years ago 
 3  11-15 years ago  6 > 25 years ago 
 
 
2.) How many years have you been a primary care trust pharmacist? 
 
 1 Up to one year  4 3-4 years  
 2 1-2 years  5 5-6 years 
 3 2-3 years  6 Other (Please specify below) 
 
…………………………………………. 
 
3.) How many whole time equivalent pharmacists work within your PCT? 
 
………………………………………………………………………………………… 
 
4.)a.) Do pharmacists currently undertake “prescribing-type activities” in any 
format within your trust?   (i.e. where the pharmacist is writing prescriptions for 
patients which may or may not be co-signed by a doctor)  
 
 1Yes  0 No  2 Don’t know  
 
b.) If yes, in what capacity? (e.g. warfarin clinic, medication review clinic) 
………………………………………………………………………………………….. 
.…………………………………………………………………………………………. 
.…………………………………………………………………………………………. 
.………………………………………………………………………………………….
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Section B: Implementation of supplementary prescribing 
 
Part A: PHARMACIST supplementary prescribing 
 
5.) Do you intend to implement supplementary prescribing (SP) by pharmacists within 
your trust by the end of 2005? 
 
 1   Yes  0   No  2 Don’t know   3 Yet to decide 
 
 
 
 
 
 
6.) How many pharmacists do you intend to train/ will be trained as 
supplementary prescribers within your trust?  
(or if you don’t know tick the box: ) 
 
During 2004:…………………..                        During 2005…………………… 
 
7.) What TYPE of pharmacist(s) are you considering training as supplementary 
prescribers? Tick all that apply  
 
 1 Community pharmacist(s)  4 PCT-based primary care 
pharmacists 
 2 GP practice-based pharmacists  5 Other (Please specify below) 
 3 Community services/Interface 
pharmacists (Hospital based) 
 
…………………………………………………………………………………………
………………………………………………………………………………………… 
………………………………………………………………………………………… 
 
8.) Describe the therapeutic area in which the supplementary prescribing by 
pharmacists will take place, & the conditions within that area for which the 
pharmacist will prescribe? (or if you don’t know tick the box: ) 
 
Therapeutic area & condition(s) 
e.g. Renal Failure pts- Anaemia & hypertension control 
 
 
 
 
 
 
If you have answered no/don’t know/yet to decide, go onto question 
11, if you have answered yes go to question 6. 
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9.) How would these service(s) be covered when the pharmacist is on annual leave/off 
sick? (Tick more than one option if necessary) 
 
 0 By a pharmacist supplementary prescriber  3 The service would not be covered 
 1 By a GP   4 Don’t know 
 2 By a nurse supplementary prescriber  5 Other (please specify below) 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
10.) Pharmacists taking on the supplementary prescribing role are taking on increased 
risk & responsibility. As there is no applied therapeutics assessment within the SP 
training (e.g. a pharmacist who will be a supplementary prescriber in an asthma 
clinic will not be assessed upon their knowledge of asthma), do you have any 
additional requirements of pharmacists to become SP’s (other than the SP course)? 
(Tick more than one box if necessary) 
 
 1 A period of experience in the 
clinical area chosen to prescribe in  
 4 I have no other requirements 
 2 A general clinical postgraduate 
qualification (e.g. clinical diploma) 
 5 CPD as per RPSGB requirements 
 3 A specialist postgraduate 
qualification in the area they are 
going to prescribe in. (e.g. 
psychiatric diploma) 
 6 Other (please specify below) 
 
………………………………………………………………………………………….. 
………………………………………………………………………………………….. 
 
 
Part B: NURSE supplementary prescribing 
 
11.)a.) Do you already have qualified nurse supplementary prescribers working within 
your trust at the moment? 
 
 1   Yes  0   No  2 Don’t know  (go to Q.12)  
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b.) Describe the therapeutic area in which the supplementary prescribing by 
nurses is currently taking place, & the conditions within that area for which 
the nurses are prescribing: (or if you don’t know tick the box: ) 
 
Therapeutic area & condition(s) 
e.g. Cardiovascular Disease, Hypertension control 
 
 
 
 
 
 
12.) Do you intend to implement or train more nurses as supplementary prescribers 
(SP) within your trust by the end of 2005? (extended nurse prescriber + 
supplementary prescriber course &/ or separate supplementary prescriber course) 
 
 1   Yes  0   No  2 Don’t know   3 Yet to decide 
 
 
 
 
 
 
13.) What TYPE of nurse(s) are you considering training as supplementary 
prescribers in YOUR trust? (Tick all that apply) 
 
 1 Practice-based nurses  5 School nurses 
 2 District nurses  6 Community paediatric nurses 
 3 Health visitors  7 Don’t know 
 4 Midwives  8 Other (Please specify below) 
   
………………………………………………………………………………………….. 
 
14.) Describe the therapeutic area in which the supplementary prescribing by 
nurses will take place, and the conditions within that area for which they will 
prescribe? (or if you don’t know tick the box: ) 
 
Therapeutic area & condition(s) 
e.g. Respiratory medicine, Asthma control 
 
 
 
 
 
 
If you have answered no/don’t know/yet to decide go to question 
16, otherwise go to question 13. 
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15.) How would these service(s) be covered when the nurse is on annual leave/off 
sick? (Tick more than one option if necessary) 
 
 0 By a GP   3 The service would not be covered 
 1 By a nurse supplementary prescriber  4 Don’t know 
 2 By a pharmacist supplementary prescriber  5 Other (please specify below) 
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
16.) Which PCT group or employee will be charged with taking forward 
PHARMACIST prescribing in your trust? (Tick more than one option if necessary) 
 
 1 PCT Non-medical prescribing group  5 Don’t know 
 2 Clinical governance lead  6 Yet to be decided 
 3 Medication management committee  7 Other (please specify below) 
 4 Pharmaceutical Adviser  
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
17.) Which PCT group or employee will be charged with taking forward NURSE 
prescribing in your trust? (Tick more than one option if necessary) 
 
 1 PCT Non-medical prescribing group  5 Director of nursing 
 2 Clinical governance lead  6 Don’t know 
 3 Medication management committee  7 Yet to be decided 
 4 Pharmaceutical Adviser  8 Other (please specify below) 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
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18.) What factors (if any) will affect the recruitment of designated medical 
practitioners (DMP) for SP trainees? (Tick more than one option if necessary) 
 
 0 DMP’s workload  5 Commitment & understanding of 
the SP role (by the DMP) 
 1 Perceived benefit to the DMP  6 Lack of funding for the role 
 2 Time/availability to do the DMP 
role 
 7 There are no factors that affect 
recruitment 
 3 Is there an established good 
working relationship between SP 
& DMP? 
 8 Other (Please specify below) 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
19.) a.) In your own opinion, do you think it will be easier to recruit designated 
medical practitioners to mentor nurses rather than pharmacists? 
 
 1   Yes  0   No  2 Don’t know  (Go to Q.20)  
  
b.) Please explain your answer below: 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
Please turn over 
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Section C: Views on supplementary prescribing 
 
 
 
 
 
  (Please tick the appropriate box) 
  Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not 
Applicable 
 
20 There is a risk that SP’s may 
not appreciate the 
significance of signs & 
symptoms that the patient 
declares to them during the 
consultation. 
 
      
21 Multiple prescribers, as a 
result   of the introduction of 
supplementary prescribing, 
will increase the prevalence 
of iatrogenic disease. 
 
      
22 Amongst other developments 
being undertaken within the 
NHS, development of SP by 
PHARMACISTS will be a 
priority within our trust. 
 
      
23 Amongst other developments 
being undertaken within the 
NHS, development of SP by 
NURSES will be a priority 
within our trust. 
 
      
24 Currently, poor IT links will 
limit the development of 
community pharmacist 
SPs. 
 
      
25 Lack of assessment of 
applied therapeutics in the 
prescribing area means that 
the training model for SP is 
not sufficiently robust. 
 
      
Please turn over 
Please indicate your views upon the following issues concerning 
supplementary prescribing (SP). 
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  (Please tick the appropriate box) 
  Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not 
Applicable 
 
26 The paperwork & 
development of individual 
clinical management plans 
will be prohibitive to the 
development of SP. 
  
      
27 The majority of pharmacists 
in primary care do not wish 
to take on the SP role. 
 
      
28 Reassessing and maintaining 
competency of SP 
pharmacists will limit the 
uptake of SP. 
 
      
29  The designated medical 
practitioner should undergo 
prescribing training 
themselves before assessing 
the prescribing competency 
of SP trainees. 
      
30 An employee SP should have 
their own indemnity 
insurance, as the trust’s own 
vicarious liability may not be 
sufficient. 
 
      
31 Non-SP pharmacists will 
regard themselves as “second 
class citizens” compared to 
prescribing colleagues. 
 
      
32 The SP role will cause 
conflict with the 
pharmacist’s role of 
providing impartial advice to 
patients upon medicines. 
 
      
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  (Please tick the appropriate box.) 
  Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
Not 
Applicable 
 
33 In the future, in my view,  it 
will be appropriate for 
undergraduate pharmacy 
students to qualify as SP’s 
when they graduate. 
 
      
34 In primary care, there will be 
more extensive uptake & use 
for pharmacists as 
INDEPENDENT prescribers 
rather than as supplementary 
prescribers. 
      
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Comments/ Other information: 
 
THANK YOU FOR TAKING PART IN THIS STUDY, YOUR TIME IS MUCH 
APPRECIATED. 
 
Any other comments upon supplementary prescribing? 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
If you would you like a copy of the questionnaire results 
sent to you when it is published, then please complete the 
enclosed reply slip. 
 
 
 
Please do contact me if you have any enquiries: 
 
Rachel Hobson, 
Teacher/Practitioner pharmacist, 
Pharmacy Practice Research Unit, 
Dept. of Pharmacy and Pharmacology, 
University of Bath, 
Claverton Down, 
BATH,  
BA2 7AY. 
 
Tel: 01225 384081 (Monday to Wednesday) 
        01793 605029 (Thursday and Friday) 
E-mail: prxrjh@bath.ac.uk  
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Topic guide for exploratory interview with clinical governance lead and co-
ordinator  
 
1. Examine their understanding of the required training to become a pharmacist 
and their opinion of the quality of clinical knowledge that pharmacists have 
(based upon previous experiences)  
2. Are they aware of pharmacists (or nurses) prescribing in any format within 
their trust? 
3.   What are their expectations of the extension of prescribing rights to 
pharmacists in secondary care? 
4.   What are their expectations of the extension of prescribing rights to nurses in 
secondary care? 
5.   What are the limitations of pharmacist prescribing? (e.g. insufficient resource, 
lack of 24hr opening of pharmacy dept., deskilling doctors etc.) 
6.   Do they think there will be any change to prescribing error rates? 
7.   Will they actively seek to develop pharmacist and /or nurse prescribing in their 
trust and if so, in which area(s)? /How will you prioritise/roll out 
pharmacist/nurse SP? 
8.  Do they have any preferences as to which grades of pharmacist/nurses should 
be prescribing? 
9.  Why do they think pharmacists (and nurses) want to (and do not want to) take 
this new role on? 
10. How will they tackle the continuing education needs of prescribing 
pharmacists and nurses? 
11. How will they tackle the reassessment and re-accreditation needs of 
prescribing pharmacists and nurses? (How will they monitor and identify poor 
service?) 
12. Should doctors be accredited to prescribe and undergo some form of re-
assessment? 
13. Will there be any competition for financial support for nurses and pharmacists 
to train as supplementary prescribers in their trust (specifically re: replacement 
costs as training costs will be funded centrally)? 
14. Ask their opinion upon specific prescribing scenarios for pharmacists (and 
nurses?) to evaluate how comfortable they are with supplementary prescribing 
in certain areas (e.g. writing discharge prescriptions, prescribing TPN, 
prescribing potassium supplements, adjusting vancomycin and gentamicin 
doses according to levels etc.) 
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
20 19 There is a risk that SP's may not 
appreciate the significance of 
signs and symptoms that the 
patient declares to them during 
the consultation 
1 
(0.5) 
2 
(2.1) 
51 
(27.9) 
31 
(32.3) 
28 
(15.3) 
19 
(19.8) 
88 
(48.1) 
37 
(38.5) 
15 
(8.2) 
7 
(7.3) 
21 20 Multiple prescribers, arising from 
the introduction of SP, will 
increase the prevalence of 
iatrogenic disease 
0 2 
(2.1) 
18 
(9.9) 
11 
(11.3) 
51 
(28) 
35 
(36.1) 
82 
(45.1) 
33 
(34) 
31 
(17) 
16 
(16.5) 
22 21 Amongst other developments 
being undertaken within the NHS, 
development of SP by 
PHARMACISTS WILL be a 
priority within our trust 
1 
(0.5) 
3 
(3.1) 
48 
(26.4) 
23 
(23.7) 
48 
(26.4) 
24 
(24.7) 
64 
(35.2) 
37 
(38.5) 
21 
(11.5) 
7 
(7.3) 
23 22 Amongst other developments 
being undertaken within the NHS, 
development of SP by NURSES 
WILL be a priority within our 
trust 
17 
(9.4) 
4 
(4.1) 
86 
(47.5) 
44 
(45.4) 
42 
(23.2) 
28 
(28.9) 
34 
(18.8) 
19 
(19.6) 
2 
(1.1) 
2 
(2.1) 
25 25 Lack of assessment of applied 
therapeutics in the prescribing 
area means that the training 
model for SP is not sufficiently 
robust 
19 
(10.6) 
10 
(10.6) 
57 
(31.7) 
23 
(24.5) 
68 
(37.8) 
28 
(29.8) 
29 
(16.1) 
27 
(28.7) 
7 
(3.9) 
6 
(6.4) 
Questionnaire Section C statements
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
26 26 The paperwork and development 
of individual clinical management 
plans will be prohibitive to the 
development of SP. 
5 
(2.8) 
9 
(9.5) 
55 
(31.1) 
31 
(32.6) 
43 
(24.3) 
17 
(17.9) 
70 
(39.5) 
34 
(35.8) 
4 
(2.3) 
4 
(4.2) 
27 27 The majority of pharmacists in 1˚ 
/2˚ care do not wish to take on the 
SP role. 
7 (4) 4 
(4.2) 
47 
(26.7) 
24 
(25) 
61 
(34.7) 
23 
(24) 
53 
(30.1) 
40 
(41.7) 
8 
(4.5) 
5 
(5.2) 
28 28 Reassessing and maintaining 
competency of SP pharmacists 
will limit the uptake of SP. 
1 
(0.6) 
1 
(1.1) 
56 
(31.5) 
19 
(20) 
40 
(22.5) 
26 
(27.4) 
78 
(43.8) 
46 
(48.4) 
3 
(1.7) 
3 
(3.2) 
29 29 The designated medical 
practitioner should undergo 
prescribing training themselves 
before assessing the prescribing 
competency of SP trainees 
16 (9) 13 
(13.8) 
77 
(43.3) 
37 
(39.4) 
25 
(14) 
15 
(16) 
56 
(31.5) 
27 
(28.7) 
4 
(2.2) 
2 
(2.1) 
30 31 An employee SP should have 
their own indemnity insurance, as 
the trust's vicarious liability may 
not be sufficient 
20 
(11.3) 
6 
(6.3) 
72 
(40.7) 
16 
(16.7) 
50 
(28.2) 
15 
(15.6) 
29 
(16.4) 
36 
(37.5) 
6 
(3.4) 
23 
(24) 
31 32 Non-SP pharmacists will regard 
themselves as "second-class 
citizens" compared to prescribing 
colleagues. 
2 
(1.1) 
1  
(1) 
13 
(7.3) 
7 
(7.3) 
35 
(19.1) 
17 
(17.7) 
104 
(58.4) 
54 
(56.3) 
24 
(13.5) 
17 
(17.7) 
Questionnaire Section C statements (cont)
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
32 33 The SP role will cause conflict 
with the pharmacist's role of 
providing impartial advice to 
patients upon medicines 
2 
(1.1) 
1  
(1) 
11 
(6.2) 
11 
(11.5) 
27 
(15.3) 
11 
(11.5) 
101 
(57.1) 
50 
(52.1) 
36 
(20.3) 
23 
(24) 
33 34 In the future, I believe that it will 
be appropriate for undergraduate 
pharmacy students to qualify as 
SP's when they graduate 
25 
(14) 
6 
(6.3) 
63 
(35.4) 
21 
(22.1) 
7 
(3.8) 
11 
(11.6) 
46 
(25.8) 
33 
(34.7) 
37 
(20.8) 
24 
(25.3) 
34 35 In 1˚/2˚ care, there will be more 
extensive uptake and use for 
pharmacists as INDEPENDENT 
prescribers rather than as 
supplementary prescribers. 
47 
(26.6) 
25 
(26) 
76 
(42.9) 
37 
(38.5) 
40 
(22.6) 
20 
(20.8) 
13 
(7.3) 
10 
(10.4) 
1 
(0.6) 
4 
(4.2) 
24 - Currently, poor IT links will limit 
the development of community 
pharmacist SPs. 
98 
(53.6) 
   72 
(39.3) 
 4 
(2.2) 
 7 
(3.8) 
 2 
(1.1) 
 
- 23 Insufficient pharmacist resource 
will be a major limitation to 
development of pharmacist SP 
within secondary care. 
 41 
(42.3) 
 36 
(37.1) 
 3 
(3.1) 
 12 
(12.4) 
 5 
(5.2) 
- 24 Lack of 24-hour opening of 
pharmacy departments will be a 
limitation to development of 
pharmacist SP. 
 10 
(10.8) 
 23 
(24.7) 
 8 
(8.6) 
 39 
(41.9) 
 13 
(14) 
Questionnaire Section C statements (cont)
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
- 30 Pharmacists who currently 
transcribe discharge prescriptions 
should be trained as SP's to 
continue this role 
 10 
(10.8) 
 20 
(21.5) 
 10 
(10.8) 
 40 
(43) 
 13 
(14) 
 
Questionnaire Section C statements (cont.) 
 
N. B. 1˚= primary care. 2˚= secondary care. 
Missing Data: primary care n=58, secondary care n= 17 
 415 
APPENDIX 8 
 416 
 
 Factors 
  1 2 3 
SP's not knowing 
significance of symptoms 
q19 
  .528   
Sp will increase iatrogenic 
disease? q20 
  .733   
SP Pharmacists will be a 
priority in our trust q 21 
    .716 
SP nurses will be a priority 
in our trust q22 
-.354   .820 
Insufficient pharmacist 
resource will be a limitation 
q23 
.370 .472   
Lack of 24 hr opening 
hours will be a limitation 
q24 
  .520   
Lack of applied 
therapeutics assessment 
q25 
  .554 .392 
Paperwork & CMP will be 
prohibitive q26 
.560     
Pharmacists in secondary 
care do not want to be SP's 
q 27 
    .628 
Reassessment & 
maintaining competency 
will limit SP q28 
.692     
Mentor should undergo 
prescribing training q29 
.599     
Discharge prescription 
prescribers as SP's? q30 
  .367   
Indemnity insurance 
required? q31 
      
Non-SP's as second-class 
citizens? q32 
-.420 .490   
Conflict in impartial 
advice? q33 
  .606   
Undergraduates to qualify 
upon graduation? q34 
.584     
Independent prescribing 
will be taken up more 
extensively q35 
.369     
 
Secondary care pattern matrix showing the factor loadings of each item on the 
extracted factors (following Oblique rotation using the Direct Oblimin method) 
N.B. Items with factor loadings less than +/- 0.3 have been removed for clarity  
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 Factors 
  1 2 3 
Conflict with 
pharmacist providing 
impartial advice q32 
.643     
Non-SP's as second-
class citizens? q31 
.476     
Poor IT links will limit 
the development of SP 
in community q24 
.445     
IP will be more 
extensively uptaken 
than SP q34 
.419     
Pharmacist SP will be 
a priority in the trust 
q22 
  .691   
Nurse SP will be a 
priority in the trust q23 
-.469 .690   
Pharmacists in primary 
care do not wish to 
become SP's q27 
  .629   
Maintaining 
competency of SP 
pharmacists q28 
.473 .564   
Undergraduates should 
qualify as SP upon 
graduation q33 
      
Lack of clinical 
assessment means SP 
training is not robust 
q25 
    .754 
Paperwork & CMP 
will be prohibitive q26 
    .646 
Ability of mentors to 
assess abilty of SP's 
q29 
    .554 
SP will increase 
iatrogenic disease q21 
.325 .311 .466 
SP's may not recognise 
the importance of 
symptoms q20 
    .312 
Indemnity insurance 
q30 
      
Primary care pattern matrix showing the factor loadings of each item on the 
extracted factors (following Oblique rotation using the Direct Oblimin method) 
 
N.B. Items with factor loadings less than +/- 0.3 have been removed for clarity  
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Topic Guide for Focus Group 
 
 
Section 1: Risks/Benefits/Implementation 
 
 Discuss the benefits of SP to the patient, the doctor, the SP and to the trust 
 Discuss the implementation of SP (secondary care) and the associated 
risks/monitoring  
o Are the risks different to IP, are they different between nurses and 
pharmacists? 
 How are the patients going to understand the role of the SP and who to contact 
when? 
 Discuss what may happen if SP does not work- what will the DoH do? 
 
Section 2: Mentors 
 
 Availability of mentors for pharmacists and nurses (factors affecting) 
 Quality of mentors/accreditation (i.e. How do we know that the mentors are 
suitably skilled at prescribing themselves??) 
 
Section 3: Liability 
 
 Professional liability in certain situations: 
o What if the diagnosis by the IP is wrong? 
o What if the CMP has an error upon it? 
o What if the IP signs off an SP but is not suitable themselves and then 
errors occur? 
 Responsibility and accountability of SP in terms of their own performance? 
 Effect upon prescribing error rate? 
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Summary of focus group findings 9
th
 April 2003. 
 
Interesting points…. 
 
 SP will be a major opportunity to improve rational prescribing 
 If a pharmacist is involved in writing TTAs then they have to be engaged 
upstream, to the extent that they have to be part of the clinical team, they have 
to interact with the patient and discuss drug therapy with them, so writing the 
TTA becomes a part of the package of care that they are delivering 
 Negative view of SP: REALISING ONES OWN LIMITATIONS. The 
accreditation package for pharmacists to become SP is essentially building 
upon their clinical competencies and at the present time, there is no mandatory 
requirement that a pharmacist that presents themselves for e.g. a paediatric 
pharmacist post of a mental health pharmacist post has to have a qualification. 
It is very much down to the pharmacist to recognise the code of ethics and I 
am not sure that this is enough for public protection. 
 Clare disagreed with this, saying that this is not independent prescribing we 
are talking about. The key to reducing risk is the CMP. 
 I think it will come down to knowing ones own limitations and being aware of 
them. My concern remains that a number of practitioners are blind to their 
own limitations, and do not refer back to the IP when they should do. 
 Poor performance should be picked up by appraisal. 
 Negative view of SP: MISSING SIGNS and SYMPTOMS. The SP may not 
appreciate the significance of signs and symptoms which the patient declares 
to them at consultation. I am comfortable with managing that in my particular 
environment where there is already a very close working relationship between 
the renal pharmacists and the renal consultants, they are next door to each 
other in the clinic, and so can go and ask them about any problems. (Clare 
thought that this would mean that the patient wasn’t stable enough to be 
handed over to a SP in the first place) 
 Risk of SP: IATROGENIC DISEASE. We may increase iatrogenic disease, 
because if you have got multiple prescribers and you get a breakdown in 
communication…. Also, people are living longer and this demographic of 
people are more prone to adverse drug reactions, so I think that increasing 
iatrogenic disease is a real risk. Unless we keep a tight focus on the patient’s 
main clinical problems, and ensure that we are not adding to the complexity in 
terms of polypharmacy. 
 Risk of SP: ADVERSE INCIDENT REPORTING. In the DoH document 
upon SP, in informing the NPSA, the independent prescriber is responsible. It 
should also be the responsibility of the SP to report adverse incidents. 
 Risk of SP: INDUSTRY-PRIVATE PARTNERSHIPS. If we get sponsored 
SP’s by the industry (as SP could impact on chronic disease management) you 
could have the Government saying to all trusts that you have to look at public 
and private sponsorship. The risk of industry seeing this as a way of by-
passing doctors in terms of another route to their marketing their products and 
so much industry sponsorship which is to promote heavily their own drugs. 
 Negative view of SP: I think there are issues for prioritising developments 
within secondary care. We are expected to deliver in terms of NHS plan, 
pharmacy in the future, Spoonful of sugar and the NSF’s. SP is not a must do 
for secondary care, it is a may do and it may help so I think I am in a position 
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of trying to develop a service and I have limited funding, where do I prioritise 
my resources??  It is a good professional opportunity to grasp, but if I was 
faced with having to choose between resourcing another specialist pharmacist 
in an area where I do not have one or rolling out SP, I know where I’d go. 
 Funding: The training has actually been underfunded by the Government. 
You couldn’t get 40 days training in the private sector for £500; a tenner a 
day. Also there is no funding for the mentor 
 Prooving cost-effectiveness: Is that another issue? –Clare didn’t seem to think 
that making an economic case was one of the bigger problems-the following 
seemed more important: 
 Evaluating patient’s thoughts: It’s who takes responsibility and who is 
accountable in terms of the process of care and I think that’s what we need to 
validate within the new system, because patients views might be different 
when they think the buck stops with you. Research still needs to validate how 
does the patient feel about the fact that you are not referring back to the 
doctor, because that might change their attitude to their care as well.   
 Problems with SP: MENTORS ABILITY TO ASSESS. I think there’s a big 
assumption there on the basis that an independent prescriber would actually be 
able to assess the competency of the other healthcare professional who came 
from a different background to them and I’m not sure that they could. 
 Potential further research: I would like a researcher to set up a model and 
talk to the local cardiac unit, who were looking to set up a model whereby the 
point of diagnosis of hypertension, so that he can randomise them into 
receiving GP care or non-medical prescribing care and actually look to see 
outcomes from both groups. Do they actually manage to get them to commit to 
compliance, because we actually allow the patient greater choice in therapy 
options. 
 Problems with SP: POOR INDEPENDENT PRACTITIONERS. I think one 
of the issues for me is when things go wrong in terms of liability. E.g. SP is 
supposed to be a voluntary thing. What if a pharmacist is pressurised to 
become a SP to work with an IP who is a poor practitioner in order to improve 
their prescribing skills. There is a clinical governance issue in that if you are 
offered dodgy plans, how do you report that, how do you deal with it so that 
their practice can be improved? –Especially a problem with single-handed GP 
practices where they are away from peer review.   
 Problems with SP: SECOND-RATE CARE? If SP stick to very conservative 
CMP’s, until they’ve got an evidence base to support it people play safe, and 
there is a risk that it may delay the introduction of new drugs that are clinically 
effective. Therefore it is very important for SP’s to prescribe black triangle 
drugs. 
 Problems with SP: INTRA-PROFESSIONAL ISSUES. Pharmacists who are 
not SP’s may become to regard themselves as second class citizens. I think 
there is a whole load of issues within the profession about how this is going to 
pan out. Is everybody going to be aspirational to be a SP? 
 Problems with SP: LIABILITY. My worry is that the SP may be quite naïve 
and everybody else covers their own back 7 the SP is left exposed. I think it is 
so important that some of the prescribers not only have indemnity in place but 
independent solid legal advice so that they are not dependent upon the trust. 
The trust may have it covered in terms of patients claiming compensation, but 
they haven’t got it covered if you are in a box being accused of manslaughter. 
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I think that that is a view that has never been discussed properly within the 
profession and that’s where there’s a lack of leadership. We need to know that 
if an incident happens it is known what to do and have a witness present, have 
some standard procedures so you do not have someone shifting the blame, 
because we will not learn from that, they will not reflect on poor practice. 
 
 Future research: Clare thinks that having a multi-centre study with 5 
hospitals that do not have pharmacists prescribing discharge prescriptions and 
5 that do will be very difficult to control as I will not be able to retain my 
control hospitals. It just will not fit in with national policies about reducing 
waiting times and speeding up discharge. There will be a dictat. I do not think 
it will be voluntary, as you state. I think that once SP is in place, I could see a 
document coming out for hospitals advising them to implement SP for 
discharge prescriptions. I could see them being forced in earlier than that 
without allowing you to follow up with your contaminated group.  
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Patient 
no. 
Gender Age Location of 
Interview 
Prescriber Clinical 
Condition 
1 F 66 GP practice GP Hypertension 
2 F 78 GP Practice GP Hypertension 
3 F 79 GP Practice GP Hypertension 
4 F 62 GP Practice GP Hypertension 
5 M 50 GP Practice GP Hypertension 
6 F 59 Hospital- 
Oncology 
Outpatient’s 
Consultant Gastrointestinal 
Cancer 
7 M 77 Hospital- 
Oncology 
Outpatient’s 
Consultant Gastrointestinal 
Cancer 
8 M 76 Hospital- 
Oncology 
Outpatient’s 
Consultant Gastrointestinal 
Cancer 
9 M 59 Hospital- 
Oncology 
Outpatient’s 
Consultant Gastrointestinal 
Cancer 
10 M 57 Hospital- 
Oncology 
Outpatient’s 
Consultant Gastrointestinal 
Cancer 
11 M 74 GP practice Pharmacist 
Supplementary 
Prescriber 
Hypertension 
12 M 56 GP practice Pharmacist 
Supplementary 
Prescriber 
Hypertension 
13 M 81 GP practice Pharmacist 
Supplementary 
Prescriber 
Hypertension 
14 M 52 GP practice Pharmacist 
Supplementary 
Prescriber 
Hypertension 
15 M 42 GP practice Pharmacist 
Supplementary 
Prescriber 
Hypertension 
16 F 63 Hospital- 
Education 
Centre 
Pharmacist 
Supplementary 
Prescriber 
Gastrointestinal 
Cancer 
17 F 67 Hospital- 
Education 
Centre 
Pharmacist 
Supplementary 
Prescriber 
Gastrointestinal 
Cancer 
18 M 61 Hospital- 
Education 
Centre 
Pharmacist 
Supplementary 
Prescriber 
Gastrointestinal 
Cancer 
 
Participant demographics in the qualitative interviews 
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Contact Practice Add 1 Add 2 Add 3 Postcode PCT 
       
Dr T Kemple 
Horfield Health 
Centre 
Lockleaze 
Road Horfield Bristol BS7 9RR Bristol North 
Dr H Lupton 
The Malago 
Surgery 
40 St Johns 
Road Bedminster Bristol BS3 4JE 
Bristol South 
and West 
Dr J Victory 
Bradgate 
Surgery 
Ardenton 
Walk Brentry Bristol 
BS10 
6SP Bristol North 
Dr C 
Whybrew 
Portishead 
Health Centre 
Victoria 
Square Portishead  
BS20 
9AQ North Somerset 
Dr R Taylor 
Shirehampton 
Health Centre 
Pembroke 
Road Shirehampton Bristol 
BS11 
9SB Bristol North 
Dr D Kessler 
Gaywood 
House Surgery North Street Bedminster Bristol BS3 3AZ 
Bristol South 
and West 
Dr R 
Jobanputra 
Southmead 
Health Centre 
Ullswater 
Road Southmead Bristol 
BS10 
6DF Bristol North 
Dr D Cox 
Brockway 
Medical Centre 8 Brockway Nailsea Bristol 
BS48 
1BZ North Somerset 
Dr M Barber 
Lawrence Hill 
Health Centre Hassell Drive Bristol  BS2 0AN Bristol North 
Dr A Wickert 
St George 
Health Centre 
Bellevue 
Road St George Bristol BS5 7PH Bristol North 
Dr W House 
St Augustines 
Surgery 
4 Station 
Road Keynsham Bristol 
BS31 
2BN 
Bath and North 
East Somerset 
Dr A Sephton 
Oaks Medical 
Practice 
Cadbury 
Heath Health 
Centre 
Parkwall 
Road Bristol 
BS30 
5HS 
South 
Gloucestershire 
Dr F 
Ormerod The Surgery 
Northwick 
Road Pilning Bristol BS32 4JE 
South 
Gloucestershire 
Dr U 
Freudenstein 
The Family 
Practice 
Western 
College Cotham Road Bristol BS6 6DF 
Bristol South 
and West 
Dr J Clement 
Gloucester 
Road Medical 
Centre 
Tramway 
House 
1a Church 
Road Bristol BS7 8SA Bristol North 
Dr C Yerbury 
Grange Road 
Surgery Bishopsworth Bristol  
BS13 
8LD 
Bristol South 
and West 
Dr I Crofton-
Briggs 
The Merrywood 
Practice 
William Budd 
Health 
Centre 
Knowle West 
Health Park 
Downton 
Rd 
BS41 
1WH 
Bristol South 
and West 
Dr K Hearn 
Montpelier 
Health Centre 
Bath 
Buildings Montpelier Bristol BS6 5PT Bristol North 
Dr M 
Hoghton 
Clevedon 
Health Centre Old Street Clevedon  
BS21 
6DG North Somerset 
Dr H Stoddart 
Kingswood 
Health Centre Alma Road Kingswood Bristol BS15 4EJ 
South 
Gloucestershire 
Dr J Wood 
Woodside 
Practice 
Brooklea 
Health 
Centre Wick Road Brislington BS4 4HU 
Bristol South 
and West 
Mr S Mowatt 
The Lennard 
Surgery 
1 Lewis 
Road 
Bedminster 
Down Bristol BS13 7JD 
Bristol South 
and West 
Dr M 
Rossdale 
Pembroke 
Road Surgery 
111 
Pembroke 
Road Clifton Bristol BS8 3EU 
Bristol South 
and West 
Dr D Bailey 
Hanham 
Surgery 
33 Whittucks 
Road Hanham Bristol 
BS15 
3HY 
South 
Gloucestershire 
Dr C Parfitt 
Clevedon 
Medical Centre Old Street Clevedon  
BS21 
6DG North Somerset 
Research practices in Bristol that get paid to take part in and host research projects 
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Pharm Nurse Section 1:  Previous experiences with 
Pharmacists/Nurses 
 
Prompt 
  What previous experience you have had of 
pharmacists/nurses?  
Situations where you have come 
across them, in a pharmacy/GP 
practice or in hospital.  MURs with 
pharmacists??? BP monitoring? 
  Is the local pharmacist/nurse helpful? 
 
 
 
 
 
Have you received any 
advice/appointment from them about 
OTCs or POMs 
diet/footcare/contraception before? 
Do you consider them to be a health 
care professional? Do you consider 
them to be an expert/knowledgable 
on medicines? 
Have you ever had a pharmacist pick 
up an error/mistake on your 
prescription or make a mistake on 
your prescription? 
  Explain what you think pharmacists/nurses do 
day to day? 
Is there a difference between 
pharmacists that work in a chemist 
shop/GP practice & those that work in 
hospital? Do they have the same 
qualifications? 
  What is your opinion of pharmacists/nurses? How do they compare to doctors and 
nurses/pharmacists? 
Who do you have a better relationship 
with? 
xxxxx xxxxx Primary Care: Have you had any OP appts in 
secondary care?- If so, who with?  
Secondary Care: Ask about GP appts, 
nurse/pharm appts 
Who they have generally had appts. 
with in other sector- healthcare 
background 
 xxxxx Tell me about your experience of having 
medication(s) prescribed for you by the 
pharmacist SP? 
 
 xxxxx How often have you seen the SP?  
 xxxxx Are there any advantages to seeing the SP? Good points- quicker access, longer 
appointments, easier to talk to? 
 xxxxx Are there any disadvantages to seeing the SP? Bad points- not the same as seeing a 
doctor, certain things you would 
rather see a doctor for? 
 xxxxx Does it bother you that you didn’t get to see the 
GP? (Ask about responsibility) 
How does it make you feel seeing the 
SP rather than the GP? 
  Section 2: Pharmacist/Nurse Prescribing 
 
Prompt 
  What do you think about pharmacists/nurses 
being able to prescribe medicines?  
Initial thoughts for/against Is it s good 
development? 
 xxxxx Pharmacists would be able to prescribe all 
medicines you can buy OTC in chemists and all 
POM medicines, including drugs for your heart, 
chemotherapy etc as independent prescibers. 
How do you feel about this? -Quite a broad range 
Do you think that pharmacists are 
capable of prescribing all types of 
medicines? 
 
xxxxxx  Nurse prescribers are able to prescribe all 
medicines you can buy OTC in chemists and 
some POM medicines, including antibiotics for 
certain conditions. Are you happy about this? 
Do you think that nurses are capable 
of prescribing all types of medicines? 
Is their drug knowledge sufficient? 
 
 xxxxx Pharmacists that independently prescribe may 
also diagnose conditions- what do you think 
about this? e.g. chesty cough vs hypertension 
What is diagnosis? Do you think 
pharmacists are capable of 
diagnosing?  
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Age= ___________        Do they want a copy of the final report? ____________ 
Travel expenses?  
Pharm Nurse Section 2:  continued 
 
Prompt 
  If a pharmacist/nurse independent prescriber 
prescribed a medicine for you who do you think 
would be responsible for that decision? 
Would you see your GP/consultant as 
being in ultimate charge of your care? 
How would the Dr know what had 
been prescribed for you? 
  Do you think there are there any advantages to 
the implementation of independent prescribing by 
pharmacists/nurses? 
Increased accessibility to healthcare? 
Proper use of their skills? Longer 
consultations? Easier to talk to than 
the doctor? 
  Do you think there are any disadvantages 
(concerns) to the implementation of independent 
prescribing by pharmacists/nurses? 
 
 
 
Do you think it is a safe system for 
patients? 
How would the performance of the 
pharmacist or nurse prescriber be 
checked? How do the pharmacists & 
nurses keep up to date? 
e.g. Pt may have a doctor, Nurse & 
Pharmacist prescribing for them 
  The pharmacist/nurse may need to do a physical 
examination before making a diagnosis and 
prescribing for the patient, how do you feel about 
this? 
 
Would it make any difference to you if 
it was a male/female 
pharmacist/nurse? 
In primary care may be a separate 
room in the pharmacy/shop 
  For pharmacists/nurses to prescribe they will 
need to have full access to your medical records, 
would you be happy about this?  
 
?Different levels of access according 
to the level of severity of the condition 
  Do you think it is necessary for 
pharmacist’s/nurses to be able to prescribe 
independently 
Will it enable pharmacists/nurses and 
doctors to work better? 
Would there be a demand for it? 
  Would you utilize a pharmacist/nurse 
independent prescriber service if your local GP 
practice or hospitals offered such a service? 
E.g. Hypertension clinic/ 
chemotherapy clinic-*ask specifically 
in site 2 about a pharm. Prescribing 
chemo!! 
 xxxxxx Do you think your experience of being a patient 
of a pharmacist SP has affected your opinion on 
the development of IP for pharmacists?  
Has it eased your mind of any 
concerns you might have had? 
  Section 3: General Questions 
 
Prompt 
xxxxxx xxxxx Would you want to be asked if it was okay to 
have a pharmacist or nurse prescribe for you 
before you actually saw them? 
How would you want this consent to 
be obtained –verbal/written in medical 
notes & signed by patient? 
 
xxxxxx xxxxx What do you think are the biggest 
barriers/hurdles to the implementation of 
independent prescribing? 
Acceptability to patients? Good 
communication links between the 
different prescribers? Do you think it 
will work well in practice? 
xxxxxx xxxxxx Do you have any preferences between seeing a 
pharmacist or a nurse prescriber? Explain why. 
Are there any groups of people you 
think may not want to see a nurse or 
pharmacist prescriber?  
xxxxxx xxxxxx Do you think that there are certain areas of 
prescribing that might be more suited to each 
health care profession? -give examples? 
E.g. Nurses only should prescribe 
dressings, doctors only should 
prescribe chemotherapy etc. 
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N.B. The publications provided in this appendix are copies of the final word versions 
of the papers/abstracts that the journals published. The final published versions have 
not been included as I was unable to convert pdf files into word files of sufficient 
quality (needed for electronic submission of this thesis) using software programmes 
that were purchased for this purpose. Scanning of the published papers did also not 
produce versions of sufficient legibility and quality. Therefore a list of the published 
references is provided below: 
 
1. Hobson RJ, Sewell GJ. UK survey of discharge prescriptions, transcribing & 
development of the hospital pharmacist-prescribing role. International Journal 
of Pharmacy Practice 2002;10 (Suppl)(September 2002):R12. 
2. Hobson RJ, Sewell GJ. Factors influencing provision of pharmacist discharge 
prescription transcription services & authorisation requirements of pharmacist-
written prescriptions. International Journal of Pharmacy Practice 
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Introduction The Audit Commission’s report “A spoonful of sugar”1 has 
identified the pharmacist as a central figure in medicines management. This 
report echoes recommendations in the Crown Report2, which advocated the 
extension of prescribing rights to pharmacists. 
Within secondary care, some pharmacists are already prescribing 
dependently, the most common role being transcribing of discharge 
prescriptions.3, 4 
Reported advantages of pharmacist discharge prescription transcription 
services (PDPTS), include increased number of pharmacist interventions, 
increased prospective interventions, decreased prescription turnover time, 
cost savings by using patient’s own drugs (POD’s), decreased out of hours 
work for the pharmacy department, decreased prescription error rate 
compared to doctors and releasing doctor & nurse time.3 4  
A recent study established that one third of 162 hospital trusts surveyed 
involved pharmacists in writing discharge prescriptions, but their overall 
impact on the total number of prescriptions being written was negligible.5  
A questionnaire was therefore developed to further explore Sexton’s findings, 
and to identify other pharmacist prescribing roles. 
 
Method The questionnaire was developed after literature review and visits to 
hospitals running PDPTS. It contained open & closed questions. Face-to-face 
interviews with pharmacists were used for validation. Single hospitals in each 
UK NHS Trust were identified using the UK Drug Information Pharmacists’ 
Group Directory and the Chemist & Druggist Directory. Ambulance trusts, 
learning disabilities trusts and community hospitals were excluded. 
 It was piloted in 20 randomly selected hospitals (July 2001), and then 
distributed (August 2001). It was addressed to the Chief Pharmacist, Principle 
pharmacist or Clinical Services Manager according to the name found.  
Responses were coded and analysed using the Statistical Package for the 
Social Sciences (SPSS) version 10.  
 
Results The questionnaire was sent to 206 NHS trusts, and the response rate 
was 66% (135/206). 49/135 (36%) of hospital pharmacy departments (HPD) 
who responded were offering PDPTS.  
Prescribing activities included pharmacist prescription amendment (n=39, 
29%), prescribing activity in pre-admission clinics (n=24, 18%) and re-writing 
drug charts (n=20, 16%). Fifty-nine HPD’s (44%) did not undertake any 
prescribing activity. 
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Amongst those HPDs that do not transcribe, 68.6% (n=59/86) undertake no 
prescribing activities (Range= 0 to 3). Amongst those that do transcribe, there 
was a wider range in the number of prescribing activities undertaken (Range= 
1 to 8), median =3, n=13/49 (26.5%).  
There was a tentative relationship between the total number of pharmacists 
employed at a hospital and the total number of pharmacist prescribing 
activities (correlation coefficient= 0.208, p= 0.018). 
Typically, the service operated from 9am to 5pm Monday to Friday (n=32, 
68.1%), and most frequently serviced the medical directorate (n=24, 51.1%), 
followed by the surgical directorate (n=17, 36.2%).  
The service was normally funded by the pharmacy department (n=28, 58.3%), 
and mainly operated by C & D grade pharmacists. 
The most frequently used model of service was pharmacists writing the 
discharge prescriptions for their own wards (n=38, 77.6%).  
Typically one (n=7) or two (n=8) pharmacists ran the service, and each 
pharmacist produced less than 5 prescriptions per day (n=25, 52.1%). 
 
Discussion The results of this survey show that the majority of HPDs who 
run a PDPTS are not having a large impact on the overall number of discharge 
prescriptions being written in the hospital. This agrees with Sexton’s results.5 
The results suggest that manpower is a key obstacle in the provision of 
PDPTS and other pharmacist prescribing roles.  HPDs could seek financial 
support for extension of prescribing services from other directorates and also 
funding for nurses & doctors.   
A limitation of this study is it would have been preferable to send the 
questionnaire to every UK hospital as opposed to one per trust.  
Future research should determine the attitudes of other healthcare 
professionals and patients to pharmacists becoming supplementary and 
independent prescribers, as support within a multidisciplinary team is key in 
effective implementation. 
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Introduction Recent reports describe the development of pharmacists 
transcribing discharge prescriptions, 1 2 but there is no published information 
on factors influencing the decision whether or not to provide this service. 
Anecdotal evidence suggests conflicting opinion upon the issue of whether a 
medical practitioner should be legally required to co-sign a prescription that 
is written by a pharmacist.  
A survey was distributed to one acute hospital from each UK NHS Trust to 
examine these two issues. 
 
Method The questionnaire was developed after literature review and visits to 
hospitals running PDPTS. It contained open & closed questions. Face-to-face 
interviews with pharmacists were used for validation. Single hospitals in each 
UK NHS Trust were identified using the UK Drug Information Pharmacists’ 
Group Directory and the Chemist & Druggist Directory. Ambulance trusts, 
learning disabilities trusts and community hospitals were excluded. 
 It was piloted in 20 randomly selected hospitals (July 2001), and then 
distributed (August 2001). It was addressed to the Chief Pharmacist, Principle 
pharmacist or Clinical Services Manager according to the name found.  
Responses were coded and analysed using the Statistical Package for the 
Social Sciences (SPSS) version 10.  
 
Results 135/206 (66%) pharmacists responded. 49/135 (36%) reported that 
they were offering PDPTS.  
The most frequently cited reason for not implementing a transcription service 
was insufficient resources n=18, followed by developing other services in 
preference to PDPTS n=7. Other reasons given were no plans/discussion 
(n=6), lack of funding (n=5), electronic prescribing development will make 
PDPTS redundant, considered an administrative role and that it was for the 
doctor’s benefit only. 
The most common reason for implementing a transcribing service was to 
reduce delays in the discharge process (72.9% n=35), followed by improved 
accuracy/decreased errors/improved quality (50% n=24). Other reasons 
included release of junior doctor time (33.3% n=16), increased efficiency, cost 
savings from re-use of patient’s own drugs, enhanced pharmacist’s role, 
improved communications with primary care, decreased duplicate 
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prescribing, save nursing time, enhanced counselling opportunities, risk 
management and improved patient care. 
Teaching hospitals employed more pharmacists (Chi-squared= 21.5, df=2, 
Asymp. Sig. = 0.000) and offered transcription services more frequently 
(48.6%) than District General Hospitals (33.7%).  
 The majority of HPD’s ask the doctor to co-sign the pharmacist written 
prescriptions (n=31, 64.6%), however 10 HPD’s (20.8%) did not and 7 HPD’s 
(14.6%) said that they sometimes did (1=missing data). The HPD’s that did 
not ask the doctor to co-sign often asked the doctor to indicate in another 
manner that the prescription was required. Two HPD’s always had the in-
patient drug chart signed by the doctor (2 HPD’s sometimes did this), 3 
HPD’s used verbal authorisation and 1 HPD used a separate authorisation 
form. Two HPD’s did not ask the doctor to authorise the prescription in any 
other manner. 
 
Discussion A main reason for not having PDPTS was lack of resources 
(n=18), this opinion would appear to be justified from the results. The most 
common reasons found in this study supporting the provision of PDPTS have 
also been proposed in published literature.1, 2 
If the pharmacist is writing the discharge prescription, there is a risk 
management issue, as the pharmacist is no longer performing the clinical 
check role. Some hospitals have overcome this issue by swapping the 
prescribing and checking roles with the doctor.1, 3 
This survey has shown that there is no consensus on authorisation 
requirements. Anecdotal evidence from this survey suggests that using the 
doctor as a second clinical check when the prescription is co-signed was not 
successful. The value of signatures on in-patient drug charts has also been 
questioned. The in-patient drug chart is not a prescription, but the authority 
to administer a medicine.  Cousins & Luscombe have suggested that as long 
as the authority to administer each drug can be traced back to either a written 
protocol or a general practitioner, is there an absolute requirement to have a 
doctor countersign the items on the inpatient chart?4 This theory could also be 
extended to the discharge prescription. Until legislation is changed to permit 
pharmacists to be supplementary prescribers, this issue will remain 
unresolved. 
A limitation of this study is it would have been preferable to send the 
questionnaire to every UK hospital as opposed to one per trust.  
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ABSTRACT 
 
Objectives: To provide quantitative data upon pharmacist discharge 
prescription transcription service (PDPTS) provided in UK hospitals. 
  
Method: Postal questionnaire survey of clinical pharmacy managers.  
 
Setting: Selection criteria included one hospital in each acute trust in the U.K.  
 
Key Findings: The response rate was 66% (135/206). PDPTS is offered by 
49/135 (36%) of hospital pharmacy departments. PDPTS was the most 
common prescribing activity undertaken by pharmacists, followed by a 
prescription amendment policy (29%), prescribing in pre-admission clinics 
(18%) and re-writing drug charts (15%). Fifty-nine department’s (44%) did not 
undertake any prescribing activity. 
Of the non-transcribing hospitals, n=59/86 (69%) undertake no prescribing 
activity (Range= 0 to 3 prescribing activities). Transcribing hospitals offer a 
wider range of prescribing activities (Range= 1 to 8 prescribing activities). 
A weak relationship was found between the total number of pharmacists 
employed per hospital and the total number of prescribing activities 
undertaken (correlation coefficient= 0.208, p= 0.018). 
The most frequently used PDPTS model involved pharmacists transcribing 
the discharge prescriptions for their own wards (n=38, 78%). The number of 
pharmacists transcribing discharge prescriptions per hospital ranges from 1 to 
89. (Mean=8, Mode=2, Median= 5, 25% percentile= 2, 75% percentile=10).  
The majority of pharmacists write less than 5 prescriptions per day (n=25, 
52%),  (n=17, 35%) are writing 5-10 prescriptions per day. 
The most common training requirement for pharmacists to start transcribing 
was an in-house training programme (n=27, 55%). The majority of 
department’s do not re-assess the ability of their pharmacists to transcribe 
(n=37, 80%).  
  
Conclusion:  Pharmacy departments have started to take on prescribing roles, 
especially transcribing discharge prescriptions. However, it would appear 
that the majority of the PDPTS schemes are not being run extensively 
throughout the hospitals. It is of concern that the principles of clinical 
governance are not being met in terms of training and re-assessment of the 
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pharmacists that are undertaking this service. In order to extend this service 
throughout hospitals, funding, resources and skill-mix maximisation need to 
be sought. This will enable patients to gain the maximum benefit from this 
service development. 
 
INTRODUCTION 
 
The recent Audit Commission report “A spoonful of sugar”1 has identified 
the pharmacist as a central figure in medicines management. The report states 
that pharmacists should concentrate on their clinical, patient-centred roles, to 
help minimize medication errors and manage risk. It also considers that 
pharmacists should reduce their traditional role of retrospective prescription 
monitoring. 
This report echoes recommendations in the Review of Prescribing, Supply & 
Administration of Medicines (Final Report) report from 19992, which 
advocated extending prescribing rights to pharmacists. 
 
Development of pharmacist prescribing in the UK can benefit from the 
experience gained previously in the United States. Pharmacist prescribing 
was first introduced in California in the late 1970’s. Since then, pharmacist 
prescribing has extended to include at least 16 states. Only one state (Florida) 
has introduced independent prescribing, where pharmacists are prescribing 
from a limited list of drugs. 3 Collaborative drug therapy management has 
become the suggested model of pharmacist prescribing, whereby the 
pharmacist has a collaborative arrangement with a physician to dependently 
prescribe certain medications as agreed in a management plan. 4-6  
 
A very similar model to this is now being proposed in England, Wales & 
Scotland, termed supplementary prescribing. The recently published MCA 
consultation document proposes that pharmacist supplementary prescribing 
will start in 2003.7 The report by the Strategy for Pharmaceutical Care in 
Scotland “The Right Medicine” also states that pharmacists should be able to 
prescribe by the end of 2003.8 It is now expected that pharmacists will start 
training in England & Wales for supplementary prescribing by spring 2003. 9 
 
Since the late 1990’s many hospital pharmacy departments have strived to re-
engineer their employee’s roles in order to provide a better service to patients. 
Suggested service developments have included pharmacists transcribing 
discharge prescriptions,10,11 12 which is similar in principal to supplementary 
prescribing.13-14 
 
There have been many reports providing evidence of the advantages of such 
schemes, which include increasing doctor & nurse time for other activities, 
increasing the number of pharmacist interventions, increased prospective 
interventions, decreasing the prescription turnover time, cost savings as 
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patient’s own drugs (POD’s) are used more often, decreasing out of hours 
work for the pharmacy department, and decreased error rate. 1, 13-20  
 
One of the key elements of the government’s White Paper, “Information for 
Health”21 is the implementation of Level 3 electronic patient record within 
100% of acute hospitals by 2005.  
When Level 3 electronic prescribing is implemented, there will still be a role 
for the pharmacist to decide upon the appropriateness of treatment on 
discharge and input the discharge prescription onto the computer. 
Pharmacists are already using electronic prescribing systems in this manner, 
and have become more integrated into the healthcare team. 22, 23, 24 
A pharmacist transcribing discharge prescription’s on clinical team’s ward 
rounds has been found to reduce the error rate on the prescriptions when 
compared to those written by doctors, double the intervention rate by the 
pharmacist, and increase the number of prospective interventions that the 
pharmacist makes.19 All of these findings fall into line with the 
recommendations of the Audit Commission report. 1 
Realisation of the benefits and the developments that can arise from such 
service provision could also help pharmacists gain acceptance within the 
clinical team as a provider of pharmaceutical knowledge, and lead to further 
development of the pharmacist’s role. 
The disadvantages of such a service relate to resource issues. For the service 
to be implemented throughout a hospital, it would be necessary to maximize 
the technician role in order to release pharmacist time from the dispensary 
and other duties. 
 
Several reports have identified other pharmacist prescribing roles, such as in 
pre-admission clinics to obtain patient medication histories and write the in-
patient drug charts as well as the discharge prescription according to set 
protocols 25, 26, 27 and also out-patient clinic prescribing.28  
 
A recent survey conducted by Sexton29 (1999) identified the services that 
hospital pharmacies were providing to facilitate seamless care upon patient 
discharge. The study established that out of 162 hospital trusts, a third 
involved pharmacists in writing discharge prescriptions, but their overall 
impact on the total number of prescriptions being written was negligible. The 
survey did not attempt to suggest reasons for this, but did report that 
managers responding to their survey stated that there were continuing 
resource and staffing difficulties. The survey did not aim to describe the 
pharmacist prescribing services. 
Literature review undertaken before the survey was developed did not 
identify any surveys that intended to provide quantitative data upon PDPTS 
provided in the UK. 
 The objectives of this survey were to identify the frequency of PDPTS 
provided in the UK and to provide further detail upon the level & type of 
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service provided and training requirements for pharmacists involved in such 
services. 
 
METHODS 
 
Pharmacists from two hospitals with an existing PDPTS were visited to 
inform the development of a written, self-completion questionnaire 
containing a mixture of open & closed questions. Construction of the 
questionnaire was also aided by the literature review undertaken before the 
survey was developed. The review elicited the pharmacist “prescribing 
activities” that department’s were questioned about in the survey. These 
included PDPTS, transcribing in-patient drug charts, various prescribing 
activities in pre-admission clinics (which often includes transcribing 
discharge prescriptions26 27) and prescription amendment policies.  
For the purposes of this study, and in the absence of a recognised definition of 
transcribing, transcription is defined as “a process where a pharmacist copies 
a list of drugs that has been prescribed by a doctor from one chart to another 
chart or prescription”. In undertaking the act of transcription, there is an 
implied professional obligation on the pharmacist to review the prescribed 
medicines & act upon any errors & assure suitability for the patient. 
The questionnaire was divided into five sections. Section A enquired about 
general demographic data, Section B enquired about different prescribing 
roles undertaken. The rest of the questionnaire sought to establish the details 
of PDPTS provision. Section C enquired about the extent of the service 
provision amongst those hospitals that offer a transcription service (i.e. 
directorates/wards covered and operating hours of the service), and the 
model of service used. Section D was about training issues (e.g. reassessment, 
types of training used) and Section E aimed to quantify the service provided 
(e.g. number of prescriptions written/day/pharmacist, advance notice 
required). Confidentiality was maintained by number-coding the 
questionnaires. 
 
Face-to-face interviews with pharmacists (from hospitals with and without a 
PDPTS) were used to validate the questionnaire. These hospitals were chosen 
from the same region as the researcher was based for ease of travel.  The 
questionnaire was then piloted in 20 randomly chosen hospitals from Wales, 
Scotland, England & Northern Ireland in July 2001. Minor adjustments to the 
instructions for completing the questionnaire were made. Advice on data 
analysis was sought from a statistician.  The questionnaire was distributed at 
the end of August 2001 to each NHS trust providing acute hospital services in 
the UK. Single hospitals from each trust were identified using a combination 
of the UK Drug Information Pharmacists’ Group Directory and the Chemist 
& Druggist Directory.30 The questionnaire was sent to one hospital from each 
trust. Any hospitals that were found to have merged with another trust were 
removed from the database.  
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The questionnaire was accompanied by a letter, which included recognised 
descriptions of independent & dependent (now supplementary) prescribing,2 
and the researcher’s description of transcribing, in order to clarify recipient’s 
understanding of the different types of prescribing. 
The covering letter was addressed to either the Chief Pharmacist, Principal 
pharmacist or Clinical Services Manager. The recipient was instructed to pass 
the questionnaire onto the most relevant person to complete it (if it wasn’t 
themselves). A freepost-addressed envelope was included for return of the 
questionnaire. 
No deadline for completion of the questionnaire was stated on the 
questionnaire or covering letter, but non-respondents were followed up by a 
telephone call after 3 weeks and then again at 6 weeks. Further copies of the 
questionnaire were sent out to those who requested them. The final deadline 
for accepting returned questionnaires was 11 weeks after they had been 
originally posted. 
Data obtained from returned questionnaires was coded and analysed with 
the Statistical Package for the Social Sciences (SPSS) version 10, and the 
significance of the association between variables was assessed using chi-
squared, Kruskal-Wallis and bivariate correlations (spearman’s rho), where 
appropriate. Data collected from the pilot questionnaires was not included in 
the final analysis. 
 
 
RESULTS 
General demographics 
A total of 234 hospital pharmacy departments were identified, of which 20 
were used for piloting the questionnaire, leaving 214 hospitals for the main 
study. Eight of these hospitals were removed after it was established that 
they had merged with another Trust, leaving 206 hospitals eligible for the 
study. Of these 206 hospitals, responses were received from 135 hospitals, 
giving a response rate of 66%. Of these, 68% (n=92) of responses came from 
District General hospitals & 27% (n=37) from teaching hospitals, and 4% from 
tertiary referral centres (n=5).  
The questionnaire was completed by Clinical pharmacist/managers (26% 
n=35), Chief Pharmacists (26% n=35) Principal Pharmacists (25% n=34), 
Pharmacy Managers (7% n=10), Deputy Chief Pharmacists (5% n=7), MI 
manager/pharmacists (4% n=5), Discharge services pharmacist (4% n=5) and 
one interface pharmacist (1%).  
The size of the hospitals varied, with bed sizes ranging from less than 100 to 
>1500, with the most common range being 401-600 (33% n=44). 
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Prescribing activities 
 
PDPTS 
36% (49/135) of hospitals were currently offering a pharmacist discharge 
prescription transcription service.  
20/135 (15%) of departments reported that they transcribe in-patient drug 
charts. The majority of department’s that re-write in-patient drug charts also 
transcribe discharge prescriptions (17/20, 85%).   
 
Prescription amendment policy 
The second most common pharmacist prescribing activity was a prescription 
amendment policy (n=39/135 29%) whereby the pharmacists can follow 
agreed protocols to change timings & frequencies of drugs or change a non-
formulary drug to a formulary alternative within the same pharmacological 
class. 
 
Pre-admission clinics 
24/135 (18%) of departments reported that they performed prescribing roles 
in pre-admission clinics. 20/135 departments stated that they had 
pharmacists that wrote patient’s normal medication onto drug charts. 12/135 
departments reported that they prescribed medicines onto a drug chart at pre-
admission clinics according to set protocols including (e.g.) analgesia, 
antibiotics, VTE prophylaxis, and 8/135 departments prescribe discharge 
medication at pre-admission clinics according to set protocols. 6/135 
departments performed 2 of these roles and 5/135 departments performed 3 
of these roles.  
 
No prescribing activity 
Hospitals with no pharmacist prescribing comprised the largest group of 
respondents (n=59, 44%). 
 
Other prescribing 
The most common “other” form of pharmacist prescribing that was reported 
was in anticoagulant clinics (10% n=13) (supplementary prescribing), and 
Total Parenteral Nutrition (TPN) prescribing (3%, n=4). Four hospitals 
reported that they have pharmacists that independently prescribe. Other 
pharmacist prescribing included chemotherapy, in cardiac rehabilitation 
clinics, migraine clinics, any P medicines and medicines that the patient had 
been taking before admission.   
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Future Plans 
Of the departments not offering a pharmacist discharge prescription 
transcription service (PDPTS), 42% (n=36/86) indicated that there had been 
discussions about pharmacist transcribing, but no decision made as yet. 34%, 
(n=29/86) indicated that there were no plans for such a development, and 
22% (n=19/86) said that they were currently developing such a service.  (2= 
missing data) 
Eleven of the departments who said they were implementing a transcription 
service intended to implement the service in 2002, and 2 departments 
intended to implement the service in 2003 (5= missing data). One department 
intended to implement the service during December 2001. 
 
Teaching hospitals employed more pharmacists (x2= 21.5, df=2, p = 0.000) 
than District General Hospitals. No tertiary referral centres transcribe. 
 
Of the non-transcribing hospitals, n=59/86 (69%) undertake no prescribing 
activity (Range= 0 to 3 prescribing activities). Transcribing hospitals offer a 
wider range of prescribing activities (Range= 1 to 8 prescribing activities). 
A weak relationship was found between the total number of pharmacists 
employed per hospital and the total number of prescribing activities 
undertaken (correlation coefficient= 0.208, p= 0.018). 
 
Prescribing systems 
On questioning upon when the pharmacy departments started their 
transcription service, one hospital stated that they have been running such a 
service since the 1980’s; all of the other hospitals that had a PDPTS had started 
the service between 1995 and 2001. 
The majority (68% n=32/47) only operate the service during normal working 
hours Monday to Friday. A few other hospitals have extended to other parts 
of the weekend, or later in the evenings but this was an exception. 
The wards/directorates in which the PDPTS was offered is illustrated in 
figure 1. The most common directorate to have a PDPTS was the medical 
directorate with 51% (n=24/47) of hospitals running the service within this 
directorate. The next most common directorate was the surgical directorate 
36% (n=17/47), followed by parts of these directorates, and care of the elderly. 
Only 11% (n=5/47) of hospitals had rolled out the service to ALL wards, plus 
one hospital provided the service to all wards minus those wards that stocked 
pre-packed drugs. One hospital operated PDPTS only in those wards where 
an electronic prescribing system (EPS) was in place. 
 
The pharmacy department mainly fund the PDPTS (58% n=28/48). Some 
hospitals have managed to obtain funding from the medical &/or surgical 
directorates (23% n=11/48) and some have received trust monies into the 
pharmacy budget (8% n= 4/48). 
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The number of pharmacists providing PDPTS per hospital ranges from 1 to 
89. (Mean=8, Median= 5, Mode=2, 25% percentile= 2, 75% percentile=10). The 
total number of pharmacists (whole time equivalent) per department that 
provides PDPTS ranges from 7 to 102 (Mean=19, Median=16, Mode=9). The 
percentage of pharmacists involved in PDPTS per department ranges from 3% 
to 100% (Mean=39%, Median=33%, Mode=33%). 
 
The model that the PDPTS is based upon is illustrated in Table 1. The first 4 
models of service listed in Table 1 were established from visits to two other 
hospitals that were running a pharmacist transcription service, and the other 
categories was from the results of the “other” option, which was examined for 
common themes. The total is greater then 49 as some respondents ticked more 
than one option for this question. The most common model used was the 
ward pharmacist model (78%, n=38/49) in which pharmacists transcribe the 
discharge prescriptions for their own ward. 
 
The majority of departments (79% n=37/47) reported using paper-based 
prescriptions for PDPTS. Nine departments have pharmacists producing 
prescriptions on electronic prescribing systems (Computer-generated 
prescriptions (n=6), paper & computer (n=3)). 
 
Table 2 illustrates how many discharge prescriptions a pharmacist transcribes 
per day. The majority of pharmacists are writing less than 5 prescriptions per 
day (52% n=25), 35% (n=17) are writing 5-10 prescriptions per day.  
The advance notice required to produce a pharmacist-written discharge 
prescription is shown in table 3. 
 
Training 
Training requirements for pharmacists who transcribe discharge prescriptions 
were explored. Table 4 illustrates that the most common training requirement 
was the completion of an in-house training programme (55% n=27), followed 
by designation by a senior pharmacist (31% n=15), and then possession of a 
clinical diploma (20% n=10). The total is greater than 49 as some respondents 
ticked more than one option for this question.  
Of the eight departments that had a formal training programme for PDPTS 
(1=missing data), five departments used tutorials, seven departments used 
observation, seven departments used supervision, and four departments used 
an examination (some hospital pharmacy departments used a combination of 
techniques). 
Of the 11 departments that did assess competency to transcribe, four did this 
via non-ward based training/assessment, four departments did ward-based 
assessment and 1 completed an annual competency review (2= missing data). 
Frequency of re-assessment of competency of the pharmacists who were 
transcribing is illustrated in Table 5. The 9 departments that did undertake 
some form of re-assessment were asked how they did this. Three departments 
used observation, two departments used a total competency assessment 
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programme, and one department used supervised transcription of discharge 
prescriptions, one department used an examination, one department used on-
going assessment via an intervention programme, and one department 
completed an audit of completed prescriptions prepared by the pharmacist. 
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Discussion 
 
Critique of method 
There are several areas where it has become apparent that further questioning 
would have been useful; 
 The percentage of the overall prescriptions written in the hospital that 
were written by pharmacists.  
 Is any other type of pharmacist assessment undertaken, as some 
hospitals commented that although they did not complete an 
assessment specifically for pharmacist’s transcription abilities, they 
did complete a whole competence assessment regularly.  
 Is the PDPTS regularly audited?  
 Opinions upon the impact of electronic prescribing on PDPTS 
 Reasons for lack of further extension of PDPTS. 
  
Difficulties obtaining an up to date list of clinical pharmacists resulted in 
some questionnaires being directed to Chief pharmacists and Principal 
pharmacists. This may have affected the response rate and also the 
information in the response, and so may have added some bias to the results. 
A manager such as a chief pharmacist or a principal pharmacist would be in-
directly involved with the service as opposed to a clinical pharmacist who 
would be directly involved with the day to day running of a transcription 
service. Another problem was identifying hospitals that had merged trusts. 
Some of these were not identified until questionnaires were returned, these 
hospitals were then removed from the results. 
It would have been preferable to use a sampling method whereby the 
questionnaire was sent to every hospital in every trust as opposed to just one 
of them. This is because some hospitals have only recently merged trusts and 
therefore they may have different pharmacist prescribing roles & 
transcription services in place from the other hospital(s) in the trust.  
However, time constraints meant that the number of questionnaires would 
have been too great to deal with. 
 
The response rate is slightly less than similar questionnaire surveys 29,31, but 
this may be due to the fact that the questionnaire was sent out in the summer. 
It is doubtful whether sending the questionnaire out at this time of year 
would have introduced any element of bias as the data collection period was 
for 11 weeks and so staffing bias was not anticipated.  
 
Prescribing activities 
The majority of departments have undertaken some form of pharmacist 
prescribing, with the most common type of pharmacist prescribing being that 
of transcribing discharge prescriptions. Those hospitals that offered a PDPTS 
also offered a wider range of other pharmacist prescribing activities than 
those hospitals not offering such a service. Also, teaching hospitals, which 
employ more pharmacists than DGH’s were able to offer PDPTS more 
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frequently. It could be suggested that staffing is a limiting issue in the 
provision of pharmacist prescribing activities. 
 
Prescribing systems 
The ward model of pharmacist transcribing was the most popular model in 
practice (n=38, 78%). Ideally, the ward pharmacist should be writing 
discharge prescriptions whilst on the ward round, when medicine 
management issues can be discussed with the whole team as a collaborative 
process.4 6 The pharmacist could write the discharge prescriptions as the ward 
round is continuing, meaning that as soon as the discharge decision is made, 
the prescription can be written, and passed onto ward technicians to process.  
 
The majority of pharmacists that are transcribing discharge prescriptions are 
writing less than 5 prescriptions per day (52% n= 25/49). As over half of the 
hospitals have less than 5 pharmacists who transcribe prescriptions, it can be 
assumed that the majority of hospitals who run such a service are not having 
a large impact on the overall number of discharge prescriptions being written 
in the hospital. This agrees with the findings of Sexton’s survey of 1999, which 
found that pharmacists were involved in writing discharge prescriptions in 
about a third of hospitals, but their impact was considered to be negligible.29 
 
The transcription services were operating during normal working hours 
Monday to Friday by the majority of department’s (n=32/47, 68%). In light of 
the fact that Slee & Farrar 32 have shown that on weekdays 50% of inpatient 
and 18% of take home prescriptions were written outside the traditional 9-
5pm working day, if a transcription service is going to have a significant 
impact, it needs to be operated over extended hours. The optimum benefit 
from this service provision may actually be from 5pm until midnight when 
junior doctors are working with minimal senior support. It could be 
hypothesized that this time would be the maximum risk for prescribing 
errors. 
 
Training 
Even though all pharmacists who are competent to practice should be able to 
transcribe discharge prescriptions, for the purposes of Clinical Governance, the 
service should be accountable.33 Therefore all pharmacists providing the service should 
be assessed against key competencies, to provide an equivalent service of a suitable 
standard.  
 
 The results show that a relatively low number of hospitals have a formalised 
training programme (n=8). This therefore suggests that when 55% (n=27) said 
that they ask their pharmacists to undertake an in-house training programme 
in order to be authorised to transcribe, some of these training programmes 
may be ad-hoc arrangements. 
The service should also be regularly audited to make sure that standards are 
being maintained. Principles of clinical governance are not being adhered to if 
these issues are not addressed.  
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Future research 
A multi-centre trial needs to be undertaken in order to investigate the 
different models of pharmacist prescribing, & the impact of this service 
development upon the pharmacy department, to enable hospitals that are not 
currently offering pharmacist-prescribing services to introduce the optimum 
service model. Also an economic study to investigate the cost/benefit ratio of 
providing such a service should be undertaken. 
 
In conclusion, 36% (49/135) of pharmacy departments have developed a 
pharmacist discharge prescription service. However, the transcription service 
offered tends to be rather ad-hoc and only available in certain wards or single 
directorates. This may well be due to resource issues. Training & competency 
assessment of this pharmacist role also appears to not meet the requirements 
of clinical governance. Literature supports the valuable patient benefits of 
such a service in terms of reduced waiting time for medicines on 
discharge16,20,14,18 and also reduced error rates1,9,19,14, The service also falls into 
line with the requirements of the Audit Commission report.1  
In order to extend this service throughout hospitals, funding, resources and 
skill-mix maximisation need to be sought. This will enable patients to gain the 
maximum benefit from this service development. 
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Figure 1: Directorates/wards where PDPTS operates. (n=49) 
 
 
Model 
Frequency (%) 
Pharmacists attend whichever ward bleeps them 3 (6) 
Ward Pharmacist model 38 (78) 
Medical pharmacist attends whichever ward 
within the medical directorate bleeps them. 
8 (16) 
Surgical pharmacist attends whichever ward 
within the surgical directorate bleeps them. 
4 (8) 
Ward model plus urgent bleeps 1 (2) 
Ward model plus only at specific times/WR 2 (4) 
Ward model plus odd prescriptions written in 
pharmacy  
1 (2) 
 
Table 1: Model of PDPTS in use.(n=49) 
 
 
 
No. of prescriptions/day  Frequency (%) 
<5 25 (52) 
5-10 17 (35) 
11-15 3 (6) 
16-20 2 (4) 
26-30 1 (2) 
Total 48 (100) 
 
Table 2: Number of pharmacist-written prescriptions / pharmacist / day.(n=49) 
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Advance notice required 
   
Frequency (%) 
Less than 1 hour 16 (33) 
1-2 hours 6 (13) 
3-4 hours 1 (2) 
24 hours 6 (13) 
No rule as such 13 (27) 
Only written whilst pharmacist is on the 
ward 
6 (13) 
Total 48 (100) 
 
Table 3: Advance notice required to produce a prescription (n=49) 
 
Training Frequency (%) 
Clinical certificate 8 (16) 
Clinical Diploma 10 (20) 
MSc in clinical pharmacy 1 (2) 
Designation by senior pharmacist 15 (31) 
2 years ward experience 7 (14) 
3 years ward experience 1 (2) 
In-house training programme 27 (55) 
No further training 7 (14) 
At least 1 year of diploma 
completed 
1 (2) 
Clinical diploma or 3 years 
experience 
1 (2) 
Training programme in 
development 
1 (2) 
 
 
Table 4: Training required for pharmacists to transcribe. (n=49) 
 
 
Frequency of reassessment 
   
Frequency (%) 
Twice a year 2 (4) 
Once a year 1 (2) 
Once every 2 years 3 (7) 
Never reassess 15 (33) 
Not reached a decision 22 (48) 
On-going assessments 3 (7) 
Total 46 (100) 
 
Table 5: Frequency of reassessment of pharmacists providing a PDPTS. (n=49) 
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ABSTRACT  
 
Objectives: To investigate the legal issues concerning authorisation of 
pharmacist transcribed discharge prescriptions and the prevalence of formal 
protocols for such a service. Secondarily, to identify the factors influencing 
the decision upon whether to provide a pharmacist discharge prescription 
transcription service (PDPTS).  
 
Method: Postal questionnaire survey of pharmacy clinical managers.  
 
Setting: Selection criteria included one hospital in each acute trust in the U.K.  
 
Key Findings: The questionnaire completion rate was 66% (135/206). Thirty-
six per-cent (49/135) of pharmacy departments reported that they offered 
PDPTS.  
The majority of pharmacy departments required a medical practitioner to 
counter-sign the pharmacist written prescription (65%, n=31, 1=missing data) 
and had a formal protocol for their PDPTS (57%, n=27, 2=missing data). 
However, seven hospitals reported that they sometimes asked the doctor to 
counter-sign/authorise the discharge prescription, & ten hospitals that they 
did not ask the doctor to counter-sign/authorise the prescription. 
The most common reasons for implementing PDPTS was to reduce delays in 
the discharge process (73% n=35), and decreased errors (50% n=24).  
Amongst pharmacy departments not providing PDPTS, the main reasons 
given for not developing PDPTS were insufficient resources (60% n=18), and 
preferentially developing other services (23% n=7).  
 
Conclusion:  
There is currently no consensus upon authorisation requirements of 
pharmacist-written discharge prescriptions and the legal position is unclear.  
The hospital pharmacy departments that “sometimes” request a medical 
practitioner’s counter-signature raise clinical governance and medico-legal 
issues, especially if their practice deviates from trust policy. 
The reasons given for implementation of PDPTS concur with previous studies. 
[1], [2], [3]  
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The most common reason to not implement PDPTS was staffing resource. 
This would seem to be supported by the fact that the greater the number of 
pharmacists that are employed, the greater the number of pharmacist 
prescribing activities can be offered.[4] 
 
 
INTRODUCTION 
 
We have previously established that in 2001, 36% of hospital pharmacy 
departments in the UK were offering pharmacist discharge prescription 
transcription services (PDPTS)[4]. There are signs that the number of hospitals 
offering such a service is increasing[5]. 
 
Review of the published literature seems to suggest that the advent of 
pharmacists writing discharge prescriptions seems to be a role that is peculiar 
to the UK. Although pharmacists in certain US States have extensive 
prescribing rights in terms of initiating, modifying and discontinuing 
medication, especially in outpatient clinics, [6-8] only one US abstract could 
be identified which concluded that pharmacists should write discharge 
prescriptions on the basis of less adverse drug events and more cost-
effectiveness when compared to those written by physicians and nurse 
practitioners. [9] No such literature could be found from European sources. 
This could well be due to discharge prescription provision not being such a 
source of delayed discharge or error in these countries. Also primary care 
may be more involved in the discharge process. 
 
 It was apparent from the first cohort of pharmacists taking the 
supplementary prescribing courses in London that the most common 
supplementary prescribing role for pharmacist prescribers in secondary care 
is outpatient medication review clinics in specialist clinical areas.[10] Personal 
communication with the London supplementary prescribing project group 
(BPC Harrogate 16th September 2003) suggests that although no pharmacists 
in the first cohort are planning to write discharge prescriptions, the issue of 
whether PDPTS could fit into the supplementary prescribing model is still 
under discussion. However, it is doubtful whether this process could fit the 
supplementary prescribing model. 
 
There is currently no legal framework for non-medical professionals to write 
discharge prescriptions. In the absence of a recognised definition of 
transcribing, it is also unclear whether the process of writing the discharge 
prescription is prescribing or transcribing.  
The current guidance in the Medicines, Ethics & Practice guide suggests that 
the process is transcription, and states that “Providing the entry (upon the 
patient’s bed card) fulfils the requirements, the details can be transposed onto 
 458 
an order form, to be used in pharmacy to prepare the take home medication. 
It is good practice for the transposition to be carried out by a pharmacist. By 
carrying out this transposition the pharmacist is NOT prescribing, as the 
original direction to supply was made by a practitioner.” [11] 
 
However, in undertaking the act of transcription, there is an implied 
professional obligation upon the pharmacist to review the prescribed 
medicines and to respond appropriately to any errors or inappropriate 
prescribing. If this process did not occur then you would not need a 
pharmacist to copy one list of medicines to another- a medical secretary 
could do this. Therefore does this professional review of the prescription 
change the process from merely transcribing to prescribing? 
One of the key issues seems to be the question of who is legally responsible 
for the prescriptions that are written by pharmacists in this situation. –
Anecdotal evidence suggests that some hospitals operating PDPTS are asking 
the doctor to co-sign the prescriptions that are written by pharmacists, whilst 
other hospitals are not. 
The Department of Health’s recent discharge document[12] suggests that the 
medical practitioner is still responsible for signing the prescription where 
medication changes have been made. This would suggest that only if the 
pharmacist reviews the drug chart & wants to change any of the medications, 
the discharge prescription would need signing by the doctor. If the 
pharmacist makes no changes to the medication, it would not need signing 
by the medical practitioner. So does this suggest that the doctor would still be 
legally responsible for the discharge prescription that is written & signed by 
a pharmacist? 
Due to the legal status & responsibility for these prescriptions written by 
pharmacists being so unclear, these issues could be considered a potential 
barrier to development of PDPTS. Therefore authorisation requirements for 
pharmacist-written discharge prescriptions were also investigated, together 
with the prevalence of formal protocols for PDPTS within hospital pharmacy 
departments offering such a service. 
There have been many reports advocating the benefits of providing PDPTS.[1-
3, 9, 13-17] It has been suggested that services such as PDPTS can speed up 
the discharge process,[2, 3, 15, 16, 18], reduce errors on discharge 
prescriptions[1, 15-18] and also help to release junior doctor time[1, 13, 15]. 
However, there is no consensus view available upon the benefits of the 
process. It is also unknown how much influence these factors have upon the 
decision to provide a PDPTS service. It is important to establish these driving 
factors, as they will be applicable for other pharmacist prescribing roles and 
the impact of these factors upon service development could be considerable.  
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METHODS 
 
Questionnaire development 
Pharmacists from two hospitals with an existing PDPTS were visited to 
inform the development of a written, self-completion questionnaire 
containing a mixture of open & closed questions. Construction of the 
questionnaire was also aided by a literature review undertaken before the 
survey was developed.  
The questionnaire included the following sections: Section A inquired about 
general demographic data, Section B inquired about different prescribing 
roles undertaken, and amongst those departments not offering PDPTS, their 
reasons for not providing this service. The rest of the questionnaire sought to 
establish the details of PDPTS provision.  Section C inquired about the extent 
of the service provision amongst those hospitals that do offer a transcription 
service (i.e. directorates/wards covered and times service is available), the 
model of service used, and their reason(s) for providing PDPTS. 
Confidentiality was maintained by number-coding the questionnaires. 
 
Validation and piloting 
Face-to-face interviews with pharmacists (from hospitals with and without a 
pharmacist transcription service) were used to validate the questionnaire. 
These hospitals were chosen from the same region as the research team for 
ease of travel.  The questionnaire was then piloted in 20 randomly chosen 
hospitals from Wales, Scotland, England & Northern Ireland during July 
2001. Minor adjustments to the instructions for completing the questionnaire 
were made as a result of this pilot study. Advice on data analysis was sought 
from a medical statistician.   
 
Main survey 
The questionnaire was distributed at the end of August 2001 to each NHS 
trust providing acute hospital services in the UK. Single hospitals from each 
trust were identified using a combination of the UK Drug Information 
Pharmacists’ Group Directory[19] and the Chemist and Druggist 
Directory.[20] The questionnaire was sent to one hospital from each trust. 
Some questionnaire responses established that hospitals had recently merged 
with another trust. If this was the case, the response from that hospital was 
removed from the database.  
The questionnaire was accompanied by a letter, which included recognised 
descriptions of independent & dependent (now supplementary) prescribing 
[21], and the researcher’s definition of transcribing, in order to clarify 
recipient’s understanding of the different types of prescribing.  
The covering letter was addressed to the Chief Pharmacist, principle 
pharmacist or clinical services manager, according to which name could be 
found in the Chemist & Druggist Directory[20]. The recipient was requested 
to pass the questionnaire onto the most relevant person to complete (if it was 
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not themselves). A freepost-addressed envelope was included for return of 
the questionnaire. 
No deadline was placed on completion of the questionnaire, but non-
respondents were followed up by a telephone call after 3 weeks and then 
again at six weeks. Further copies of the questionnaire were sent out to those 
who requested them. The final deadline for accepting returned 
questionnaires was 11 weeks after they had been originally posted. 
Data obtained from returned questionnaires were coded and analysed using 
the Statistical Package for the Social Sciences (SPSS) version 10, and the 
significance of the association between variables was assessed using chi-
squared and Kruskal-Wallis, and bivariate correlations (Spearman’s rho) 
where appropriate. 
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Results  
 
General demographics 
A total of 234 hospital pharmacy departments were identified, of which 20 
were used for piloting the questionnaire, leaving 214 hospitals for the main 
study. Eight of these hospitals were removed after it was established that 
they had merged with another Trust, leaving 206 hospitals eligible for the 
study. Of these 206 hospitals, responses were received from 66 per cent 
response rate (n=135). Sixty-eight per cent of responses (n=92) from district 
general hospitals, 27 per cent (n=37) from teaching hospitals, and 4 per cent 
(n=5) from tertiary referral centres.  
The questionnaire was completed by clinical pharmacist/managers (26 per 
cent, n=35), chief pharmacists (26 per cent, n=35) principal pharmacists (25 
per cent, n=34), pharmacy managers (7 per cent, n=10), deputy chief 
pharmacists (5 per cent, n=7), medicines information manager/pharmacists 
(4 per cent, n=5), discharge services pharmacist (4 per cent, n=5) and one 
interface pharmacist (1 per cent, n=1).  
The size of the hospitals varied, with bed numbers ranging from <100 to 
>1,500, with the most common being 401-600 (33 per cent, n=44). 
Thirty-six per-cent (49/135) of pharmacy departments reported that they 
offered PDPTS.  
 
Responsibility and accountability 
 
Although the majority of hospitals operating PDPTS had a formal protocol for 
the service in place, (57 per cent, n=27), a substantial number did not have a 
protocol in place (43 per cent, n=20) however, 6 of these hospitals were in the 
process of drawing one up. (2= missing data) 
 
The majority of hospitals that offer PDPTS ask the doctor to counter-
sign/authorise the prescription written by the pharmacist before the patient is 
discharged (65 per cent n=31/48) (1=missing data). However, seven hospitals 
reported that they sometimes asked the doctor to counter-sign/authorise the 
discharge prescription, & ten hospitals that they did not ask the doctor to 
counter-sign/authorise the prescription. 
Those pharmacy departments that did not ask the doctor to co-sign the 
prescription often asked the doctor to indicate in some other manner that they 
wanted the pharmacist to write the prescription and were satisfied that the 
current medication was suitable for the patient at discharge. Three 
departments used verbal authorisation, two departments asked the doctor to 
sign the in-patient drug chart, two departments “sometimes” asked the doctor 
to sign the in-patient drug chart and one asked the doctor to sign a separate 
form. Two departments did not ask the doctor to indicate in any other 
manner of his/her authorisation to write the prescription. 
Among the hospitals that “sometimes” asked the doctor to counter-sign the 
pharmacist-written prescription, only one hospital had an alternative method 
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of authorisation, which was to sometimes ask the doctor to counter-sign the 
in-patient drug chart. 
 
All of the hospitals were asked if the doctor indicated in any other manner 
that he/she gave authorisation for certain drugs to be prescribed on discharge 
by the pharmacist (Table 1). The most common method used for indicating 
which drugs the patient was to be discharged upon was verbal authorisation 
(15 per cent, n=7), (1=missing data) followed by the doctor sometimes signing 
the drug chart (13 per cent, n=6). The twenty-six reported methods of 
authorisation other than countersigning were used by twenty-one pharmacy 
departments indicating that some departments used several different 
authorisation methods. The remaining twenty-seven pharmacy departments 
did not use any other methods of authorisation. 
 
Factors that influence the provision of a PDPTS 
 
Pharmacists in hospitals that do offer PDPTS (n=49/135) were asked their 
reasons for offering the service, via an open question. (1=missing data) The 
results are presented in Table 2. Most hospitals gave more than one reason for 
providing PDPTS. The most common reason for implementing PDPTS was to 
speed up the discharge process (73 per cent, n=35), followed by to improve 
accuracy/decrease errors/improve quality (50 per cent, n=24). Thirty-three 
per cent (n=16) stated that the service was implemented to release junior 
doctor time.  
 
Of the departments not offering a pharmacist discharge prescription 
transcription service (PDPTS), 42% (n=36/86) indicated that there had been 
discussions about pharmacist transcribing, but no decision made as yet. 34%, 
(n=29/86) indicated that there were no plans for such a development, and 
22% (n=19/86) said that they were currently developing such a service.  (2= 
missing data) 
The pharmacy departments that had no plans to implement PDPTS were 
asked, via an open question, for their reasons against introducing this service. 
The results are shown in Table 3.  
The most frequently cited reason for not implementing a transcription service 
was insufficient resources (58 per cent, n=18), followed by development of 
other medicines management services in preference to pharmacist 
transcription of discharge prescriptions (e.g. Patient’s Own Drugs (PODs) and 
one-stop dispensing) (23 per cent, n=7, 4=missing data) 
At no point were legal issues suggested as a factor against the provision of 
PDPTS.  
 
At the end of the questionnaire, respondents were asked whether they had 
any further comments. In this section, amongst the hospitals that did not 
provide PDPTS, a total of 24 comments were made. 11 of these hospitals 
commented that they were currently considering the implementation of 
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PDPTS, although 4 hospitals also commented that this did depend upon 
staffing/funding resources. 3 hospitals also positively commented that there 
were clear benefits of PDPTS. Only two comments suggested that there would 
be opposition of PDPTS implementation by medical staff: 
 
1.) “Despite continuous problems with delayed discharges due to TTO’s not 
being ready, we are likely to meet resistance to pharmacists transcribing 
TTO’s from our medical director. He is of the opinion that pharmacists 
should not write on prescription charts at all, but should be educating & 
instructing the junior doctors on how to do it.” 
 
2.) “A pilot project run 2-3 years ago of a pharmacist writing discharge 
prescriptions for medical patients worried medical staff so much that they 
got their act together (temporarily). There were problems predicting discharge 
doses e.g. reducing steroid doses. The project was not continued.”  
 
As stated earlier, some hospitals were not introducing PDPTS due to other 
services or electronic prescribing being implemented preferentially instead 
(Table 3). Three similar comments were also made in the open comments 
section about the potential impact of electronic prescribing upon the need for 
PDPTS: 
  
3.) “This will be superseded by electronic prescribing”  
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Discussion 
 
Responsibility & accountability 
Although PDPTS is widespread, the results of this study indicate that there is 
a lack of consensus on authorisation requirements for pharmacist-written 
prescriptions. The Medicines Act 1968 [22] does not define what a 
prescription is or what a hospital is. It is therefore not surprising that there is 
no authoritative interpretation of the legality of prescriptions written by non-
medically qualified personnel.[23] However, this position does not seem to be 
a perceived barrier to pharmacists when implementing PDPTS. 
 
  A few hospitals commented that although it was in their official policy that 
the doctor should always sign the prescription (and had indicated this in their 
questionnaire response), in practice this did not always happen. Some 
respondents indicated that they sometimes obtained a doctor’s counter-
signature on their pharmacist-written discharge prescriptions. This approach 
is unlikely to be compliant with their protocols and raises a clinical 
governance issue. If there are mistakes on the prescriptions produced in this 
scenario, who is responsible and accountable for the overall quality of the 
prescription, shortcomings in care or even harm to the patient?  
Those hospitals operating PDPTS without having a formal protocol in place 
(43 per cent, n=20) are also not following the principles of clinical governance 
as they do not have an accountable, safe system in place and are not 
providing their employee pharmacists with formalized support.  
 
Another perceived problem in the provision of PDPTS is that prescribing and 
clinical checking roles are not separated thus creating a risk management 
issue. Some hospitals have overcome this issue by swapping the prescribing 
and checking roles with the doctor, so that the pharmacist writes the 
prescription and the doctor checks and signs it.[1, 2] 
However, it could be argued that due to time constraints upon the doctor, the 
prescription in this situation may be authorised, but the clinical check may 
not always happen.  
 
There is currently no legal route for non-medical professionals to write 
discharge prescriptions. A patient group direction (PGD) is a written direction 
relating to supply and administration, or just administration, of a prescription 
only medicine (POM) (or Pharmacy-only medicines (P) and general sales list 
medicines (GSL) to persons generally (subject to specified exclusions) in 
specific situations and is signed by a doctor or dentist and a pharmacist.[24] 
The advent of PGD’s would not enable pharmacist prescribing of discharge 
prescriptions as the drugs and clinical situation need to be specified in the 
PGD. 
Similarly, for PDPTS to fit into the proposed model for supplementary 
prescribing, a clinical management plan would need to be written for every 
patient with a pharmacist-written discharge prescription. This is clearly 
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impractical. This obstacle may mean that some hospitals will continue with 
their own methods of authorisation of discharge prescriptions instead of 
attempting to conform with the requirements of supplementary prescribing. 
 
It is apparent that there are several unanswered legal issues surrounding 
PDPTS.  
• It is unclear whether the process itself is transcribing or prescribing. – 
Would a court of law view that a process whereby a list of medications 
was reviewed by a pharmacist and written on a document that was 
later accepted for dispensing at a pharmacy was not in fact prescribing 
but something else entirely? 
• Who is legally responsible for the prescriptions that are written in this 
scenario? Therefore, who should authorise these prescriptions? 
 
Therefore central guidance from the Department of Health and tailored 
provision of training and assessment from higher education institutions 
should be provided for this specific role, as per the supplementary 
prescribing model. Without standardised guidelines for this process, it could 
be viewed as a disaster waiting to happen. 
 
Factors that influence the provision of a PDPTS 
The most frequent reason cited for providing a PDPTS was to speed up the 
discharge service (73 per cent, n=35). Published studies provide evidence to 
support this reasoning.[2, 3, 15, 16, 18]  
The system where medical practitioner’s write patient’s discharge 
prescriptions at the end of the ward round when the consultant has decided 
that the patient is medically fit to go home is flawed, and leads to long 
waiting times for patients.[3]  
The Department of Health’s current discharge document suggests that in 
order to improve & speed up the discharge process, the roles of junior doctors 
and pharmacists in taking medication histories on admission and writing up 
take home medication needs to be reviewed. [12] It also suggests that the 
discharge process should be planned for at the earliest opportunity. Therefore 
by pharmacists writing discharge prescriptions in a more timely manner, the 
discharge process could be more efficient. If PDPTS was combined with a 
“one-stop” dispensing service[25] the discharge prescription processing time 
could be even further reduced, with both the prescription and supply of 
medications for discharge being managed by pharmacy.  
 
The next most commonly cited reason for providing a PDPTS was to reduce 
errors on prescriptions/improve accuracy (50 per cent, n=24). This reason is 
also supported by published literature,[1, 15, 16, 18] and also by the Audit 
Commission report “A spoonful of sugar,”[17] which has reported that 
pharmacists are five times more accurate than doctors in writing discharge 
prescriptions. Prescribing by newly qualified doctors is currently under 
particular scrutiny as a result of changes in junior doctor training.[26] 
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It is apparent that extending prescribing rights to pharmacists will help 
towards meeting the Government targets of reducing serious medication 
errors by 40% by 2005.[27] The presence of a pharmacist on clinical ward 
rounds has also been shown to prevent further errors occurring,[17] 
suggesting that pharmacists are also well placed to make interventions and 
review medication on the ward round as part of PDPTS.  
If these systems were in place the flow of work in the dispensary would also 
be improved as errors would be rectified before the discharge prescription 
was written[18].  
 
Thirty-three per cent (n=16) of departments operating a PDPTS stated that 
one of their reasons for implementing the service was to release junior doctor 
time. Junior doctor time would not only be saved by not having to write the 
discharge prescriptions, but also from the reduced amount of time having to 
answer their bleep to rectify errors and omissions with the pharmacy 
department. The time saved by doctors from implementing such a service has 
been estimated as seven hours per doctor over a 3-month period,[1] 2 hours 
per doctor per week[13] and also 45 minutes per doctor per day.[15] Some 
pharmacy departments have managed to obtain funding for extra 
pharmacists to perform this role from resources provided to reduce junior 
doctors working hours.[28] This may be an option for consideration by those 
hospitals that had not implemented PDPTS due to funding problems. 
 
One of the main reasons for not introducing PDPTS was lack of resources 
(n=18), and this claim is supported by the fact that the more pharmacists that 
are employed, the more pharmacist prescribing activities can be 
implemented.[4] Although insufficient pharmacist resource is a major 
obstacle to PDPTS implementation, if pharmacy services are examined there 
are many ways in which departments can become more efficient in the way 
that they work, for example, by moving towards a pharmacist-free 
dispensary, and developing ward pharmacy teams of a pharmacist and 
technicians and assistants.[29-31] This re-examination of the way that 
pharmacy departments work may release some pharmacist time for new roles 
including prescribing.  
The first and second comments made by questionnaire respondents in the 
results section illustrate potential difficulties some pharmacy departments 
may have in extending their role. Views upon the extension of the pharmacist 
role by medical staff may be due to individual personalities and beliefs of the 
medical practitioner, who may not fully understand the level of training that 
pharmacists receive. This situation may improve if chief pharmacists are 
elevated to the equivalent of a clinical director, and are members of the trust’s 
management executive, as recommended by the Audit Commission report “A 
Spoonful of Sugar”.[17] The chief pharmacist will then be in a stronger 
position to develop changes in pharmacist’s practice. Also the implementation 
of the government plans for pharmacists to become supplementary 
prescribers will mean that this type of opinion will inevitably change.[32] 
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When level 3 electronic prescribing is implemented, there will still be a role 
for the pharmacist to decide upon the appropriateness of treatment on 
discharge and input the discharge prescription onto the computer. 
Pharmacists are already using electronic prescribing systems in this manner, 
and have become more integrated into the healthcare team. [28-33] Therefore, 
the advent of electronic prescribing should not be seen as the end of the 
involvement of pharmacists in the discharge process, which was inferred in 
the third comment presented in the results section. 
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Tables: 
 
Authorisation method Frequency (%) 
Doctor always signs the in-patient chart 4 (8) 
Doctor sometimes signs the in-patient chart 6 (13) 
Doctor signs a separate authorisation form 4 (8) 
Doctor authorises discharge prescription in medical notes 3 (6) 
Doctor verbally authorises the discharge prescription 7 (15) 
Doctor writes information on the in-patient chart about 
discharge 
2 (4) 
No alternative authorisation method used 27 (56) 
 
 
Table 1: Methods of authorisation of pharmacist-written discharge prescriptions by 
the doctor (other than counter-signing the discharge prescription).(n=48) 
 
 
Reason 
Frequency (%) 
Speed up the discharge process 35 (73) 
Improve accuracy/decrease errors 24 (50) 
Reduce junior doctor time 16 (33) 
Increase efficiency in dispensing process 9 (19) 
Cost savings Re: use of PODs 7 (15) 
Enhance pharmacist role/job satisfaction 6 (13) 
Improve communication with primary care 5 (10) 
Decrease waste prescribing 4 (8) 
Increased counselling opportunities 2 (4) 
Decrease nursing time 2 (4) 
Risk management 1 (2) 
Improve patient care 1 (2) 
 
Table 2: Reasons FOR provision of a PDPTS (n=48) 
 
 
Reason Frequency (%) 
Insufficient resources 18 (62) 
Other services being developed preferentially 7 (24) 
No plans/Discussion as yet about providing PDPTS 6 (21) 
Lack of funding 4 (14) 
Electronic prescribing system under development, so not 
applicable 
4 (14) 
Viewed as an administrative role 2 (7) 
Service would be for the doctor’s benefit only 1 (3) 
 
Table 3: Reasons NOT to provide PDPTS. (n=29) 
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 Abstract 
 
Purpose  To provide information on the implementation of supplementary 
prescribing by pharmacists within primary and secondary care in England. 
 
Methods  Postal questionnaire survey of chief pharmacists within secondary 
care and primary care trust pharmacists in primary care in England.  
 
Results   The response rate was 68% for both surveys.  Both sectors intended to 
implement supplementary prescribing by pharmacists by the end of 2005 
(57%, n=55 and 56%, n=100 respectively). 
The majority of the chief pharmacists did not believe that it would be more 
difficult to recruit designated medical practitioners (DMPs) to supervise 
supplementary prescribing training for pharmacists as opposed to nurses 
(67%, n=43), whereas the largest group of primary care trust pharmacists did 
think this would be the case (47%, n=86). Reasoning included “GPs do not 
understand a pharmacist’s skills/ do not have an established relationship 
with them”, “Pharmacists are viewed as being business focused/ non-NHS” 
and “pharmacists are seen as a threat.” 
Within secondary care, the clinical areas in which pharmacists were intending 
to work as supplementary prescribers were those where they already had 
established roles. Within primary care, the main clinical areas for pharmacists 
were influenced by those areas in the new General Medical Services (GMS) 
Quality and Outcomes Framework for general practitioners (GPs). 
 
Conclusion  Although the intentions of chief pharmacists and primary care 
trusts are very similar in terms of implementation of supplementary 
prescribing, the results of this study illustrate that community pharmacists 
face more obstacles, such as obtaining funding for new prescribing services 
from the new pharmacy contract. 
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Introduction 
 
On 21st November 2002, it was announced that supplementary prescribing by 
nurses and pharmacists was going to become legalized in the United 
Kingdom, pending legislative changes. [1] Pharmacists started training in 
England & Wales for supplementary prescribing in spring 2003, [2] and the 
first pharmacist-written prescription was reported in March 2004. [3] 
Supplementary prescribing has been defined as “a voluntary prescribing 
partnership between an independent prescriber and a supplementary 
prescriber, to implement an agreed patient-specific clinical management plan 
with the patient’s agreement.” [4]  Whereby the independent prescriber is a 
fully registered medical practitioner or dentist, whose responsibility is to 
assess patients with undiagnosed conditions and to decide upon the clinical 
management required for that patient, including prescribing. 
(A glossary is included within this paper to define UK-specific terminology.) 
It has recently been announced that supplementary prescribing will be 
extended to registered chiropodists/podiatrists, physiotherapists, 
radiographers[5] and also optometrists[6].  
There are currently 532 registered supplementary prescribing pharmacists 
(June 2005) out of a total of 44,951(2005) pharmacists on the register (1.2%), 
however, not all of these may currently be utilizing their new prescribing 
skills. [7]  
This new role has been viewed as a major step forward in the development of 
the pharmacists role. Although this is the first time that pharmacists are 
legally able to prescribe, it has been acknowledged that pharmacists had 
already been “prescribing” and had circumvented problems that arose from 
the legislative controls upon prescribing, by asking doctors to sign 
prescriptions that they had written. [8, 9] For example, several UK reports 
have identified prescribing roles such as in pre-admission clinics, to obtain 
patient medication histories and to write the in-patient drug charts as well as 
the discharge prescription according to set protocols[10-12], outpatient clinic 
prescribing,[13]and writing discharge prescriptions[14-17]. The model of 
supplementary prescribing may not be suitable for all of these prescribing 
roles, especially writing discharge prescriptions. 
 
The development of the prescribing role for pharmacists parallels practice 
issues in other countries, notably the establishment of collaborative practice 
agreements in the USA. The development of supplementary prescribing has 
been informed by this collaborative drug therapy management model. In this 
model, the pharmacist has a collaborative arrangement with a physician to 
dependently prescribe certain medications as agreed in a management plan. 
[18-20] In some cases, clinical pharmacy specialists are also prescribing 
independently, especially in veteran’s affairs medical centres, which allow 
greater freedom to prescribe under locally agreed protocols.[21, 22] 
Since some pharmacists in the USA have been involved in prescribing 
medications for patients as part of drug therapy management services for 
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such a long time, much has been learnt from their experiences in the 
development of pharmacist prescribing in the UK.  Experience in the USA has 
also shown that even when legislation is in place for pharmacist prescribing 
to take place, certain barriers, such as establishing a working relationship 
with physician colleagues, have to be overcome in order for a successful 
service to be developed.[23]With the aid of such experience, it is hoped that 
the introduction of supplementary prescribing in the UK will be more 
straightforward. 
The supplementary prescribing training programme comprises at least 26 
taught days (25 for pharmacists) at a higher education institution and 12 days 
“learning in practice”. This time would normally be spread over a period of 3 
to 6 months. [4] The time spent “learning in practice” is supervised by a 
medical practitioner, who is known as the “Designated Medical Practitioner.” 
A nurse wishing to train as a supplementary prescriber must be a 1st level 
registered nurse or registered midwife, should have the ability to study at  
undergraduate degree level, at least 3 years post-registration clinical nursing 
experience, will usually be E grade or above and have the support of their 
employer.[4] 
A pharmacist wishing to train as a supplementary prescriber must be fully 
registered, have the ability to study at a minimum of undergraduate degree 
level, have at least 2 years experience as a pharmacist post registration and 
the support of their employer. [4] 
A chiropodist/podiatrist, physiotherapist or radiographer must have the 
ability to study at a minimum of undergraduate degree level, and must have 
at least 3 years relevant post qualification experience and have the support of 
their employer[5] (It is anticipated that optometrists will have similar training 
requirements). 
The supplementary prescriber is responsible for the continuing care of 
patients who have been clinically assessed by an independent prescriber. This 
continuing care may include prescribing, which will usually be informed by 
clinical guidelines and will be consistent with individual treatment plans; or 
continuing established treatments by issuing repeat prescriptions, with the 
authority to adjust the dose or dosage form according to the patient’s needs 
and as defined by a clinical management plan. There should be provision for 
regular clinical review by the assessing clinician. [24] 
Supplementary prescribing is primarily intended for use in managing specific 
chronic medical conditions which must be specified in the clinical 
management plan. 
It is intended that supplementary prescribing will provide patients with 
quicker and more efficient access to medicines, and make the best use of the 
skills of trained nurses and pharmacists. It is also hoped that the process will 
help to release doctors time so that they can concentrate on patients with 
more complicated conditions and more complex treatments. [4] 
Although medicines legislation permits the introduction of supplementary 
prescribing across the UK, it is for the devolved administrations in Scotland, 
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Wales and Northern Ireland to decide whether and how it is implemented for 
the NHS in their countries. [4]  
Further detail upon supplementary prescribing can be found at the 
Department of Health’s website. [25] 
There is no national strategy to guide which clinical areas supplementary 
prescribers should practise in, or where areas of expertise should be 
developed. Without this, development of supplementary prescribing will 
happen in an ad hoc way. [26] This represents a missed opportunity to target 
these extra prescribing resources upon health areas that need improvement 
within the population, such as heart disease.  Therefore it is important to 
establish which clinical areas pharmacists and nurses are using their 
supplementary prescribing qualification in, so that it may be possible to start 
considering whether the clinical areas are most beneficial from a strategic 
viewpoint. Chiropodists/podiatrists, physiotherapists, radiographers and 
optometrists will use their prescribing skills in very narrow, specialist areas, it 
is therefore not expected that there will be any overlap of their prescribing 
area with other non-medical prescribers. 
Although supplementary prescribing has been a very topical subject in the 
pharmacy profession, there is no information available yet on how 
supplementary prescribing is currently being implemented within primary 
and secondary care, and in which clinical areas. Also the further role 
extension to independent prescribing (where the pharmacist/ nurse/ other 
health care professional has full responsibility for the diagnosis, monitoring 
and on-going treatment of a specified patient’s condition) will benefit from 
the experience gained with supplementary prescribing.  It is estimated that 
the legislation for independent prescribing by pharmacists will be in place by 
the end of 2005, [27] after the consultation period finished in May 2005[28]. 
 
The main differences between pharmacist prescribing in the USA and the UK 
are that in the UK, supplementary prescribing represents a more co-
ordinated, centralized approach, where the same model is being used 
nationally, with an associated formal training process and stipulated 
competencies (in areas including communication, consultation skills and 
diagnostic skills) that the pharmacist needs to achieve in order to qualify as a 
supplementary prescriber. Unlike the USA, where the pharmacist prescriber 
needs to be credentialed by their individual institution[23]to provide drug 
therapy management services, in the UK, once the pharmacist has attained 
the supplementary prescriber qualification, they can move to any secondary 
or primary care trust and the supplementary prescriber qualification will be 
recognized (However, the non-medical prescriber does always need to 
prescribe within the limits of their own competencies). 
Collaborative practice protocols are very similar to the clinical management 
plan (CMP) that is used in supplementary prescribing, but a CMP has to be 
written individually for each patient that is seen, and also has to be agreed by 
the patient and the independent prescriber. Therefore rather than a general 
protocol being produced which applies to all patients being seen with a 
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certain condition, the CMP is very much a tailored document for each patient 
that is seen by the non-medical prescriber. 
  
The objectives of this research work were to establish how chief pharmacists 
in secondary care, and primary care pharmacists in primary care, were 
implementing pharmacist supplementary prescribing within their trusts. The 
study would also provide detail on the numbers of pharmacists who were 
being trained as supplementary prescribers, which type of pharmacists were 
being trained and the therapeutic area they would be working in.  
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Methods 
 
A questionnaire was designed which was sent to pharmacists in primary and 
secondary care trusts who would be overseeing implementation of 
supplementary prescribing by pharmacists. 
Within secondary care, the chief pharmacist of the trust would be responsible 
for this, whereas for primary care, the person who would manage the 
development of supplementary prescribing was less clear. 
General practices in England are grouped into primary care trusts (PCTs) 
which hold the healthcare budget (for both primary and secondary care) for 
approximately 120,000 patients. [29] The PCT can invest in, develop and 
commission primary and community care health services. 17 Pharmacists are 
employed by PCTs to control drug prescribing budgets. Some primary care 
pharmacists are entitled “pharmaceutical advisors” whose role also includes 
policy development. Most work with individual GPs to assist with drug 
audits and medication review.  
The establishment of this new professional group of pharmacists was not 
linked to a deliberate plan or change in health policy with respect to 
pharmacist development. [29] Therefore not all PCTs in England employ a 
pharmacist, or may employ them only on a sessional basis. Therefore it was 
decided to aim the questionnaire at a more generic title of “primary care trust 
pharmacist” if there was not a named pharmaceutical adviser available. If a 
PCT did not employ a pharmacist, then they were not included in the survey. 
The survey was limited to acute secondary care NHS trusts and primary care 
trusts in England as the health care provision is set up differently in Wales, 
Scotland and Northern Ireland.  
 
Questionnaire development 
 
Construction of the questionnaire was aided by literature review. A list of 
pharmacists holding important positions in England (policy-
making/academic) were also identified, and asked to advise on key questions 
with respect to supplementary prescribing.  
 
Unstructured interviews were then held individually with a clinical 
governance lead, a nurse educator on a supplementary prescribing course, a 
chief executive of a hospital and a clinical governance co-ordinator (n=4) in 
order to develop a more detailed perspective on the issues and risks 
surrounding the development of supplementary prescribing. 
These data were then used to suggest topics for discussion at a focus group 
(n=4). The focus group was arranged in order to more clearly define the key 
areas which the questionnaire ought to investigate. The focus group’s 
participants included a professor of pharmacy practice, a nurse senior lecturer 
who had developed a supplementary prescribing training course, a chief 
pharmacist and a clinical governance lead. The focus group were asked to 
discuss issues surrounding the risks and benefits of supplementary 
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prescribing, and also its implementation. Issues surrounding the designated 
medical practitioners (such as availability and quality) were also discussed 
along with responsibility and accountability. The data from this focus group 
was audiotaped and transcribed verbatim. The data was then reviewed 
systematically in order to refine developing categories of data. Key themes 
that emerged from this data were used to develop the questions in the 
questionnaire. 
 
One questionnaire was designed for chief pharmacists (CP) of secondary care 
acute hospital trusts, and a very similar questionnaire, with minor differences 
in orientation, was designed for primary care trust pharmacists (PCTP). The 
questionnaire was divided into three sections. Section A contained closed 
questions which inquired about demographic data about themselves and 
their trust. Section B contained mostly closed questions and one open 
question about recruitment of designated medical practitioners. This section 
inquired about the implementation of supplementary prescribing within the 
trust and Section C used closed questions in the format of a Likert scale in 
order to measure the respondent’s attitude to a number of statements about 
supplementary prescribing. Detailed results from section C of this 
questionnaire will be discussed in a further publication. Confidentiality was 
maintained by number-coding the questionnaires. 
Advice from a medical statistician and also ethical permission for the study 
was sought and obtained (from multi-centre research and ethics committee 
(MREC)). 
 
Validation and piloting 
 
In order to assess face validity of the secondary care questionnaire, one CP 
was observed whilst completing the questionnaire and discussed any 
ambiguities that arose with the researcher, and another CP completed the 
questionnaire and posted it back with written comments. Minor adjustments 
were therefore made to the question structure to clarify these ambiguities. 
Although this process does not constitute full validation, face validity was 
further assessed in responses to the pilot questionnaire for both primary and 
secondary care. 
In order to validate the primary care questionnaire, one PCTP completed the 
questionnaire and provided feedback via telephone and the other PCTP 
completed the questionnaire and provided written feedback. 
Reliability of the survey tool cannot easily be tested (test-re-test reliability) as 
it would produce survey fatigue if re-tested in the same, limited, population.  
 
During February & March 2004, the secondary care questionnaire was piloted 
in 17 randomly selected hospitals from the sample (n=168). 
At the same time, the primary care questionnaire was piloted in 30 randomly 
selected pharmacists from the sample (n=303).  Several amendments were 
made to the questionnaire after piloting. Some questions were removed in 
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order to reduce the length of the questionnaire and some questions had extra 
options added or removed from them. Therefore, data collected from the pilot 
questionnaires were not included in the final analysis.  
 
Main Survey 
 
Both questionnaires were distributed in May 2004. The secondary care 
questionnaire was posted to CPs within every NHS trust in England 
providing acute hospital services. Single hospitals within each trust were 
identified using a combination of the Chemist & Druggist Directory[30] and 
the Guild of Healthcare pharmacists’ chief pharmacist mailing list [31]. The 
questionnaire was randomly sent to one hospital from each trust, (using a 
random number generator). Responding hospitals which had merged with 
another trust were removed from the study. 
The primary care questionnaire was sent to the named PCTP/pharmaceutical 
advisor within each primary care trust (a questionnaire was not sent to the 
primary care trust if they did not employ a pharmacist) in England. The 
primary care trusts and named pharmaceutical advisers/PCTP were 
identified using Medendium[32]. 
 
Following piloting, a total of 151 hospital pharmacy departments were 
included in the main study. Eight of these hospitals were removed from the 
study after it was established that they had merged with another trust or were 
not an acute trust, leaving 143 hospitals for the study. 
For primary care, after piloting, 273 primary care trusts were included in the 
main study. Two of these trusts were removed from the study after it was 
established that they were not a primary care trust or did not have a 
pharmacist employed as a pharmaceutical advisor. This left 271 primary care 
trusts eligible for the study.  
 
The questionnaires were accompanied by a letter to explain the study and a 
freepost envelope was included for return of the questionnaire. 
Follow-up was via a second mail shot of the questionnaire to non-responders 
after 3 weeks, and then a telephone follow up after a further 4 weeks 
(secondary care) or another questionnaire mail shot (primary care). After a 
further 3 weeks a last mail-shot of the questionnaire was sent out to any 
remaining non-responders. A final deadline for accepting returned 
questionnaires was set at 13 weeks after the questionnaires had originally 
been posted. 
The larger sample size in the primary care group required the use of postal 
(rather than telephone) follow up. 
The data was also analyzed by region/strategic health authority that the 
hospital or primary care trust (PCT) was from in order to assess whether there 
were any poor responses from particular regions. 
Data obtained from returned questionnaires were coded and analyzed using 
the Statistical Package for the Social Sciences (SPSS) version 11, and the 
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significance of the association between variables was assessed using the non-
parametric tests chi-squared, Kruskal-Wallis, Mann-Whitney U and bivariate 
correlations (Spearman’s rho), where appropriate.  
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Results 
 
General demographics 
 
Of the 143 hospitals, responses were received from 97 (68% response rate) and 
for the primary care trusts (n=271), responses were received from 183 (68% 
response rate). 
No particular patterns emerged when assessment of response rate from 
regions was undertaken. 
 
Secondary care  
 
Sixty-two per cent of responses (n= 58) came from CPs of district general 
hospitals, 35 per cent (n=33) from teaching hospitals and 3 per cent (n=3) from 
tertiary specialist hospitals. 
The size of the hospitals varied, with bed sizes ranging from 201-400 to >1500, 
with the most common ranges being 401-600 (25%, n=23) and 1001 to 1500 
(25%, n= 23). 
Other demographic data can be found in Table 1. 
 
Pharmacist supplementary prescribing 
 
Secondary care  
When asked about their intentions to implement supplementary prescribing 
by pharmacists, the majority of CPs stated that they intended to implement 
the service by the end of 2005 (57%, n= 55) and 14 per cent (n=14) stated that 
they were not going to implement supplementary prescribing by pharmacists 
by the end of 2005. Some CPs did not know what their intentions were (29%, 
n= 28).  
The total number of pharmacists employed by the trust was found to have a 
significant influence upon the intention to implement supplementary 
prescribing by pharmacists (p=0.004, kruskal-wallis test, df=3). Therefore, as 
the number of pharmacists employed by the trust increased, it was more 
common to intend to implement supplementary prescribing.  
The CPs who intended to implement pharmacist supplementary prescribing 
planned to train between 0 to 14 pharmacists (mean +/- S.D.= 3 ±3) during 
2004, and between 1 to 24 pharmacists (mean +/- S.D.= 3 ±4) during 2005. 
There was a significant relationship between the number of pharmacists to be 
trained as supplementary prescribers during 2004 and the number of hospital 
beds that the hospital has, with the highest mean rank being for those 
hospitals with 601-800 beds (p=0.012, Kruskal Wallis test, df=5), this was also 
found to be the case for 2005 (p=0.003, Kruskal Wallis test, df=5). 
There was also a moderate positive correlation between the total number of 
pharmacists employed by the trust and the number of pharmacists to be 
trained as supplementary prescribers during 2004 (r=0.54 n=39 p=0.000), 
again this was also found to be the case for 2005 (r=0.57 n=36 p=0.000). 
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With respect to the total number of pharmacists to be trained during 2005, a 
significant relationship was also found between this and the hospital type, 
with teaching hospitals being significantly more likely to train more 
pharmacists in 2005 than other hospital types (p=0.026, kruskal-wallis test, 
df= 2)  
When asked which grade of pharmacist(s) they intended to train as 
supplementary prescribers, the majority of CPs stated D grades (85%, 
n=46/54) followed by E grades (70%, n=38/54) (missing data=1) The different 
clinical areas of supplementary prescribing targeted by CPs are presented in 
Table 2. 
A significant relationship was found between the total number of pharmacist 
supplementary prescribing activities being offered and the type of hospital, 
with teaching hospitals more likely to be offering more pharmacist 
supplementary prescribing activities (p=0.007, kruskal-wallis test, df=2). 
There was a moderate positive correlation between the total number of 
pharmacists employed by the trust and the total number of pharmacist 
supplementary prescribing activities being offered (r=0.59 n=43 p=0.000). 
A moderate positive correlation was also found between the total number of 
pharmacist supplementary prescribing activities being offered (i.e. the 
different clinical areas) and the total number of non-supplementary 
prescribing pharmacist prescribing activities being undertaken currently 
(r=0.53 n=35 p=0.001). 
The person who will assume responsibility for prescribing if the SP is away 
was most commonly a junior doctor (56%, n=30/54), followed by a consultant 
(39%, n=21/54) or another pharmacist supplementary prescriber (37%, 
n=20/54). Some CPs indicated that no cover would be provided for the 
service (24 per cent, n=13/54) or that they didn’t know how the service would 
be covered (13 per cent, n=7/54) (missing data=1). 
Additional training requirements (additional to the standard supplementary 
prescribing training) most commonly included a period of clinical experience 
in the clinical area that the pharmacist supplementary prescriber would be 
working in (89 per cent, n=49/55), followed by possession of a clinical 
diploma (73%, n=40/55) and undertaking the Royal Pharmaceutical Society of 
Great Britain’s (RPSGB’s) continuing professional development (CPD) 
requirements (55%, n=30/55). 
 
Primary care 
 
When asked about their intentions to implement supplementary prescribing 
by pharmacists, the majority of PCTPs stated that they intended to implement 
the service by the end of 2005 (56%, n=100) and 9 per cent (n=17) stated that 
they were not going to implement supplementary prescribing by pharmacists 
by the end of 2005. Some PCTPs did not know what their intentions were 
(35%, n=63). 
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The total number of pharmacists employed by the trust was found to have a 
significant influence upon the intention to implement supplementary 
prescribing by pharmacists (p=0.008, kruskal-wallis test, df=3). 
The PCTPs who intended to implement pharmacist supplementary 
prescribing intended to train between 0 to 6 pharmacists (mean and standard 
deviation= 2 ±1) during 2004, and between 1 to 10 pharmacists (mean and 
standard deviation= 3 ±2) during 2005. No statistically significant 
relationships were found to affect the numbers of pharmacists to be trained in 
2004 or 2005. 
When asked which type of pharmacist they were going to train as 
supplementary prescribers, the most common response was primary care 
based pharmacists (in PCT’s) (67%, n=68/102) followed by general 
practitioner (GP) practice-based pharmacists (55%, n=56/102) and then 
community pharmacists (45%, n=46/102) (missing data=3). 
The different clinical areas of supplementary prescribing that the primary care 
trust pharmacists were going to implement pharmacist supplementary 
prescribing in are presented in Table 2. 
No significant relationships were found to affect the total number of 
pharmacist supplementary prescribing activities on offer. 
The person who will assume responsibility for prescribing if the SP is away 
was most commonly intended to be a GP (37%, n=38/102) followed by a 
nurse supplementary prescriber (21%, n=21/102) or a pharmacist 
supplementary prescriber (15%, n=15/102). A large proportion of PCTPs 
indicated that no cover would be provided for the service when the 
pharmacist was away (32%, n=33/102) or that they didn’t know how the 
service would be covered (26 per cent, n=26/102) (missing data=3). 
Additional training requirements (additional to the standard supplementary 
prescribing training) included most commonly undertaking the Royal 
Pharmaceutical Society of Great Britain’s (RPSGB’s) continuing professional 
development (CPD) requirements (64%, n=65/101) followed by a period of 
clinical experience in the clinical area that the pharmacist supplementary 
prescriber would be working in (60%, n=61/101) and possession of a clinical 
diploma (50%, n=50/101) (missing data=4). 
 
Supplementary prescribing implementation 
  
Secondary care 
 
The factors affecting recruitment of designated medical practitioners are 
presented in Table 3. 
The CPs were then asked whether in their own opinion, it will be easier to 
recruit designated medical practitioners (DMP) for nurses rather than 
pharmacists. The majority of the CPs did not agree with this statement (67%, 
n=43). Thirty-three percent (n=21) did agree with the statement, and 30% 
(n=29) did not know (missing data= 4). The most common reasons given 
amongst those who agreed with the statement was that nurses already have 
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an established working relationship with doctors (50%, n=8), followed by 
nurses are already working as prescribers (31%, n=5). A wider range of 
reasons were given amongst those who disagreed with the statement, 
including, that the problems are identical for both professions (31%, n=8), that 
it would be dependent on the relationship with the DMP and the benefit to 
the DMP (27%, n=7), and that pharmacists are highly specialized and well 
regarded (23%, n=6).   
 
Primary care 
 
The factors affecting recruitment of DMPs are presented in Table 3. 
The PCTPs were asked who would be charged with taking forward 
pharmacist supplementary prescribing within their trust. The results are 
presented in Table 4. 
The PCTPs were then asked whether in their own opinion, it would be easier 
to recruit designated medical practitioners for nurses rather than pharmacists. 
The majority of PCTPs agreed with this statement (47%, n=86) Twenty-eight 
percent (n=50) did not agree with this statement and 25% (n=46) did not 
know (missing data=1).  
A wider range of reasons were given amongst those who agreed with the 
statement, including, that nurses already have an established working 
relationship with doctors (87%, n=69), followed by nurses are already 
working as prescribers (27%, n=21). Respondents also stated that GPs do not 
understand pharmacist’s skills and have no relationship with them (15%, 
n=12), that it would be more difficult for employees of trusts (11%, n=9) and 
that pharmacists are viewed as being business focused or non-NHS (10%, 
n=8). 
The most common reasons given amongst those who disagreed with the 
statement was that the problems are identical for both professions (48%, 
n=13), that pharmacists have good working relationships (26%, n=7) that it 
would be dependent on the relationship with the DMP and the benefit to the 
DMP (15%, n=4), and that it depends on whether the person is a trust 
employee (15%, n=4). 
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Discussion 
 
Pharmacist supplementary prescribing 
 
The percentage of CPs and PCTPs intending to implement supplementary 
prescribing by the end of 2005 was similar. Within primary care, it was most 
common for primary care trust and general practitioner (GP) based 
pharmacists to be trained as supplementary prescribers rather than 
community pharmacists. This observation suggests that there are some 
potential obstacles for community pharmacists when it comes to developing 
this role. These obstacles can include lack of on-line access to the patient’s 
medical records, lack of a private area within the community pharmacy for 
the consultation to take place, difficulties in establishing funding for 
developing the service from the PCT and also lack of an established good 
working relationship with local GPs. It is therefore apparent that for 
community pharmacists to fully develop this opportunity to prescribe and 
develop services for patients, they have a lot more barriers to overcome than 
pharmacists in secondary care.   
 
When it comes to provision of cover for the pharmacist supplementary 
prescribing service in secondary care, it was most commonly being provided 
by junior doctors. However, it has been suggested that provision of a 
pharmacist service would provide a more superior prescription service in 
terms of safety and overall quality of the prescriptions[15, 33-36]. Therefore 
would it be acceptable for the annual leave, sickness cover and over-
night/weekend cover to be provided by a more inferior service? The aim 
should be to provide 24 hour service provision if the prescribing service is 
being provided for in-patients, however, with limited pharmacist numbers, 
this would be unfeasible for most hospital trusts.  
  
The most common clinical areas that were being served by supplementary 
prescribing pharmacists in secondary care reflect those areas where 
pharmacist prescribing input has already been established (Table 2).  
Total parenteral nutrition (TPN) is the most common area that CPs were 
training pharmacists to be supplementary prescribers in, and there have 
already been reports of trained supplementary prescriber pharmacists 
working in this area.[37, 38] This is an area where pharmacists have a long 
established role as part of nutrition teams within most hospitals[39], and also 
have a key input in the individual composition of TPN prescriptions for 
patients. Pharmacists have also had established roles in the areas of 
oncology/haematology, cardiology and anticoagulation, [38, 40-50] so it is not 
surprising to see these clinical areas amongst those where pharmacists are 
prescribing.  
It is also not surprising to see therapeutic areas such as renal, rheumatology, 
HIV and care of the elderly as areas where pharmacists are being trained as 
supplementary prescribers[37, 38, 42, 51]. These again, are areas where 
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pharmacists have long had established clinical roles in [52, 53] and also are 
areas where pharmacist prescribing is well suited due to the polypharmacy, 
complexity of the medication (e.g. numerous drug interactions) and multiple 
concurrent conditions that are often associated in these conditions/areas.  
Some therapeutic areas that are being targeted for SP have associated NSFs 
and other published national guidance available.  
 
The publication of the National Service Framework for older people [54] 
which sets standards in care, recommended that all elderly people should 
normally have their medications reviewed at least annually, and for those 
taking four or more medicines should have a review 6 monthly, and that 
older people should get more help from pharmacists in using their medicines. 
Therefore one would expect that this area would be targeted for pharmacist 
supplementary prescribing.  
The National Service Framework for Renal Services was published in January 
2004[55], which emphasizes the extensive role that pharmacists can have in 
optimizing medication in this area. So again, this would be an expected area 
for pharmacists to become supplementary prescribers in. 
Another therapeutic area that was commonly identified as being one where 
pharmacists were being trained as supplementary prescribers was for 
surgical/orthopaedic pre-admission clinics. As described for the other 
therapeutic areas, pharmacists had a well developed role in this area before 
the advent of supplementary prescribing. Pharmacists were involved in 
taking medication histories, writing the patients current medication onto the 
in-patient drug chart during these clinics, and also following protocols for 
standard antibiotic prophylaxis and thromboprophylaxis to be written onto 
the in-patient drug chart as well[9-12, 56-59]. Therefore by training 
pharmacists as supplementary prescribers it will negate the need for the 
doctor to co-sign the in-patient drug charts and will legitimize roles that are 
already being undertaken.  
 
 
 
Primary care has focused its supplementary prescribing training on quite 
different areas from secondary care. This may be due to the implementation 
of the new General Medical Services (GMS) contract in April 2004, for GPs. 
[60] In this new contract, payment for their services focuses upon improving 
the overall quality of clinical care for their patients. Within the GMS contract, 
the Quality and Outcomes Framework specifies disease categories where 
more comprehensive service provision will be rewarded with more 
substantial payments. The top five clinical areas that have been identified for 
primary care pharmacist supplementary prescribers (Table 2) are all areas 
which have been specified in the Quality and Outcomes Framework –
Hypertension, coronary heart disease (CHD)/hyperlipidaemia, diabetes 
mellitus, asthma and COPD. Therefore GP practices will be targeting 
development of services in these areas in order to enhance their payments. 
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These areas are also subject to detailed guidance published over the past few 
years in the form of National Service Frameworks (NSFs), (the coronary heart 
disease NSF was published in March 2000, [61] the diabetes NSF in 2001[62]) 
and also specialist guidelines developed by the British Thoracic Society and 
the Scottish Intercollegiate Guidelines Network for Asthma [63] and National 
Institute for Clinical Excellence (NICE) guidelines for COPD[64], and by the 
British Hypertension Society for hypertension. [65] Therefore these clinical 
areas are extremely suitable for pharmacists to undertake supplementary 
prescribing as the clinical management plans can refer to these national 
guidelines for the pharmacist to follow. 
 
Pharmacist supplementary prescribing in mental health appears to be an 
uncommon therapeutic area in both primary and secondary care, which is 
rather surprising considering that it is a clinical area identified in the Quality 
and Outcomes Framework, and that there is a National Service 
Framework[66] for this therapeutic area. 
The United Kingdom Psychiatric Pharmacy Group (UKPPG) and College of 
Mental Health Pharmacists (CMHP) have published a statement upon their 
position with respect to supplementary prescribing. [67] They are advising 
their members that they believe that in order to be a competent 
supplementary prescriber in mental health they require membership of 
CMHP on top of the normal supplementary prescribing training 
requirements. This is the only specialist clinical pharmacy group to have any 
additional requirements. This may have a negative effect upon pharmacists 
wishing to become supplementary prescribers in this area, or alternatively 
reflects an attitude within mental health that prescribing in this area is more 
complex than other therapeutic areas.  
 
Primary care respondents indicated that provision of cover for the pharmacist 
supplementary prescriber services would be provided by a nurse 
supplementary prescriber in preference to another pharmacist supplementary 
prescriber, if a GP was not going to be used. This may be due to primary care 
having a large resource of qualified nurse supplementary prescribers, and 
also because the therapeutic areas that most pharmacists are going to work in 
have clear, detailed guidance available, and are not as complex areas as some 
of the therapeutic prescribing areas in secondary care. 
However, it also suggests that no distinction is being made between the type 
of prescribing that a pharmacist in e.g. a cardiac clinic will undertake 
compared to that by a nurse. Therefore if the type of prescribing is identical 
by both professions then a nurse would be chosen to run a clinic in preference 
to a pharmacist because the salaries for experienced clinical pharmacists and 
community pharmacists are higher than nurses. This means pharmacists will 
have to establish niche areas (such as more complex polypharmacy areas) for 
their more expensive clinical expertise, and that a distinction will have to be 
made about what types of clinics the different professions are going to hold in 
each clinical area. 
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Supplementary prescribing implementation 
 
As there is not a standardized competency framework for pharmacists once 
they have qualified, there is no national differentiation between the skills 
necessary e.g. to be a clinical pharmacist versus a senior clinical pharmacist. 
Therefore it is already difficult for doctors to be able to understand the 
knowledge and competency of different pharmacists at ward level when 
requesting advice. The development of supplementary prescribing will 
therefore make it even more difficult for doctors (and other health care 
professionals) to distinguish between the skills of various pharmacists.  Other 
studies have already suggested that this development will cause confusion. 
[68] Therefore, recent work has been undertaken in order to develop a 
competency framework for pharmacists within primary and secondary care. 
[69] Although this will mean that all pharmacists entitled “senior clinical 
pharmacist” will have the same skills and competency from trust to trust, it 
does not help the confusion that may be caused by some pharmacists being 
able to prescribe and others not. 
Community pharmacists will also face difficulties, in terms of understanding 
which health care professional has which type of prescribing rights when 
presented with prescriptions by a large range of different health care 
professionals. It will also cause confusion to the general public, as some 
community pharmacies will have pharmacists that can prescribe medicines 
for their e.g. heart condition, but other pharmacies will not. Therefore it is 
important that the general public are well informed about this development. 
 
Although both primary and secondary care rated time commitment and 
workload as being the two most important factors affecting recruitment of 
DMP’s, the major difference between primary care and secondary care, was 
that primary care also highlighted the lack of funding for the role as well. For 
secondary care, this is not such an issue as all doctors are employees of the 
NHS, so by taking up the role of DMP, it is helping the organization that they 
are paid by. Also in the majority of cases, it will also help their own clinical 
area as well, by releasing the doctor’s time to deal with more complex cases, 
and improving access to services for patients. 
For primary care, GPs receive payment individually according to the services 
they offer. Therefore in order to supervise a supplementary prescribing 
trainee, the GP may expect to receive payment for it, unless there is a clear 
business case presented to their practice, outlining the benefits from the 
service that will be provided. Therefore this may make it difficult for those 
nurses and pharmacists who are not employees of a practice to actually 
recruit a DMP to supervise their training. 
 
When asked whether recruitment of DMPs would be more difficult for 
pharmacists rather than nurses, the majority of chief pharmacists disagreed 
with this statement, but the majority of primary care trust pharmacists agreed 
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with it. Other than the reasons outlined above, in primary care, pharmacists 
also have less day to day contact with doctors than pharmacists in secondary 
care, which may mean that GPs do not fully understand the skills that 
pharmacists have, and therefore do not see the potential for development of 
pharmacist prescribing services. Upon examination of their reasoning,  
reasons such as “GPs do not understand a pharmacist’s skills/ do not have an 
established relationship with them”, “Pharmacists are viewed as being 
business focused/ non-NHS” and “pharmacists are seen as a threat” certainly 
illustrate the need for pharmacists in primary care/community pharmacy to 
develop closer working relationships with their local GPs to overcome these 
barriers. 
  
The person(s) in charge of taking forward supplementary prescribing for 
pharmacists in primary care are quite varied (Table 4). For primary care this 
array of different people will inevitably lead to different PCTs having 
different priority levels for implementation of this development and also 
extensiveness of implementation will vary considerably. The implementation 
will also be affected by the new community pharmacy contract, which is in 
the process of being implemented. [70] The first and second tiers of the 
contract are termed essential and advanced services, and these services will 
be funded via a national agreement. However, the third tier of enhanced 
services, which may include supplementary prescribing services, will be 
commissioned by PCTs. So if a PCT does not see a need for a particular 
service, pharmacists will not get paid for providing it. [71]  
Again, it is essential for community pharmacists to make their PCTs aware of 
the services they are capable of providing and the benefits that can be derived 
from such services for the local population. 
It has been suggested that further reorganization of PCTs will happen now 
that the general election has occurred, whereby mergers of PCTs would 
reduce their number from 303 to 100-150 across England. This is because there 
is a growing belief that many trusts are perhaps ineffective organizations, 
unable to commission acute healthcare effectively and unable to fulfill public 
health responsibilities. [72] If this reorganization happens, then the 
commissioning of enhanced services for pharmacies may be even more 
difficult until PCTs have settled any structural reorganization. 
 
The development of supplementary prescribing services will also need to 
make sense for community pharmacy businesses as well. Although many 
multiple pharmacy businesses have been able to offer services such as 
cholesterol testing for free, smaller, independent pharmacies cannot offer such 
services without recompense. It is extremely important that pharmacy 
businesses maintain a united front when negotiating payment for 
supplementary prescribing services from PCTs.  
 
The lack of national strategy to guide which therapeutic areas are more in 
need of pharmacist supplementary prescriber’s input may mean that some 
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patient groups may still have reduced access to services, and that doctors 
working within these areas will still have unmanageable workloads and 
waiting lists. It would therefore seem sensible for Department of Health 
guidance to be made available, suggesting target areas where this role 
development is more urgent than others. 
 
The way in which supplementary prescribing is being implemented in 
primary and secondary care suggests that one model of non-medical 
prescribing may not be the “one-size fits all” answer that had been hoped for. 
Primary and secondary care are very different in terms of funding, inter-
professional relationships and methods of working, which means that slightly 
different models of non-medical prescribing may be needed. Due to the 
necessity of producing a clinical management plan for the patient’s condition 
that is being treated by the pharmacist SP, SP is more suited for the 
management of chronic conditions in primary care rather than acute 
conditions that are seen in secondary care.  
The reasoning for implementing supplementary prescribing also needs to be 
questioned. It has been suggested that the main driver relates to resource 
issues within the NHS and to curb escalating healthcare costs[68] rather than 
improve quality of prescribing. Therefore further evaluation of the 
implementation of supplementary prescribing in terms of overall quality of 
prescribing will be crucial to prove that in the very least, the quality is not 
inferior to that of medical practitioner prescribing. 
The impending development of independent prescribing may well offer more 
flexibility for secondary care non-medical prescribers, and also overcome 
some of the highlighted difficulties that community pharmacists will face 
with respect to supplementary prescribing. Therefore independent 
prescribing rights may be more welcomed than the current supplementary 
prescribing model. 
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Critique of method 
 
The response rate was sufficient when compared to other similar 
questionnaire surveys[17, 73, 74]. 
Telephone follow-up of CPs was found to be difficult as these people are 
extremely busy and therefore secretaries preferred to take a message rather 
than let the lead researcher speak directly to the CP. This may have reduced 
the response rate achieved. 
For PCTPs, it was noted that the list of named pharmacists in the spring 2003 
guide for primary care trusts[32] was often inaccurate. On subsequent mail 
shots, the named pharmacist was therefore removed and changed to 
“Primary care trust pharmacist” in order to improve the response rate. 
Although it would have been preferable to use the same follow-up 
methodology for both surveys, due to the larger sample size of primary care 
trust pharmacists compared to secondary care pharmacists, telephone follow-
up was not undertaken for the primary care pharmacists. Instead an extra 
mail shot was undertaken. This was because it would have taken more time 
than was available to complete the telephone follow up for such a large 
sample size. As the same response rate was achieved for both questionnaire 
surveys it was not anticipated that the slightly different follow-up 
methodology affected the integrity of the survey results. 
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Conclusion 
 
Although the intentions of CPs and PCTPs are very similar in terms of 
implementation of supplementary prescribing, the results illustrate that there 
are significantly more barriers to its establishment within primary care, 
especially for community pharmacists.  
Within primary care, SP appears to be implemented in order to develop new 
services. However, within secondary care, the results suggest that the model 
is being used more often to legitimize services that are already being 
provided. This suggests that secondary care may well be awaiting the 
introduction of independent prescribing for pharmacists before developing 
their prescribing role. 
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Glossary 
 
1st level registered nurse -a nurse who is registered in sub-part 1 of the 
nurses’ part of the professional register (Nursing and Midwifery Council). 
Chief Pharmacist -the pharmacy lead for the Trust (Primary or Secondary) in 
all aspects of pharmacy services.   
Clinical Governance -the system of steps and procedures adopted by the 
NHS to ensure that patients receive the highest possible quality of care.  
Clinical Diploma -a postgraduate course which qualified pharmacists can 
undertake, which comprises of advanced level clinical pharmacy.  
Community Pharmacist -a pharmacist who works in a retail pharmacy 
business. Their role includes supervising the safe dispensing of medicines, 
provision of advice upon medicines use, health promotion and services to 
specific patient groups. 
Consultant -a specialist doctor within secondary care, who has expertise in a 
certain clinical area. GPs refer patients to consultants for expert advice on the 
patient’s management. 
D Grade Pharmacist –usually has a postgraduate qualification and at least 5 
years of clinical experience. The pharmacist will normally specialize in a 
clinical area. 
District General Hospital -the most common type of hospital within the UK, 
and deals with patients who are acutely ill. 
E Grade Pharmacist -has more clinical specialism and expertise. Their role 
may also include some form of staff and budget management 
E Grade Nurse -usually has a minimum of 6 months post registration 
experience. Nurses specialise in a clinical area at this level by undertaking 
post-registration courses.  
Fully registered –healthcare professionals who have undertaken the required 
training programme and become recognized as a qualified professional by 
having their name on their profession’s register. 
General Practitioner A physician whose practice is based on a broad 
understanding of all illnesses. The first port of call for patients when they are 
unwell. Based in practices within the local community. 
Junior doctor -the first year after completion of undergraduate medical 
training (Pre-registration). 
National Service Framework (NSF) are long term strategies for improving 
specific 
areas of care. These government documents set out the targets for evidence 
based medicine in specific disease areas or population groups.  
Primary Care Trust These control primary health services and consist of GPs 
and other healthcare professionals. They are responsible for the planning and 
securing of health services and improving the health of a local population.  
Secondary Care Trust -are responsible for the provision of Health care 
services provided by medical specialists, and are found in most large towns 
and cities.  
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Strategic Health Authority England is split into 28 Strategic Health 
Authorities. They are responsible for developing strategies for the local health 
services and ensuring high-quality performance. They manage the NHS 
locally and are a key link between the Department of Health and the NHS. 
They also ensure that national priorities (such as programmes for improving 
cancer services) are integrated into local plans. 
Tertiary Specialist Hospital Some trusts also act as regional or national 
centres of expertise for more specialised care, while some are attached to 
universities and help to train health professionals. 
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Abstract 
 
Objective (of the study)  To provide data on the views of chief pharmacists (CPs) and 
primary care trust pharmacists (PCTPs) on the risks and concerns surrounding 
supplementary prescribing. 
 
Setting Secondary and primary care within England.  
 
Method  Postal questionnaire surveys of chief pharmacists and primary care trust 
pharmacists.  
 
Main Outcome Measure Significance of the association between the extracted factors. 
 
Results   The response rate was 68% for both the primary care (183/271) and 
secondary care surveys (97/143).  
The survey tool was subjected to factor analysis and reliability testing. For both 
sectors, the three factors that were extracted described concerns over the training 
model for supplementary prescribing, concerns about the professional 
competency/responsibility of the supplementary prescribers once trained, and 
positivity about the implementation of supplementary prescribing. 
For both sectors, as trusts have more experience of supplementary prescribing by 
nurses, the respondents had less concerns about the supplementary prescribing 
training model. 
For secondary care, as the total number of pharmacists employed within the Trust 
increases, the respondents had less concerns over the limitations of the supplementary 
prescribing training model.  
 
Conclusion  Although both sectors have concerns over the training model for 
supplementary prescribing and also professional competence and responsibility once 
trainees qualify,  there is overall, a positive attitude towards supplementary 
prescribing and there is a belief that pharmacists wish to take this role on. 
 
Keywords prescription; pharmacist; factorial analysis; questionnaire; nurse; risk 
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Risks and concerns about supplementary prescribing: Survey of primary and 
secondary care pharmacists. 
 
Introduction 
 
Supplementary prescribing is in its infancy in the UK and there are currently 635 
registered supplementary prescribing pharmacists (August 2005) out of a total of 
46,490 (2005) pharmacists on the register (1.4%). A more detailed discussion on the 
scope of supplementary prescribing has been presented previously.[1]  
 It has also recently been announced by the Department of Health that pharmacist 
prescribing powers have been extended after a consultation upon independent 
prescribing by pharmacists. During 2006, pharmacists who have qualified as 
independent prescribers will be able to prescribe any licensed medicines for any 
medical condition (with the exception of controlled drugs). (Also extended formulary 
nurse prescribers will be able to do this as from Spring 2006)[2] 
Therefore the developing prescribing role by pharmacists is a hot topic for debate in 
the UK at the moment.[3] 
Development of pharmacist prescribing in the UK has drawn upon the experience 
gained in the United States with pharmacist prescribing. Pharmacist prescribing was 
first introduced in California in the late 1970’s, and since then has been extended to at 
least 16 states. Only one state (Florida) has introduced independent prescribing, where 
pharmacists are prescribing from a limited list of drugs.[4] A collaborative drug 
therapy management model is used in the United States for pharmacist prescribing, 
whereby the pharmacist has a collaborative arrangement with a physician to 
dependently prescribe certain medications as agreed in a management plan. 
Supplementary prescribing in the UK is a similar model, but unlike pharmacist 
prescribing in the United States where a generic management plan is produced for a 
certain condition, instead a tailored clinical management plan is produced for each 
patient that the pharmacist is going to prescribe for. 
In the rest of Europe, NewZealand and Australia, pharmacists do not have the right to 
prescribe. Although in many European countries, pharmacists are active in preventing 
and correcting drug-related problems (such as Belgium, France, Germany, The 
Netherlands, Norway, Sweden), pharmaceutical care is in its infancy in the majority 
of Europe. It has been suggested that European pharmacists have a lack of authority to 
take an active part in decision-making for drug prescribing, and lack support from 
some physicians to be part of the healthcare team.[5] It is now recognised that there 
needs to be substantial changes made to most university’s curriculum in Europe in 
order to arm pharmacists with the suitable knowledge and skills to implement 
pharmaceutical care efficiently.[5] 
Although Europe is not at the stage where pharmacist prescribing can be 
implemented, lessons can be learnt from pharmacist prescribing experience in the UK, 
which can support further development of the clinical role for pharmacist colleagues 
in Europe.  
We have previously reported that the majority of chief pharmacists within secondary 
care in England intended to implement supplementary prescribing by pharmacists by 
the end of 2005 (57 per cent, n=55)[1] This was also similar for primary care trust 
pharmacists (56 per cent, n=100). Chief pharmacists (CP) in secondary care, and 
primary care trust pharmacists (PCTP) in primary care will need to decide how 
extensively they intend to implement supplementary prescribing by pharmacists 
within their trust and will oversee its implementation. They will also have to develop 
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a strategic plan for utilising this development in the optimum manner for patients 
dependent upon available staffing resource.  
Pharmacists are employed by PCTs to control drug prescribing budgets. Some 
primary care pharmacists are entitled “pharmaceutical advisors” whose role also 
includes policy development. Most work with individual GPs to assist with drug 
audits and medication review. These pharmacists will have an important role in 
overseeing the development of supplementary prescribing within primary care trusts. 
Although implementation of supplementary prescribing by nurses will more than 
often be overseen by a different person within the trust such a senior nurse, that 
person will need to liaise with the CP or PCTP as these people have the expertise to 
advise upon issues such as medicines management and clinical governance 
concerning medicines and prescribing. 
Liaison between these health professionals will also ensure that the patients are 
receiving the supplementary prescribing service from the most appropriate health care 
professional.  
Therefore CPs and PCTPs will have an interest in the development of nurse 
prescribing within their trust (and vice-versa) and it is clear that development of 
prescribing by non-medical health care professionals within a trust will benefit from 
input from both professions. 
The implementation of supplementary prescribing will be influenced by many 
external factors such as attaining funding of the service, funding for the training itself, 
funding for backfill whilst the pharmacist is training and ability to recruit a designated 
medical practitioner (DMP) to supervise part of the training. It may also be influenced 
by the perceptions that the people who may be in overall charge of implementation 
have with respect to supplementary prescribing.  
During the consultation process for supplementary prescribing[6], many issues and 
risks with the proposed supplementary prescribing model were raised with the 
Department of Health[7]. Although some of these envisaged problems were dealt with 
as part of the consultation process, some negative perceptions and issues that were 
raised may have had an impact on health care professional’s perceptions of 
supplementary prescribing. 
Although SP is currently the only legal form of pharmacist prescribing in the UK, 
several reports have identified other pharmacist prescribing roles (NON-
supplementary prescribing), such as in pre-admission clinics (to obtain patient 
medication histories, write their in-patient drug chart and discharge prescription)[8] 
[9, 10], out-patient clinics[11] and discharge management[12-16] which may be 
taking place without using the SP model. Previous experience of these types of 
prescribing within a trust may also influence CPs and PCTP’s opinions upon how 
successful SP will be.  
 
The work reported here was part of a larger study of supplementary prescribing, part 
of which has previously been reported [1] 
Only the results of section C of the questionnaire survey will be presented in 
this paper. In this section of the questionnaire, the respondent’s attitude to a 
number of statements about supplementary prescribing was measured on a 
five point likert scale. 
 
Aim of the Study 
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The objectives of this part of the study were to investigate the perceptions of chief 
pharmacists and primary care trust pharmacists upon the risks and concerns 
surrounding supplementary prescribing, using a questionnaire survey as the research 
tool. 
 
Method 
 
Questionnaire development 
Construction of the questionnaire was aided by literature review. A list of 
pharmacists holding important positions in England (policy-
making/academic) were also identified, and their suggestions upon key 
questions that need answering with respect to supplementary prescribing 
were sought.  
 
Semi-structured interviews were then held individually with a clinical governance 
lead, a nurse educator on a supplementary prescribing course, a chief executive of a 
hospital and a clinical governance co-ordinator (n=4) in order to develop a more 
detailed perspective on the risks and concerns surrounding the development of 
supplementary prescribing. 
All of this data was then used to suggest topics for discussion at a focus group.  A 
more detailed description of the development of the questionnaire has been described 
previously.[1]  
 
One questionnaire was designed for chief pharmacists of secondary care acute 
hospital trusts, and a very similar questionnaire, with minor differences in 
orientation, was designed for primary care trust pharmacists. The 
questionnaire was divided into three sections. Section A inquired about 
general demographic data about themselves and their Trust. Section B 
inquired about the implementation of supplementary prescribing within their 
trust and Section C measured the respondent’s attitude to a number of 
statements about supplementary prescribing. A Likert scale was used in 
section C to score the level of agreement to each item on a five point scale. 
According to convention, the high numbers indicated agreement and the 
scales were subsequently reversed for negative questions. Confidentiality was 
maintained by number-coding the questionnaires. A medical statistician 
advised on data analysis. Ethical permission for the study was obtained from 
the multi-centre research and ethics committee (MREC). 
 
Validation and piloting 
In order to assess face validity of the secondary care questionnaire, one CP was 
observed whilst completing the questionnaire and discussed any ambiguities that 
arose with the researcher, and another CP completed the questionnaire and posted it 
back with written comments about any ambiguities. Minor adjustments were then 
made to the question structure to clarify these ambiguities. Although this process does 
not constitute full validation, face validity was further assessed in responses to the 
pilot questionnaire for both primary and secondary care. 
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In order to validate the primary care questionnaire, one PCTP completed the 
questionnaire and provided feedback via telephone and the other PCTP completed the 
questionnaire and provided written feedback. 
Reliability of the survey tool cannot easily be tested (test-re-test reliability) as it 
would produce survey fatigue if re-tested in the same, limited, population.  
For section C of the questionnaire, construct validity was used to assess the validity of 
the scale. 
During February & March 2004, the secondary care questionnaire was piloted 
in 17 randomly selected (via a random number generator) hospitals from the 
sample (n=168). 
At the same time, the primary care questionnaire was piloted in 30 randomly selected 
(via a random number generator) pharmacists from the sample (n=303).  Several 
amendments were made to the questionnaire after piloting. Some questions were 
removed in order to reduce the length of the questionnaire and some questions had 
extra options added or removed from them. Therefore, data collected from the pilot 
questionnaires were not included in the final analysis.  
 
Main Survey 
Both questionnaires were distributed in May 2004. The secondary care questionnaire 
was sent to named CPs within every NHS trust in England providing acute hospital 
services. Details of the handling of the questionnaire and follow-up have been 
described previously.[1]  
 
Following piloting, a total of 151 hospital pharmacy departments were included in the 
main study. Eight of these hospitals were removed from the study after it was 
established that they had merged with another trust or were not an acute trust, leaving 
143 hospitals for the study. 
For primary care, after piloting, 273 primary care trusts were included in the main 
study. Two of these trusts were removed from the study after it was established that 
they were not a primary care trust or did not have a pharmacist employed as a 
pharmaceutical advisor. This left 271 primary care trusts eligible for the study.  
 
Data obtained from returned questionnaires were coded and analysed using 
the Statistical Package for the Social Sciences (SPSS) version 11. 
The data was also analysed by region/strategic health authority that the 
hospital or primary care trust (PCT) was from in order to assess whether there 
were any poor responses from particular regions. 
 
Factor analysis 
Factor analysis was used to explore the relationships thought to exist between 
the items in section C of the questionnaire and to assess the degree to which 
items were measuring the same concept. 
Principal components analysis (PCA) was used as the method of extracting 
the factors from the item population. The extracted factors were rotated 
obliquely using the direct oblimin method, interpreted and tested for internal 
reliability[17].  
The significance of the association between the factors themselves and 
between the factors and responses to certain questions in sections A & B of the 
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questionnaire was assessed using the non-parametric tests chi-squared, 
Kruskal-Wallis and bivariate correlations (Spearman’s rho), where 
appropriate.  
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Results 
 
General demographics 
Of the 143 hospitals, responses were received from 97 (68 per cent response rate) and 
for the 271 primary care trusts, responses were received from 183 (68 per cent 
response rate). 
No particular patterns emerged when assessment of response rate from regions was 
undertaken. 
 
Validation processes 
The frequencies of responses to the survey items in section C were explored during 
the process of construct validity (see Table 1-Questionnaire section C statements) 
here). Construct validity was assessed by considering whether the responses to 
individual statements are consistent with other similar statements in the questionnaire. 
 
Secondary care 
The percentage of respondents whom stated that they did intend to implement 
supplementary prescribing by pharmacists within their trust by the end of 2005, and 
also agreed/strongly agreed with the statement “Development of supplementary 
prescribing by pharmacists will be a priority within the trust” was n=21 (38.1 per 
cent). 
The percentage of respondents whom stated that they did intend to implement 
supplementary prescribing by nurses within their trust by the end of 2005, and also 
agreed/strongly agreed with the statement “Development of supplementary 
prescribing by nurses will be a priority within the trust” was n=28 (46.6 per cent). 
 
Primary care 
The percentage of respondents whom stated that they did intend to implement 
supplementary prescribing by pharmacists within their trust by the end of 2005, and 
also agreed (no-one strongly agreed) with the statement “Development of 
supplementary prescribing by pharmacists will be a priority within the trust” was 
n=39 (39.0 per cent). 
The percentage of respondents whom stated that they did intend to implement 
supplementary prescribing by nurses within their trust by the end of 2005, and also 
agreed/strongly agreed with the statement “Development of supplementary 
prescribing by nurses will be a priority within the trust” was n=85 (62.0 per cent). 
 
As a result of this process, no statements were removed from the survey at this stage. 
 
Factor analysis 
Bartlett’s test of sphericity was significant (p<0.001) for both the primary & 
secondary care questionnaire. Also the Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy was adequate for both questionnaires. This verifies that the 
majority of items within the survey were sufficiently related to each other to proceed 
with factor extraction. More than half the items had a correlation coefficient of greater 
than 0.3, for both questionnaires, suggesting a strong correlation between the items. 
Six factors were extracted using PCA with an eigenvalue greater than 1 for the 
secondary care questionnaire, and on review of the scree plot, either three or five 
factors could be retained. However, after examining both models and advice from a 
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medical statistician, a three factor model was thought to be the most appropriate 
explanation of the data. This explained 40.5 per cent of the total variance.  
For the primary care questionnaire, seven factors were extracted using PCA with an 
eigenvalue greater than 1. On review of the scree plot and discussion with a medical 
statistician, three factors were retained, which explained 37.0 per cent of the total 
variance. The extracted factors were rotated using oblique rotational methods. 
For the secondary care questionnaire, item thirty-one did not load at all on the factors 
and therefore this item was dropped at this stage. Items 30 and 35 (See Table 1-
Questionnaire section C statements) do not load significantly on any factor 
(significance= factor loading>0.4), and therefore these two items would be further 
assessed on the internal consistency of the extracted factors. 
For the primary care questionnaire, items 30 and 33 (See Table (1-Questionnaire 
section C statements) did not load at all on the factors and therefore these questions 
were dropped at this stage. Item 20 did not load significantly on any factor and 
therefore this item would be further assessed on the internal consistency of the 
extracted factors. 
 
Testing the internal consistency of the extracted factors 
The internal consistency of items within a factor was ascertained. The reliability 
coefficient (Cronbach’s coefficient alpha) was calculated to indicate the strength of 
the relationship of each item within the factor. The consistency of the factor 
constructs are presented in (See Table 2-Reliability coefficients of the extracted 
subscales).  
 
Secondary care 
Assessment of the individual reliability coefficient for each item in the extracted 
factors suggested that items 22, 32 and 35 needed to be removed from factor one, 
items 30 and 32 needed to be removed from factor two and item 25 from factor 3 as 
they adversely affected the internal consistency of the extracted factor. 
 
Primary care 
Assessment of the individual reliability coefficient for each item in the extracted 
factors suggested that items 23 and 31 needed to be removed from factor one, item 21 
needed to be removed from factor two and item 20 from factor 3 as they adversely 
affected the internal consistency of the extracted factor. 
 
Testing the overall reliability of the scale 
Item-total correlations were assessed, which compares the scores on individual 
statements with the total score of the scale. Statements were considered for rejection if 
their item-total correlation was below 0.2. 
Also the overall correlation between items within the scale was measured using the 
Cronbach’s alpha score. A reliability coefficient of 0.7 or above is recommended 
which would imply that seventy per cent of the measured variance is reliable and 
thirty per cent is owing to random error. 
 
Secondary care 
The reliability scores as outlined above therefore suggest removing items 30, 31 and 
35 from the overall scale. As item 32 was removed from two of the three factors upon 
internal consistency measurement, the overall Cronbach’s alpha coefficient was also 
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calculated for the scale minus this item as well. This produced the best overall 
Cronbach alpha for the scale =0.75, (minus items 30,31,32 and 35). 
 
Primary care 
The reliability scores as outlined above therefore suggest removing items 20, 30 and 
33 from the overall scale. However, the best overall Cronbach alpha score for the 
scale is with items 23,30,31 and 33 removed from the scale= 0.602. Therefore this 
overall reliability coefficient score coupled with the poor internal consistency of the 
extracted factors suggests that this scale is not reliably measuring the attitudes on the 
scale. 
 
Interpreting the factors 
See Table 3- Interpretation of the emergent factor constructs (Secondary Care)) and 
Table 4- Interpretation of the emergent factor constructs (Primary care)). -Display the 
interpretation of the emergent constructs. The factor analysis process had grouped 
various statements from the questionnaire that were related to each other into each 
factor. The items within each of these emergent factors were then reviewed and the 
concepts underlying them were described and interpreted.  
 
Exploring the factor scores 
The distributions of the scores for the extracted factors are summarised in Table 5 -
Distribution of scores (Secondary care)) and Table 6- Distribution of scores (Primary 
care). Spearman’s rho was used to explore the relationships between the total scores 
for the extracted factors. (See Table 7- Correlations between the factors). Summarises 
the relationships between the factors. 
 
Secondary care 
There was a strong association between factor one and two. Positive attitude towards 
limitations of the supplementary prescribing training model may be related to a 
positive attitude that trained supplementary prescribers will not encounter issues that 
threaten their professional competence or responsibility. 
 
Primary care 
There was a strong association between factor one and three. The positive attitude that 
trained supplementary prescribers will not encounter issues that threaten their 
professional competence or responsibility (Also that issues such as IT provision will 
not be an obstacle and that independent prescribing will not be more useful.) may be 
related to a positive attitude towards limitations to the supplementary prescribing 
training model. (Also that they did not think that multiple prescribers would increase 
the prevalence of iatrogenic disease.) 
 
Therefore the same strong association was found amongst secondary and primary 
care. 
 
Exploring relationships between the factors and the respondents 
Table 8- Correlations between the factor scores and respondents presents the 
relationships between factor scores and relevant questionnaire responses. 
 
Secondary care 
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There was a weak to moderate association between factor one and the total number of 
pharmacists employed in the trust. This suggests that as the total number of employed 
pharmacists increases the respondents had less concerns over the limitations of the 
supplementary prescribing training model. 
There was also a weak to moderate association between factor one and the total 
number of current pharmacist prescribing activities (NON-supplementary 
prescribing). This suggests that as the trust has more of these prescribing activities 
being undertaken, there are less concerns over the limitations of the supplementary 
prescribing training model. 
There was also a slightly stronger association between factor one and the total number 
of current nurse supplementary prescribing activities. Suggesting that as trusts have 
more experience of supplementary prescribing by nurses, the respondents have less 
concerns over the supplementary prescribing training model. 
 
A relationship was found between factor one and the intention to implement 
pharmacist supplementary prescribing by the end of 2005. Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they did not have concerns over the supplementary prescribing training 
model. 
A relationship was also found between factor three and the intention to implement 
pharmacist supplementary prescribing by the end of 2005.  Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they thought that implementation of supplementary prescribing was 
going to be a priority within their trust and that pharmacists wanted to take on this 
role. 
 
Primary care  
There was a weak to moderate association between factor two and the total number of 
pharmacists employed in the trust. This suggests that as the total number of employed 
pharmacists increases the respondents thought that implementation of supplementary 
prescribing would be a priority within their trust, that pharmacists did want to take on 
this role and that reassessment and maintaining competency would not be an issue 
once qualified. 
A strong association was found between factor three and the total number of current 
pharmacist prescribing activities (NON-supplementary prescribing). As the number of 
current pharmacist prescribing activities (NON-supplementary prescribing) increases, 
the respondents had less concerns over the limitations of the supplementary 
prescribing training model and professional competency and responsibility issues. 
A relationship was found between factor two and the intention to implement 
pharmacist supplementary prescribing by the end of 2005. Respondents were more 
likely to state that they were intending to implement supplementary prescribing by 
pharmacists if they thought that implementation of supplementary prescribing was 
going to be a priority within their trust, and that pharmacists did want to take this role 
on. Also that reassessment of the trained supplementary prescriber and maintenance 
of competency would not be an issue. 
A relationship was found between factor one and the intention to implement or train 
more nurses as supplementary prescribers within your trust by the end of 2005. 
Respondents were more likely to state that they were intending to implement 
supplementary prescribing by nurses if they thought that supplementary prescribers 
would not encounter issues that threaten their professional competency or 
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responsibility once qualified. They would also not consider that IT provision would 
be a problem or that independent prescribing would be more useful than 
supplementary prescribing. 
A relationship was also found between factor two and whether pharmacists currently 
undertake “prescribing-type activities” (NON-supplementary prescribing) in any 
format within the trust. Respondents who answered yes to this question were more 
likely to think that implementation of supplementary prescribing would be a priority 
within the trust and that pharmacists did want to take this role on. Also that 
reassessment of the trained supplementary prescriber and maintenance of competency 
would not be an issue. 
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Discussion 
 
Comments upon individual items in the scale  
 
For question 19 (secondary care)/ 20 (primary care) (Table 1), the majority of primary 
and secondary care disagreed with this statement. Open comments were made that 
there is a risk for ANY prescriber that they will not appreciate the signs and 
symptoms being declared to them by the patient. Also, clinical governance should 
help to prevent this sort of problem occurring, thorough maintenance of competency 
from on-going continuing professional development and audit. 
For question 20 (secondary care)/ 21 (primary care), several open comments were 
made. As long as good communication between prescribers was maintained then this 
should reduce the risk of iatrogenic disease. Good communication should be 
improved when level 3 electronic prescribing is implemented[18]. Comments were 
also made that this may be more applicable to nurse supplementary prescribers, 
especially those who prescribe in a very narrow, specialist area, who may not be 
aware of the impact that their drug initiation may have on concurrent conditions that 
the patient may have. For pharmacists, this may not be such an issue due to their 
broad knowledge of pharmacotherapeutics. 
 
For question 25 (for both primary and secondary care), there were some comments 
made that they would agree that the lack of assessment of applied therapeutics in the 
prescribing area for nurses (not pharmacists) meant that the supplementary 
prescribing model was not robust. Certainly, the descriptive research regarding the 
pharmacological knowledge base of community nurses has consistently suggested that 
they may have knowledge deficits.[19-21] It will therefore be very important, in terms 
of risk management, to ensure that the principles of clinical governance are adhered 
to. Trusts need to ensure that they have an accountable and safe system in place, with 
formalised support for their non-medical prescribers, to ensure that patient safety is 
maintained. Undoubtedly, pharmacists will have a major part in the development of 
such a system. 
However, the people answering this question and making these comments were 
pharmacists, so there could have also been some professional bias in their responses 
and comments. 
  
Initial evaluation of the supplementary prescribing training for pharmacists suggests 
that the trainees would prefer there to be more training in physical examination and 
consultation skills within the courses investigated, and less basic pharmacology and 
pharmacokinetics[22]. Although the participants in this study tended to be 
experienced senior clinical pharmacists, who would be expected to have a good 
knowledge of basic pharmacology and pharmacokinetics, it does suggest that the 
requirements of nurses and pharmacists are very different in terms of training needs to 
become supplementary prescribers. It would therefore seem appropriate for profession 
specific courses to be utilised rather than generic supplementary prescribing courses. 
 
Although pharmacists do have a standardisation of their original basic qualification, 
like nurses, there is no form of competency assessment once qualified to formerly 
differentiate the skills and expertise for example, of a senior clinical pharmacist from 
an aseptic production pharmacist. Antoniou et al have been working on the 
development of a competency framework for pharmacists within secondary and 
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primary care that will, if taken on by the profession, help to eradicate this issue[23]. If 
the standardised competency framework was tied in with the requirements for 
pharmacist supplementary prescribers, it will make the prescribing role a safer one for 
both the prescriber and the patient, and would tackle some of the concerns about lack 
of therapeutics assessment within the SP training. Similar requirements would of 
course, be necessary for nurse supplementary prescribers.  
 
Although it was most common for primary and secondary care respondents to agree 
with the question 29, (for both primary and secondary care) that DMPs ought to 
undertake prescribing training themselves before assessing the prescribing 
competency of other health care professionals, there were comments made that this, 
however, would not happen, and that if it were a requirement, there would be even 
less medical practitioners willing to take on the DMP role. However, it has been 
suggested that in the future, ALL health-care professionals who are going to prescribe 
ought to pass a “prescribing exam” before they start prescribing. (Personal 
communications, Professor Judy Cantrill, BPC 2003) This would seem to be a fair 
approach, and would help to avoid the situation described at a hospital in the Wirral 
where pre-registration house officers are not allowed to prescribe for their first 6 
weeks of practice without close supervision.[24] It would also avoid the perception of 
increased medication prescribing errors being made when newly-qualified doctors 
start prescribing as well as reduce opportunity for litigation. 
 
Question 33/32 (secondary care/primary care) upon conflict within the pharmacist’s 
role with respect to being a prescriber and providing impartial advice to the public, 
was included after it had been suggested that this might be an issue for pharmacists 
especially in community pharmacies where it may not be possible to separate the 
prescribing and dispensing roles. However, the majority of respondents in primary 
and secondary care disagreed with this statement, and comments were made that the 
pharmacist’s professional and ethical duties would prevent this from happening. 
 
Question 34/33 (secondary/primary care) suggested that undergraduate pharmacy 
students should qualify as supplementary prescribers upon graduation. The majority 
of secondary care respondents disagreed with this statement whereas primary care 
respondents mainly agreed with it. For those who disagreed with this statement, the 
comments suggest that it was thought to be appropriate to teach the principles and 
theory of supplementary prescribing at undergraduate level, but that there was a 
period of practice as a pharmacist required before becoming a qualified 
supplementary prescriber. However, it seems that the intentions of the Department of 
Health are to consolidate all of the supplementary prescribing training into the 
undergraduate course over the next few years, so that they will qualify upon 
graduation.[25] It is possible that primary care has less concerns about pharmacy 
graduates attaining the SP qualification upon graduation, as newly-qualified 
pharmacists in primary care have much more autonomy upon qualification, and often 
manage their own pharmacies.  
 
Both primary and secondary care respondents agreed to question 35/34 
(secondary/primary care) upon whether independent prescribing would be more 
useful than supplementary prescribing (SP). For secondary care respondents, this may 
reflect that SP is for chronic disease management and therefore the SP model does not 
suit secondary care very well because it manages acute illness.  
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Primary care respondents also agreed with the statement, which may reflect that for 
community pharmacists, independent prescribing may be more suitable and fit in with 
the majority of their premises not being located within GP surgeries. It would be 
especially suitable for their role in dealing with minor ailments and minor injuries. It 
was commented that for practice pharmacists, dealing with chronic conditions, that 
supplementary prescribing would be the prescribing model of choice. 
 
Factor scores 
The distribution of scores for the 3 factors in primary and secondary care illustrate 
that both sectors have a tendency towards negativity about the supplementary 
prescribing training model. For secondary care, the concerns were around the 
paperwork & the clinical management plan that needs to be developed, how 
reassessment of on-going competency of the supplementary prescriber will take place, 
the suitability of the designated medical practitioner (DMP) to supervise the training 
and about undergraduate pharmacy students qualifying as supplementary prescribers 
upon graduation. For primary care, they had the same concerns over the paperwork 
involved and the suitability of the DMP to supervise, but also had concerns over the 
lack of clinical assessment in the SP training and the risk of increased prevalence of 
iatrogenic disease due to poor communication between prescribers.  
Both sectors also have concerns about professional competence/responsibility once 
that pharmacists and nurses qualify as supplementary prescribers. For secondary care 
the concerns were around the risk of increased prevalence of iatrogenic disease due to 
poor communication between prescribers, the conflict that arises with the 
pharmacist’s role of provision of impartial advice to patient’s about medicines, the 
lack of clinical assessment in the SP training and supplementary prescribers not 
understanding the significance of symptoms that are declared to them during the 
consultation. For primary care, they had the same concerns about impartial advice 
provision, increased prevalence of iatrogenic disease but also had concerns about how 
reassessment of on-going competency of the supplementary prescriber will take place, 
the obstacles that poor information technology provision will bring, and that 
independent prescribing will be more useful. 
 
However, both sectors are positive about the implementation of supplementary 
prescribing, and believe that pharmacists wish to take this role on. People who scored 
highly on factor 1 (secondary care) or factor 3 (primary care) either did not perceive 
SP to require much effort on their part, or, if they did, that the effort was worth it.  
Therefore it would appear that although the profession has concerns about the training 
model and competency of supplementary prescribers once qualified, there is an 
understanding of the importance of this development, and that it needs to be taken 
forward within the constraints presented. 
A small survey of community pharmacist’s views upon supplementary prescribing 
would seem to support this finding of positivity about the implementation of 
supplementary prescribing. The survey found that a large majority wanted to become 
supplementary prescribers although only a few of them were currently in training for 
the role and that SP was being viewed very positively in terms of increased use of 
clinical knowledge, job satisfaction, responsibility and patient benefit[26].    
 
Exploring relationships between the factors and the respondents   
The results suggest that as respondent’s had more experience of non-medical 
prescribing within their trust (such as pharmacists writing discharge prescriptions) 
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they were less likely to have concerns over the SP training model. Therefore the 
concerns that respondents had about training may not turn out to be an issue in 
practice.  
 
Reflection on findings in an international context 
On the basis of the UK experience, consideration should be given to the introduction 
of prescribing into the education programmes of pharmacists at an early stage if the 
supplementary prescribing model is to be developed in other countries. Where 
specialisation exists, for example the hospital pharmacy specialisation programmes in 
France and Spain, training in prescribing in secondary care could be included 
relatively easily. This issue should be discussed on a wider level, and perhaps 
European initiatives such as the Bologna Agreement could be used as a means of 
introducing prescribing practice into the undergraduate pharmacy curriculum. 
 
Critique of method 
A critique of the method with regards to the full questionnaire has been reported 
previously[1], therefore this critique will focus upon section C alone. 
It was noted that some respondents commented in the open comments section of the 
questionnaire that if the questions in section C were dealt separately with nurses and 
pharmacists, they would have answered the questions slightly differently.  
There were also some comments made that in some of the questions in section C, the 
term “primary care” was used, which can be misunderstood as just meaning PCT 
pharmacists. –It is only recently that PCT pharmacists have been more often 
recognised as being their own specialist sector, separate from community pharmacy. 
Therefore the term “primary care” should no longer be used as a general term to 
collectively describe PCT pharmacists and community pharmacists, without further 
definition. 
Respondents also commented that they would like to be able to make open comments 
to explain their answers to each item in section C. Some respondents did this anyway, 
where they felt they needed to qualify their answer. Although this is useful, it is also 
not usual for attitude scales to allow extra space for explanation of their response. 
Also, the longer a questionnaire survey is, the more negative impact it will have on 
the response rate. However, the comments were taken note of, and are referred to in 
the discussion of the results.  
 
Construct validity did not work as well as expected. On reflection, the questions used 
for this validity test, were probably not as closely related as they should have been. 
Even if chief pharmacists or primary care trust pharmacists intended to implement 
supplementary prescribing, this does not necessarily mean that it would also be a 
priority within the trust. The two statements that were explored to assess construct 
validity only address one aspect of construct validity for this issue and do not prove 
anything with regard to the other statements that were included in the questionnaire. 
Extensive assessment of construct validity is not achievable when assessing such a 
narrow frame of questions. Therefore further questions should have been put into 
section C which correlated more closely with questions in section B, in order to test 
construct validity more effectively. 
 
Representation of PCTs from a pharmaceutical adviser in the focus group and in the 
semi-structured interviews would have helped to improve the overall reliability of the 
scale for the primary care questionnaire.  
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The attitude scale for secondary care did produce a statistically valid Cronbach’s 
alpha value for the overall scale, however, none of the Cronbach’s alpha values for 
the extracted factors demonstrated a high level of internal consistency (as recognised 
in standard textbooks of what constitutes a reasonable level of consistency, reliability 
coefficient >0.7) (Table 2). This would suggest that some caution is needed when 
interpreting the meaning of the factors and their associations. 
 
Unfortunately the scale for section C for primary care did not produce an overall high 
level of internal consistency (Cronbach’s alpha value), and neither did the individual 
extracted factors (Table 2). This suggests that the scale is not measuring what it was 
intended to for primary care. Since an almost identical scale for secondary care did 
have an overall high level of internal consistency (Cronbach’s alpha value), (and 
therefore was measuring what was intended reliably) it suggests that the scale items 
needed further development to make them more suitable for primary care. The poor 
Cronbach’s alpha values for the extracted factors were apparent in terms of 
developing an overall meaning for the factor (Panel 2). Some of the individual items 
did not “fit into” the group as well as other items.  
An original assumption was made that PCT advisers were a homogenous group, and it 
is apparent that this is not the case, as they may have very different pharmacy 
backgrounds, have very different job roles and influence within their PCT. Also, the 
respondents were not all entitled pharmaceutical advisers, so may have had roles with 
very different focuses within the PCT. Different PCTs will also have different 
healthcare provision pressures upon them, which will be affected by whether they 
look after a rural or urban population. Also, if there is a large proportion of dispensing 
doctors within a PCT, this may have a negative effect upon the development of 
pharmacist supplementary prescribing due to there being a previous history of 
disagreement between the two professions upon the need for separation of prescribing 
and dispensing. 
Although the scale does not have a high level of internal consistency in terms of the 
Cronbach’s alpha value achieved, the results can be used to provide some insight into 
the views of primary care trust pharmacists upon the risks and issues surrounding 
supplementary prescribing in primary care, and to also highlight differences in those 
views between primary and secondary care.    
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Conclusion 
It would appear that although the Department of Health may feel that the training 
model and patient safeguards that have been put into place are sufficient, there are 
still concerns within both primary and secondary care about the supplementary 
prescribing model (such as the lack of clinical assessment during training) and also 
professional competence and responsibility once trainees qualify. It is apparent that in 
order for supplementary prescribing to be a safe system for patients, pharmacists will 
have a central role in the development process in terms of risk management and the 
safe use of medicines. The Department of Health may need to provide more support 
for this role, showcase examples of good practice, and support research into the role 
in order to provide an evidence-base that SP is providing patients with at least an 
equivalent service to doctors, and is also increasing access to healthcare for patients, 
without compromising safety. Only then will SP be more extensively implemented. 
Although CPs and PCTPs have these concerns, overall there is a positive attitude 
towards supplementary prescribing and there is a belief that pharmacists wish to take 
this role on. 
 
Further work needs to be undertaken to further develop a survey tool to evaluate 
views of primary care trust pharmacists upon the risks and issues of supplementary 
prescribing more effectively. 
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Table 1: Questionnaire Section C statements 
Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
20 19 There is a risk that SP's may not 
appreciate the significance of 
signs & symptoms that the patient 
declares to them during the 
consultation 
1 
(0.5) 
2 
(2.1) 
51 
(27.9) 
31 
(32.3) 
28 
(15.3) 
19 
(19.8) 
88 
(48.1) 
37 
(38.5) 
15 
(8.2) 
7 
(7.3) 
21 20 Multiple prescribers, arising from 
the introduction of SP, will 
increase the prevalence of 
iatrogenic disease 
0 2 
(2.1) 
18 
(9.9) 
11 
(11.3) 
51 
(28) 
35 
(36.1) 
82 
(45.1) 
33 
(34) 
31 
(17) 
16 
(16.5) 
22 21 Amongst other developments 
being undertaken within the NHS, 
development of SP by 
PHARMACISTS WILL be a 
priority within our trust 
1 
(0.5) 
3 
(3.1) 
48 
(26.4) 
23 
(23.7) 
48 
(26.4) 
24 
(24.7) 
64 
(35.2) 
37 
(38.5) 
21 
(11.5) 
7 
(7.3) 
23 22 Amongst other developments 
being undertaken within the NHS, 
development of SP by NURSES 
WILL be a priority within our 
trust 
17 
(9.4) 
4 
(4.1) 
86 
(47.5) 
44 
(45.4) 
42 
(23.2) 
28 
(28.9) 
34 
(18.8) 
19 
(19.6) 
2 
(1.1) 
2 
(2.1) 
25 25 Lack of assessment of applied 
therapeutics in the prescribing 
area means that the training 
model for SP is not sufficiently 
robust 
19 
(10.6) 
10 
(10.6) 
57 
(31.7) 
23 
(24.5) 
68 
(37.8) 
28 
(29.8) 
29 
(16.1) 
27 
(28.7) 
7 
(3.9) 
6 
(6.4) 
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
26 26 The paperwork & development of 
individual clinical management 
plans will be prohibitive to the 
development of SP. 
5 
(2.8) 
9 
(9.5) 
55 
(31.1) 
31 
(32.6) 
43 
(24.3) 
17 
(17.9) 
70 
(39.5) 
34 
(35.8) 
4 
(2.3) 
4 
(4.2) 
27 27 The majority of pharmacists in 1˚ 
/2˚ care do not wish to take on the 
SP role. 
7 (4) 4 
(4.2) 
47 
(26.7) 
24 
(25) 
61 
(34.7) 
23 
(24) 
53 
(30.1) 
40 
(41.7) 
8 
(4.5) 
5 
(5.2) 
28 28 Reassessing & maintaining 
competency of SP pharmacists 
will limit the uptake of SP. 
1 
(0.6) 
1 
(1.1) 
56 
(31.5) 
19 
(20) 
40 
(22.5) 
26 
(27.4) 
78 
(43.8) 
46 
(48.4) 
3 
(1.7) 
3 
(3.2) 
29 29 The designated medical 
practitioner should undergo 
prescribing training themselves 
before assessing the prescribing 
competency of SP trainees 
16 (9) 13 
(13.8) 
77 
(43.3) 
37 
(39.4) 
25 
(14) 
15 
(16) 
56 
(31.5) 
27 
(28.7) 
4 
(2.2) 
2 
(2.1) 
30 31 An employee SP should have 
their own indemnity insurance, as 
the trust's vicarious liability may 
not be sufficient 
20 
(11.3) 
6 
(6.3) 
72 
(40.7) 
16 
(16.7) 
50 
(28.2) 
15 
(15.6) 
29 
(16.4) 
36 
(37.5) 
6 
(3.4) 
23 
(24) 
31 32 Non-SP pharmacists will regard 
themselves as "second-class 
citizens" compared to prescribing 
colleagues. 
2 
(1.1) 
1  
(1) 
13 
(7.3) 
7 
(7.3) 
35 
(19.1) 
17 
(17.7) 
104 
(58.4) 
54 
(56.3) 
24 
(13.5) 
17 
(17.7) 
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
32 33 The SP role will cause conflict 
with the pharmacist's role of 
providing impartial advice to 
patients upon medicines 
2 
(1.1) 
1  
(1) 
11 
(6.2) 
11 
(11.5) 
27 
(15.3) 
11 
(11.5) 
101 
(57.1) 
50 
(52.1) 
36 
(20.3) 
23 
(24) 
33 34 In the future, I believe that it will 
be appropriate for undergraduate 
pharmacy students to qualify as 
SP's when they graduate 
25 
(14) 
6 
(6.3) 
63 
(35.4) 
21 
(22.1) 
7 
(3.8) 
11 
(11.6) 
46 
(25.8) 
33 
(34.7) 
37 
(20.8) 
24 
(25.3) 
34 35 In 1˚/2˚ care, there will be more 
extensive uptake & use for 
pharmacists as INDEPENDENT 
prescribers rather than as 
supplementary prescribers. 
47 
(26.6) 
25 
(26) 
76 
(42.9) 
37 
(38.5) 
40 
(22.6) 
20 
(20.8) 
13 
(7.3) 
10 
(10.4) 
1 
(0.6) 
4 
(4.2) 
24 - Currently, poor IT links will limit 
the development of community 
pharmacist SPs. 
98 
(53.6) 
   72 
(39.3) 
 4 
(2.2) 
 7 
(3.8) 
 2 
(1.1) 
 
- 23 Insufficient pharmacist resource 
will be a major limitation to 
development of pharmacist SP 
within secondary care. 
 41 
(42.3) 
 36 
(37.1) 
 3 
(3.1) 
 12 
(12.4) 
 5 
(5.2) 
- 24 Lack of 24-hour opening of 
pharmacy departments will be a 
limitation to development of 
pharmacist SP. 
 10 
(10.8) 
 23 
(24.7) 
 8 
(8.6) 
 39 
(41.9) 
 13 
(14) 
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Question 
No. 
Statement Strongly 
Agree 
No. (%) 
Agree  
No. (%) 
Uncertain  
No. (%) 
Disagree  
No. (%) 
Strongly 
Disagree  
No. (%) 
1˚ 2˚  1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 1˚ 2˚ 
- 30 Pharmacists who currently 
transcribe discharge prescriptions 
should be trained as SP's to 
continue this role 
 10 
(10.8) 
 20 
(21.5) 
 10 
(10.8) 
 40 
(43) 
 13 
(14) 
 
N. B. 1˚= Primary Care. 2˚= Secondary Care. 
Missing Data: Primary Care n=58, Secondary Care n= 17 
 
 
 
Table 2: Reliability coefficients of the extracted subscales 
No. of items Coefficient Factor construct 
Primary Care Secondary Care Primary Care Secondary Care 
One 5 5 0.519 0.597 
Two 4 6 0.587 0.694 
Three 4 3 0.555 0.622 
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Table 3: Interpretation of the emergent factor constructs (Secondary Care) 
 
Factor one: Limitations of the 
SP training model  
High scoring respondents were being positive 
about SP, were willing to put more effort into the 
development of SP (if necessary) and they thought 
there would not be many limitations to the SP 
training model. 
Low scoring respondents were being negative 
about the SP training model, were less likely to put 
much effort into the development of SP and were 
agreeing that there were problems with it. 
 
Factor two: Professional 
competence/responsibility 
issues once trained 
High scoring respondents were being positive 
about SP and were suggesting that trained 
supplementary prescribers will not encounter 
issues that threaten their professional competence 
or responsibility. 
Low scoring respondents were being negative 
about SP and were suggesting that trained 
supplementary prescribers would encounter issues 
that threaten their professional competence or 
responsibility. 
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Factor three: How commonly 
SP will be implemented 
High scoring respondents had more will to 
introduce SP and were suggesting that 
implementation would be a priority within trusts 
and that pharmacists in secondary care did want to 
take on this role. 
Low scoring respondents had less will to introduce 
SP and were suggesting that implementation of SP 
would NOT be a priority within their trust and that 
pharmacists did NOT want to take on this role. 
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Table 4: Interpretation of the emergent factor constructs (Primary care) 
 
Factor one: Professional 
competence/responsibility 
issues once trained plus 
limitations to uptake of SP 
High scoring respondents were being positive about SP 
suggesting that trained supplementary prescribers will 
not encounter issues that threaten their professional 
competence or responsibility. Also that issues such as IT 
provision will not be an obstacle and that IP will not be 
more useful. 
Low scoring respondents were being negative about SP 
and were suggesting that trained supplementary 
prescribers would encounter issues that threaten their 
professional competence or responsibility. 
They also thought that IT provision would affect 
implementation of SP and that IP would be of more use. 
Factor two: How 
commonly SP will be 
implemented plus 
limitations to uptake of SP 
High scoring respondents had more will to introduce SP 
and were suggesting that implementation would be a 
priority within trusts and that pharmacists in secondary 
care did want to take on this role. Also that reassessment 
& maintaining competency once qualified was not an 
issue. 
Low scoring respondents had less will to introduce SP 
and were suggesting that implementation of SP would 
NOT be a priority within their trust and that pharmacists 
did NOT want to take on this role. Also that 
reassessment & maintaining competency once qualified 
was an issue. 
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Factor three: Limitations 
of the SP training model 
plus Professional 
competence/responsibility 
issues once trained 
High scoring respondents were being positive about SP, 
were willing to put more effort into the development of 
SP (if necessary) and that they thought there would not 
be many limitations to the SP training model. 
They also did not think that multiple prescribers would 
increase the prevalence of iatrogenic disease. 
Low scoring respondents were being negative about the 
SP training model, were less likely to put much effort 
into the development of SP and agreed that there were 
problems with the SP training model. 
They also thought that multiple prescribers would 
increase the prevalence of iatrogenic disease. 
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Table 5: Distribution of scores (Secondary care) 
 
Factor one: Limitations of 
the SP training model 
Normal distribution of scores 
The tendency towards lower 
scores indicates that the 
respondents agreed that there 
were limitations to the SP 
training model. 
Mean scale score: -1.73 
Std. deviation: 3.42 
Median scale score: -2.00 
Minimum score: -8.00 
Maximum score: 10.00 
Factor two: Professional 
competence/responsibility 
issues once trained 
Normal distribution of scores 
The small tendency towards 
lower scores indicates that 
respondents agreed that there 
were professional 
competency/responsibility 
issues post qualification. 
Mean scale score: 0.86 
Std. deviation: 4.09 
Median scale score: 1.00 
Minimum score: -7.00 
Maximum score: 11.00 
Factor three: How 
commonly SP will be 
implemented 
Skewed distribution of scores 
The higher proportion of high 
scores indicates that 
respondents were positive 
about the implementation of 
SP, that it would be a priority 
of trusts and that pharmacists 
wanted to take the role on. 
Mean scale score: 0.22 
Std. deviation: 2.23 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 6.00 
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Table 6: Distribution of scores (Primary care) 
 
Factor one: Professional 
competence/responsibility 
issues once trained plus 
limitations to uptake of 
SP 
Skewed distribution of scores 
The higher proportion of lower 
scores indicates that 
respondents were being more 
negative about SP and were 
suggesting that trained 
supplementary prescribers 
would encounter issues that 
threaten their professional 
competence or responsibility 
and that IT provision would 
affect implementation of SP 
and that IP would be of more 
use. 
 
Mean scale score: -0.58 
Std. deviation: 2.54 
Median scale score: -1.00 
Minimum score: -7.00 
Maximum score: 6.00 
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Factor two: How 
commonly SP will be 
implemented plus 
limitations to uptake of 
SP 
Skewed distribution of scores 
The higher proportion of high 
scores indicates that 
respondents were positive 
about the implementation of 
SP, that it would be a priority 
of trusts and that pharmacists 
wanted to take the role on. 
Reassessment & competency 
maintenance were not viewed 
as being an issue once 
qualified. 
Mean scale score: 0.29 
Std. deviation: 2.55 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 6.00 
Factor three: Limitations 
of the SP training model 
plus Professional 
competence/responsibility 
issues once trained 
Skewed distribution of scores 
The higher proportion of lower 
scores indicates that 
respondents were being more 
negative about the SP training 
model and were agreeing that 
there were problems with it. 
They also thought that multiple 
prescribers would increase the 
prevalence of iatrogenic 
disease. 
Mean scale score: 0.21 
Std. deviation: 2.55 
Median scale score: 0.00 
Minimum score: -6.00 
Maximum score: 7.00 
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Table 7: Correlations between the factors 
 
 Spearman’s Correlation coefficient rho (n=169-174 primary care) (n=88-92 
secondary care) 
(P value) 
Percentage variance explained 
Factor One Factor Two  
Primary Care Secondary Care Primary Care Secondary Care 
Factor two 0.309 
(P=0.000) 
9.5 per cent 
0.511 
(P=0.000) 
26.1 per cent 
  
Factor three 0.415 
(P=0.000) 
17.2 per cent 
No significant 
relationship 
0.173 
(P=0.024) 
3 per cent 
No significant 
relationship 
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Table 8: Correlations between the factor scores and respondents 
 
 Correlation coefficient rho  
(P value) 
Percentage variance explained 
n 
Spearman’s Rho Factor One Factor Two Factor Three 
 Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Primary Care Secondary 
Care 
Total number of WTE 
pharmacists employed 
by trust 
No 
significant 
results 
0.303 
(P=0.008) 
9.2 per 
cent 
76 
0.267 
(P=0.000) 
7.1 per 
cent 
170 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
Total number of 
current pharmacist 
prescribing activities 
(NON-SP) 
No 
significant 
results 
0.300 
(P=0.021) 
9.0 per 
cent 
59 
No 
significant 
results 
No 
significant 
results 
0.441 
(P=0.008) 
19.4 per cent 
35 
No 
significant 
results 
Total number of 
current nurse 
prescribing activities 
(SP) 
No 
significant 
results 
0.359 
(P=0.011) 
12.9 per 
cent 
49 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
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 Chi squared 
(P value) 
Df 
Highest mean ranking (Yes answer) 
n 
Kruskal Wallis Factor One Factor Two Factor Three 
 Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Primary 
Care 
Secondary 
Care 
Intention to implement 
pharmacist SP by end 
of 2005 
No 
significant 
results 
20.523 
(P=0.000) 
3 
57.75 
92 
12.224 
(P=0.007) 
3 
96.95  
172 
No 
significant 
results 
No 
significant 
results 
14.128 
(P=0.003) 
3 
55.92 
96 
Intention to 
implement/train more 
nurse SP’s by  end of 
2005? 
9.659 
(P=0.022) 
2 
126.88 (No 
answer) 
174 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
Do pharmacists  
undertake “prescribing-
type activities” (NON-
SP) in your trust? 
No 
significant 
results 
No 
significant 
results 
8.913 
(P=0.012) 
2 
106.64  
173 
No 
significant 
results 
No 
significant 
results 
No 
significant 
results 
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A SURVEY OF NURSE SUPPLEMENTARY PRESCRIBING 
IMPLEMENTATION IN PRIMARY AND SECONDARY CARE IN ENGLAND. 
 
Hobson R and Sewell G 
 Department of Pharmacy and Pharmacology, University Of Bath, Claverton Down, 
Bath. BA2 7AY  (R.J.Hobson@bath.ac.uk) 
   
Introduction There are currently 4,151/672,897 (0.62%) qualified nurse 
supplementary prescribers (31st March 2005). Although supplementary prescribing 
(SP) is a topical subject within healthcare professions, there is little information 
available on how SP is being implemented within primary and secondary care, and in 
which clinical areas. 
The aim of this survey was to describe how SP was being implemented within 
primary and secondary care in England. Only those results pertaining to nurse 
supplementary prescribing will be presented here. 
 
Method A postal questionnaire survey of chief pharmacists within secondary care 
(n=143) and primary care trust pharmacists in primary care (n=271) in England was 
distributed in May 2004. A literature review, semi-structured interviews and a focus 
group were used to design the questionnaire. It contained open and closed questions. 
The questionnaire was validated (n=4) by pharmacists in the target population, and 
piloted in approximately 10% of the target population (n=17 chief pharmacists and 
n=30 PCT pharmacists). Results from the pilot were not included in the main results 
of the survey. Responses were coded and analyzed using the statistical package for the 
social sciences (SPSS) version 11. 
  
Results  The response rate was 68% for both the primary care (183/271) and 
secondary care surveys (97/143). Fifty-eight per cent (n=56/97) of secondary care 
chief pharmacists stated that they had trained nurse supplementary prescribers 
working within their trust, compared to 75% (n=136/183) within primary care trusts. 
The top clinical areas for nurse supplementary prescribing are very similar for 
primary and secondary care, with Asthma, Diabetes, COPD and Heart Failure all 
appearing in the top five clinical areas. These conditions are established areas for 
specialist nursing input. There was a wide range of people reported to be responsible 
for taking forward supplementary prescribing for nurses within primary care, but most 
commonly, it was the director of nursing (52% n=95/182 (1=missing data)) followed 
by the PCT non-medical prescribing group (38% n=70/182 (1=missing data)) and the 
pharmaceutical adviser (31% n=56/182 (1=missing data)). 
 
Conclusion 
Nurse supplementary prescribing appears to be taking longer to establish within 
secondary care. The reasoning for this finding is likely to be multifactorial. Primary 
care has more experience of nurse prescribing and the model of SP is tailored for 
chronic disease management. Development of supplementary prescribing within 
primary care may be rather fragmented given the wide range of people charged with 
taking nurse supplementary prescribing forward. The lack of national strategy to 
guide which clinical areas supplementary prescribers should practice in, or where 
areas of expertise should be developed, may precipitate variability in patient 
accessibility to healthcare across different parts of the UK, which is relevant to 
pharmacist supplementary prescribers as well. 
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A qualitative evaluation of patient opinion on pharmacist and nurse independent 
prescribing (IP). 
 
RJHobson and JA Scott. University of Bath, Pharmacy & Pharmacology Department, 
Claverton Down, Bath BA2 7AY, UK. 
 
Focal Points: Community pharmacists in particular have many more barriers to deal 
with before the public will have confidence in their prescribing services when 
compared to nurses. Public promotion of pharmacist’s skills and clinical governance 
assurances will be essential to gain public confidence in IP. 
 
Introduction: Evaluation of supplementary prescribing (SP) by pharmacists to date 
has provided limited data regarding patient’s opinions of pharmacist SP1. Report’s of 
patient opinion of nurse prescribing suggest increased convenience, improved access 
to healthcare and better use of healthcare professionals’ time. Concerns focus on 
nurses having insufficient experience to prescribe.2-4 The purpose of this research was 
to investigate patient opinion on the development of pharmacists and nurses as 
independent prescribers. Opinions of patients who have and haven’t used SP services 
will be invaluable to examine views on Independent Prescribing (IP). Of specific 
interest is their perception of the benefits, concerns and preference of which health 
professional they would consult. Identification of these factors will allow 
misconceptions and barriers to be tackled.  
 
Method: Qualitative methodology, using depth interviews was used. Eighteen 
interviews (n=5 primary care (GP-led), n=5 secondary care (Consultant-led), n=5 
primary care (Pharmacist SP-led) and n=3 secondary care (Pharmacist SP-led)) took 
place with patients in Bristol, Swindon and Brighton. Patients interviewed in primary 
care had hypertension and those in secondary care had gastro-intestinal (GI) cancers. 
They were randomly sampled from a list of patients under the care of one prescriber 
at each centre. Participants were aged between 42 to 81 years of age (n=11 male and 
n=7 female). Interviews took place within the NHS trusts between January and 
August 2006. Ethics approval was obtained for the patient interviews. A topic guide 
was developed using literature review. All interviews were tape recorded with consent 
and fully transcribed. After transcription, each interview was examined and analysis 
for emergent themes was undertaken using interpretative phenomenological analysis. 
 
Results: Participants shared common views upon the benefits of IP and necessary 
controls regardless of the type of professional. They also had common concerns about 
IP, including doubting their ability to deal with more serious conditions and their 
diagnostic skills. Concerns were based upon issues of change and acceptance where 
some participants prefer the traditional doctor model, considering the IP service 
inferior. Nurse prescribing was more acceptable than pharmacist prescribing because 
nurses were considered to be trustworthy, caring and a devoted profession who are the 
central figure in an individual’s healthcare, with whom relationships are established. 
It was noted by some participants that nurses already had a prescribing role. 
Generally, community pharmacists were perceived by some participants as being 
“non-NHS”, not being a healthcare provider and as having a negative image. 
Participants doubted the privacy of community pharmacies, whether they had the 
necessary space to provide a professional IP service and had clinical governance 
concerns. However, participants did acknowledge the expert drug knowledge that 
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pharmacists have and their accessibility. Participants that had experienced pharmacist 
SP were positive about the experience and it enforced views that pharmacists would 
be capable as IPs. Patients felt empowered due to a more concordant approach 
compared with doctor consultations. They also viewed SP pharmacists as being 
specialists compared to community pharmacists. Participants that had not experienced 
SP tended to have more intrinsic barriers towards IP. Participants with hypertension 
were more vocal about their opinions than those with GI cancers. The participants 
with hypertension discussed how knowledgeable pharmacists are more frequently but 
were more negative about their value, status and their dispensing role.   
 
Discussion: Community pharmacists have more barriers to overcome before the 
public will accept their prescribing services when compared to nurses. This is because 
the public do not currently visualise them as healthcare providers and do not 
understand the knowledge and skills that they have. Public promotion of pharmacist’s 
skills and assurance of clinical governance will be essential to gain public confidence 
in IP.  
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